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Abstract 
Since the discovery of mesenchymal stromal cells (MSCs) ability to repair 
craniofacial defects and immunomodulatory properties, they became focus of 
research due to their cellular therapeutic potential. The Advanced Therapeutics 
Department within the Scottish National Blood Transfusion Service (SNBTS) has 
developed standardised methodologies for the isolation of MSCs from pancreatic 
islets, visceral adipose tissue, liposuction aspirate, bone marrow and umbilical 
cord. However, studying and comparing their in vivo function and the 
immunomodulatory potential is essential prior to their use within a clinical 
setting. The immunomodulatory abilities of human MSCs have been studied using 
mouse models that lack a control for mismatched major histocompatibility 
complex molecule expression. For this reason, this study aimed to objectively 
compare the phenotype and potential immunomodulatory functions in vivo of 
murine MSCs isolated from the bone marrow (BM MSCs), islets of Langerhans (Is 
MSCs) and adipose tissue (Ad MSCs) in a stringent, standardised manner, without 
any species or gender mismatch that could lead to both cell-mediated and 
humoral immune responses.  
First, for use within a clinical settings MSCs need to be infused and home and 
engraft into the target tissue. However, most cells get entrapped in the lung and 
only a small percentage home and remain in the target tissue. Size could be 
essential to avoid lung entrapment and this study has described that murine BM 
MSCs are slightly smaller than Is and Ad MSCs, suggesting that they could be a 
better source of MSC if being delivered intravenously. Moreover, chemokine 
receptor expression targets immune cells into specific tissues. Comparison of 
chemokine receptor transcription showed that Ad MSCs have a greater 
transcription of CXCR4 combined with a very low transcription of other 
chemokine receptors, suggesting that they will more likely suffer from lung 
entrapment compared to BM and Is MSCs. BM MSCs have the highest transcription 
of CCR7 and CXCR6, and therefore, we hypothesise that BM MSCs will be more 
successful to reach lymphoid organs. Is MSCs have a greater potential to migrate 
towards the kidneys due to higher transcription of CCR1 and CXCR3. Ad MSCs, on 
the contrary, transcribed statistically significantly more CCR3 than Is and BM 
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MSCs and therefore, they have a greater potential to migrate towards the skin if 
they avoid entrapment within lungs.  
Under resting conditions, MSCs from the three tissue sources were able to 
secrete chemokines at similar levels; however, this secretion did not produce a 
recruitment of leukocytes above control levels. Inflammatory stimulation led to 
increased secretion of chemokines where Is MSCs secreted the highest levels of 
CCL2, CCL5, CXCL1 and CXCL10, while CXCL12 was secreted at higher levels by 
BM MSCs. CCL2, CCL5 and CXCL1 are strong chemoattractans, but despite the 
higher secretion by Is MSCs under inflammatory conditions, Ad MSCs were able to 
recruit significantly more leukocytes in vivo than BM and Is MSCs. More 
importantly, Ad MSCs were the only MSCs able to produce the recruitment of T 
cells. Recipient cytotoxic cells are considered detrimental in clinical settings, 
but they are essential to initiate MSC-mediated immunosuppression; thus, we 
could hypothesise that Ad MSCs have a greater immunosuppression potential 
than BM and Is MSCs.  
Chemokines not only have leukocyte recruitment properties, as examples, 
CXCL1, CXCL2 and CXCL12 have angiogenic properties while CXCL10 has 
angiostatic potential. Chemokines are not the only molecules secreted by MSCs 
with the potential to regulate angiogenesis. Ad MSCs secreted the most IL-6, 
which can promote VEGF secretion, but Is MSCs secreted the most VEGF under 
resting and stimulatory conditions, which combined with the increased secretion 
of CXCL1, CXCL2 and CXCL12, we hypothesise that Is MSCs could have greater re-
vascularisation potential. 
Altogether, this study highlights that MSCs from different sources differ in their 
ability to recruit and immunomodulate surrounding immune cells in vivo. These 
differences have the potential to influence their clinical performance. 
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1 Introduction 
This study arises from the lack of consensus in understanding the 
immunomodulatory roles of mesenchymal stromal cells (MSCs), which has 
contributed to the controversial results in the literature as a consequence of the 
different isolation, enrichment and culture protocols, as well as the intrinsic 
variability among MSCs derived from different donors and tissues. For this 
reason, the aim of this study was to isolate, study and compare through a 
stringent set of standardised techniques murine bone marrow (BM), islets of 
Langerhans (Is) and adipose tissue (Ad)-derived MSCs to better understand the 
role of MSCs in inflammation and to study the effect of tissue source of isolation 
in the orchestration of inflammation. Given the nature of this work, this 
introductory section will provide an extensive overview of the immune system 
and MSCs. Firstly, the cellular and molecular mechanisms involved in the 
response to an inflammatory agent will be detailed. Secondly, the chemokine 
family will be reviewed due to its role in the migration of immune cells under 
homeostatic and inflammatory conditions. Lastly, I include a broad review of 
MSCs discussing topics such as the impact of MSC tissue of origin in the 
phenotype and function, the role of these cells within the immune response and 
the clinical uses of MSCs.  
1.1 The immune system 
Inflammation can be defined as a localised protective response process after 
injury or destruction of tissues to eliminate the injurious agent. Inflammation is 
characterised by four classical signs described by Celsus: rubor (redness), calor 
(increased heat), tumour (swelling) and dolor (pain). However, in the nineteenth 
century Virchow added a fifth sign, functio laesa (loss of function) (Rather, 
1971).  
The inflammatory response is driven by the immune system, a complex network 
of cells and organs that protect the body by recognition and elimination of 
nonself components. It is extremely important for the immune system to achieve 
a good self-nonself discrimination to avoid an overactive and misguided immune 
response against components normally present in the body, as this would lead to 
chronic inflammation and autoimmune diseases. The immune system has two 
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major arms working together to protect the host, the innate and the adaptive 
immune responses.  
1.1.1 The innate immune response 
The innate immune response is not specific to particular pathogens or damage, 
but it is of extremely high relevance the first hours and days of exposure to a 
new pathogen. The first barriers to prevent infection are skin and other 
epithelial surfaces that act as physical barriers to microorganisms. The inner 
part of these epithelial surfaces is covered with a mucus layer that protects 
against chemicals, physical damages and infections (Nochi and Kiyono, 2006).  
Damage of these barriers gives microorganisms access to the body. 
Microorganisms have pathogen-associated molecular patterns (PAMPs), which 
must be rapidly recognised as nonself components by the immune system to 
neutralise the invading pathogen. PAMPs are of various types and they are 
usually molecules with essential functions for the pathogens and thus, molecules 
with low genetic variability. As an example, prokaryotic organisms use 
formylmethionine for mRNA translation initiation instead of the methionine 
residue used by eukaryotic organisms; this is easily recognised by the immune 
system. Moreover, microorganisms usually have outer surface molecules not 
present in humans that act as immunostimulants, such as lipopolysaccharide 
(LPS) on gram negative bacteria and lipoteichoic acids (LTA) on gram positive 
bacteria (Abraham and Medzhitov, 2011). Bacterial and viral genomes can also 
act as PAMPs due to the presence of CpG unmethylated dinucleotides flanked by 
two 5′ purine residues and two 3′ pyrimidines (Abraham and Medzhitov, 2011). In 
the case of viruses, viral DNA or RNA can also be recognised as PAMPs, leading to 
the activation of the immune response (Luecke and Paludan, 2016).  
To recognise PAMPs, cells of the immune system express pattern recognition 
receptors (PRRs). However, the immune system does not only produce a 
response to microbial pathogens, but also to haemorrhagic shock, tissue injury, 
cell necrosis and reperfusion injury (Raymond et al., 2017). In the presence of 
damage or stress, cells release damage-associated molecular patterns (DAMPs), 
which are also able to activate the immune response via PRR-mediated 
recognition (Gallucci and Matzinger, 2001). PRRs include: toll-like receptors 
  23 
 
(TLRs); C-type lectin receptors (CLRs); nucleotide-binding oligomerization 
domain (Nod) like receptors (NLRs); retinoic-acid-inducible gene-I (RIG-I) like 
receptors (RLRs); and receptor for advanced glycation end products 
(RAGE)(Raymond et al., 2017).  
TLRs were the first PRRs to be discovered and are the most widely studied. 
There are 10 receptors in humans (TLR1-TLR10), and despite some overlapping 
ligands for the receptors, each TLR has specific molecular recognition patterns. 
TLRs recognise PAMPs both within and outwith the cell as TLR1, TLR2, TLR4, 
TLR5, TLR6 and TLR10 are expressed on the cell membrane while TLR3, TLR7, 
TLR8 and TLR9 are expressed within intracellular vesicles of innate immune cells 
(Raymond et al., 2017). TLR1 recognises triacylated lipopeptides via 
dimerization with TLR2 (Takeuchi et al., 2002). TLR2 on its own is involved in 
gram positive bacteria recognition by interaction with peptidoglycans and LTA on 
their surface (Schwandner et al., 1999). Moreover TLR2, in combination with 
TLR6, is able to recognise diacylated bacterial lipoproteins (Takeuchi et al., 
2001). TLR3 recognises retroviruses by interaction with double stranded RNA 
(Termeer et al., 2002). TLR4 is involved in the recognition of LPS from gram 
negative bacteria (Termeer et al., 2002), structural proteins from viruses (Del 
Cornò et al., 2016), mannan (a cell wall polysaccharide) from fungi (Figueiredo 
et al., 2012), glycoinositolphospholipids from Trypanosoma (Dos-Santos et al., 
2016) and endogenous high mobility group box (HMGB) nuclear proteins from 
distressed cells (Yu et al., 2006). TLR5 is the cognate receptor for flagellin, an 
essential protein of the flagella of bacteria (Hayashi et al., 2001). TLR7 and 
TLR8 are both involved in the recognition of single stranded viral RNA (Heil et 
al., 2004). TLR9 is involved in the recognition of the CpG regions (Hemmi et al., 
2000). The function of TLR10 remains unknown but it has been associated with 
the B cell lineage as antibody mediated engagement of TLR10 on primary human 
B cells suppresses B cell proliferation, cytokine production, and signal 
transduction (Hess et al., 2017).  
CLRs are expressed on the surface of dendritic cells (DCs) and are able to 
recognise bacterial, fungal and viral PAMPs and DAMPs (Yamasaki et al., 2008). 
Intracellular PAMPs are mainly recognised due to NLRs, even if NLRs can also 
recognise DAMPs (Fritz et al., 2006). Interaction with NLRs leads to the 
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formation of inflammasomes, which activates caspase 1 and produces 
interleukin-1β (IL-1β), promoting and amplifying the immune response (Pétrilli 
et al., 2007). Moreover, NLRs are also able to produce pyroptosis, an 
inflammatory form of cell death, due to the activation of caspase 1 (Fitzgerald, 
2010). RLRs are the cognate receptors for RNA viruses (Loo et al., 2008) while 
RAGE acts as a receptor for the products of nonenzymatic glycation and 
oxidation of proteins/ lipids (AGEs) (Wautier et al., 2001), HMGB1 (Rouhiainen et 
al., 2004) and S100 proteins (Hofmann et al., 1999). 
1.1.1.1 Cells of the innate immune system 
Every single cellular component from the blood is derived from a common 
progenitor haematopoietic stem cell (HSC) in the bone marrow. These HSCs are 
multipotent as they can engender all types of blood cells (Orkin, 2000). 
Multipotent cells, such as stem cells, have the ability of both self-renew and 
differentiate; HSCs can differentiate into two lineages of lower potential, the 
common lymphoid progenitor (CLP) and the common myeloid progenitor (CMP). 
CLPs give rise to lymphocytes and natural killer (NK) cells, while CMPs 
differentiate into granulocyte/ monocyte precursors (GMPs) and megakaryocyte/ 
erythrocyte precursors (MEPs). GMP is the precursor of granulocytes, 
macrophages, mast cells and myeloid DCs, while MEPs differentiate into 
platelets and erythrocytes. Granulocytes can further differentiate into 
neutrophils, eosinophils, basophils and monocytes. Figure 1-1 provides an 
overview of this system.  
Cells of the immune system recognise pathogens or results of trauma, become 
activated and react against them. These cells are activated in a precisely 
regulated order, starting with tissue resident macrophages, mast cells, 
neutrophils, monocytes and recruited macrophages and later on, with cells of 
the adaptive immune system, T helper cells, cytotoxic T cells and B cells (Metz 
and Maurer, 2009). The activation of these cells leads to a fast recruitment of 
immune cells to sites of trauma due to the secretion of cytokines and 
chemokines. Further information about these molecules will be provided in 
Section 1.2.  
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Figure 1-1. Schematic representation of the immune cell development and differentiation 
processes.  
HSCs can differentiate into common myeloid progenitors (CMP) or common lymphoid progenitors 
(CLP). CMPs can then further differentiate into megakaryocyte/ erythrocyte precursors (MEP) or 
granulocyte/ monocyte precursor (GMP). MEPs can further differentiate into megakaryocytes and 
erythroblasts while GMPs can further differentiate into neutrophils, basophils, mast cells, 
eosinophils and monocytes. Monocytes can engender myeloid DCs and macrophages. CLPs can 
differentiate into natural killer (NK) cells, B cell progenitors and T cell progenitors. B cell progenitors 
can further differentiate into plasma and memory cells while T cell progenitor can give rise to T 
helper and T cytotoxic cells (Orkin, 2000). 
 
1.1.1.1.1 Mast cells 
 
Mast cells (MCs) are large, long-lived cells that are developed from CD34+ 
pluripotent progenitor cells in the bone marrow and circulate in blood and 
lymphatic vessels in an immature state. These cells migrate to connective 
tissues and perivascular sites, where they undergo maturation upon interaction 
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with stem cell factor (SCF) and IL-3 (Haig et al., 1994). Mature MCs are usually 
found in tissues interfacing external environments and near to blood vessels to 
behave as a first line defence. Morphologically, the main feature of these cells is 
the presence of cytoplasmic granules; MCs are not a homogenous population and 
their heterogeneity is based on their granule content.  
MCs can be activated via immunoglobulin (Ig) E-dependent (Rivera et al., 2008) 
and IgE-independent manners (Gilfillan and Rivera, 2009), leading to the 
secretion of their cytoplasmic granule contents. Allergens interact with high 
affinity IgE receptors on the surface of MCs, leading to the subsequent cross 
linking (Rivera et al., 2008). On the other hand, MCs contain other receptors on 
their surfaces able to recognise and become activated by cytokines, 
neurotransmitters and anaphylatoxins (Gilfillan and Rivera, 2009). Among the 
mediators secreted by MCs, histamine, serotonin and proteases are found at high 
concentrations. MCs also secrete newly synthesised mediators, such as tumour 
necrosis factor (TNF) (Olszewski et al., 2007), leukotrienes, prostaglandins and 
platelet-activating factors (Boyce, 2007). Moreover, MCs are also able to secrete 
cytokines and chemokines, transmit microRNAs and secrete exosomes (Skokos et 
al., 2003). Altogether, MCs are involved in the regulation of permeability, 
secretion, peristalsis, nociception, angiogenesis and innate and adaptive 
immunity (Lee and Lee, 2016). MCs deregulation is involved in allergic responses 
(Stelekati et al., 2007), multiple sclerosis (Krüger, 2001), bowel disease (Lee and 
Lee, 2016), arthritis (Nigrovic and Lee, 2005) and cancer (Ribatti, 2016). 
1.1.1.1.2 Neutrophils 
 
Neutrophils are short-lived phagocytes that account for 40-70% of white blood 
cells in mammals. Neutrophils have a multi-lobed nucleus, making their 
identification very easy by histological staining. Neutrophils are essential in 
innate immunity as they are the first leukocytes to be recruited to sites of 
trauma upon inflammation (Nourshargh and Alon, 2014); their role is so pivotal 
that individuals with congenital neutrophils deficiencies can die due to 
opportunistic infections (Keszei and Westerberg, 2014).  
The granulocyte-colony stimulating factor (G-CSF)/ IL-17 axis is involved in the 
homeostatic regulation of neutrophil production, mobilization and clearance, 
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which is modulated by the circadian rhythm, the presence of microbiota and 
lipid mediators (Tan and Weninger, 2017). Under the influence of signals such as 
CXCL8, CXCL2, or vascular endothelial growth factor (VEGF), neutrophils are 
recruited to tissues (Pignatti et al., 2005). However, to arrive at the specific 
tissue, circulating neutrophils must undergo a multi-step process known as the 
“leukocyte adhesion cascade”, where neutrophils need to extravasate the 
vascular endothelium and breach the basement membrane to arrive to the 
interstitial space. Once at the site of injury, neutrophils have several 
mechanisms to attack microorganisms. First, neutrophils are able to engulf 
microorganisms by a mechanism called phagocytosis leading to their degradation 
in lysosomes (Lee et al., 2003, Faurschou and Borregaard, 2003). Neutrophils 
secrete neutrophil extracellular DNA traps (NETs) that immobilise and target 
pathogens (Brinkmann et al., 2004). Lastly, neutrophils secrete cytokines and 
chemokines, and in this way, induce the recruitment of immune cells to amplify 
the inflammatory response.  
Neutrophils have also been described to be involved in angiogenesis (Aldabbous 
et al., 2016), inflammation resolution and wound healing (Hahn et al., 2016). In 
mice, CXCL2 attracts proinflammatory neutrophils, which express CD11b and GR-
1 and have a low expression of CXCR4, while proangiogenic neutrophils are 
recruited by VEGFa and secrete matrix metallopeptidase 9 (MMP9) 
(Christoffersson et al., 2012). In humans, neutrophils capable of suppressing T 
cells are CD16BRIGHT CD62LDIM (Pillay et al., 2012). Moreover, acute systemic 
inflammation lead to the discovery of two distinctive neutrophil populations with 
opposing roles, CD16DIM CD62LBRIGHT and CD16BRIGHT CD62LBRIGHT (Kamp et al., 
2012). These findings have made immunologists consider the existence of two 
different neutrophil populations that could be recruited independently of one 
another.  
Due to the inflammatory functions of neutrophils, over activation of neutrophils 
leads to extensive tissue damage in pathologies as chronic obstructive pulmonary 
disease (Hoenderdos and Condliffe, 2013), rheumatoid arthritis (Wright et al., 
2014) and cancer (Spicer et al., 2012) among others.  
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1.1.1.1.3 Monocytes 
 
Monocytes are circulating white blood cells that account for 2% and 8% of 
nucleated cells in the blood in mice and humans, respectively. Monocytes 
develop from the granulocyte/ macrophage progenitor in the bone marrow and 
circulate in blood; CCR2 is required for monocytes to leave the bone marrow and 
reach the bloodstream (Tsou et al., 2007). There are three main subsets of 
monocytes in humans, which are termed as classical, intermediate and non-
classical monocytes. CD14 is a marker of human monocytes and each group 
expresses it at different levels. Classical monocytes are CD14HIGH CD16-, have 
proinflammatory roles and give rise to inflammatory macrophages in tissues 
(Yona et al., 2013). Classical monocytes produce, and secrete, reactive oxygen 
species (ROS), TNF-α and IL-1β. Moreover, they express CCR2, which allows them 
to leave the bone marrow and mediate increased monocyte attraction during 
inflammation (Zawada et al., 2012). Early in development, classical monocytes 
can differentiate into intermediate monocytes, which can then differentiate into 
non-classical monocytes. The non-classical monocytes are CD14LOW CD16HIGH, 
have an anti-inflammatory role and give rise to profibrotic and anti-
inflammatory macrophages (Yona et al., 2013). The so called intermediate 
monocyte population is CD14HIGH CD16LOW and gives rise to monocyte derived DCs 
(Ziegler-Heitbrock et al., 2010). Non-classical monocytes express low levels of 
CCR2 but high levels of CX3CR1, which allows them to patrol vessels wall and 
invade by interaction with CX3CL1 (Yang et al., 2014).  
It is important to mention that there is a lack of homology between mice and 
humans regarding phenotypic markers in monocytes and monocyte-derived cells, 
which hindered the identification of homologous populations between species. 
Mice possess two subsets of monocytes according to their expression of Ly6C, 
CCR2 and CX3CR1. The use of transcriptomics, metabolomics, proteomics, and 
epigenomics has enabled the identification of homology between Ly6CHIGH 
CCR2HIGH CX3CR1LOW and CD14++ CD16- and between Ly6CLOW CCR2LOW CX3CR1HIGH 
and CD14+ CD16+ monocytes (Reynolds and Haniffa, 2015). The Ly6CLOW CCR2LOW 
CX3CR1HIGH, in mice, and CD14+ CD16+ monocytes, in human, have a patrolling 
role along the vascular endothelium where they are involved in tissue repair. On 
the other hand, Ly6CHIGH and CD14++ monocytes perform pro-inflammatory 
functions (Reynolds and Haniffa, 2015, Yang et al., 2014). These populations do 
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not have a perfect overlap with the human monocyte subsets even if the roles of 
monocytes observed in the immune response look similar (60). 
1.1.1.1.4 Macrophages 
 
Macrophages are a subset of phagocytic cells involved in the engulfment and 
digestion of cellular debris, microorganisms, cancer cells and anything unhealthy 
for the host. Macrophages were thought to emerge only from circulating 
monocytes, which had been recruited to tissue. However, Schulz et al. showed 
that macrophages could emerge independently of HSCs as they found yolk sac-
derived precursors during embryonic development (Schulz et al., 2012). 
Moreover, some tissue macrophages solely emerge from embryonic precursors 
(Van Gassen et al., 2015). Macrophages can be found in every tissue of the body; 
however, their nomenclature is based upon their tissue of origin, as an example, 
osteoclasts in bone, Kupffer cells in the liver and microglia in the brain. Tissue 
of residency comes together with functional specialization e.g. bone resorption 
by osteoclasts, breakdown of red blood cells by Kupffer cells or neural network 
maintenance and development by microglia (Reynolds and Haniffa, 2015). As 
previously mentioned, there is a lack of homology between mice and humans 
regarding phenotypic markers in the mononuclear phagocyte system. Murine 
macrophages are characterised by the expression of CD11b, CD68, CSF1R and 
F4/80 (Wynn et al., 2013), phenotypic markers shared by human macrophages 
with the exception of F4/ 80, which is expressed on human eosinophils (Hamann 
et al., 2007). To my knowledge, few comparative analyses between murine and 
human macrophages have been performed and cross species comparisons in 
health and disease have not been rigorous. There are inter-species variations in 
response to inflammation between human and mouse in vitro derived 
macrophages; upon LPS-mediated stimulation murine macrophages upregulate 
iNOS while human macrophages induce the transcription of CCL20, CXCL13, IL-
7R, P2RX7 and STAT4 (Schroder et al., 2012). 
Macrophages are not only phagocytes, but also release effector molecules 
involved in the recruitment of other immune cells upon damage. Macrophages 
can recognise both DAMPs and PAMPs, which makes them one of the first lines of 
response to damage. According to their functional phenotype, macrophages can 
be subdivided into three populations: classically activated or proinflammatory 
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M1 macrophages, alternatively activated macrophages and regulatory or anti-
inflammatory macrophages. Alternatively activated macrophages and anti-
inflammatory macrophages are usually referred as M2 macrophages. M1 
macrophages are induced by interferon (IFN)-γ and are involved in T helper (Th) 
1-related immune responses, while anti-inflammatory macrophages are 
activated by TLR agonists and are involved in Th2-related immune responses. 
Alternatively induced macrophages are activated by IL-4, IL-10 and IL-13 and are 
involved in the resolution of inflammation and in development and tissue repair 
(Van Gassen et al., 2015). Due to the ability of macrophages to secrete both pro-
and anti-inflammatory molecules and attract other immune cells, they are 
involved in the development of cancer (Olefsky and Glass, 2010, Fuentes-
Duculan et al., 2010, De Palma and Lewis, 2011). Tumour cells secrete several 
chemoattractants, including CCL2, CCL3, CCL4, CCL5, CCL8 and VEGF, among 
others. The release of these chemoattractants leads to the migration of 
monocytes through the circulatory system towards the tumour, and once they 
leave the circulatory system to infiltrate the tissue, monocytes differentiate into 
macrophages. Pro-inflammatory macrophages can exert anti-tumour responses 
via the secretion of inflammatory cytokines like IFN-γ, IL-12 or TNF-α. However, 
secretion of cytokines and growth factors, including IL-4, macrophage colony-
stimulating factor and granulocyte-macrophage colony-stimulating factor by 
tumour cells promotes the differentiation of monocytes towards an anti-
inflammatory phenotype, where macrophages secrete TGF-β, IL-10, VEGF, IL-17 
and IL-23, dampening the anti-tumour response and promoting angiogenesis, 
tumour growth and metastasis (Noy and Pollard, 2014, Dandekar et al., 2011).   
1.1.1.1.5 DCs 
 
DCs are mononuclear professional phagocytes that emerge from haematopoietic 
bone marrow progenitor cells. However, unlike neutrophils, they do not fully 
digest the phagocytosed material, they process it into peptide fragments, and 
present self and nonself antigens to CD4+ and CD8+ T cells using Major 
Histocompatibility Complex (MHC) Class I and MHC Class II molecules 
respectively. In this way, DCs can activate the adaptive immune response; 
therefore, they connect the innate and adaptive immune responses (Steinman, 
2006).  
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DCs are found in an immature state circulating in the blood. These cells express 
low levels of MHC Class II molecules but do express pattern recognition receptors 
to recognise PAMPs and DAMPs and CD40L. Upon interaction with pathogens, 
PPRs stimulate DC maturation, and PPRs and CD40 signalling increase the 
expression of MHC Class II and co-stimulatory molecules CD80/ CD86 and CCR7 
expression (Caux et al., 1994, Sozzani et al., 1998). Matured DCs are then able 
to migrate through the blood stream to the spleen, or through the lymphatic 
vessels to the lymph nodes, were they interact with T cells in T zones. Upon 
interaction with T cells, DCs can induce the activation of both naïve and memory 
T cells or they can also induce T-cell tolerance, depending on the expression of 
co-stimulatory molecules on their surface (Heath and Carbone, 2001). 
1.1.1.1.6 Eosinophils 
 
Eosinophils are a subset of granulocytes that emerge from GMPs in the bone 
marrow and leave to the periphery, where they are found in several different 
tissues including the thymus, spleen, ovary, uterus, mammary glands and lower 
gastrointestinal tract. 
Eosinophils interact with PAMPs, DAMPs, cytokines and chemokines via the 
expression of their cognate receptors, which leads to their activation and 
recruitment to sites of inflammation (Kita, 2011). Once activated, eosinophils 
undergo non-cytotoxic degranulation to release chemical mediators. Human 
eosinophil granules contain major basic protein (MBP), MBP2, eosinophil cationic 
protein (ECP), eosinophil peroxidase (EPO), eosinophil derived neurotoxin (EDN), 
and β-glucuronidase, which are proinflammatory molecules (Kita, 2011). 
Moreover, eosinophils also secrete immunomodulatory enzymes (indoleamine 2, 
3 dioxygenase [IDO]), lipids (leukotriene and prostaglandin), cytokines (IL-2, IL-
4, IL-5, IL-10, IL-12, IL-13, IL-16 and IL-18) and chemokines (CCL3, CCL5 and 
CL11). The release of these mediators upregulates the vascular adhesion system 
as well as increases the vascular permeability, allowing the recruitment of 
immune cells. This mechanism is so powerful that it can be harmful for the host 
if not properly regulated; eosinophil mediated inflammation is associated with 
allergic inflammation. Eosinophils are most popularly known for their roles in 
allergic and parasitic infections but they also play roles in post-natal mammary 
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gland development (Gouon-Evans et al., 2000, Shi, 2004, Andersson et al., 2014, 
Tani et al., 2014).  
1.1.1.1.7 Basophils 
 
Basophils are large circulating white blood cells that account for less than 1% of 
circulating white blood cells. Basophils are developed from the granulocyte/ 
macrophage progenitors in the bone marrow and circulate in blood.  
Basophils contain histamine in their granules and express the high affinity IgE 
receptor FcεRIα. Basophils can be activated by several signals including 
cytokines, Igs, proteases and antigens; even if the most studied mechanism is 
the IgE mediated one (Siracusa et al., 2011). Upon stimulation, basophils secrete 
histamine, cytokines (IL-3, IL-4, IL-6, IL-9 and IL-13 among others) and 
chemokines (CCL3 and CCL5), promoting vascular permeability and increasing 
the recruitment of immune cells. Moreover, basophils are also able to act as 
antigen presenting cells for small molecules (haptens) (Otsuka et al., 2013).  
1.1.1.1.8 NK cells 
 
NK cells are lymphocytes that were originally thought to emerge from a common 
lymphoid progenitor in the bone marrow. Nowadays, it is known that NK cells 
can differentiate and mature not only in the bone marrow, but also in the 
thymus, lymph nodes, liver, spleen, tonsils, uterus and mucosa associated 
lymphoid tissue, where they then enter into the circulation (Cooper et al., 
2009). NK cells emerge from a lymphoid progenitor but they differ from T and B 
cells due to their inability to produce a somatic rearrangement of their surface 
Ig and the lack of T cell receptors.   
NK cells are an essential defence against virus and emerging tumours. NK cells 
are highly cytotoxic and can mediate their activity via tightly regulated 
mechanisms. NK cells express in their surface Killer-cell Ig-like receptors (KIRs), 
which are able to recognise MHC Class I molecules. This interaction avoids the 
activation of NK cells, promoting self-tolerance. A common survival mechanism 
shared between virally infected and tumour cells, is based on the 
downregulation of MHC Class I molecules to avoid the recognition of nonself-
antigens by the immune system. However, the absence of MHC Class I molecules 
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makes them a good target for NK cells; in the absence of MHC Class I, NK cells 
become activated and thus, cytotoxic (Raulet, 1992).  
Once activated, NK cells can be cytotoxic in several ways. First, NK cells induce 
apoptosis by secreting cytoplasmic granules with perforins and granzymes. 
Perforins promote the disruption of the membrane generating a pore by which 
granzymes are able to enter into the targeted cell promoting apoptosis (Warren 
and Smyth, 1999). NK cells take part in antibody-dependent cell-mediated 
cytotoxicity as they express on their surface FcϒRIII (CD16) receptors. Infected 
cells become opsonised with antibodies, which can be recognised by FcϒRIII 
receptors leading to NK cell activation and the subsequent release of granules 
(Smyth et al., 2002). Moreover, NK cells are able to induce caspase-dependent 
apoptosis in cells expressing death receptors as Fas/ CD95 (Caligiuri, 2008). NK 
cells can act quickly as they can become activated by cytokines (IL-2, IL-12, IL-
15, IL-18 and CCL5) and interferons, allowing them to contain viral infections 
while the adaptive immune system generates a more specific response (Smyth et 
al., 2002). 
1.1.1.2 Humoral immunity 
The immune response is not only orchestrated by cells, but also by 
macromolecules present in extracellular fluids such as complement proteins and 
secreted antibodies.  
The complement system is a complex network of proteins involved in the 
clearance of damaged cells and defence against invading microorganisms. These 
proteins are synthesised in the liver and secreted into the blood where they 
circulate in an inactive form. Activation of these molecules can take place via 
three biochemical pathways; the classical, the alternative and the lectin 
pathway (Figure 1-2).  
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Figure 1-2. Schematic representation of the complement cascade.  
There are three pathways of complement activation: the classical pathway, which is activated by 
the binding of antibodies to the C1q component of the complement system; the lectin pathway, 
which is triggered by the interaction of microbial carbohydrates bound to surface molecules on 
bacteria with the C1q component of the complement system; and the alternative pathway, which is 
constitutively active.  
 
The classical pathway becomes activated via antigen-antibody immune 
complexes while the lectin pathway becoming activated by microbial 
carbohydrates bound to surface molecules on bacteria. The alternative pathway 
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does not need to become activated as it is constitutively active; however, the 
activation of the other pathways leads to the amplification of its activity (Reddy 
et al., 2017). Activation of these pathways produces the protease-mediated 
cleavage of C2 and C4 proteins leading to the formation of C3 convertase 
(C4bC2a). C3 convertase produces the cleavage of C3 to give rise to C3a, a 
potent anaphylatoxin, and C3b, which binds to the C3 convertase complex to 
generate C5 convertase. This converts C5 into C5a, another anaphylatoxin, and 
C5b, which makes a complex with C6, C7, C8 and C9 proteins. This complex, 
known as the membrane attack complex, promotes lysis of microbes. However, 
the complement pathway is not only involved in membrane attack, but also in 
phagocytosis and inflammation. C3b interacts with the surface of the pathogens 
promoting phagocytosis by opsonisation. The release of the anaphylatoxins leads 
to macrophage and neutrophil attraction and mast cell degranulation, 
generating an inflammatory environment. 
1.1.2 The adaptive immune response 
The innate immune system protects the host against pathogens, but it lacks 
immunological memory and what is more important, it is not antigen specific. 
The adaptive immune response is restricted to vertebrates and cartilaginous fish 
and it requires between 4-7 days before it begins while it also generates 
immunological memory towards specific antigens. 
The adaptive immune system relies on somatic hypermutation and V(D)J 
recombination, a site-specific recombination process in the Ig and T cell 
receptor (TCR) genes, to generate a huge variety of antigen receptors. The 
heavy chain of the Ig and the β chain of the TCR have a variable (V), a diversity 
(D) and a joining segment (J) as well as a constant domain (C); while the light 
chain of the Ig and the α chain of the TCR have the V and J segments as well as 
the constant domain. As examples, the locus for the β chain is formed by 42 
gene segments for the V region, 2 for D, 12 for J and 2 for C while the locus for 
the α chain includes 43 gene segments for the V region and 58 J segments 
(Turner et al., 2006). Each of the V, D, J and C segments are flanked by 
conserved recombination signal sequences. In the heavy chain of the Ig and the β 
chain of the TCR, V(D)J recombination initiates by the introduction of double 
stranded DNA breaks between one D and one J segment, followed by the 
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rearrangement of the D and J segments and the removal of the DNA between 
those two segments (Figure 1-3). The DJ recombination is followed by the 
introduction of double stranded DNA breaks in the V segments, leading to the 
VDJ rearrangement; this is the first step in the recombination of the light chain 
of the Ig and the α chain of the TCR. In this manner, the different combinations 
of the V, D and J segments by the different chains of the Ig and the TCR leads to 
the generation of thousands of different receptors from a single DNA molecule. 
These rearrangements produce an irreversible change in the DNA that is passed 
down to the progeny. Upon exposure to the proper antigen, clonal expansion of 
the specific antigen receptor-containing cells takes place. This mechanism 
generates immunological memory, promoting a more efficient clearance of the 
pathogen in subsequent encounters.  
 
Figure 1-3. Schematic representation of V(D)J recombination.  
V(D)J recombination initiates by the introduction of double stranded DNA breaks between one D 
and one J segment, followed by the rearrangement of the D and J segments and the removal of the 
DNA between those two segments. DJ recombination is followed by the introduction of double 
stranded DNA breaks around one V segment, leading to the VDJ rearrangement.  
 
1.1.2.1 T cells 
T cells are a type of white blood cell that emerge from the CLP in the bone 
marrow. They are known as T cells because they leave the bone marrow in order 
to reach the thymus, where they become mature. Immature T cells (thymocytes) 
undergo a selection where they become gradually reprogrammed into helper 
(CD4+), cytotoxic (CD8+) or regulatory T (Treg) cells.  
Within the thymic cortex, thymocytes lack the expression of both CD4 and CD8 
and they undergo TCR gene rearrangement. Upon the expression of the β chain 
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of TCR, immature T cells simultaneously express CD4 and CD8, becoming double 
positive cells, which is the largest population of cells within the thymus. At this 
stage of maturation, the double positive cells undergo a process of positive 
selection where they need to prove the functionality of their TCR by interacting 
with self-peptides presented by MHC molecules with intermediate affinity. 
Double positive cells unable to bind MHC Class I or MHC Class II molecules 
undergo apoptosis while the rest persist by survival signals. In this manner, 
positive selection enables the differentiation of double positive cells towards 
single positive cells; cells that recognise MHC Class I will differentiate towards 
CD4- CD8+ cells, while cells that interact with MHC Class II differentiate towards 
CD4+ CD8- cells. Single positive cells are now able to enter the medulla of the 
thymus where they undergo a negative selection. Immature T cells are exposed 
to the presence of self-antigens and those cells binding to MHC Class I or MHC 
Class II with high affinity are targeted for apoptosis to avoid the proliferation of 
autoreactive T cells. However, a small percentage will survive negative selection 
and differentiate towards regulatory T cells. Cells that do not have a high 
affinity towards self-peptides are now able to mature and become naïve T cells, 
leave the thymus and migrate towards secondary lymphoid organs, where they 
will be able to interact with their cognate antigen and differentiate into effector 
cells (Germain, 2002), (Caramalho et al., 2015).  
T helper cells (TH cells) are essential in the adaptive immune system as they 
regulate the antibody class switching in B cells, activation and growth of 
cytotoxic T cells, phagocytosis by macrophages and even suppression of the 
immune response. Naïve CD4+ cells become activated upon exposure to peptide 
antigens by MHC Class II molecules expressed on the surface of antigen 
presenting cells. Th cells can differentiate into different subsets, Th1, Th2, Th9, 
Th17, T follicular helper (Tfh) and inducible Treg, according to the signals they 
receive from the surrounding environment and the type of immune response that 
is required in each specific situation (Abbas et al., 1996). Cytotoxic T cells, also 
known as T killer cells, are involved in the destruction of cancer cells, virus 
infected cells and even in transplant rejection, as well as in maintenance of 
immune tolerance. Unlike their CD4+ counterparts, they recognise antigens 
presented by MHC Class I molecules, which leads to their activation and the 
subsequent release of perforins, granzymes and interferons, leading to the 
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target cell’s death (Andersen et al., 2006). Regulatory T cells, also known as 
suppressor T cells, are essential for self-immunological tolerance and 
autoimmune diseases prevention. Moreover, they have immunosuppressive roles 
as they downregulate T cell mediated immune responses as well as suppress 
autoreactive T cells (Vignali et al., 2008). Tregs express on their surface the CD4 
and CD25 biomarkers, are FOXP3+, and have been postulated to emerge from the 
same progenitor as naïve CD4+ T cells (Curiel, 2007).  
Upon activation of both CD4+ and CD8+ lymphocytes, clonal expansion takes 
place and a small proportion of cells will become life-long memory cells, in 
order to produce a fast response after subsequent infections (Farber et al., 
2014). 
1.1.2.2 B cells 
B cells are a type of white blood cell that emerge from the CLP in the bone 
marrow. B cells express B cell receptors (BCRs) on their surface, which have to 
undergo V(D)J recombination to enable the interaction with specific antigens 
(Brack et al., 1978). Each pre-B cell has the potential to express different BCR 
chains, however, each B cell can only express a single type of BCR, which is 
achieved by allelic exclusion, where the activation of one allele inhibits the 
activation of the rest. Developing B cells in the bone marrow undergo a selection 
process to ensure the capability of these BCRs to interact with antigens and at 
the same time, to avoid interaction with self-antigens (LeBien and Tedder, 
2008). After this selection, immature B cells leave the bone marrow and go to 
the spleen, where they differentiate into naïve B cells, that can be follicular 
(FO) or marginal zone (MZ) B cells according to the signals they receive.  
Naïve B cells are able to circulate in blood and lymph, as well as to go to 
secondary lymphoid organs such as the spleen, lymph nodes, tonsils and Peyer's 
patches. B cell activation begins when they interact with specific antigen 
presented by antigen presenting cells in the lymph nodes. Activated B cells are 
now able to migrate to the border between the T cell zone and the follicle 
within the lymph node to interact with the proper antigen-specific helper T cell 
(Okada et al., 2005). Upon interaction with the cognate T cell, clonal expansion 
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of the B cell takes place, giving rise to short-lived plasma cells, long-lived 
plasma cells or memory cells (Noelle and Snow, 1990).  
Plasma cells, also called effector cells, are antibody-secreting white blood cells. 
It is important to consider that there are five different types of antibodies (IgM, 
IgG, IgA, IgE and IgE), but each plasma cell produces only one type of antibody, 
as once differentiated, plasma cells are no longer able to switch antibody 
classes. The production of antibody secreting B cells is a two-step process. In the 
first step, immediate protection is provided by the activation of B cells by an 
antigen receptor-dependent signal, which promotes differentiation towards 
short-lived plasma cells that secrete antibodies. This is a fast response but the 
affinity towards the antigen is moderate. In the second step, activated B cells 
are able to re-enter the B cell follicle and proliferate to generate a germinal 
centre with the help of follicular helper T cells. Germinal centres promote 
proliferation and somatic hypermutation to generate high-affinity antigen 
receptors. Affinity maturation enables the proliferation of B cells with high 
affinity towards antigen receptors and in this way, those highly specific B cells 
exit the germinal centre and differentiate into memory B cells or long-lived 
plasma cells that secrete antibodies with the highest affinity for the antigen 
(Nutt et al., 2015). The secreted antibodies will be circulating in the 
bloodstream as well as permeating other fluids to find cognate foreign antigens 
and lead to the destruction of the pathogen producing them. Antibody-antigen 
binding can lead to neutralisation, complement activation or phagocytosis by 
immune cells expressing Fc receptors, which interact with the Fc region of 
antibodies.  
Memory B cells are dormant B cells that circulate through the blood to protect 
the host against subsequent infections. These cells have the same B cell 
receptor as the cells that were activated in the first infection and are 
programmed to rapidly differentiate into antibody secreting cells; for this 
reason, they promote a faster and stronger antibody response upon interaction 
with the antigen than that which gave rise to the activation of their parent B 
cell (Kurosaki et al., 2015). 
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1.2 Chemokines 
As already described, the immune system is a complex network of cells that 
need to orchestrate their interactions to generate a proper defence response. 
Upon injury, cells of the immune system are induced to move to sites of 
inflammation. Chemically induced cell movement can be classified in terms of 
direction of the movement. In the case of chemokinesis, the induced movement 
is random and undirected while in chemotaxis, a directed movement towards 
the chemical takes place. In order to communicate, the immune system uses 
chemokines, small heparin-binding proteins that induce chemotaxis of 
circulating immune cells (Charo and Ransohoff, 2006).  
The term chemokines derives from the combination of the words chemotactic 
and cytokines. Chemokines are a family of small (~8-14 KDa) homologous 
proteins involved in the regulation of cell migration under both inflammatory 
and physiological conditions that are highly conserved throughout vertebrate 
evolution (Zlotnik and Yoshie, 2000b). Since the identification of the first 
chemokines in the late 1980s, many chemokines have been identified due to the 
development of expressed sequence tag databases and bioinformatics, leading to 
a confusing nomenclature. For this reason, a standardised nomenclature was 
established based on the structure of the molecules (Zlotnik and Yoshie, 2000b). 
1.2.1 Structural classification 
Chemokines were classified taking into account their amino acid sequence, more 
specifically, the presence of a conserved tetra cysteine motif expressed at the 
amino terminus of the peptide, which is considered to be chemokines’ molecular 
signature (Baggiolini et al., 1997). The relative position of the N-terminal first 
two consensus cysteine residues provides the basis for the classification of 
chemokines (Rot and von Andrian, 2004) (Table 1-1). This motif is of high 
relevance as the cysteines included on it form two covalent disulphide bonds 
pairing the first with the third and the second with the fourth cysteines (Zlotnik 
and Yoshie, 2012); these bonds are important for achieving the tertiary structure 
of the protein and therefore, for forming the functional protein. 
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Table 1-1. Chemokines classification.  
Chemokine classification according to the relative position of the N-terminal first two consensus 
cysteine residues and the components of each subfamily. 
Chemokine subfamilies Cysteine residues configuration Components 
   CC CC C C CCL1-CCL28 
   CXC CXC C C CXCL1-CXCL17 
   XC XC 
 
C XCL1-XCL2 
   CX3C CXXXC C C CX3CL1 
 
 
Figure 1-4. Highly conserved molecular signature of the chemokine subfamilies. 
Chemokines are classified into 4 families according to the cysteine residues close to the amino 
terminus of the protein and the disulphide bonds originated due to these residues. XCL1 and XCL2 
have just one cysteine residue near the amino terminus that enables the generation of a disulphide 
bond (A), while CC chemokines have two consecutive cysteine residues in the amino terminal (B) 
and CXC chemokines have two cysteine residues separated by only one non-conserved amino 
acid residue “X” (C). Fraktalkine, the only known member of the CX3C chemokine family, has two 
cysteine residues separated by three non-conserved amino acid residues “X” (D). The presence of 
two cysteine residues in the amino terminal of the protein enables the generation of two disulphide 
bonds. CX3CL1 and CXCL16 contain a mucin-like domain linked to a hydrophobic, and therefore 
transmembrane, domain and an intracellular tail that makes them be expressed as cell surface 
bound chemokines. However, these chemokines can be found in soluble forms too. [Image 
modified from Panda et al. (Panda et al., 2016)]. 
 
1.2.1.1 CC chemokines 
CC chemokines, also known as the β chemokines, are the first and largest 
subfamily and are so named because the N-terminal first two consensus cysteine 
residues are adjacent to each other. There are currently 28 chemokines in this 
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family (CCL1-CCL28), which were numbered according to the order in which they 
were discovered. CC chemokines tend to attract mononuclear cells, such as 
monocytes, lymphocytes and some granulocytes to sites of inflammation (Alam 
et al., 1992a). Many of the genes for the CC chemokines are clustered on human 
chromosome 17 (Weber et al., 1996) or on murine chromosome 11 (Zlotnik et 
al., 2006).  
The best characterised CC chemokines are monocyte chemoattractant protein 1 
(MCP1) and macrophage inflammatory protein 1 α (MIP1α), called CCL2 and CCL3 
respectively according to the systemic nomenclature. CCL2 is the most potent 
histamine releasing factor for basophils, while CCL3 has modest histamine 
releasing activity (Alam et al., 1992b, Alam et al., 1992a). Both chemokines are 
potent agonists for monocytes (Wolpe and Cerami, 1989) and basophils (Alam et 
al., 1992a) during the acute immune response. CCL2 is a potent agonist for 
neutrophils (Wolpe and Cerami, 1989) and both CD4+ and CD8+ T cells (Taub et 
al., 1993). RANTES, currently known as CCL5, is chemotactic for monocytes 
(Alam et al., 1994), CD4+ T cells (Schall et al., 1990) and eosinophils (Kameyoshi 
et al., 1992). Some chemokines such as CCL2, CCL3 and CCL5 are produced by 
several cells in large amounts, while others are very specifically produced by 
particular tissues or cell types, such as CCL25, CCL27 and CCL28 which are 
respectively specific for thymus and intestine, skin keratinocytes and certain 
mucosal epithelial cells.  
1.2.1.2 CXC chemokines 
CXC chemokines, also known as the α chemokines, are the second major 
subfamily of chemokines and are so named because the N-terminal first two 
consensus cysteine residues are adjacent to each other with the addition of a 
single amino acid residue interposed between them. There are currently 
seventeen chemokines in this family (CXCL1-CXCL17). CXC chemokines can be 
further categorised into Glu-Leu-Arg (ELR)+ and ELR− CXC chemokines, according 
to the presence or absence of the motif ELR at the NH2 terminus. CXCL1, CXCL2, 
CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8 belong to the ELR+ subfamily (Murphy et 
al., 2000). Many of the genes for the CXC chemokines are clustered on human 
chromosome 4 (Weber et al., 1996) or on murine chromosome 5 (Zlotnik et al., 
2006).  
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When trying to address the function of these chemokines, it was observed that 
some CXC chemokines, such as the platelet factor 4 (CXCL4), were inhibitors of 
angiogenesis (Maione et al., 1990) while others, such as interleukin-8 (IL-8 or 
CXCL8), have potent angiogenic properties (Koch et al., 1992). Even if these two 
chemokines have a significant homology, their roles are completely opposite. 
When comparing their sequences, the main difference was the presence of an N-
terminal tripeptide motif glutamate (E)-leucine (L)-arginine (R) called ELR motif 
nearby to the CXC motif. CXC chemokines with the ELR motif promote 
angiogenesis upon interaction with endothelial cells, and the addition of this 
motif to the N-terminal domain of CXCL4 resulted into a molecule with potent 
angiogenic properties (Hébert et al., 1991, Clark-Lewis et al., 1993). For this 
reason, CXC chemokines are functionally divided based on the presence of the 
ELR motif nearby to the CXC motif; ELR positive CXC chemokines promote 
angiogenesis (Strieter et al., 2005), cell proliferation (Mockenhaupt et al., 2003) 
and survival during development (Li et al., 2003), while ELR negative CXC 
chemokines tend are more angiostatic.  
CXCL8 is the archetype of the CXC chemokines and is the most potent attractor 
of neutrophils to sites of trauma in humans. Moreover, CXCL8 enhances cell 
survival and proliferation as well as angiogenesis. CXCL8 precursors are kept 
within endothelial cells in Weibel Palace bodies to be released after injury and 
recruit neutrophils to sites of acute inflammation. Due to the differences in 
pathogen driven evolutionary experiences between mouse and human, some 
inflammatory chemokines are not present in both species (Zlotnik and Yoshie, 
2000b). Mice lack CXCL8, but they have CXCL1 and CXCL2, both neutrophils 
chemoattractants (Hol et al., 2010). 
1.2.1.3 XC chemokines 
XC chemokines, also known as the γ chemokines, are so named because they 
lack one of the first two consensus cysteine residues in the N-terminal region 
and retain the fourth one. There are just two chemokines in this subfamily XCL1 
(lymphotactin α) and XCL2 (lymphotactin β). The gene that encodes 
lymphotactin maps to chromosome 1 (Kelner et al., 1994). 
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XCL1was first detected in activated CD8+ T cells from thymus and spleen and in 
activated CD4- CD8- TcRαβ+ thymocytes (Yoshida et al., 1995); therefore, it was 
associated with the Th1 response (Dorner et al., 2002). Dorner et al. found that 
lymphotactin has a relevant role in the development of efficient cytotoxic 
immunity in vivo (Dorner et al., 2009). 8 to 36 hours after antigen recognition by 
DCs, when T cell and DCs interact, CD8+ T cells secrete high amounts of XCL1, 
which increased the survival and differentiation of CD8+ T cells towards IFN-γ-
secreting effectors and leading to an increase of the pool of antigen-specific 
CD8+ T cells in vivo. However, XCL1 depletion avoids the development of 
cytotoxicity to antigens cross-presented by CD8+ DCs (Dorner et al., 2009). 
Moreover, XCL1 mediates the accumulation and the interaction with thymic DCs, 
which are key for the proper development of natural regulatory T cells (Lei et 
al., 2011). 
1.2.1.4 CX3C chemokines 
The last chemokine subfamily is a single entity, rather than a group, and the last 
one to be discovered (Bazan et al., 1997). CXXXCL1 or CX3CL1 chemokine, also 
known as fractalkine, is so named because the N-terminal first two consensus 
cysteine residues are adjacent to each other with the addition of three amino 
acid residues interposed between them. The gene encoding CX3CL1 maps to 
chromosome 16 (Bazan et al., 1997). 
Unlike the majority of the chemokines, CX3CL1 can be found in two forms, 
either as a ligand anchored to the membrane or as a soluble ligand (Bazan et al., 
1997). CXCL16 is the only other chemokine which seems to have a 
transmembrane conformation (Matloubian et al., 2000). Under normal 
conditions, CX3CL1 is synthesised as an intracellular precursor, which is 
transported to the membrane where it is anchored to the membrane by an 
extended mucin-like stalk (Garton et al., 2001). This cell-surface-bound 
conformation allows it to act as an adhesion molecule to cells with the cognate 
receptor; for example, it promotes strong adhesion of leukocytes on activated 
primary endothelial cells (Bazan et al., 1997). Once CX3CL1 is on the surface, 
the release of the extracellular domain takes place via metalloproteinase-
dependent cleavage. Tumour necrosis factor-α converting enzyme (TACE) is the 
protease involved in the generation of the soluble ligand (Garton et al., 2001). 
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The soluble CX3CL1 chemokine works as a T cell and monocyte chemoattractant 
(Bazan et al., 1997).  
1.2.2 Functional classification  
Chemokine nomenclature is based on their structural classification; however, 
they can also be sorted out into two functional categories. Chemokines can be 
homeostatic or proinflammatory depending on when they are expressed and 
their in vivo function. However, some chemokines are multifunctional and they 
can have a dual function; therefore, some inflammatory chemokines can have 
homeostatic roles under certain conditions while some homeostatic chemokines 
can be upregulated under certain injury conditions. 
1.2.2.1 Inflammatory chemokines 
Inflammatory chemokines were the first ones discovered as they are upregulated 
after tissue damage. In the early 1990s, activated cells of the immune system 
were studied, allowing the identification of many chemokines due to the 
abundance of their transcripts in these cells (Zlotnik and Yoshie, 2012). Those 
chemokines that are expressed by a variety of cells only after injury are 
classified as inflammatory.  
Inflammatory chemokines are essential as they become upregulated and induce 
the recruitment of leukocytes in the presence of infection, inflammation, tissue 
injury and tumours. Inflammatory chemokines can be expressed in any place in 
the body; as an example, all nucleated cells are able to express CCL2 to induce 
the attraction of cells to site of injury. These chemokines are said to be 
promiscuous and their receptors unfaithful, as a single ligand has broad receptor 
selectivity and a single receptor has a broad number of agonists (Bachelerie et 
al., 2014). Even if this mechanism seems to lack specificity (and makes this field 
a challenge to understand), it facilitates  the fast recruitment of effector cells 
into almost any tissue to restore the injury and protect the host.  
The most relevant inflammatory chemokines are clustered, in the case of CC 
chemokines, many are localised on chromosome 17 in humans and on 
chromosome 11 in mice, while many CXC chemokines are clustered on 
chromosome 4 in humans and on chromosome 5 in mice (Zlotnik et al., 2006). 
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The explanation for the existence of these clusters is based on gene duplication, 
which produces two copies of a gene that can evolve independently and develop 
specialised functions (Wagner, 2001, Zlotnik et al., 2006). For this reason, 
clustered genes share characteristics that do not apply to the non-cluster 
chemokines, such as promiscuous ligand-receptor relationships (Figure 1-5) and a 
poor correlation between species, as happens between human and mouse 
(Yoshie et al., 2001, Zlotnik et al., 2006, Hughes and Nibbs, 2018).  
1.2.2.2 Homeostatic chemokines 
Even if the first chemokines to be identified were the inflammatory ones, the 
high degree of conservation among chemokines and the development of 
expressed sequence tag databases and bioinformatics allowed the identification 
of new chemokines (Zlotnik and Yoshie, 2000b). Unlike inflammatory 
chemokines, the expression of homeostatic chemokines is constitutive and cell 
or tissue specific (Zlotnik and Yoshie, 2012). Moreover, they are involved in the 
recruitment of cells involved in adaptive immunity, such as lymphocytes or DCs. 
Homeostatic chemokines are involved in the organization of the immune system 
and regulate the movement of lymphocyte and DC subsets during normal 
processes of tissue maintenance or development (Zlotnik and Yoshie, 2000a). A 
good example is CXCL12, which is essential for the migration of HSCs in 
embryonic development and in lymphocytic circulation and immune surveillance 
in the postnatal life (Kabashima et al., 2007, Zlotnik and Yoshie, 2000a).  
In both human and mouse, homeostatic chemokines are encoded by non-
clustered genes; thus, the limited gene duplication makes these chemokines 
much less promiscuous than their counterparts (Figure 1-5). Actually, many of 
these chemokines have very restrictive ligand-receptor relationships (Zlotnik and 
Yoshie, 2000b).  
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Figure 1-5. Mammalian chemokine receptors and their known interactions with chemokines 
and other molecules. 
The above diagram shows the complexity of the relationship between chemokine receptors and 
chemokine ligands. Chemokine receptors interact with several different chemokines and at the 
same time, a chemokine molecule can interact with several receptors. Chemokines are arranged 
numerically in columns and a colour-code was used to represent whether they are in humans and 
mice, humans only, or mice only (see Key). Chemokine receptors are colour-coded and are linked 
to their known ligands (see Key). The colour of the linking key indicates the species in which the 
interaction has been demonstrated (see Key). Non-chemokine proteins, including drugs, known to 
interact with the chemokine receptors are also represented (see Key). Image from Hughes et al.  
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1.3 Chemokine receptors 
1.3.1 Structure 
Chemokine ligands must interact with chemokine receptors and 
glycosaminoglycans (GAGs) in order to induce cell migration. GAGs can be part 
of proteoglycans on cells or can be part of the extracellular matrix and they act 
by promoting chemokine immobilization to induce the migration of chemokine 
receptor expressing cells.  
Chemokine receptors are seven-transmembrane spanning proteins between 340 
and 370 amino acids long that constitute the largest division of the γ subfamily 
rhodopsin-like seven-transmembrane receptors (Griffith et al., 2014). Chemokine 
receptors can be classified into two groups: G protein-coupled chemokine 
receptors, also known as classical receptors, and atypical chemokine receptors, 
which lack the motif that enables coupling to G proteins. The chemokine 
receptor genes were also generated via gene duplication as a large cluster in 
human chromosome 3. However, as happens with chemokine ligands, chemokine 
receptors are well conserved among species; they have conserved structural, 
and therefore, functional, properties (Clark-Lewis et al., 1993, Clark-Lewis et 
al., 1995). One of the key motifs conserved among classic receptors is the 
DRYLAIV motif (D: Aspartate; R: Arginine; Y: Tyrosine; L: Leucine, A: Alanine; I: 
Isoleucine; V: Valine), also known as DRY motif. This motif is located on the 
second intracellular loop of the receptors and is essential for the G protein-
coupled intracellular response. The presence of this motif allows the production 
of a calcium flux following the chemokine ligand-chemokine receptor interaction 
(Graham et al., 2012).  
Chemokine receptors have the N-terminus on the extracellular side of the cell 
membrane, as this region is involved in ligand recognition and initial binding. 
The ligand binding process has been described as a two-step mechanism 
(Monteclaro and Charo, 1996, Pease et al., 1998). In the initial step, the N-
terminus of the chemokine receptor interacts with the chemokine core domain 
through a high-affinity bond producing the immobilization of the chemokine 
ligand. This arrest allows the formation of low-affinity interactions between the 
ligand and the receptor (Monteclaro and Charo, 1996, Pease et al., 1998). Once 
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the ligand has completely interacted with the receptor, the receptor becomes 
activated leading to down-stream signalling cascades. The chemokine receptor 
contains several serine and threonine residues that can be phosphorylated, 
providing additional regulatory mechanisms.  
The elucidation of the three-dimensional structures of the chemokine receptors 
allowed confirmation of the structural characteristics of these receptors and 
confirmed the ability of some receptors, such as CXCR4, to homodimerise (Wu et 
al., 2010). Different approaches has been used to solve the three-dimensional 
structures of these chemokines, including X-ray, crystallography for CXCR4 (Wu 
et al., 2010) and CCR5 (Tan et al., 2013) and nuclear magnetic resonance 
spectroscopy for CXCR1 (Park et al., 2012). The discovery of the three-
dimensional structure is of high relevance as it allows a better understanding of 
chemokine ligand-receptor interactions and therefore, it provides the first step 
for the rational design of antagonist for clinical use. 
1.3.2 CC chemokine receptors 
Classical chemokine receptors are divided into 4 subfamilies in relation to the 
subfamily of their major chemokine ligands (Zlotnik et al., 2006). CC chemokine 
receptors are the first family of chemokine receptors and they are involved in 
the interaction with CC chemokines. There are 10 chemokine receptors in this 
family (CCR1-CCR10). The first receptors to be identified were those involved in 
inflammatory responses. In fact, CCR1, CCR2, CCR3 and CCR5 are considered to 
be the classical inflammatory CC chemokine receptors.  
CCR2 has been identified on the surface of a subset of inflammatory cells, such 
as monocytes, activated memory T cells, B cells and basophils in humans. CCR2 
is essential for the recruitment of inflammatory monocytes into tissue. For 
example, CCR2 is crucial after acute myocardial infarction, as it supports 
monocyte recruitment that are able to differentiate into matrix 
metalloproteinases and TNF-α secreting macrophages that promote ventricular 
remodelling (Kaikita et al., 2004). However, it has been shown that CCR2 is not 
the only chemokine receptor involved in leukocyte recruitment into tissue, as 
CCR2 knockout mice were able to support effective macrophage infiltration via 
CCR1 and CCR5 (Dagkalis et al., 2009). This is an example of the redundancy 
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that takes place in organisms, and more specifically in this context, in the 
immune response (Rot and von Andrian, 2004). Redundancy is of high relevance 
as it ensures the efficiency of the most relevant functions; however, it also 
means that it is complex to target these receptors therapeutically as they create 
a complex network that is not fully understood.  
CCR5 is expressed on peripheral DCs, CD34+ haematopoietic progenitor cells and 
activated Th1 lymphocytes and is of high significance as it works as a major 
coreceptor for human immunodeficiency virus-1 (HIV-1) infection (Bleul et al., 
1997).  
CCR7 is an archetypic homeostatic receptor as it is involved in the cellular 
organisation of secondary lymphoid organs; CCR7 is crucial as it guides the 
patrolling immune cells into secondary lymphoid organs (Förster et al., 1999). 
The migration of lymphocytes is impaired in CCR7-deficient mice, leading to 
alterations in all secondary lymphoid organs. Moreover, the antibody response is 
delayed as activated DCs and T cells fail to exit from the peripheral tissue into 
the lymph nodes in CCR7 deficient mice. CCR7, as expected due to its 
homeostatic role, has a quite restrictive ligand-receptor relationships as it just 
has two ligands, CCL19 and CCL21 (Vander Lugt et al., 2013). 
1.3.3 CXC chemokine receptors 
CXC chemokine receptors are involved in the interaction with CXC chemokines. 
There are 8 chemokine receptors in this family (CXCR1-CXCR8) and most are 
found on neutrophils and lymphocytes. CXCR1-3 are inflammatory receptors 
while the rest are homeostatic. All ELR+ CXC chemokines interact with CXCR1 
and CXCR2, which are both involved in the migration of neutrophils during the 
inflammatory response (Ludwig et al., 1997). In addition, ELR+ CXC chemokines 
also promote angiogenesis (Strieter et al., 2005), cell proliferation (Mockenhaupt 
et al., 2003) and survival during development (Li et al., 2003). CXCR1 interacts 
with high affinity with CXCL8, which is released at high concentrations after 
trauma to stimulate cell migration and to enhance endothelial cell survival, 
proliferation, angiogenesis and the reconstruction of the matrix (Levashova et 
al., 2007, Li et al., 2003). Rodents lack an equivalent CXC chemokine ligand to 
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CXCL8; however, they have two homologous receptors, CXCR1 and CXCR2, able 
to coordinate cell migration during inflammation (Levashova et al., 2007). 
CXCR3 is mainly expressed on Th1 lymphocytes and some B cells and NK cells. 
This receptor is highly upregulated following cell activation and its ligands are 
CXCL9, CXCL10 and CXCL11. There are two isoforms of this receptor, CXCR3a 
and CXCR3b, which differ in their interaction partners, as CXCR3b can also 
interact with CXCL4 (Struyf et al., 2011). CXCR3 is involved in several 
inflammatory and autoimmune diseases such as insulitis and type 1 diabetes 
mellitus (Frigerio et al., 2002) and rheumatoid arthritis (Patel et al., 2001).  
CXCR4 is a very important homeostatic chemokine receptor expressed in both 
the immune and the central nervous system. Upon interaction with its cognate 
ligand CXCL12, CXCR4 induces the migration of resting leukocytes and 
haematopoietic progenitors. CXCL12 is important as the ligand-receptor 
interaction is responsible for the retention of HSCs in the bone marrow niche 
(Zou et al., 1998). It is such an important receptor that mice lacking this 
receptor die perinatally due to haematopoietic and cardiac defects. CXCR4 is 
upregulated during the implantation window, therefore, the prenatal death 
could also take place due to an inappropriate implantation (Dominguez et al., 
2003). Inhibition of CXCR4 using a small molecule inhibitor, AMD3100 
(plerixafor), induces the mobilisation of haematopoietic progenitors from the 
bone marrow into peripheral tissues (Liles et al., 2003). This discovery was a 
compelling advance in the stem cell transplantation field. CXCR4 is also relevant 
as it is a major coreceptor for HIV-1 (Feng et al., 1996, Donzella et al., 1998) 
and AMD3100 has been shown to block viral entry of HIV-1 into some host cells 
(Donzella et al., 1998).  
CXCR5, like CCR7, is involved in the organization of secondary lymphatic tissues. 
The only cognate ligand of CXCR5 is CXCL13, which is produced by DCs of B cell 
zones in the lymph nodes to induce the migration of B cells expressing CXCR5 (Yu 
et al., 2002). Moreover, T helper cells upregulate CXCR5 to migrate to B cell 
zones in the lymph nodes and in this way, contributes to the adaptive immune 
response. CXCR5 is of relevance in disease as it is specifically expressed in 
Burkitt’s lymphoma (Gunn et al., 1998). Moreover, CXCR5 upregulation has a 
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positive correlation with lymph node metastases in breast cancer patients as this 
axis regulates epithelial to mesenchymal transition (Biswas et al., 2014).  
CXCR6 has also been identified as an entry coreceptor for viral infection. In the 
case of HIV-1, it is a minor coreceptor as almost every strand of the virus infects 
cells using CXCR4 and/ or CCR5 (Liao et al., 1997). However, CXCR6 is important 
for simian immunodeficiency virus (SIV) as it acts as a major coreceptor for 
infection (Elliott et al., 2015).  
1.3.4 XC chemokine receptor 
XC chemokine receptor is involved in the interaction with XC chemokines; there 
is just one receptor in this subfamily (XCR1) and it is known as lymphotactin 
receptor (Zlotnik and Yoshie, 2000b). XCR1 is expressed by a subset of DCs 
having roles in antigen cross-presentation and immunity against viruses and 
cancer (Ohta et al., 2016). The XCR1-XCL1 axis is involved in the modulation of 
both the localization and function of T cells and DCs; thus, this axis is involved in 
several autoimmune diseases such as rheumatoid arthritis (Blaschke et al., 2003) 
or Crohn’s disease (Middel et al., 2001). Moreover, XCR1 is involved in the 
progression of several cancers as it is positively correlated with bone metastasis 
in non-small cell lung cancer (Wang et al., 2015); it promotes cell migration and 
proliferation in epithelial ovarian carcinoma (Kim et al., 2012); and it is 
expressed in diffuse large B cell lymphoma initially manifesting in the bone 
marrow (Yamashita et al., 2011).  
1.3.5 CX3C chemokine receptor 
The last family of chemokine receptors is also a single entity and is known as 
CX3CR1 or fractalkine receptor. Expression of this receptor has been found on T 
cells, NK cells and monocytes and microglial cells of the central nervous system. 
CX3CR1 plays a major role on the survival of monocytes (Landsman et al., 2009), 
while CX3CR1 signalling pathway modulates microglial activation and therefore, 
interactions with neurons and synapses (Paolicelli et al., 2014). In addition, 
CX3CR1 is relevant for macrophage mediated apoptotic cell engulfment as 
CX3CL1 is released from apoptotic lymphocytes (Truman et al., 2008).  
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1.3.6 Chemokine receptor signalling 
It is important to remember that classic chemokine receptors are G protein-
coupled receptors; therefore, the binding of a chemokine ligand to its receptor 
leads to changes in the G proteins. Before ligand interaction, the receptor is 
bound to a heterotrimeric G protein complex, formed by α, β and γ subunits, 
which has associated a guanosine diphosphate (GDP) molecule to its α subunit, 
making the heterotrimeric G protein inactive. However, binding of an agonist to 
the receptor produces a conformational change in the receptor, which leads to 
the allosteric activation of the Gα subunit. The activated Gα subunit releases GDP 
and exchanges it for guanosine triphosphate (GTP), triggering the dissociation of 
the G protein from the receptor as well as from each other, yielding a Gα-GTP 
monomer and a Gβγ heterodimer, which are now free to interact and modulate 
other intracellular proteins. The receptor is now internalised and the cell is 
desensitised. 
As shown in Figure 1-6, ligand interaction can lead to a multitude of downstream 
pathways determined by the ligand, the receptor and the physiological context 
in which the binding takes place (Rot and von Andrian, 2004). There are multiple 
different G proteins and the binding of an agonist can lead to the activation of 
different G proteins depending on the capability to induce the stabilization of 
specific guanine-nucleotide exchange factors. 
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Figure 1-6. Schematic summary of chemokine-mediated G protein-coupled receptor 
signalling. 
Chemokine ligand interaction with its cognate receptor can lead to a multitude of downstream 
pathways determined by the ligand, the receptor and the physiological context in which the binding 
takes place. Before ligand interaction, the receptor is bound to a heterotrimeric G protein complex, 
formed by α, β and γ subunits, which has associated a guanosine diphosphate (GDP) molecule to 
its α subunit, making the heterotrimeric G protein inactive. However, binding of an agonist to the 
receptor produces a conformational change in the receptor, which leads to the allosteric activation 
of the Gα subunit. The activated Gα subunit releases GDP and exchanges it for guanosine 
triphosphate (GTP), triggering the dissociation of the G protein from the receptor as well as from 
each other, yielding a Gα-GTP monomer and a Gβγ heterodimer, which are now free to interact and 
modulate other intracellular proteins. The receptor is now internalised and desensitised. 
 
Several Gα proteins are able to regulate the calcium ion flux (Wu et al., 1993, 
Rollins et al., 1991). Gαs and Gαi both regulate adenylate cyclase, Gαs subunit 
induces its activity while Gαi acts as an inhibitor. Adenylate cyclase catalyses the 
conversion of adenosine triphosphate (ATP) to cyclic-adenosine monophosphate 
(cAMP). Cytosolic cAMP levels regulate the activity of ion channels, such as 
calcium, as well as serine/ threonine protein kinase A (PKA), which can also 
produce a calcium influx. Gαq/11 regulates phospholipase C-β (PLCβ), which 
produces inositol trisphosphate (IP3) and diglyceride (DAG) by catalysing the 
cleavage of the membrane-bound phosphatidylinositol 4,5-bisphosphate (PIP2). 
IP3 produces the release of calcium ions from the endoplasmic reticulum while 
DAG activates protein kinase C (PKC), leading to further downstream signalling.   
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Gα proteins are also responsible for cytoskeleton regulation (Gu et al., 2003). 
Gα12/13 allosterically activates three members of the cytosolic small GTPase Rho 
family (p115-RhoGEF, PDZ-RhoGEF, and LARG). Once it is activated Rho can 
activate Rac1, promoting lamellipodia formation at the leading edge of cells and 
its subsequent movement.  
Moreover, the Gβγ heterodimer by itself is able to modulate the activity of 
potassium and calcium channels, as well as adenylate cyclase and PI3K. In this 
manner, the mitogen-activated protein kinase pathway gets activated leading to 
cell polarisation and movement towards the highest concentration of 
chemokines (Patel et al., 2013).  
1.3.7 Atypical chemokine receptors (ACKRs) 
ACKRs, like the classical chemokine receptors, are seven-transmembrane 
spanning proteins; however, ACKRs have a missing or modified DRYLAIV motif in 
the second intracellular loop, which disables the coupling to G-proteins and 
therefore, the classical chemokine receptor mediated cell signalling (Ulvmar et 
al., 2011).  
There are currently five receptors in this family (ACKR1-ACKR5) which can 
interact with a wide range of chemokine ligands. These receptors were thought 
to be silent because they fail to induce cell migration; nevertheless, they are 
not, as upon interaction with ligands ACKRs are internalised. After 
internalisation, two outcomes can take place. On the one hand, ligands can be 
internalised and targeted for lysosomal degradation. On the other hand, 
internalisation can be followed by transcytosis, a process allowing the transport 
of chemokines across biological barriers in order to take them to less 
approachable microanatomical domains (Graham et al., 2012). The main goal of 
these receptors is to regulate chemokine availability within tissues. 
1.3.8 Chemokines and chemokine receptors in disease 
1.3.8.1 Inflammatory diseases 
As has already been discussed, it is essential for the immune system to achieve 
self-nonself discrimination to avoid the development of chronic inflammation 
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and autoimmune disease. Tissues of patients with inflammatory conditions show 
upregulated levels of specific chemokines and their receptors. In inflammatory 
rheumatic diseases, CXCL8 (Seitz et al., 1992) as well as XCL1 (Blaschke et al., 
2003) have been shown to be present in synovial fluid. Furthermore, CXCL8 is 
also upregulated in patients suffering active ulcerative colitis (Mahida et al., 
1992). Rheumatoid arthritis patients not only have increased XCL1 and CXCL8 
levels in synovial fluid, but also have CCL2, CCL3, CCL5 and CXCL12 levels 
increased in their joints, which leads to the recruitment of pro-inflammatory 
cells into synovial tissues (Shadidi et al., 2003). CCR5, CCR6, CCR7, CXCR3, 
CXCR4 and CXCR5 have also been found to be involved in B cell synovial cytokine 
production and activity (Nanki et al., 2009). Chemokines are also involved in 
psoriasis pathophysiology; CXCR3 has been found to induce lymphocyte 
recruitment to the skin leading to inflammation (Flier et al., 2001). 
1.3.8.2 Human Immunodeficiency Virus (HIV) 
The human immunodeficiency virus is a lentivirus discovered in 1983 that targets 
and destroys immune system cells of the host leading to the development of 
acquired immunodeficiency syndrome (AIDS) (Barré-Sinoussi et al., 1983). Due to 
the failure of the immune system, AIDS allows the appearance of life-
threatening opportunistic infections as well as cancer development. HIV has a 
huge propensity for genetic variation, mainly within the envelope gene, making 
it very difficult to develop a vaccine capable of targeting all the variants and 
therefore, preventing infection (Berkower et al., 1989). However, the virus 
cannot mutate at sites related with crucial functions.  
The entry of the virus into host cells takes place through glycoproteins in the 
envelope of the virus, more accurately, glycoprotein (gp) 120. CD4 gp is able to 
induce CD4+ T cell specific antigen responses after interaction with MHC Class II 
molecules; however, gp120 is also able to interact with CD4 leading to 
conformational changes in gp120 that promote the exposure of chemokine 
receptor binding regions on the surface of the virus (Silberman et al., 1991).  
Once the virus is showing the chemokine receptor binding regions, it needs to 
interact with the corresponding receptors, CCR5 and CXCR4, as they act as 
coreceptors promoting the entry of the virus into the host cells (Bleul et al., 
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1997). In the initial stage of the infection, HIV uses CCR5 as a coreceptor to 
target monocytes, macrophages and CCR5+ Th1 cells. For this reason, it is known 
as M-tropic HIV at this stage. To infect lymphocytes, the virus uses CXCR4, which 
is known as the T-tropic or X4-tropic stage of the infection. At this stage, the 
immune system is already much weakened leading to AIDS.  
There have been several approaches to target CD4, CCR5 and CXCR4 to reduce 
the ability of HIV to target the immune system. Among these three coreceptors, 
CCR5 seems to be most relevant as individuals with a defective expression of 
CCR5 are resistant to infection with HIV-1 (Liu et al., 1996). Moreover, the usage 
of natural CCR5 ligands in vitro produces a decrease in the infection rate due to 
competition events between the virus and the natural ligands (Cocchi et al., 
1995). In addition, Clerici et al. showed that patients with increased CCL5 levels 
seem to be refractory to the progression of HIV infection to AIDS (Clerici et al., 
1996). According to studies done in 1996, approximately 1% of people of 
northern European descent have a non-functional CCR5 receptor activity and are 
known to have the CCR5Δ32 mutation. This mutation is characterised by the 
absence of 32 base pairs of the second extracellular loop impairing the receptor 
activity. CCR5Δ32 homozygous individuals are highly resistant to HIV-1 infection, 
while Δ32 heterozygotes can become infected but the progression of the disease 
is much slower, taking longer to develop AIDS (Huang et al., 1996).  
On the one hand, CCR5Δ32 is not only protective for HIV-1, but also for graft 
rejection (Fischereder et al., 2001) and inflammatory disorders such as asthma 
(Srivastava et al., 2003) and rheumatoid arthritis (Pokorny et al., 2005). On the 
other hand, CCR5Δ32 produces a more apparent disease in patients with 
pulmonary sarcoidosis and an increased requirement for corticosteroids (Petrek 
et al., 2000). Moreover, CCR5Δ32 mutation increases the risk of suffering a 
lethal encephalopathy after infection with West Nile virus (Glass et al., 2006).  
1.3.8.3 Cancer 
It is important to consider that even if cancer appears as a result of the 
accumulation of genetic and epigenetic changes (Joyce, 2005), those alterations 
are not enough to provide malignant properties to cancer cells (Sounni and Noel, 
2013). Tumours must develop essential properties to progress and develop; these 
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are induced by the tumour microenvironment. The tumour microenvironment 
provides the necessary signals that turn on transcription factors from 
development or embryology programs allowing the necessary mesenchymal 
phenotypes to invade distant tissues and establish a new environment (Sounni 
and Noel, 2013). 
Tumour cells work in close interaction with the extracellular matrix and with 
genetically stable cells that constitute the tumour microenvironment (Fang and 
Declerck, 2013). The tumour microenvironment describes the non-cancerous 
cells present in the tumour, which includes fibroblasts, myofibroblasts, 
neuroendocrine cells, adipose cells, immune and inflammatory cells and the 
blood and lymphatic vascular networks (Chen et al., 2015). The interactions 
between tumour cells and the tumour microenvironment have a deep influence 
on cancer development and progression and contributes to almost all of the 
hallmarks of cancer (Hanahan and Weinberg, 2011). The stromal cells that 
interact with the tumour are not only from neighbouring tissues, but also 
endothelial progenitor cells, myeloid and lymphoid inflammatory cells, and 
mesenchymal cells that have been recruited from the bone marrow (Fang and 
Declerck, 2013). Once these cells are within the tumour microenvironment, the 
signals originating from the tumour make them progressively switch from non-
malignant cells with a neutral or anti-tumorigenic role towards cancer-
associated fibroblasts (CAF), tumour-associated macrophages (TAM) or vascular 
and perivascular cells with a pro-tumorigenic role (Fang and Declerck, 2013) 
(Figure 1-7). Therefore, signals originating from the tumour cells induce the pro-
tumorigenic nature of the microenvironment, while the signals originated by 
these cells promote tumour development. 
Tumour formation and maintenance, as organs, requires the self-renewal of 
cancer cells. This self-renewal property is provided by cancer stem cells (CSCs) 
(Wang et al., 2013). CSCs can develop from the normal tissue stem cells due to 
oncogenic mutation or can be normal somatic cells that acquire oncogenic 
mutations that give them the ability to self-renew and differentiate into 
specialised, mature cell types (Adjei and Blanka, 2015). The tumour stroma also 
recruits MSCs from the circulation and nearby tissues by secreting CXCL12 and 
CCL2. Recruited MSCs secrete CCL5, which induces migration, invasion and 
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metastasis of cancer cells due to the malignant transformation of CAFs and TAMs 
(Karnoub et al., 2007). Thus, the tumour microenvironment allows the 
recruitment and activation of CSCs through chemokines and those CSCs secrete 
more chemokines that enhance the pro-tumorigenic role of the tumour 
microenvironment. Nevertheless, it has also been shown that MSCs are able to 
inhibit Akt protein kinase activity and downregulate B cell lymphoma 2 (Bcl2) in 
cancer, inducing apoptosis (Qiao et al., 2008).  
 
Figure 1-7. Schematic representation of the effect of cancer cells in tumour 
microenvironment.  
Secretion of cytokines and growth factors, including IL-4, macrophage colony-stimulating factor and 
granulocyte-macrophage colony-stimulating factor by tumour cells promotes the generation of a 
tumour promoting environment where fibroblasts and macrophages switch from being anti-
tumorigenic to have a pro-tumorigenic role. Cancer associated fibroblasts (CAFs) and tumour 
associated macrophages (TAMs) secrete pro-inflammatory molecules that recruit further TAMs as 
well as promoting angiogenesis, tumour growth and metastasis 
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CAFs secrete growth factors, transforming growth factor β, hepatocyte growth 
factor, insulin like growth factor 1/ 2, and chemokines (CCL2 mainly) that 
enhance angiogenesis and therefore, proliferation and invasion of cancer cells 
due to the activation or transformation of both the microenvironment and the 
cancer cells (Adjei and Blanka, 2015). Many tumours secrete monocyte 
chemoattractant proteins, such as CCL2, producing an increase of TAMs, which 
mediate immunoinhibitory effects and facilitate tumour metastasis by 
generating changes in the tumour microenvironment. In fact, the blockade of 
CCL2-CCR2 signalling by monoclonal antibodies, such as CNTO 888, has been 
shown to augment CD8+ T cell mediated responses and to inhibit metastatic 
seeding (Tsai et al., 2014).  
CXCL8 and CXCL1 are usually upregulated in the tumour microenvironment, 
leading to an aberrant recruitment of neutrophils and angiogenesis (Sparmann 
and Bar-Sagi, 2004).  
CCR7 and CXCR4 both have very important roles controlling the migration of 
immune cells to secondary lymphoid organs. CCR7 has been found to be 
upregulated in many cancers, including gallbladder cancer (Hong et al., 2016), 
non-small cell lung cancer (Sun et al., 2015) and oesophageal squamous cell 
carcinoma (Irino et al., 2014) among others, promoting metastasis. Moreover, 
CXCR4 and CCR7 enhance metastasis by inhibiting anoikis, a programmed cell 
death that takes place when anchorage-dependent cells detach from the 
extracellular matrix (Kochetkova et al., 2009). Lastly, signal transducers and 
activators of transcription (STATs), nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB) and hypoxia inducible factor 1α (HIF1α) are also 
involved in inflammation and are deregulated in many cancers. HIF1α produces 
an increase of CXCR4, promoting metastasis by both metastatic migration 
towards CXCL12 and inhibition of anoikis.  
1.3.8.4 Transplant rejection  
Organ transplantation is one of the greatest achievements in medicine as it is 
the unique life-saving strategy for patients with irreversible failure of a wide 
range of organs, such as kidney, heart, lung, pancreas and liver (Salvadori and 
Bertoni, 2014). However, the main problem of this strategy is that the long-term 
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outcome can be jeopardised due to tissue or organ rejection. To avoid rejection, 
patients are supplied with immunosuppressants; however, these drugs further 
aggravate their quality of life as they are prone to infections, neoplasms, 
nephrotoxicity and diabetogenicity (Crescioli, 2016). Due to the role of 
chemokines in inflammatory and immune responses, it was not a surprise to find 
that they had a major role in transplant rejection and that they were the 
molecules involved in alloreactive cell recruitment (Heidt et al., 2011).  
Chemokine ligands and their receptors are involved in transplant rejection due 
to their role driving and directing leukocyte migration, promoting an 
inflammatory environment surrounding the graft. Upon transplantation, 
inflammatory cytokines, such as IL-1, IFN-γ and TNF-α, are released at both local 
and systemic levels. This inflammatory environment promotes the release of 
pro-inflammatory chemokines, as CCL2, CXCL8, CXCL9, CXCL10 and CXCL11, by 
endothelial cells (Barker et al., 2014). The relevance of chemokines in graft 
rejection was shown when it was observed that neutralization of intra-graft 
CXCL10 allowed longer graft survival and therefore, a better outcome (Hancock 
et al., 2000).  
 
1.4 The stromal compartment 
The stromal compartment is the connective tissue of any organ and it includes a 
wide range of cells with a similar phenotype but different cellular functions. 
Among these cells, fibroblasts are the most common population, while 
mesenchymal stromal cells are present at a very low percentage. The stromal 
compartment is a major component of immune responses as it secretes a wide 
range of mediators to generate a pro-inflammatory or an anti-inflammatory 
environment according to the signals it receives.  
1.4.1 Mesenchymal Stromal Cells 
Mesenchymal stromal cells (MSCs) were first named in 1976 by Alexander 
Friedenstein as colony-forming unit fibroblasts (CFU-Fs). These cells were 
spindle shaped, clonogenic in monolayer cultures and could serve as feeders in 
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the bone marrow for haematopoietic stem cells (Friedenstein et al., 1976). The 
term mesenchymal stem cell was first used by Maureen Owen in 1985 because of 
their ability to self-renew and the potential to differentiate into discrete 
connective tissues cells. Although MSCs where first isolated from bone marrow, 
they can be isolated from a wide range of tissues around the body, including 
umbilical cord, cord blood, placenta, dental pulp, periodontal ligament, adipose 
tissue and from the islets within the pancreas (Lv et al., 2014).  
Due to different culture conditions and the intrinsic variability among MSCs 
derived from different donors and strains, there is controversy regarding MSCs 
properties in the literature. For this reason, the International Society of Cellular 
Therapy (ISCT) proposed to call these cells mesenchymal stromal cells (Horwitz 
et al., 2005) and specified the criteria that human cells had to reach in order to 
be defined as MSCs. These criteria are plastic-adherence when maintained in 
standard culture conditions and specific surface antigen expression along with 
the potential to differentiate into osteoblasts, adipocytes and chondroblasts. 
MSCs must express CD105, CD73 and CD90 and, as additional criteria, they must 
lack the expression of haematopoietic antigens such as CD45, CD34, CD14 or 
CD11b, CD79α or CD19 and MHC Class II (Dominici et al., 2006). MSCs express 
human leukocyte antigen (HLA)-DR isotype upon stimulation with IFN-γ; in this 
case, cells are still termed MSCs but they have to be qualified with adjectives 
such as activated, licensed or stimulated MSCs to explain that the cells are not 
in a baseline state. MSCs not only express these markers, but also variable levels 
of other markers as CD29, CD44, CD166, CD146 and CD271, which can allow the 
isolation of tissue specific MSCs. CD271, for example, allows the identification of 
bone marrow MSCs (BM MSCs) (Álvarez-Viejo et al., 2015).  
Ideally, these characteristics should allow the identification of MSCs; however, 
MSCs are similar to fibroblasts in that they have a similar morphology and are 
plastic-adherent (Haniffa et al., 2009). Moreover, human dermal fibroblasts have 
also been proven to have tripotency (Junker et al., 2010) and immunoregulatory 
functions similar to MSCs (Haniffa et al., 2007) and to express most MSC markers 
such as CD105, CD73 and CD90 (Schwab et al., 2008). Fibroblast contamination is 
a potential impediment for regenerative medicine due to their senescence and 
tumour transformation upon long-term expansion (Zhou et al., 2006); thus, 
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proper MSC isolation is essential. CD146 expression has been found to be weak 
for fibroblasts and high for MSCs (Lv et al., 2014) and CD166 was significantly 
higher in MSCs; therefore, these two markers could allow the discrimination 
between MSCs and fibroblasts. However, according to Halfon et al., markers 
discriminating MSCs from fibroblasts are downregulated in human MSCs of 
passage 6; murine MSCs are difficult to expand and therefore, are not well 
described (Halfon et al., 2011).  
1.4.2 Tissue of origin of MSCs impacts their phenotype and 
function 
MSCs can be isolated from a wide range of tissues around the body, including 
umbilical cord, cord blood, placenta, Wharton’s jelly, dental pulp, periodontal 
ligament, adipose tissue and from the islets within the pancreas (Lv et al., 
2014). BM MSCs are considered the gold standard and are the most used MSCs in 
the clinic; however, their isolation requires an invasive and painful procedure. 
As MSCs can be isolated from a large variety of tissues, alternative sources could 
be more suitable for clinical use. Adipose tissue, umbilical cord and islets are a 
potentially better source for MSC isolation as they are easily accessible and MSCs 
can be isolated in larger amounts; moreover, as these tissues are clinical waste 
there is no burden on the donor. As an example, adipose tissue yields a 500-fold 
higher frequency of colony forming units (CFU-F) than bone marrow and can be 
obtained very easily (Fraser et al., 2006); MSCs from the umbilical cord could 
also be a good choice as they are very abundant and they are ontogenically 
primitive (Choudhery et al., 2013).  
Comparison of MSCs from different sources have shown that they are all 
phenotypically similar as they all have the spindle-like morphology and similar 
surface expression levels of the markers stated by the ISCT. However, they differ 
in origin, proliferative rate, differentiation potential, immunomodulatory 
capacity and cytokine secretion profiles (Hass et al., 2011, Wu et al., 2018). 
Adipose tissue derived MSCs (Ad MSCs) have a greater ability to differentiate into 
adipocytes compared to BM MSCs and umbilical cord derived MSCs (UC MSCs), 
while UC MSCs differentiate much more easily in osteoblasts than Ad and BM 
MSCs (Han et al., 2017). Few studies compared the immunomodulatory potential 
of MSCs among tissues; even if they all used a mixed lymphocyte reaction assay 
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or T cell proliferation measurement assays upon CD3/ CD28 stimulation the 
results are contradictory. On the one hand, Puissant et al. did not find statistical 
differences between BM MSCs and Ad MSCs in the inhibition of T cell 
proliferation (Han et al., 2017, Puissant et al., 2005). On the other hand, Ribeiro 
et al. determined that Ad MSCs have a stronger effect on T cell activation 
compared to BM MSCs and UC MSCs (Ribeiro et al., 2013), while Xishan et al. 
showed that BM MSCs had the highest immunosuppressive effect (Xishan et al., 
2013). Little is known about the migratory abilities of MSCs according to their 
tissue of origin, which should be considered for clinical studies with these cells.  
It is also very important to consider the species variation in the MSCs biology. 
Immunosuppressive effects of MSC have been reported for both mice and humans 
but there are important differences regarding the genomic stability, the 
spontaneous expression of neural markers, self-renewal and differentiation 
capabilities, as well as the immunoregulatory capacities (Scuteri et al., 2014, 
Hass et al., 2011). Under the same culture conditions, cytokine-mediated 
inflammatory stimulation of human and murine BM MSCs led to differential 
increase of the expression levels of IDO and inducible nitric oxide synthase 
(iNOS); human BM MSCs expressed high levels of IDO and little iNOS, and mouse 
MSCs expressed very low levels of IDO and high levels of iNOS. The 
immunosuppressive mechanism of MSCs is poorly understood but IDO and iNOS, 
respectively in humans and mice, have been shown to be involved, at least in 
part, in the suppressive effect of MSCs on cytotoxic cell proliferation, and thus, 
immunomodulation (Ren et al., 2009). For these reasons, the transfer of results 
obtained from animal MSCs must be carefully interpreted. 
1.4.3 MSCs and the immune system 
In 1997 the ability of MSCs to repair a craniofacial defect (Kadiyala et al., 1997) 
was demonstrated, while in 1998 it was observed that MSCs grown and expanded 
ex vivo in culture were able to give rise to long-lasting connective tissue cells 
after injection into irradiated isogenic mice (Pereira et al., 1998). In 2005, MSCs 
were found to be weakly immunogenic due to their lack of HLA antigens and co-
stimulatory molecules as CD80 and CD86. This property, in combination with 
their ability to be immunosuppressive, immunomodulatory and regenerative in 
both human and animal models led to an increasing interest in the therapeutic 
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potential of MSCs (Keyser et al., 2007, Klyushnenkova et al., 2005). MSCs are 
found in perivascular locations in vivo, more precisely within epithelial niches 
close to the vessel walls, which enables blood vessel formation and the 
recruitment and interaction with immune cells (Liu et al., 2014). MSCs can 
interact with, and immunomodulate, not only the innate and the adaptive 
responses, but also the humoral immune system. Moreover, MSCs have been 
shown to recruit more leukocytes and to have stronger immunomodulatory and 
anti-inflammatory properties in the presence of inflammation; therefore, this is 
mimicked in vitro by stimulating MSCs with a cocktail of TNF-α, IFN-γ and/ or IL-
1β, also known as licensing of MSCs (Krampera et al., 2006, Krampera et al., 
2007, Di Nicola et al., 2002, Beyth et al., 2005).  
1.4.3.1 MSCs and the humoral immune system 
As previously mentioned in Section 1.1.1.2, the humoral immune system is 
composed of macromolecules present in extracellular fluids such as complement 
proteins and secreted antibodies.  
Interaction of MSCs with the complement system has been described, but it is 
not fully understood. Infusion of MSCs leads to complement activation after their 
contact with serum due to the expression of complement receptors C3aR and 
C5aR, allowing chemotaxis of MSCs towards the complement components C3 and 
C5 and leading to increased resistance to oxidative stress and prolonged survival 
by MSCs (Li and Lin, 2012, Schraufstatter et al., 2009). But at the same time, 
licensing of MSCs with TNF-α and IFN-γ leads to the secretion of complement 
factor H, which inhibits the formation of C5 and C3 convertases and the 
subsequent activation of the complement system and inflammation (Tu et al., 
2010b). Moreover, BM MSCs can secrete C3 protein, inhibiting the 
immunoglobulin production by B cells without affecting their activation status 
(Lee et al., 2014). Antibody secretion leads to the activation of the classical 
pathway of the complement system as well as to opsonization upon antibody 
binding to a target. Thus, by dampening Ab secretion, MSCs avoid the secretion 
of C3a and C5a anaphylatoxins that would lead to further activation of T cells 
and macrophages, mast cell degranulation and chemotaxis of immune cells that 
would lead to increased inflammation.  
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1.4.3.2 MSCs and the innate immune system 
As discussed in Section 1.1.1, the innate immune response is essential in the 
process of inflammation and is involved in transplant rejection and autoimmune 
diseases (Murphy et al., 2011, Prame Kumar et al., 2018). For this reason, it is 
essential to understand the interaction and the immunomodulatory and anti-
inflammatory effect of MSCs on the cells of the innate immune system to 
understand the role of MSCs within a clinical setting.  
1.4.3.2.1 MSCs and monocytes and macrophages 
 
Macrophages are phagocytic immune cells, the everyday essential in host 
defence and tissue homeostasis and, monocytes can differentiate into pro-
inflammatory or anti-inflammatory macrophages depending on 
microenvironmental signals. MSCs have been described to promote the 
differentiation of monocytes into M2 anti-inflammatory macrophages through a 
poorly understood mechanism involving the secretion of IDO, prostaglandin E2 
(PGE2) and tumour necrosis factor-inducible gene 6 (TSG-6) (Wise et al., 2014, 
Choi et al., 2011, Németh et al., 2009). Moreover, differentiation of monocytes 
into M2 prolongs MSC survival (Freytes et al., 2013). Contradictorily, in a murine 
model of GVHD, Galleu et al. described how MSCs must be targeted by cytotoxic 
T cells to undergo apoptosis, as engulfment by macrophages leads to the 
production and secretion of IDO by macrophages, which are capable of 
mediating immunosuppression (Galleu et al., 2017). 
1.4.3.2.2 MSCs and neutrophils 
 
Neutrophils are fast responders to inflammatory signals and can exert their 
inflammatory role in three different manners: phagocytosis, degranulation and 
the formation of NETs. MSCs have been described to increase the phagocytic 
potential of neutrophils and at the same time, to reduce the respiratory burst of 
neutrophils by suppressing the production of nitric oxide and hydrogen peroxide 
by active neutrophils, diminishing in this way their inflammatory potential and 
NET formation (Joel et al., 2019, Jiang et al., 2016). 
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1.4.3.2.3 MSCs and DCs 
 
MSCs are also able to supress the immune response by interfering with the 
maturation and activation process of DCs and the subsequent activation of T 
cells. MSCs secrete IL-6 and PGE2 suppressing the maturation of granulocyte 
macrophage colony stimulating factor (GMCSF) and IL-4 stimulated monocytes 
into DCs (Jiang et al., 2005, Spaggiari et al., 2009). Co-culture of MSCs and DCs 
promotes the secretion of the anti-inflammatory cytokine IL-10 by DCs while 
impairing their ability to endocytose, upregulate co-stimulatory molecules and 
secrete IL-12 and TNF-α (Aggarwal and Pittenger, 2005, Zhang et al., 2004). 
1.4.3.2.4 MSCs and NK cells 
 
As previously described in Section 1.1.1.1.8, NK cells recognise, and target, cells 
expressing low levels of MHC Class I, which makes MSCs a target for NK cells. 
However, co-culture of NK cells and MSCs under inflammatory conditions leads 
to the upregulation of MHC Class I in MSCs to avoid NK cell-mediated 
cytotoxicity, while downregulating the expression of NK cell activation receptors 
(Spaggiari et al., 2006, Poggi et al., 2005). Additionally, MSCs secrete TGF-β1 
and PGE2 which inhibits proliferation and IFN-γ production of IL-2 and IL-15 
activated NK cells (Sotiropoulou et al., 2006). These findings suggest that under 
resting conditions NK cells would be able to recognise and kill MSCs, while MSC 
licensing increases the immunoregulatory potential of MSCs and enables the 
regulation of the activation state of NK cells.  
1.4.3.3 MSCs and the adaptive immune system 
The innate immune system is a collection of non-specific mechanisms to protect 
the host against pathogens, while the adaptive immune response generates 
immunological memory towards specific antigens. The adaptive immune system 
can also generate self-reactive antibodies which can give rise to autoimmune 
diseases and it is also essential in developing immunotolerance. Thus, it is 
essential to understand the interaction, and the immunomodulatory and anti-
inflammatory effect of MSCs, on the adaptive immune system to understand the 
role of MSCs within a clinical setting. 
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1.4.3.3.1 MSCs and T cells 
 
T cells are key mediators in inflammation and MSCs have been shown to suppress 
T cell proliferation both directly and indirectly (Di Nicola et al., 2002). BM MSCs 
interact with T cells via the engagement of programmed cell death protein 1 
(PD1) in vitro, suppressing T cell proliferation (Augello et al., 2005). Engulfment 
of apoptotic MSCs by macrophages leads to IDO secretion, which has been 
described to promote T cell anergy, a tolerance mechanism in which the T cell 
remains alive but is inactivated following an antigen encounter (268). 
Furthermore, humans and murine MSCs secrete high levels of PGE2 in vitro, 
PGE2 inhibits TCR signalling, and inhibitors of PGE2 production decreased the 
immunosuppresive effect on T cells (Puccetti and Grohmann, 2007, Wiemer et 
al., 2011, Aggarwal and Pittenger, 2005). Another soluble factor that seems to 
be involved in the suppression of T cell proliferation is adenosine. Interaction 
between MSCs and T cells leads to increased production of adenosine by MSCs, 
which interacts with adenosine A2A receptor on the surface of T cells reducing 
their proliferation in both human and mice (Sattler et al., 2011, Haddad and 
Saldanha-Araujo, 2014). MSCs secrete hepatocyte growth factor (HGF) and IL-10, 
which in combination with IDO and PGE2 leads to T cell proliferation inhibition 
and differentiation into Tregs (Meisel et al., 2004). Moreover, secretion of IL-6, 
IL-10 and PGE2 by MSCs suppresses maturation and the antigen presentation 
potential of DCs, reducing CD4+ T cell proliferation in an indirect manner 
(Aggarwal and Pittenger, 2005). MSCs can reduce IFN-γ secretion by Th1 cells 
while promoting an increased secretion of IL-4 by Th2 cells and increase the 
number of Tregs (Aggarwal and Pittenger, 2005). Therefore, MSCs can modulate 
T cell responses by inhibiting antigen specific T cell responses and promoting the 
differentiation of CD4+ T cells into Tregs.  
1.4.3.3.2 MSCs and B cells 
 
MSCs inhibit B cell proliferation and activation in vitro, as well as differentiation 
via the programmed death 1 pathway (Augello et al., 2005). CCL2 and C3 
secretion by MSCs results in the inhibition of immunoglobulin synthesis and 
secretion (Feng et al., 2014, Lee et al., 2014). As previously explained, by 
dampening Ig secretion, MSCs avoid the secretion of C3a and C5a anaphylatoxins 
that would lead to further activation of T cells and macrophages, mast cell 
degranulation and chemotaxis of immune cells that would lead to increased 
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inflammation. However, MSCs can also support the proliferation and 
differentiation of antibody-releasing B cells and this is inflammatory signal 
dependent, more precisely, IFN-γ dependent. Licensing of MSCs with IFN-γ 
increases the immunoregulatory potential of MSCs and enables the 
immunoregulation of B cells (Krampera et al., 2006, Saparov et al., 2016).  
1.4.4 MSCs clinical use 
In 1997, MSCs were shown to repair a craniofacial defect (Kadiyala et al., 1997), 
leading to an increasing interest in the therapeutic potential of MSCs due to 
their tissue regenerative capacity, which could be highly beneficial within the 
clinic for tissue degrading diseases such as rheumatoid arthritis and multiple 
sclerosis (Kemp et al., 2010, Sakaguchi et al., 2005). Moreover, their 
immunosuppressive and immunomodulatory properties led to the idea of MSCs 
being used in the treatment of autoimmune disorders and to suppress graft 
rejection and graft versus host disease (GVHD) (Farini et al., 2014). More 
importantly, the low expression of HLA molecules results in MSCs having poor 
immunogenicity in vitro, in pre-clinical and in human studies, which enables the 
use of allogeneic donors (Klyushnenkova et al., 2005, Koc et al., 2002). On top of 
this, MSCs can be isolated from a variety of tissues and can be easily expanded 
for mass production of a good manufacturing practice (GMP)-grade cell product. 
As a result, MSCs have huge potential as cellular therapeutics within different 
diseases including GVHD and type 1 diabetes mellitus (T1DM) among others.  
1.4.4.1 MSCs migratory capacity 
For MSCs to be effective within a clinical setting, MSCs must migrate to sites of 
tissue injury. MSCs have been shown to migrate to sites of injury. As examples, 
after cerebral ischemia MSCs have been shown to migrate into sites of brain 
injury (Mahmood et al., 2003, Chen et al., 2001) and in a model of allograft 
rejection, MSCs were able to migrate into the infarcted myocardium (Barbash et 
al., 2003). However, an engraftment study using three different administration 
methods in cardiac disease proved that only 1 to 5% of delivered cells engraft 
within the target site regardless of the delivery route (Freyman et al., 2006). 
Intravenous (IV) infusion of MSCs leads to engraftment of MSCs mostly in the 
lungs, which is likely generated by the small capillary size, the large size of the 
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cells and their strong adhesive properties. However, MSCs can also be found in 
the spleen, liver, bone marrow, thymus, kidney and skin seconds or minutes 
after IV injection, but, it is still unknown if MSCs migrate specifically to these 
organs or they just get trapped (Devine et al., 2003, Fischer et al., 2009, 
Freyman et al., 2006, Schrepfer et al., 2007).  
The mechanisms used by MSCs to migrate from periphery into tissue injury 
remain unknown, but it is likely that they comprise a combination of adhesion 
molecules and chemokines and their receptors. To support this hypothesis, there 
is a large body of literature describing the constitutive expression of chemokine 
receptors on MSCs. CCR1, CCR7, CXCR2, CXCR6, CX3CR1 and, more importantly, 
CXCR4 are decisive receptors in the context of homing. However, the expression 
of these markers varies among reports in the literature due to tissue source of 
isolation, cell culture methods and passage number of the cells. CXCR4 has been 
described as a major player in directing MSC homing to sites of injury but some 
groups have described no expression of this receptor on MSCs (Von Luttichau et 
al., 2005), some have found a small expression (Wynn et al., 2004) whilst others 
have shown functional CXCR4 in MSCs (Kortesidis et al., 2005). Murine BM MSCs 
have been described to express CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, 
CCR9, CCR10, CXCR3, CXCR4 and CXCR7 and to have functional CCR3, CCR4, 
CCR5, CCR7, CCR10 and CXCR4 (Alexeev et al., 2013). Ad MSCs have higher 
CXCR4 expression and migration capacity than BM MSCs and more interestingly, 
the chemokine receptor profile is sensitive to time in culture (Heirani-Tabasi et 
al., 2017). In addition, expression of chemokine receptors and ligands can be 
upregulated by cytokine-mediated stimulation and hypoxia (Croitoru-Lamoury et 
al., 2007, Jin et al., 2018). All this together suggests that MSCs isolated from 
different sources exhibit differential chemokine receptor expression and 
therefore, differential homing potential to sites of inflammation, which could be 
of high relevance to enhance migration when using MSCs as cellular 
therapeutics.  
1.4.4.2 MSCs in Graft Versus Host Disease and Solid Organ Transplantation  
Some haematological malignancies and blood cells disorders, such as sickle-cell 
anaemia, can be treated with allogeneic haematopoietic stem cell transplant 
(HSCT). These allografts contain mature T cells that can target and eradicate 
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malignant cells in the recipient; however, these cells can also target the 
recipient as nonself leading to GVHD (Korngold and Sprent, 1978).  
To better understand GVHD, mouse models were created using radiation or 
chemotherapy to deplete haematopoietic cells and reconstituting the immune 
system with allogeneic bone marrow cells. Due to the immunomodulatory and 
anti-inflammatory properties of MSCs, it was hypothesised that MSCs could 
improve the engraftment of HSCs and increase the longevity of the graft by 
diminishing GVHD. Infusion of BM MSCs in an MHC mismatched mouse model of 
HSCT showed that BM MSCs decreased the severity of GVHD while promoting 
graft survival. These results were coupled with reduced infiltration of T cells and 
inhibition of the co-stimulatory molecules CD80 and CD86 on host DCs (Wen et 
al., 2015).  
In humans, GVHD is treated with high-dose corticosteroids but 40 to 60 % of 
patients develop steroid resistance, which has a very poor prognosis. For these 
patients, a promising alternative to immunosuppressants is MSC infusion. 
Between 2001 and 2007, 55 patients who had developed steroid resistance were 
infused with 1 to 5 doses of MSCs obtained from matched sibling donors, 
haploidentical donors and third-party HLA-mismatched donors. 70% of the 
patients showed clinical improvement and 54% of the patients had complete 
responses to the treatment regardless of donor major histocompatibility 
matching (Le Blanc et al., 2008). The first industry-sponsored phase III trial of 
MSCs for treatment of steroid-refractory GVHD was completed in 2009 and was 
deemed a failure as complete remission at day 28 after infusion of MSCs was not 
increased compared to placebo. This study included both children and adults 
with any grade of steroid-resistant GVHD. However, children were described to 
respond better to allogeneic MSC treatment and gut and liver GVHD were 
observed to be more responsive than skin GVHD. Taking this into account, a new 
study to treat paediatric GVHD was performed and in 2018 it was shown to be 
successful as MSC infusion significantly improved day 28 overall response in 
steroid-refractory GVHD paediatric subjects (Galipeau and Sensébé, 2018). For 
this reason, MSCs are being studied as a promising strategy to regulate anti-
donor immune responses in solid organ transplantation (SOT) to achieve long-
term stable graft function without the need for immunosuppression. Phase 1 
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clinical trials have been carried out in kidney, liver and lung transplantation 
infusing allogeneic BM MSCs or UC MSCs and in all the cases MSC-treated patients 
showed good graft function at one year (Soeder et al., 2015, Sun et al., 2018, 
Keller et al., 2018). More importantly, time of MSC infusion has been shown to 
be critical; MSC infusion prior to transplantation leads to migration of MSCs to 
lymphoid organs where they promote the expansion of Tregs. In contrast, MSC 
infusion after kidney transplantation resulted in premature graft dysfunction 
coupled with neutrophils and complement deposition (Casiraghi et al., 2012). 
This is likely explained by the lack of MSC licensing; infusion of MSCs post-
transplantation does not enable interaction of the MSCs with the inflammatory 
environment for long enough to exert their anti-inflammatory and 
immunomodulatory properties (Krampera, 2011). 
1.4.4.3 MSCs in Diabetes Type 1 
Type 1 Diabetes mellitus is a chronic autoimmune disorder resulting in the 
destruction of the insulin producing beta cells in the islets of Langerhans as a 
result of targeting islet cell autoantigens. Autoreactive T cells are considered 
the main effectors of beta cell destruction but macrophages, DCs and B cells are 
also involved (Yoon and Jun, 2005). The most comprehensive analysis to date 
concludes that there are 350,000 people in the UK living with T1DM, costing the 
NHS £1 billion per year (Stedman et al., 2020).  
Daily insulin injections with the aim of restoring blood glucose levels is the most 
common method of treatment for individuals with T1DM. T1DM can be fatal if 
untreated and in some cases the disease cannot be well controlled with insulin, 
leading to hypoglycaemic unawareness. For these patients, the Scottish National 
Blood Transfusion Service (SNBTS) offers an islet transplant service to re-
establish glycaemic awareness and have a better control of the disease. This 
procedure involves the isolation of islets of Langerhans from the pancreas of a 
donor to infuse them into the diabetic patient. The pancreas of diabetic patients 
is the site of autoimmune destruction and surgical intervention in this organ is 
highly complicated. Due to the high irrigation and the unique blood supply that 
promotes a tolerogenic state, the liver is the recipient of these cells. The 
success of the procedure avoids the patients having to use insulin. However, the 
success rate, defined as absence of insulin requirement 3 years after the 
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intervention, is just 44% due to long term deterioration and rejection (Bruni et 
al., 2014). For this reason, there is undergoing research on protecting the islets 
from recipient immune attack; current proposals include physically 
encapsulating the islets within a semi-permeable membrane consisting of 
polymer (Sakata et al., 2012) and MSCs co-transplantation to immunoregulate 
and dampen inflammation improving graft survival (Figliuzzi et al., 2014).  
Two main models have been used to study the effect of MSC administration in 
T1DM, the non-obese diabetic (NOD) mouse model and the administration of 
streptozotocin (STZ). NOD mice have a defective cytotoxic T lymphocyte-
associated protein 4 (CTLA4) gene, which is essential in the suppression of T 
cells. In this way, spontaneous autoimmune diseases are generated, including 
T1DM-like β cell destruction (Kikutani and Makino, 1992). The administration of 
STZ damages β cells resulting in the accumulation of immune cells and immune 
mediated destruction of β cells. Both of these models have shown that MSC 
administration can protect against T1DM when MSCs are administered before 
onset and that they can reverse the disease when MSCs are administered after 
onset as they can revert hyperglycaemic animals to normal blood glucose levels 
(Madec et al., 2009). Co-transplantation of insulin producing islets of Langerhans 
and MSCs has shown that MSCs can significantly delay graft rejection (Forbes et 
al., 2020), improve insulin secretion (Kerby et al., 2013) and delay allograft 
rejection (Ben Nasr et al., 2015). These observations have been paired with a 
decrease of CD4+ T cells, an increase of Th2 response mediated by a switch in 
cytokine secretion, an induction of T regulatory cells and an increase in 
vascularization (Madec et al., 2009, Forbes et al., 2020).  
 
1.5 Thesis aims 
This introduction has highlighted the anti-inflammatory and immunomodulatory 
potential of MSCs for use as cellular therapeutics in several diseases, including 
autoimmune diseases, cancer and transplantation. As SNBTS provides an islet 
transplant service, the particular interest of this thesis is focused on the co-
infusion of MSCs with islets of Langerhans to increase engraftment and survival 
of the islets. Nonetheless, our interest is not limited to this and the knowledge 
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generated in this thesis extends understanding of the immunomodulatory 
potential of MSCs within any clinical setting. It is important to bear in mind that 
most of the literature regarding phenotype, function and immunomodulatory 
properties is focused on human BM MSCs, while there is a lack of understanding 
of MSCs isolated from other tissues or other species. Murine MSCs have been 
described to be more difficult to expand in culture than human or rat MSCs, 
which results in a smaller body of literature on murine MSCs (Caroti et al., 
2017). However, mouse models are essential for performing mechanistic studies 
and preclinical testing of new therapeutics, which makes it essential to 
understand the phenotype, function and immunomodulatory properties of 
murine MSCs. 
A PhD study comparing human MSCs from tissues considered medical waste- 
islets and adipose tissue- to BM MSCs has already been performed (Thirlwell, 
2018), but this study could not take into account the xeno-challenge of using 
human MSC in the mouse models. Thus, the use of autologous murine MSCs to 
study and compare the immune reactivity and immunomodulatory potential of 
MSCs from different sources is essential. 
Chemokines are master regulators of immune cell trafficking under resting and 
inflammatory conditions; for this reason, this study set out to understand the 
chemokine receptor expression of murine MSC types. This would let us 
understand whether tissue of origin could affect the migration to specific target 
tissues if infused systemically. For local infusion, low expression of chemokine 
receptors could be preferred to avoid MSCs from migrating away from the graft 
site.  
Moreover, it was essential to understand how tissue of origin could influence the 
interaction of MSCs with their surrounding environment after infusion into a 
patient. Understanding the recruitment potential and the interaction between 
immune cells and MSCs isolated from different sources would provide insight of 
MSCs anti-inflammatory, immunomodulatory and pro-regenerative capacity in 
vivo. To study this, we analysed the chemokine and immunomodulatory protein 
secretion profiles of MSCs isolated from various sources and their interaction 
with immune cells in a mouse air pouch model. Altogether, the layout of this 
study and overall aims of each chapter are outlined below:  
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1. The aim of Chapter 3 was to fully phenotype BM, Is and Ad derived MSCs 
at rest and under inflammatory stimulation (MSC licensing).  
2. The aim of Chapter 4 was to assess and compare the mRNA expression of 
the most relevant chemokines and their receptors by MSCs at rest and 
under inflammatory stimulation. Moreover, we aimed to determine if the 
expression patterns of chemokines would persist at protein level at rest 
and under inflammatory stimulation.  
3. The aim of Chapter 5 was to determine the immune cell attraction profile 
of MSCs at rest and under inflammatory stimulation in vivo, assessing in 
this manner the functionality of the secreted chemokines.  
4. The aim of Chapter 6 was to assess and compare the mRNA expression of 
toll-like receptors, the complement system family and other 
immunoregulatory and anti-inflammatory molecules by MSCs at rest and 
under inflammatory stimulation. Moreover, we aimed to determine if the 
expression patterns would persist at protein level at rest and under 
inflammatory stimulation to better understand the immunomodulatory 
potential of MSCs isolated from different sources.  
In this manner, by looking at the chemokine and chemokine receptor expression, 
the immune cell attraction profile and the expression of immunoregulatory, anti-
inflammatory and angiogenic molecules by MSCs isolated from different sources 
we aimed to understand MSC properties and functions in vitro and in vivo. This 
knowledge would enable the prediction of roles for these cells and preferential 
MSC tissue of isolation to be administered as cellular therapeutics within specific 
clinical settings. 
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2 Materials and Methods 
2.1 Cell culture methods 
2.1.1 Growing and harvesting cells 
Manipulation of cells was done in all cases in a sterile environment using a 
laminar flow hood with HEPA filtration. Mesenchymal stromal cells were grown 
in Dulbecco's Modified Eagle Medium (DMEM) with high glucose and sodium 
pyruvate (Invitrogen) supplemented with 20% (v/v) heat-inactivated foetal calf 
serum (FCS) (Invitrogen) and 2 mM glutamine (Sigma), which is referred as 
complete medium. 3T3 Mouse Embryonic Fibroblasts (MEF) cell line (ATCC CRL-
2752) was grown in DMEM with high glucose and sodium pyruvate supplemented 
with 10% (v/v) FCS. Cells were maintained and grown in a humidified incubator 
at 37 ⁰C and 5% CO2. 
Cultures were examined daily for growth using a Zeiss optical microscope and 
when cultures achieved a cell density of greater than 80% confluence, cells were 
sub-cultured. Briefly, the medium was removed, and the cells were washed 
twice with Dulbecco's phosphate-buffered saline (DPBS) (Sigma). To detach the 
cells, cells were incubated with TrypLE™ Express Enzyme (Thermo). TrypLE was 
then inactivated in the flask with medium. Cells were then placed into a 15 ml 
falcon tube and spun down at 400 x g for 5 minutes, the supernatant was then 
removed, and cells were resuspended into an appropriate volume of culture 
medium (0.26 ml/ cm2). Cells were then distributed into new flasks at 3500 
cells/ cm2 for sub-culturing or samples were taken. A passage here describes 
detaching the cells from the flask and re-seeding them into a new one. 
2.1.1.1 Cell counting 
Cells were counted using a Neubauer Haemocytometer (Hawksley). Dead cells 
were excluded using Trypan blue (Sigma). Trypan blue was diluted 1:10 in 
phosphate-buffered saline (PBS). Cell were incubated for 5 minutes at room 
temperature with a 1:1 dilution of Trypan blue and loaded into the 
haemocytometer chamber. Live cells in the 4 large outer squares were counted, 
divided by 4 to obtain the average cell number, multiplied by 2 to account for 
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the trypan blue dilution and then by 104 to get the number of cells per 1 ml of 
the cell suspension.  
2.1.1.2 Freezing cells 
Cells were washed in PBS, detached with TrypLE as described above, spun down 
and resuspended at a density of approximately 1x106 cells/ mL in Cellbanker cell 
freezing media (Amsbio). 1 mL aliquots were transferred to 2 mL cryo-vial 
(Thermo-scientific) and stored in a freezing vessel (Nalgene, Hereford), 
containing isopropanol. This was then placed at -80 ⁰C (cooling 1 ⁰C per minute) 
and transferred to liquid nitrogen tanks within two days.  
2.1.1.3 Thawing cells 
Cells were recovered from liquid nitrogen and rapidly thawed in a 37 ⁰C water 
bath. The cells were then transferred from a cryo-vial to a 15 mL falcon tube. 
Warmed culture medium was slowly added drop by drop until cells were 
suspended in 7 mL of culture medium. The cells were then spun down at 300 x g 
for 5 minutes and supernatant was discarded. The remaining pellet was then 
resuspended in the appropriate amount of culture medium and transferred to 
tissue culture flask(s).  
2.1.2 MSCs isolation 
To isolate MSCs, female mice aged 7 to 8 weeks were used in all the cases. 
Details on how MSCs were isolated are described below. All tissues were 
processed within 30 minutes following animal death to ensure high cell viability.  
2.1.2.1 Isolation of Bone Marrow derived mesenchymal stromal cells (BM 
MSCs) 
Mice were killed with CO2 or cervical dislocation and the cadaver was laid with 
the abdominal side facing up, the limbs were stretched and fixed with pins and 
then the skin was sterilised using 70% ethanol. The skin from the hind limbs was 
removed by pulling toward the foot, which is cut at the anklebone. This 
eliminates further contact of the hind limb with the animal’s fur, which is a 
source of contaminating bacteria. Muscles, ligaments and tendons were 
dissociated from tibias and femurs using micro dissecting scissors and surgical 
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scalpel. Then, hind limbs were dissected from the trunk of the body by cutting 
along the spinal cord with care not to damage the femur. Hind limbs were stored 
on ice in Hanks' Balanced Salt Solution (HBSS) (Sigma) while awaiting further 
dissection or digestion. 
Further dissection of the hind limbs was performed under the hood. Muscle and 
connective tissue from both the tibia and the femur were further removed and 
each hind limb was dissected by cutting through the knee joint. The ends of the 
tibia and femur were cut just below the end of the marrow cavity. A 27 G needle 
attached to a 10 mL syringe with complete medium was inserted into the spongy 
bone, exposed by removal of the growth plate, and was used to flush the bone 
marrow out, which was collected in a 100 mm sterile Petri dishes (Fisher). 
Plates were incubated at 37 ⁰C with 5% CO2 in a humidified chamber leaving the 
solid mass in the medium, without disturbing them. On Day 5 cells were washed 
with DPBS twice and trypsinised for 2 minutes at 37 ⁰C, then the trypsin was 
neutralised using complete medium. The trypsinization lasted less than 2 
minutes as longer digestion is harmful for MSCs and could lift non MSCs from the 
dish. Cells were then placed into a 15 mL falcon tube and spun down at 400 x g 
for 5 minutes, the supernatant was then removed, and cells were resuspended in 
an appropriate volume of culture medium (0.26mL/cm2). Cells were then 
distributed into new flasks at 3500 cells/cm2. From then on, cells were checked 
daily for growth and medium was changed every 2-3 days to remove dead cells. 
When cells achieve a confluency of 80%, MSCs were passaged as described in 
Section 2.1.1.  
2.1.2.2 Isolation of Pancreatic Islet derived mesenchymal stromal cells (Is 
MSCs) 
To ensure the viability of the islets mice were killed by cervical dislocation and 
immediately laid with the abdominal side facing up. A midline incision was made 
around the abdomen and the skin was retracted using straight tweezers. The 
thoracic cavity was opened and heart and ribs were removed to provide a better 
access to the liver. The liver was then pushed up to the thoracic cavity and the 
intestines and stomach were pushed to the left. The rectum was cut and the 
intestines were taken out of the abdomen by pulling out from the rectum to 
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increase the visibility of the pancreas. The mesenteric fat attached to the 
intestines was removed to avoid confusion with the pancreas. Once the pancreas 
was visible, the spleen was identified and lifted to facilitate the access to the 
tail of the pancreas, which has been described to have a higher and more 
compact number of islets compared to the head of the pancreas (Elayat et al., 
1995). The pancreas was then micro-perfused with 4 mL of 0.6 mg/mL cold 
collagenase P in HBSS using a 30 G needle with a 5 mL syringe.  
Pancreas was then removed from the abdomen and put into 1 mL of 0.6 mg/mL 
collagenase P in HBSS on ice. Next, 10 mL of warm HBSS was added to the tissue 
and the collagenase was activated by placing the tissue at 37 ⁰C for 19 minutes. 
After digestion, collagenase was inactivated by adding 10 mL of cold HBSS. 
Tissues were then agitated twice per second for a minute. 40 mL of room 
temperature HBSS was then added to the tissue, which was followed by 
centrifugation at 1200 x g for 2 minutes. The supernatant was discarded and the 
pellet was resuspended in 10 mL of HBSS. The sample was then filtered through 
a 400 µm cell strainer. An extra 10 mL of HBSS was added to the tube containing 
the islets to ensure all the islets went through the filter. Samples were 
centrifuged at 1200 x g for another 2 minutes; the supernatant was discarded 
and the pellet was dried. The pellet was then resuspended into Histopaque 1077 
(Sigma) and HBSS was carefully added without resuspending it with the 
Histopaque 1077. Centrifugation of the sample at 1200 x g for 20 minutes with 
the brake off leads to the generation of a density gradient, also known as Ficoll 
gradient centrifugation, that allows the isolation of the islets from the remaining 
acinar tissue (Orloff et al., 1987). Islets were carefully removed with a Pasteur 
and where counted under the microscope.  
Islets were centrifuged and plated out on 100-mm sterile Petri dishes (Fisher) at 
a concentration of 10 islets/ cm2 and were cultured at 37 ⁰C in 5% CO2 in MSC 
culture medium. At day 7, MSC cells had already started the migration from the 
islets to the plate and therefore, media was carefully replaced and then changed 
every 3-4 days. Once the cells had reached 80% confluency the adherent MSCs 
were passaged as described in Section 2.1.1 with an exception; to remove islets 
and cell debris cells were passed through a 100 µM cell strainer. The cells were 
counted using a haemocytometer and classified as passage 2 (P2).  
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2.1.2.3 Isolation of Adipose Tissue derived mesenchymal stromal cells (Ad 
MSCs) 
Animals were sacrificed as above. A midline incision was made around the 
abdomen and the skin was retracted using straight tweezers. The muscular wall 
was then opened to expose the liver and intestines. Perigonadal adipose tissue 
was harvested. Adipose tissue was digested using 0.2mg/mL Collagenase P 
(Roche) and 0.1mg/mL DNAse (Roche) in HBSS for 40 minutes at 37 ⁰C. After 
incubation, collagenase was inactivated using medium and the soft tissues were 
plated into 100 mm sterile Petri dishes (Fisher).  
Plates were incubated at 37 ⁰C with 5% CO2 in a humidified chamber leaving the 
solid mass in the medium, without disturbing it. On Day 5 cells were washed 
with DPBS twice and trypsinised for 2 minutes at 37 ⁰C, then the trypsin was 
neutralised using complete medium. Cells were then placed into a 15 mL falcon 
tube and spun down at 400 x g for 5 minutes, the supernatant was then removed 
and cells were resuspended in an appropriate volume of culture medium 
(0.26mL/cm2). Cells were then distributed into new flasks at 3500 cells/cm2. 
From then on, cells were checked daily for growth and medium was changed 
every 2-3 days to remove dead cells. When cells achieve a confluency of 80%, 
MSCs were passaged as described in Section 2.1.1.  
2.1.3 MSC licensing with stimulatory molecules  
When cultures achieved a cell density >80% confluence, the medium was 
discarded and the cells were washed twice with DPBS. MSC culture medium was 
replaced with medium supplemented with stimulatory molecules as detailed in 
Table 2-1.   
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Table 2-1. List of inflammatory reagents used for MSC licensing. 
Name given 
in figures 
Reagent Company Final 
concentration 
Cyt Interferon-γ  Peprotech 40 ng/mL  
Tumour Necrosis Factor-α  Peprotech 40 ng/mL  
Interlukin-1β  Peprotech 40 ng/mL  
LPS Lipopolysaccharides from 
Escherichia coli O127:B8 
Sigma 
Aldrich 
100 ng/mL  
LTA Lipoteichoic acid from 
Staphylococcus aureus 
Sigma 
Aldrich 
100 ng/mL  
Poly I:C Polyinosinic–polycytidylic 
acid sodium salt  
Sigma 
Aldrich 
4 mg/mL 
 
Three different licensing conditions were tested.  
In the first one, cells were stimulated for 48 hours, after which they were 
washed twice with PBS and fresh culture medium was added; cells were 
harvested 24 hours later.  
In the second condition, cells were washed twice with PBS, the culture medium 
was replaced with fresh medium and the cells were left growing for 48 hours. 
Cells were then washed twice with PBS, the culture medium was replaced with 
supplemented medium and the cells were harvested 24 hours later. 
 In the last condition, cells were stimulated for 48 hours, after which cells were 
washed twice with PBS and were stimulated again for another 24 hours. Figure 
2-1 illustrates the time points at which supplemented medium was added. 
Culture medium, collected at the same time as the cells were harvested, was 
kept for experimental procedures.  
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Figure 2-1. Diagrammatic illustration of the time course of the MSC licensing. 
 
2.1.4 Differentiation assays 
MSCs were differentiated into adipocytes, chondrocytes and osteoclasts using 
the Mouse Mesenchymal Stem Cell Functional Identification Kit (R&D Systems) 
following the manufacturer’s instructions. All reagents and materials are listed 
in the manufacturer’s handbook.  
2.1.4.1 Adipogenesis and osteogenesis 
MSCs from different sources were plated at 2.1x104 (adipogenesis) or 4.2x103 
(osteogenesis) confluency in 4-well Nunc™ Lab-Tek™ Chamber Slides (Thermo 
Fisher Scientific). Cells were cultured in 0.5mL/well 90% α-MEM, 10% (v/v) FCS 
and 1% (v/v) 100X Penicillin-Streptomycin-Glutamine. For adipogenesis, when 
MSCs reached 100% confluency, culture medium was replaced by 0.5mL/well of 
adipogenic differentiation medium (10μl/mL of Adipogenic Supplement added to 
α-MEM culture medium). For osteogenic differentiation, once cells were 50-70% 
confluent, culture medium was replaced with 50 μl/mL of osteogenic 
supplement added to α-MEM culture medium. From then on, in both cases, 
freshly prepared supplemented culture medium was replaced every 3-4 days for 
14-21 days. Cells were then fixed and stained as stated in Section 2.3.2.1.  
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2.1.4.2 Chondrogenesis 
For the differentiation of MSCs into chondrocytes, 2.5x105 MSCs were transferred 
into a 15mL conical tube in chondrogenic culture medium (99% DMEM/ F12, 1% 
Insulin-Transferrin-Selenium supplement and 1% Penicillin-Streptomycin-
Glutamine) and spun down at 200 x g for 5 mins at room temperature. 
Supernatant was poured off and MSCs were resuspended in chondrogenic culture 
medium and spun again at 200 x g for 5 mins. MSCs were left in the chondrogenic 
culture medium as a pellet and placed into the incubator with the 15 mL conical 
tube lids slightly loosened for gas exchange. Chondrogenic culture medium was 
replaced every 2-3 days with caution so as not to disturb the pellet and cultured 
for 21 days. After 21 days, the spherical mass of cells was removed and prepared 
for cryosectioning and further staining as explained in Section 2.3.2.  
2.1.5 Depletion of CD45 positive population 
Flow cytometry-based analysis of Islet derived MSCs showed a CD45 positive 
population. To further examine this population, CD45 MicroBeads (Miltenyi 
Biotec) were used to isolate the CD45 positive cells. Cell separation buffer was 
prepared by diluting MACS BSA Stock Solution (Miltenyi Biotec) 1:20 in autoMACS 
Rinsing Solution (Miltenyi Biotec). 
Cells were harvested as explained in Section 2.1.1. Cells were then counted and 
centrifuged at 300 x g for 10 minutes and the supernatant was pipetted off. The 
cell pellet was then resuspended in 90 µL of degassed buffer per 107 cells. Next, 
10 µL of CD45 MicroBeads per 107 cells were added and the mix was incubated 
for 15 minutes on ice. Cells were then washed by adding 2 mL of buffer per 107 
cells and centrifuged at 300 x g for 10 minutes. The supernatant was removed 
and cells were resuspended in 500 µL of buffer. Cells were then ready for 
magnetic separation. The CD45 depletion was done using LS Columns (Miltenyi 
Biotec) and the MACS MultiStand (Miltenyi Biotec) separator. The LS columns 
were placed in the magnetic field of the separator and columns were prepared 
by rinsing with 3 mL of the buffer. The cell suspension was then applied onto the 
column and the unlabelled cells, which passed through the column, were 
collected. The column was washed three times with 3 mL of buffer. The total 
effluent was collected and labelled as CD45- cells. To harvest the magnetically 
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labelled cells, columns were removed from the separator and placed on a 
suitable collection tube. 5 mL of buffer was pipetted onto the column and the 
cells were flushed out by firmly applying the plunge supplied with the column. 
This fraction was labelled as CD45+ cells. Cells were then distributed into new 
flasks at 3500 cells/ square2 for sub-culturing or samples were taken. 
 
2.2 Molecular biology  
2.2.1 Ribonucleic acid (RNA) extraction from cells 
Pipettes, bench surfaces, tubes and labware were cleaned before use with 
RNase AWAY® and DNA AWAY™ Surface Decontaminants (Molecular BioProducts) 
to reduce the degradation of RNA from environmental RNases. A pellet of a 
maximum of 5 x 106 cells was disrupted and homogenised using the QIAshredder 
system (Qiagen) and total RNA was then extracted with the RNeasy Mini Kit 
(Qiagen) according to the manufacturer’s instructions, which included the 
optional DNase digestion step using the RNase Free DNase Set (Quiagen). RNA 
was eluted by the addition of 50 µL of RNase free water. The concentration and 
quality of the RNA samples was tested by ultraviolet absorption at 260/280 nm in 
a ThermoFisher Nanodrop 1000 spectrophotometer. The quality of the RNA was 
tested in a 1% agarose gel. RNA was immediately used or stored at -80 ⁰C in an 
eppendorf tube until needed; RNA was quantified after each defrost.  
2.2.2 RNA reverse transcription  
RNA was reverse-transcribed by QuantiTect Reverse Transcription Kit (Qiagen), 
which includes a genomic DNA elimination step. Genomic DNA elimination of 1µg 
of RNA was performed using the reaction mixture explained on Table 2-2 and 
incubating the mixture for 2 minutes at 42 ⁰C and then placing it immediately on 
ice. Reverse transcription was accomplished using the reaction mixture detailed 
in Table 2-3 and applying an initial step at 42 ⁰C for 15 minutes followed by a 
denaturation step at 95 ⁰C for 3 minutes. cDNA was stored at -20 ⁰C until it was 
required for gene expression studies. Reverse transcription controls were used to 
ensure the efficacy of this project; these controls were made by replacing the 
enzyme with RNase free water.  
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Table 2-2. Reaction mixture for genomic DNA elimination using the QuantiTect Reverse 
Transcription Kit (Qiagen).  
Reagent  Volume (µl) Final concentration 
gDNA Wipeout Buffer, 7x 2 1x 
Template RNA, 1 µg Variable 1x 
RNase free water  Up to 14 NA 
 
Table 2-3. Reaction mixture for RNA reverse transcription using the QuantiTect Reverse 
Transcription Kit (Qiagen). 
Reagent  Volume (µl) Final concentration 
Quantiscript Reverse Transcriptase 1 1x 
Quantiscipt RT Buffer, 5x 4 1x 
RT Primer Mix 1 1x 
Entire genomic DNA elimination 
reaction 
14 NA 
 
2.2.3 Primer design 
Pairs of primers were designed to relatively quantify the amount of specific 
cDNA in a sample by SYBR Green. The cDNA sequences used to design the 
primers were obtained from the NCBI Nucleotide database, which is available 
online at: https://www.ncbi.nlm.nih.gov/nucleotide/. Primers were designed 
using the Primer 3 Plus software, which is available online at: 
http://primer3plus.com/cgi-bin/dev/primer3plus.cgi. To ensure an accurate 
amplification and a high efficiency, primers were designed using strict criteria. 
Primers had to be between 18 and 24 base pairs (bp) in length, with 20 bp as the 
optimal length. The GC content had to be between 40% and 60%, with 50% the 
ideal percentage, avoiding stretches of more than 4 G or C bases and avoiding 
more than two G or C bases in the last 5 bases situated at the 3’ end of each 
primer. The melting temperature (Tm) should be as close to 60 ⁰C as possible and 
the amplicon size should be less than 150 bp. However, the most important was 
that the 3’ self-complementary should not be higher than 1 while the self-
complementary should not be higher than 2. In the cases in which all these 
criteria could not be matched, all the conditions but the 3’ self-complementary 
were relaxed.  
To ensure the specificity of the primers for the gene of interest the BLAST 
analysis online tool (https://blast.ncbi.nlm.nih.gov/Blast.cgi) was used. For 
SYBR Green assay custom made primers were obtained from Integrated DNA 
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Technologies (Table 2-5). To further confirm the specificity of the primers, the 
primers were first used to run a PCR reaction with any cDNA containing the gene 
of interest. The reaction mixture was set up as outlined in Table 2-4 and the 
cDNA was amplified as follows: an initial step at 98 ⁰C for 3 minutes, 35 cycles of 
denaturation at 98 ⁰C for 10 seconds, followed by the annealing at the Tm of 
each pair of primers for 30 seconds and elongation at 72 ⁰C for 20 seconds. The 
35 cycles were followed by a final elongation step at 72 ⁰C for 10 minutes. The 
PCR product was then run at 75 V in a 1% agarose gel and specificity was 
confirmed if a single amplification product with the expected molecular weight 
was observed.  
Table 2-4. Reaction set up for PCR indicating the reagents and their concentrations.  
Reagent  Volume (µl) Final concentration 
Phusion HF Buffer x5 5 1x 
dNTPs (10mM) 0.5 200 µM each dNTP 
Forward primer (10µM) 1.25 0.5 µM 
Reverse primer (10µM) 1.25 0.5 µM 
DMSO 0.75 3% 
Phusion DNA Polymerase 0.25 0.5 U 
cDNA (1:5)  1 NA 
ddH2O Up to 25 NA 
 
Table 2-5. List of forward and reverse primers used during this study.  
Gene Forward primer Reverse primer 
CD45 TGGTGTGCAGCTATGAGCAA GTCCATTCTGGGCGGGATAG 
CD45 GACAACCTTCGTGCCCAAAC TGACGAGTTTTACACCGCGA 
B2M GGTGACCCTGGTCTTTCTGG TGTTCGGCTTCCCATTCTCC 
CCL2 AGCCAACTCTCACTGAAGCC GCGTTAACTGCATCTGGCTG 
CCL3 CAGCCAGGTGTCATTTTCCT CAGGCATTCAGTTCCAGGTC 
CCL4 TGACCAAAAGAGGCAGACAGAT GCTGTGCCACATCTCTTGGT 
CCL5 CTGCTGCTTTGCCTACCTCT ACACACTTGGCGGTTCCTT 
CCL7 TGAAAACCCCAACTCCAAAG TTAGGCGTGACCATTTCACA 
CCL9 CTCACAACCACGGACCTACA CACTGGGGAAGACCAAAGAA 
CCL11 GCACCCTGAAAGCCATAGTCT TGGGGTCAGCACAGATCTCT 
CCL19 GTGCCTGCTGTTGTGTTCAC CAAGACACAGGGCTCCTTCTG 
CCL20 CGACTGTTGCCTCTCGTACA CTTCATCGGCCATCTGTCTT 
CXCL1 CCGAAGTCATAGCCACACTCA AGGTGCCATCAGAGCAGTCT 
CXCL2 CCTCAACGGAAGAACCAAAG AGGCACATCAGGTACGATCC 
CXCL5 GCCCTACGGTGGAAGTCATA GTGCATTCCGCTTAGCTTTC 
CXCL10 GCTCAAGTGGCTGGGATG GAGGACAAGGAGGGTGTGG 
CXCL12 CCTCAACCCACCATGCTCAT GAGACAGTCTTGCGGACACA 
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Gene Forward primer Reverse primer 
CXCL13 CATACCCAACCCACATCCTT GCCTGTTCTCAAATAGCCTTTC 
CXCL16 TGCTGACCCTTTGCCTCTAC GGCTGGCTTGGACTAAATAACA 
CCR1 GCCCTCATTTCCCCTACAA CGGCTTTGACCTTCTTCTCA 
CCR2 TGTGGGACAGAGGAAGTGG GGAGGCAGAAAATAGCAGCA 
CCR3 ACCTTCGGCTCTTTTTCCAC TGTTCTTTCCATTTTCTCACCA 
CCR4 GCACCAAGGAAGGTATCAAGG TGAACAGGACCAGAACCACA 
CCR5 GGATTTTCAAGGGTCAGTTCC GAAGACCATCATGTTACCCACA 
CCR6 TCTTCACCCCTTTGCTGTTT GCTCTGTGCCTCTTGGAGTT 
CCR7 ATTGCTGCTGAGGGAAGAG ACTTTTGGCTGTCGTTTTGG 
CCR8 CCCTTTGCCATCCTCCTGTT ATGGCTCTGGTCCTGTTGTG 
CCR9 GAGTCTTGCTCCCAATCCAC TAGGTTCCCACCATCCAAAC 
CCR10 CCTGCTCTGCTCCTACTGAGA CCTGGGATTGTTTCTTTAGCC 
CXCR1 TGTCCCTTCTGAGCTTGCTG CCAAGAAGGGCAGGGTCAAT 
CXCR2 TGTCTGCTCCCTTCCATCTT CCATTTCCTCTCCTCCACCT 
CXCR3 AGTGCTTGTCCTCCTTGTAGTTG GGTGTTGTCCTTGTTGCTGA 
CXCR4 CTACAGCAGCGTTCT CAT CCT CTTTTCAGCCAGCAGTTTCCT 
CXCR5 ACTGTGATCGCTCTG CAC AA GTGCAGGTGATGTGGATGGA 
CXCR6 GACTCTGGGGTTCTT CCT GC CAGCAGGAACACAGCCACTA 
CX3CL1 CAACTTCCGAGGCACAGGAT AGATGTCAGCCGCCTCAAAA 
ACKR1 CCCTATGCAACCTGGGCTAC TGGGGTTCAGGCAAGCATAG 
ACKR2 TTCTCCCACTGCTGCTTCAC TGCCATCTCAACATCACAGA 
ACKR3  TGTCCCTGCCTGATACCTACT GGACAGCAAAGCCCAAGATG 
ACKR4 CCGAGACCCAACCATCAACA TCCACACTTTGCCCACTTGT 
CX3CL1 CAACTTCCGAGGCACAGGAT AGATGTCAGCCGCCTCAAAA 
CX3CR1 ACCCCTTTATCTACGCCTTTG CTGTCCTGCCTGCTCCTCT 
XCR1 GGGATCAAGTTCCGCAGACA ATGTGCCCATCCTCTCCTCT 
IL1R1 CCGAACCGTGAACAACACAA TCAATCTCCAGCGACAGCAG 
IL1R2 GATGTCTGGGCATCTGCTTTC CCCTTGGAGCCCAATGCTAT 
TNFRSF1a GCTGTTGCCCCTGGTTATCT ATGGAGTAGACTTCGGGCCT 
TNFRSF1b CAGGACCCTTGGCGTTACAT TTGGCAAGGTGGTTGTCAGT 
IFNGR2 CCAGCAATGACCCAAGACCA TTCGGCTCCAGCAACCTATG 
IFNGR1 ACGGTGATCTGTGAAGAGCC TGCGTCTTTGTGTCGGAGTT 
TLR1 GGCACGTTAGCACTGAGACT GCTGACGGACACATCCAGAA 
TLR2 CGTTGTTCCCTGTGTTGCTG GGATAGGAGTTCGCAGGAGC 
TLR3 GAACAACGCCCAACTGAACC GAGAAAGTGCTCTCGCTGGT 
TLR4 GCATGGCTTACACCACCTCT TTTGTCTCCACAGCCACCAG 
TLR5 TCTCCAGACGCCTCATCTCA GTTCCAAGCGTAGGTGCTCT 
TLR6 ACGAAGCTGACTTTCCTGGG GTGAGCAACTGGGAGCAGAT 
TLR7 ACCCATACTTCTGGCAGTGC CCAAGGCATGTCCTAGGTGG 
TLR8 TGCACATTCCCTGGAGACAC AGAGGAAGCCAGAGGGTAGG 
TLR9 AATGGCTCTCAGTTCCTGCC CCTGCAACTGTGGTAGCTCA 
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Gene Forward primer Reverse primer 
TLR11 CCTTACCTTGACTGGCTGGG GCAAGATGCCAAAAGGTGCA 
TLR12 ATTCCAGGAGCTCCAGCAAC CTTACCCAGGTGAAGCAGGG 
TLR13 CAAGTGCCAGCTCTCCTTCA TGGCTCAGATCTAGGCTGGT 
C1QA AAGGGTCGCATTTACCAGGG GCCGAGGGGAAAATGAGGAA 
C1QB TCTTCCTGCCTCTAGGGACC CCTGCTGCTGTCCTCAGAAA 
C1QC CCAACAGCGTCTTCTCTGGT CAGGAACCAGGGTGGACTTC 
C1R AGCAGCAATGCAGTGGATCT TGGTGTAGTGCAGCTTCCAG 
C1Sa TAGAGCCGTCAGAGAGCTGT TTCCTCGATGCCTCCTGAGA 
C2 ATCACCTTTGCCTCTCAGCC TCCGTCACATCCTGGGATCT 
C3 TGCTGGCCTCTGGAGTAGAT AGGCAGTCTTCTTCGGTGTG 
C3AR1 CCCCAAGACATTGCCTCCAT GACTGTGTTCACGGTCGTCT 
C4 TCGCAGACATCACCCTCCTA GCCCGTCAGTCTCAAAGTGA 
C5 CCTGCTGAAGCCCAAGAGAA GCAGGGTGTTTTCAAGCAGG 
C5AR1 GCCTAGCTGCTCCTTTTCCA TCATGAGGATCCTGGGCTCA 
C6 AGGAGAGCCCAGAGGAGAAG GGCTCGACTGGTCTTGACAA 
C7 CGTGTGAGCAAGGAGTCCTT CAACCTCCATCAACCCCTCC 
C8A AACTGCCGGTGTCAGTGTAG CTGACCAGGAACTCCAGCAG 
C8B GGGGCATCTACGAGTACACG CTCCAGCACAGGCAGTAACA 
C8G ACCTACTGTCCGTAGCAGGT ATAGTGCTGATGGGGGAGGT 
CD46 GGAGCTCTTATCCCCATGCC GACTGAGTGTGGAAGGCACA 
CD59 TGGTAGCCCAGCACAATGAG TGTGAGGCTAACAGCTGTGG 
CFB GTCAGGCCCTGGAGTACCTA TCTTTTGGTCTCGGGTCTGC 
CFD CAATCTGCGCACGTACCATG CCACGTAACCACACCTTCGA 
CFH ACAACGGGTTTTCACCACCT GTGCAACGAAGGTAGTCCCA 
CFHR1 TGGTCACCAACTCCGAAGTG AGCCTTGATTGCAGACCACT 
CFI GCGGGGGTAGTGTGTTACAA TCGCTTTGGTCTCCACAGTC 
CFP GGCCCTGCTCAGTTACATGT AGCTGCCACTCAAGAGTTCC 
CR1L GGATTCCAGAAGGGGTTGGG TTCCAGCTGCCATCAGACTG 
CR2 GCCCCGATCCAGAAGTCAAA TGCCGTTCATGATGAAGCCT 
ITGAX CAAGATGCCACCAAGGTCCT CGAATGATGCTTGCAGCCTC 
ITGB2 GCAGAAGGACGGAAGGAACA CCAGATGACCAGGAGGAGGA 
CD142 TGCTTCTCGACCACAGACAC ATAGGCCCAGGTCACATCCT 
CD274 CAGCAACTTCAGGGGGAGAG CTGTGATCTGAAGGGCAGCA 
COX2  CATCCCCTTCCTGCGAAGTT GGCCCTGGTGTAGTAGGAGA 
GMCSF AGGCTAAGGTCCTGAGGAGG GGGCTTCTTTGATGGCCTCT 
HGF TGAGTTATGTGCTGGGGCTG CACATCCACGACCAGGAACA 
IDO 1 TGGTGGAAATCGCAGCTTCT TTGACGCTCTACTGCACTGG 
IDO 2 ACCTCCCTCGTCCCTTAGTC AGAGAGTAAGCAGGGGAGGG 
IFN CACAGCCCTCTCCATCAACT GCATCTTCTCCGTCATCTCC 
IL-10 CAGAGAAGCATGGCCCAGAA GCTCCACTGCCTTGCTCTTA 
IL-1B CGCTCAGGGTCACAAGAAAC GAGGCAAGGAGGAAAACACA 
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Gene Forward primer Reverse primer 
IL-6 TTCCATCCAGTTGCCTTCTT ATTTCCACGATTTCCCAGAG 
iNOS GAGCCACAGTCCTCTTTGCT CAACCTTGGTGTTGAAGG G 
MMP9 AAACCCTGTGTGTTCCCGTT CCTTTAGTGGTGCAGGCAGA 
TGF- 1 CTTTGTACAACAGCACCCGC CATAGATGGCGTTGTTGCGG 
TNF- CACCACCATCAAGGACTCAA GAGGCAACCTGACCACTCTC 
TSG-6 CGGATACCCCATTGTGAAAC TCCTTTGCATGTGGGTTGTA 
VEGF a AACGATGAAGCCCTGGAGTG GCTGGCTTTGGTGAGGTTTG 
VEGF b AGAGTGCTGTGAAGCCAGAC GATGATGTCAGCTGGGGAGG 
VEGF c AACCTCCATGTGTGTCCGTC TGCTGAGGTAACCTGTGCTG 
VEGF d TTCAGGAGCGAACATGGACC CCACAGCTTCCAGTCCTCAG 
 
2.2.3.1 Buffers and reagents for agarose gel electrophoresis 
Table 2-6. List of buffers and reagents for agarose gel electrophoresis and their 
composition  
Solution Composition Concentration 
10% TAE TRIS 
Glacial acetic acid  
EDTA 
0.4 M 
17.4 M  
0.5 M 
1% agarose gel Agarose 
SYBR Safe DNA gel stain  
TAE  
1% (w/v) 
7% (v/v) 
1x 
 
Length of DNA was assessed with the use of GeneRuler 1 kb DNA Ladder (Thermo 
Fisher Scientific) and GeneRuler 100 bp DNA Ladder (Thermo Fisher Scientific).  
2.2.4 Quantitative reverse transcription PCR (qRT-PCR) 
To quantitatively study gene expression a SYBR Green quantitative reverse 
transcription PCR assay was performed using the Applied Biosystems 7900HC Fast 
Real-Time PCR Systems detection system (Applied Biosystems).  
Reactions were set up in 96 well plates as outlined in Table 2-7 and cDNA was 
amplified as follows: denaturation and polymerase activation at 95 ⁰C for 3 
minutes, amplification during 40 cycles at 95 ⁰C for 3 s followed by 60 ⁰C for 30 
s. The direct detection of the PCR products was followed by the measurement of 
the fluorescence released from the SYBR Green I Dye when it binds to the 
double-stranded product after each cycle.  
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Table 2-7. Reaction set up for real time quantitative PCR analysis indicating the reagents, 
and their concentrations. 
Reagent  Volume (µl) Final concentration 
PerfeCTa SYBR Green FastMix with 
ROX dye (VWR) x 2  
20 1x 
Forward primer (100 µM) 0.3 0.75 µM 
Reverse primer (100 µM) 0.3 0.75 µM 
cDNA (1:5)  4 NA 
ddH2O Up to 40 NA 
 
All samples were processed in triplicate. In all cases, samples were tested using 
the beta-2 microglobulin (B2M) gene as reference for data normalization. The 
difference between the Ct value and the housekeeping gene (ΔCt) was calculated 
for each point of the triplicated sample:  
∆𝐶𝑡 = 𝐶𝑡 (𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒) −  𝐶𝑡(𝐻𝑜𝑢𝑠𝑒𝑘𝑒𝑒𝑝𝑖𝑛𝑔 𝑔𝑒𝑛𝑒) 
 
As this study did not have a reference sample, data were represented as 2(-ΔCT), 
which enables the visualization of expression levels of specific genes normalised 
to B2M for each sample. Due to the nature of normalisation, genes that 
generated a CT of 35 or above resulted in 2(-ΔCT) less than, or equivalent to, 
~0.0001. Genes with 2(-ΔCT) values similar to ~0.0001 are marked with a red box 
on the following graphs and are likely not transcribed at meaningful levels by 
MSCs. 
 
𝑮𝒆𝒏𝒆 𝒆𝒙𝒑𝒓𝒆𝒔𝒔𝒊𝒐𝒏 =  𝟐− ∆𝑪𝒕 
 
As triplicates had been done, the median of the RQ values of each sample was 
used for statistical analysis. All the experiments were done at least three times 
and the average and standard deviations were calculated. D’Agostino-Pearson 
omnibus normality test was used in order to determine if the values come from a 
Gaussian distribution. Due to the low sample size, data was considered to be 
non-parametric and differences between the samples were analysed using the 
appropriate statistical tests, which are indicated in the figure legends. 
Differences were considered to be statistically significant at p < 0.05. 
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2.3 Protein analysis 
2.3.1 Flow cytometry  
2.3.1.1 Flow cytometry staining 
When cultures achieved a cell density of greater than 80% confluence, the 
medium was removed and the cells were washed twice with DPBS. To detach the 
cells, cells were incubated with TrypLE™ Express Enzyme at 37 ⁰C for 10 minutes 
and the enzyme was inactivated with medium. Cells were then distributed for 
both sub-culturing and flow cytometry experiments. Cells were centrifuged at 
400 x g for 5 minutes following washing, detachment and enzyme inactivation.  
For fixable cell viability staining, after the detachment and centrifugation of 
cells the supernatant was discarded and cell pellets were resuspended in PBS 
and centrifuged again at 400 x g for 5 minutes. The supernatant was removed 
and cell pellets were resuspended in an appropriate volume of PBS buffer. The 
staining was done using the appropriate amount of the fixable viability dye 
eFluor506. Cells were then ready for cell surface staining.  
For cell surface immunofluorescence staining, cells were centrifuged and cell 
pellets were resuspended in fluorescence-activated cell sorting (FACS) buffer (2% 
FCS, 2 mM EDTA in DPBS) and were centrifuged again at 400 x g for 5 minutes. 
The supernatant was removed and cell pellets were resuspended in an 
appropriate volume of FACS buffer. Cells were distributed between FACS tubes 
with 1 million of cells per tube. The stains were carried out using the 
appropriate amount of each antibody followed by vortex and incubation at 4 ⁰C 
for 30 minutes in the dark. Upon incubation, cells were washed with FACS buffer 
and centrifuged at 400 x g for 5 minutes. The supernatant was discarded and cell 
pellets were resuspended in 300 µL FACS buffer and kept on ice until needed for 
flow cytometry.  
For nuclear protein staining, Fixation/ Permeabilization Solution Kit 
(BioSciences) was used. Following cell surface protein staining, cells were 
washed and thoroughly resuspended in 100 µL of BD Cytofix/ Cytoperm solution 
and incubated at 4 ⁰C for 20 minutes. Cells were then washed twice in 1x Perm/ 
Wash solution. Fixed and permeabilised cells were then resuspended in 50 µL of 
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Perm/ Wash solution containing antibody and were left incubating at 4 ⁰C for 30 
minutes in the dark. Upon incubation, cells were washed with FACS buffer and 
were resuspended in 300 µL FACS buffer and kept on ice until needed for flow 
cytometry. 
To calibrate the flow cytometer, single stains were done using UltraComp 
eBeads (Thermo); fluorescence minus one (FMO) controls were used to 
accurately gate positive staining due to the fluorescence spread of the lasers in 
the different channels. Data were acquired using the Fortessa (BD BioSciences) 
or the MACSQuant (Miltenyi Biotec) flow cytometers and analysed using the 
FlowJo version 10 software.  
2.3.1.2 Surface molecule phenotype of MSCs 
At P3, MSCs were left to grow until they were 80% confluent, detached from the 
flasks as described in Section 2.1.1 and prepared for flow cytometry as 
previously detailed in Section 2.3.1.1 using the “MSC phenotyping” panel of 
antibodies listed in Table 2-8 and run on Fortessa. Cells isolated from the islets 
required further characterisation using the “Islet characterisation” panel of 
antibodies listed in Table 2-8.   
2.3.1.3 Surface molecule phenotype of MScs in homeostatic vs inflammatory 
conditions 
At P3, MSCs were left to grow until they were 80% confluent, the medium was 
discarded and the cells were washed twice with DPBS. MSC culture medium was 
replaced with medium supplemented with stimulatory molecules as outlined in 
Section 2.1.3. After 72 hours of the first media change, cells were detached 
from the flasks as described in Section 2.1.1 and prepared for flow cytometry as 
previously detailed in Section 2.3.1.1 using the “MSC phenotyping in 
inflammation” panel of antibodies listed in Table 2-8 and run on the MACSQuant. 
2.3.1.4 Analysis of epithelial origin of Islet derived MSCs 
To analyse the cell types enclosed within the islets of Langerhans, islets were 
harvested as described in Section 2.1.2.2 and were purified by hand–picking the 
islets. Islets were then incubated with 2.5 mL of trypsin-
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ethylenediaminetetraacetic acid (EDTA) for 15 minutes at 37 ⁰C with shaking. 
Trypsin was inactivated with culture medium and cells were washed twice prior 
to staining the cells as stated in Section 2.3.1.1 using the “Islet 
characterisation” panel of antibodies listed in Table 2-8. Samples were run on 
the MACSQuant.  
2.3.1.5 Proliferation analysis 
To analyse the percentage of proliferative cells and its relationship with the 
CD45 status, cells were harvested as outlined in Section 2.1.1 and were stained 
as follows. First, the extracellular staining was performed as explained in 
Section 2.3.1.1 with the antibody panel listed in Table 2-8. To determine the 
percentage of proliferative cells, the nuclear protein Ki67 was used. Expression 
of Ki67 occurs during G1, S, G2, and M phase, while in G0 phase the Ki67 protein 
is not detectable. Intranuclear staining was done according to the 
manufacturer’s instructions. Shortly, after the extracellular staining, the cell 
pellet was loosened by vortexing. 3 mL of precooled 70% ethanol was added to 
the cell pellet while vortexing, followed by 30 seconds of extra vortexing and 
incubation at -20 ⁰C for 1 hour. After incubation, cells were washed with FACS 
buffer three times and resuspended in 100 µL. Ki67 antibody or the appropriate 
isotype was then added, and cells were left incubating at room temperature in 
the dark for 30 minutes. Cells were then washed twice with FACS buffer. All the 
antibodies used for proliferation analysis are listed in Table 2-8. 
2.3.1.6 Defining the immune cell attraction profile of MSCs in vivo 
The immune cell attraction profile of MSCs was tested in vivo by introducing 
MSCs into air pouch created in the dorsal skin of mice (described in Section 
2.4.2). Cell surface immunostaining was performed as detailed in Section 2.3.1.1 
using the “innate immune response” and “adaptive immune response” panel of 
antibodies listed in Table 2-8. 
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Table 2-8. List of antibodies use for flow cytometry during this study. 
 Antibody panel Antigen Fluorophore Clone Dilution  Supplier 
Phenotyping MSCs 
CD73 BV 421 TY/11.8 1:200 BioLegend 
CD19 BV 510 6D5  1:200 BioLegend 
CD11b BV 650 M1/70 1:200 BioLegend 
MHC Class II BV 785 M5/114.15.2 1:200 BioLegend 
CD90 FITC 30-H12  1:200 Miltenyi 
CD34 PE MEC14.7 1:200 BioLegend 
CD45 PE/Cy7 30-F11 1:200 BioLegend 
CD105 APC MJ7/18  1:200 BioLegend 
CD64 FITC X54-5/7.1 1:200 BioLegend 
Viability dye  Draq7   1:200 BioStatus 
MSC phenotyping in 
Inflammation 
CD73 BV 421 TY/11.8 1:200 BioLegend 
Fixable 
viability dye  
eFluor 506   1:1000 eBioscience 
CD166 FITC eBioALC48 1:200 eBioscience 
MHC Class I PE M1/42 1:200 BioLegend 
CD146 PE/Cy7 ME-9F1  1:200 BioLegend 
CD 271 APC REA648 1:200 Miltenyi 
MHC Class II APC/Cy7 M5/114.15.2 1:200 BioLegend 
Islet characterisation 
Fixable 
viability dye 
eFluor 506   1:1000 eBioscience 
Vimentin FITC RV202 1:200 Abcam 
CD45 PE/Cy7 K041ES 1:200 Biolegend 
CD45 PE/Cy7 I3/2.3 1:200 Biolegend 
CD326 
(EpCAM) 
APC G8.8 1:200 eBioscience 
Proliferation analysis 
Fixable 
viability dye 
eFluor 506   1:1000 eBioscience 
ki67 FITC 16A8 1:200 Biolegend 
IgG2a isotype 
control 
FITC RTK2758 1:200 Biolegend 
CD45  PE/Cy7 K041ES 1:200 Biolegend 
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 Antibody panel Antigen Fluorophore Clone Dilution  Supplier 
Innate immune 
response 
CD45 BV421 30-F11  1:200 Biolegend 
Fixable 
Viability dye 
eFluor 506   1:1000 eBioscience 
Siglec F 
  
FITC 
S17007L 1:200 Biolegend 
F4/80  PE BM8  1:200 Biolegend 
CD11c  PerCP/Cy5.5 N418 1:200 Biolegend 
CD11b  PE/Cy7 M1/70  1:200 Biolegend 
Ly6g  APC 1A8  1:200 Biolegend 
Ly6c  APC/Cy7 HK1.4 1:200 Biolegend 
Adaptive immune 
response 
CD45 BV421 30-F11  1:200 Biolegend 
Fixable 
Viability dye 
eFluor 506   1:1000 eBioscience 
CD8 alpha  PE 53-6.7 1:200 Biolegend 
CD73  PerCP/Cy5.5 TY/11.8 1:200 Biolegend 
CD4  PE/Cy7 RM4-5  1:200 Biolegend 
NK1.1  APC PK136  1:200 Biolegend 
B220  APC/Cy7 RA3-6B2  1:200 Biolegend 
  
2.3.1.7 Flow cytometry analysis 
Prior to any analysis of flow cytometry experiments the following strategy was 
used to identify the live cells within the sample. As shown in Figure 2-2, this 
strategy started by gating the cells of interest using FSC and SSC. As the flow 
cytometer registers signals caused by debris and micro-particles present in the 
sample, a threshold of 50.000 was applied in the FSC, which allowed a better 
identification of the population. Doublets where excluded using SSC-H and SSC-A 
while live cells were gated based on exclusion of a live/dead cell marker. The 
exclusion of dead cells is essential as dead cells produce false positives as they 
have increased autofluorescence levels and higher non–specific binding of 
antibodies. Analysis of the data was performed using version 10 of the FlowJo 
software.  
  97 
 
 
Figure 2-2. Flow cytometry basic cell gating strategy. 
All the flow cytometry experiments were analysed following this initial gating strategy to identify 
single live cells. A) The first step was focused on identifying cells with the appropriate size and 
granularity, B) followed by single cells gating to avoid clumps of cells. C) Due to the 
autofluorescence of death cells, a live dead marker was used to identify non-stained, and therefore, 
live cells. D) Cells were then gated for further analysis. In this specific example, life cells were 
classified into CD45 positive and negative.  
 
Multicolour flow cytometry panels can lead to fluorescence spread from the 
lasers into different channels. In order to identify a positive from a negative 
population we used a fluorescence minus one controls, which are samples that 
contain all the antibodies present in the panel minus one. For this reason, FMO 
controls were prepared for each fluorophore present in the panel. In this way, 
FMO controls behave as negative controls, letting the user know how the other 
fluorophores in the panel affect each channel, allowing a clear distinction 
between negative and positive staining as shown in Figure 2-3. 
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Figure 2-3. Use of Fluorescence Minus One (FMO) controls to accurately identify positive and 
negative populations.  
A) BV650-CD11b FMO contains all the fluorochromes in the panel but BV650, the one 
corresponding to CD11b, to allow the identification of the fluorescence spread from the different 
lasers into BV650 channel. B) PeCy7-CD45 FMO contains all the fluorochromes in the panel but 
PeCy7, the one corresponding to CD45, to allow the identification of the fluorescence spread from 
the different lasers into PeCy7 channel. C) Use of FMOs allowed the accurate identification of 
positive and negative populations in full stained samples.  
 
2.3.2 Immunocytochemistry 
2.3.2.1 Immunocytochemistry for adipocytes and osteocytes 
MSCs that had undergone adipogenic and osteogenic differentiation were grown 
and treated as described in Section 2.1.4.1. MSC differentiation medium was 
aspirated and cells were washed twice with 1 mL of PBS and then fixed with 0.5 
mL of 4% paraformaldehyde in PBS for 20 mins at RT. Cells were washed three 
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times with 0.5 mL of 1% bovine serum albumin (BSA) (Thermo Fisher Scientific) 
in PBS for roughly 5 mins each wash. The cells were permeabilised and blocked 
with 0.5 mL of 0.3% Triton X-100 (Thermo Fisher Scientific), 1% BSA and 10% 
normal donkey serum (Sigma) in PBS for 45 mins. After blocking, cells were 
incubated with 300 μL/ well of the appropriate primary antibody (Table 2-9). 
Cells were left at 4 ⁰C overnight. A negative control was run using PBS containing 
0.3% Triton X-100, 1% BSA, and 10% normal donkey serum with no primary 
antibody and another negative control was run using PBS containing 0.3% Triton 
X-100, 1% BSA, and 10% normal donkey serum with an isotype. After the 
incubation, cells were washed three times with 0.5 mL of 1% BSA in PBS for 5 
mins each wash. Cells were then incubated with a diluted appropriate secondary 
antibody (Table 2-9) for 60 mins, in the dark, at room temperature. Cells were 
washed three times with 0.5 mL of 1% BSA in PBS for 5 mins each wash.  
For nuclear visualization during fluorescent imaging PBS was removed, chambers 
were removed from the slide and one drop of ProLong Gold Antifade Mounting 
solution with DAPI (Thermo Fisher Scientific) was added to each well. Slides 
were sealed using DPX Mounting Media & Section Adhesive and slides were 
covered with 22 x 50 mm cover slips (Academy). All slides were imaged with a 
Zeiss epifluorescence microscope using the appropriate fluorescence channels 
and magnifications. Images were prepared using Zen software. 
2.3.2.2 Immunocytochemistry for chondrocytes 
The pellet of cells was washed twice with 1 mL of PBS, then fixed with 0.5 mL of 
Zinc formalin solution overnight at 4 ⁰C. The pellet was then washed twice with 
1 mL PBS for 5 mins. The pellet was carefully removed and placed into a 
cryomould. Cryosectioning was carried out as detailed in Section 2.3.2.2.1. Using 
a liquid barrier pen, a hydrophobic barrier was drawn around each section and 
cells were then blocked and permeabilised with 0.15 mL of 0.3% Triton X-100, 1% 
BSA, and 10% normal donkey serum in PBS at room temperature for 45 minutes. 
After blocking, sections were incubated with the appropriate primary antibody 
(Table 2-9) working solution overnight at 4 ⁰C. A negative control was run using 
PBS containing 0.3% Triton X-100, 1% BSA, and 10% normal donkey serum with no 
primary antibody and another negative control was run using PBS containing 0.3% 
Triton X-100, 1% BSA, and 10% normal donkey serum with an isotype control 
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antibody. Sections were washed three times with PBS containing 1% BSA for 5 
mins. Sections were then incubated in the dark for an hour with an appropriate 
secondary antibody (Table 2-9). Sections were washed three times with PBS 
containing 1% BSA for 5 mins. Sections were then washed once with distilled 
water and excess water was removed.  
For nuclear visualization during fluorescent imaging PBS was removed, chambers 
were removed from the slide and one drop of ProLong Gold Antifade Mounting 
solution with DAPI was added to each well. Slides were sealed using DPX 
Mounting Media & Section Adhesive and slides were covered with 22 x 50 mm 
cover slips. All slides were imaged with a Zeiss epifluorescence microscope using 
the appropriate fluorescence channels and magnifications. Images were 
prepared using Zen software. 
2.3.2.2.1 Cryosectioning  
 
Cells were placed in a small cryomould, OCT compound (Tissue-Tek) was gently 
poured on top, avoiding any air bubbles, samples were then snap frozen in liquid 
nitrogen and placed in the -80 ⁰C freezer until sectioning. Frozen moulds were 
placed into the cryostat (Bright Instruments) at -25 ⁰C and sectioned 8 μm thick 
onto superfrost glass slides.  
2.3.2.3 Immunocytochemistry for islets and islet derived MSCs 
10-20 islets per chamber or 3500 cells/cm2were seeded in a 4-well Nunc™ Lab-
Tek™ Chamber Slide™ (Thermo Fisher Scientific) and cells were allowed to grow 
for 7-10 days. Wells were then washed three times with 0.5 mL of room 
temperature PBS. 0.5 mL of 4% paraformaldehyde in PBS was added to each well 
and was left for incubation for 20 minutes at room temperature. 4% 
paraformaldehyde was then removed, and wells were washed three times with 
0.5 mL of PBS for 5 minutes with agitation. 0.5 mL of permeabilization and 
blocking buffer (1% BSA, 10% goat serum and 10% Triton x100 in DPBS) were 
added per well to block non-specific antibody binding and was incubated for 1 
hour at room temperature with shaking.  
Primary antibody was diluted into the permeabilization and blocking buffer 
according to the manufacturer’s instructions; 1:100 for EpCAM monoclonal 
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antibody and 1:200 for Vimentin monoclonal antibody. The blocking buffer was 
removed from the 24 well plate and 200 µL of the diluted antibodies were added 
into each well and left incubating at 4 ⁰C overnight or for 1 hour at room 
temperature. After the incubation, wells were washed three times with 0.5 mL 
of room temperature PBS for 5 minutes with shaking. Secondary antibody was 
diluted into the permeabilization and blocking buffer according to the 
manufacturer’s instructions (1:400). 200 µL of the diluted secondary antibodies 
were added into each well and was left incubating for 1 hour at room 
temperature protecting the plate from the light. After the incubation, wells 
were washed three times with 0.5 mL of room temperature PBS for 5 minutes 
with shaking while protecting the plate from the light. All the antibodies used 
for immunocytochemistry are listed in Table 2-9.  
For nuclear visualization during fluorescent imaging, PBS was removed, 
chambers were removed from the slide and one drop of ProLong Gold Antifade 
Mounting solution with DAPI was added to each well. Slides were sealed using 
DPX Mounting Media & Section Adhesive and slides were covered with 22 x 50 
mm cover slips. All slides were imaged with a Zeiss epifluorescence microscope 
using the appropriate fluorescence channels and magnifications. Images were 
prepared using Zen software. 
Table 2-9. List of antibodies used for immunocytochemistry in this study. 
Antigen Host/ Isotype Fluorophore Clone Supplier 
EpCAM Mouse/ IgG1 Unconjugated 323/A3 Invitrogen 
Vimentin Mouse/ IgM Unconjugated J144 Invitrogen 
Mouse IgG1 Mouse/ IgG1 Unconjugated P3.6.2.8.1 Invitrogen 
Mouse IgM Mouse/ IgM Unconjugated 11E10 Invitrogen 
Mouse IgG1 Goat / IgG AF 488 Polyclonal Invitrogen 
Mouse IgM Goat / IgG AF 568 Polyclonal Invitrogen 
FABP4 Goat/ IgG Unconjugated Polyclonal R&D Systems 
Collagen II Sheep/ IgG Unconjugated Polyclonal R&D Systems 
Osteopontin Goat/ IgG Unconjugated Polyclonal R&D Systems 
Goat IgG Goat/ IgG Unconjugated Polyclonal Invitrogen 
Sheep IgG Sheep/ IgG Unconjugated Polyclonal Invitrogen 
Goat IgG Donkey/ IgG NL557 Polyclonal R&D Systems 
Sheep IgG Donkey/ IgG NL558 Polyclonal R&D Systems 
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2.3.3 Western Blotting  
2.3.3.1 Buffers and reagents for Western Blotting 
Table 2-10. List of buffers and reagents for Western Blotting and their composition  
Solution Composition Concentration 
RIPA buffer Tris-HCl 1M pH 7.4 
NP-40  
Sodium deoxycholate 
SDS 
NaCl 
EDTA 
Sodium fluoride 
50 mM 
1% (v/v)  
0.5% (w/v) 
0.1% (v/v) 
150 mM 
2 mM 
50 mM 
10x SDS running buffer TRISBase 
Glycine 
SDS 
0.25 M 
2 M 
0.035 M 
Blocking solution  
 
Milk Powder 
Tween 20 
in PBS 
10% (w/v) 
0.1% (v/v) 
10x TG TRIS 
Glycine 
0.48 M 
0.39 M 
Transfer buffer 10x TG 
MeOH 
SDS 20% 
10% (v/v) 
20% (v/v) 
0.19% (v/v) 
 
Molecular weight of proteins was assessed with the use of PageRuler™ Prestained 
Protein Ladder, 10 to 180 kDa (Thermo Fisher Scientific). 
2.3.3.2 Sample preparation  
To isolate splenocytes, mice aged 10 weeks were killed with CO2 or cervical 
dislocation and the cadaver was laid with the abdominal side facing up, the 
limbs were stretched and fixed with pins and then the skin was sterilised using 
70% ethanol. A midline incision was made around the abdomen and the skin was 
retracted using straight tweezers. The muscular wall was then opened to expose 
the liver and intestines. The liver was then pushed up to the thoracic cavity and 
the intestines and stomach were pushed to the left, which enables access to the 
spleen. Spleen was then harvested and placed in 1% BSA RPMI 1640 medium 
(Thermo Fisher Scientific). To isolate splenocytes, the spleen was transferred 
into a 70 μm cell strainer and was mashed with the plunger from a 2 mL syringe. 
Grinding circular movements were used to homogenise the tissue. 20 mL of PBS 
were used to wash out the cells from within the strainer. The homogenised cell 
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suspension was then centrifuged at 300 x g for 10 minutes at room temperature 
and the supernatant was discarded. Cells were then resuspended into 10 mL PBS 
and passed through a 40 μm cell strainer and centrifuged at 300 x g for 10 
minutes at room temperature. 1mL per sample of ACK lysing buffer (Thermo 
Fisher Scientific) was used to remove the red blood cells from the spleen. 
Samples were incubated at room temperature for 1 minute and were then 
diluted in 20 mL of PBS followed by centrifugation at 300 x g for 10 minutes at 
room temperature. The supernatant was removed and discarded and the cell 
pellet was resuspended in 1 mL of PBS and the suspensions were transferred into 
microcentrifuge tubes and centrifuged for 2 minutes at 1000 rpm. The 
supernatant was removed and discarded.  
MSCs and 3T3 MEF cells were harvested as detailed in Section 2.1.1.  
2.3.3.3 Sample lysis  
Cells were lysed using radioimmunoprecipitation assay (RIPA) lysis buffer 
containing leupeptin (2 μg/mL), aprotinin (2 μg/mL), Na3VO4 (1mM) and pefabloc 
(0.5 mM) leaving them on ice for 30 minutes and centrifuged for 15 minutes at 
13,000 g at 4 ⁰C. The supernatant was then recovered and protein 
concentrations were determined using the Thermo Scientific Pierce ™ BCA 
Protein Assay Kit (Thermo Fisher Scientific). SDS to 1x was added and samples 
were boiled at 95 ⁰C for 5 minutes.  
2.3.3.4 Western Blot  
Samples were boiled in loading buffer and separated on a 10% SDS-PAGE at 80V 
until the samples were inside the gel and then the intensity was increased to 
120V till the blue front of the gel disappeared. 2.5 μL of protein ladder was 
loaded as a molecular weight reference. Proteins were transferred to a 
Polyvinylidene Difluoride (PVDF) membrane (Amersham Pharmacia Biotech) using 
a wet blotter at 25 V. Membranes were then blocked for 1 hour with blocking 
solution shaking at room temperature, followed by incubation on a rocking 
platform at 4 ⁰C with primary antibodies overnight. All the antibodies used in 
this study are listed in Table 2-11. After 3 washes with TBST 1x, membranes 
were incubated with horseradish peroxidase-conjugated secondary antibodies for 
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1 h. Antigen-antibody complexes were detected by using Clarity Western ECL 
Substrate solution (BioRad) and images acquired using darkroom development 
techniques for chemiluminescence.  
Table 2-11. List of antibodies used for Western Blot in this study. 
Antibody Host Dilution in 5% 
milk TBST 
Product reference 
Anti-CD45 Rat 1:1000 BioLegend (103101) 
Anti--actin Mouse 1:5000 Sigma Aldrich (SAB1305567) 
Anti-mouse Mouse 1:5000 Sigma Aldrich (GENXA931-1ML) 
Anti-rat Goat 1:5000 BioLegend (405405) 
 
2.3.4 Luminex 
Conditioned media from the samples used for transcript work were collected for 
Luminex analysis. The mouse personalised premixed magnetic multi-analyte kit 
was used in accordance with the manufacturer’s instructions (R&D systems). All 
reagents and standards were included in the kit and prepared as outlined in the 
guidelines. Briefly, samples were diluted 1:2 with calibrator diluent (75μl in 75 
μL). 10 μL of the pre-coated microparticle cocktail was added to each well of 
the 96 well microplates, followed by either 50 μL sample or 50 μL standard, 
sealed and placed on an orbital shaker (0.12 mm orbit at 800 ± 50 rpm) for 2 
hours at room temperature. The plates were washed twice with 100 μL/ well 
wash buffer and then incubated with 50 μL/ well anti-biotin detector antibody 
for 1 hour at RT on the shaker (0.12 mm orbit at 800 ± 50 rpm). The plates were 
washed as previously described and 50 μl/ well of streptavidin-phycoerythrin 
was added and incubated for 30 minutes at room temperature. Microparticles 
were resuspended in 100 μL/ well of wash buffer and immediately read on a Bio-
Rad analyser.  
2.3.4.1 Analysis of results 
The Luminex analysis was acquired on a Luminex 100 Bio-Rad instrument. Each 
microparticle bead region was designated as stated on the certificate of 
analysis. When beads are injected into the flow cell, a small number can 
aggregate and go through as doublets. To avoid this, the doublet discriminator 
channel measures the amount of light scatter from the particles that flow past 
the laser and specific gates were set between 8000 and 16,500 to ensure that 
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only beads of the correct size were measured. Mean Fluorescence intensity (MFI) 
was acquired. Total protein concentrations were determined using the Thermo 
Scientific Pierce ™ BCA Protein Assay Kit (Thermo Fisher Scientific) and were 
used for normalization of the data. Each bar represents an n of 3 and is plotted 
as mean ± SEM. Statistical tests included One Way ANOVA in conjunction with a 
Tukey’s compare all comparisons test when comparing across MSCs from 
different sources. Students T test was used when comparing stimulated vs 
unstimulated within one tissue source.  
 
2.4 In Vivo Procedures  
2.4.1 Animal Welfare 
All animals were housed within the Biological Central Research Facility. All 
experiments received ethical approval and were performed under the auspices 
of a UK Home Office License.  
Mice used during this study were C57BL/6, which have fully functional innate 
and adaptive compartments of the immune system. 6–week old mice were 
obtained from Charles River Europe and before any procedure was carried out, 
mice were given 7 days within the Biological Central Research Facility for 
adjustment and settling. After experimental procedures, mice were euthanised 
using a recognised Schedule 1 technique.  
2.4.2 Murine Air pouch Model  
2.4.2.1 Induction and maintenance of the air pouch model 
C57BL/6 female mice were put under general anaesthesia, inhaled isoflurane, 
before and during the procedure. To ensure that the air injected into the air 
pouch was sterile, the syringes were prepared in a sterile laminar flow hood. 
3mL of sterile air was injected subcutaneously into the intracapsular area of the 
mouse to create an air pouch. After 3 days, a top-up of 3 mL sterile air was 
injected into the air pouch. A third top up of 1 mL sterile air was injected 2 days 
later, followed by an injection of 1x106 resting or stimulated MSCs in 1 mL of 
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sterile PBS or sterile PBS alone (control animals) 24 hours later. Cells or PBS 
controls were left in the air pouch for 24 hours before mice were sacrificed. 
2.4.2.2 Fluorescent labelling of MSCs 
In vivo tracking studies require specialised probes that are nontoxic to living 
cells and do not alter the immune response if introduced into a host. Cell 
Tracker Green CMFDA (Invitrogen) was used to fluorescently label the cells. To 
stain the cells, culture media was removed and 5 μM warm Cell Tracker Working 
Solution was added and left incubating for 30 minutes at 37 ⁰C/ 5% CO2/ 95% 
humidity. Cell Tracker Working Solution was prepared according to the 
manufacturer’s instructions. Briefly, the lyophilised product was dissolved in 
DMSO to a final concentration of 10 mM, which was further diluted in serum free 
medium. After incubation with the Cell Tracker, the Cell Tracker Working 
Solution was removed, and cells were washed twice with PBS prior to injecting 
them into mice.  
2.4.2.3 Dissection and preparation of the air pouch samples  
Immediately after sacrifice, 3 mL of FACS buffer was injected into the air 
pouches of the mice and mice were gently shaken to allow the FACS buffer to 
mix throughout the air pouch to ensure an optimal retrieval of immune cells. 
The air pouch content was then drained and kept on ice until 
immunofluorescence staining was performed as outlined in Section 2.3.1.6. 
To separate the overlying soft tissues from the air pouch membrane, a small 
incision was made into the dorsal skin overlying the air pouch to reveal the 
membrane, which was separated from the overlying skin. The membrane was 
then placed into 1 mL of Hank’s balanced salt solution (Sigma) and kept on ice. 
To digest the membrane, 87.5 μg of liberase (Sigma) was added to each sample 
and was left incubating at 37 ⁰C for 1 hour on a thermo–shaker incubator at 900 
rpm. Once membranes were fully digested, cells were passed through a 70 μm 
sterile cell strainer (Corning) to remove any remaining debris and create a single 
cell suspension. Cells were then washed twice in PBS and immunofluorescence 
staining was performed as explained in Section 2.3.1.6. 
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3 Phenotyping MSCs  
3.1 Introduction and aims 
Stem cells are cells which can both self–renew and differentiate into different 
multiple lineages depending on the potency of the cell. Based on their origin and 
their differentiation potential, stem cells can be divided into different 
categories such as embryonic stem cells, induced pluripotent stem cells or 
mesenchymal stromal cells. Stability, safety and a highly accessible stem cell 
source are requirements for the use of stem cells as cellular therapeutics for 
future clinical applications. The crucial limitation of stem cell graft survival is 
recognition by the recipient of alloantigen. However, MSCs avoid allogenic 
rejection due to the low levels of MHC Class I expression and the lack of MHC 
Class II and co-stimulatory molecules expression such as CD80, CD40 and CD86. 
This characteristic, in addition to their ability to self–renew and differentiate, 
has risen the biological and clinical interest of MSCs (Horwitz et al., 2005).  
MSCs were first isolated from the bone marrow but they can be isolated from a 
wide range of tissues around the body including umbilical cord, cord blood, 
placenta, Wharton’s jelly, dental pulp, periodontal ligament, adipose tissue and 
pancreas among others (Lv et al., 2014). However, tissue source of origin directs 
phenotype and biological activity. For example, differences in the expression of 
surface markers CD49d, CD54, CD34 and CD106 have been identified between 
bone marrow derived MSCs (BM MSCs) and adipose tissue derived MSCs (Ad MSCs) 
(De Ugarte et al., 2003). Regarding their differentiation potential, BM MSCs have 
been described to possess stronger osteogenic and lower adipogenic 
differentiation potential compared to Ad MSCs (Xu et al., 2017), while the ability 
to trans-differentiate to neural precursors is higher in Ad MSCs compared to bone 
marrow, skin and umbilical cord derived MSCs (Urrutia et al., 2019). The in vitro 
expansion capacity of cells is important for cell therapy and tissue origin has 
been described to have an impact on this, as umbilical cord derived MSCs have a 
higher proliferation capacity than BM MSCs (Baksh et al., 2004). Discrepancies in 
findings between studies are not uncommon within the MSC literature. As an 
example, the immunosuppressive capacity was measured by their ability to 
inhibit the activation and proliferation of T cells in two different studies (Ribeiro 
et al., 2013, Xishan et al., 2013) and Ribeiro et al. stated that Ad MSCs have 
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greater immunosuppressive ability compared to BM MSCs while Xishan et al. 
stated the opposite.  
Due to different isolation/ enrichment protocols, culture conditions and the 
intrinsic variability among MSCs derived from different donors/ tissues the 
characteristics of MSCs differ, leading to controversial results through the 
literature. For this reason, with the aim of making studies easier to compare, 
the International Society for Cell Therapy (ISCT) proposed minimal criteria for 
defining human MSCs. These criteria include adherence to plastic under standard 
culture conditions; surface expression of the “stemness” markers CD105, CD73 
and CD90 with lack of expression of CD45, CD11b, CD34 and MHC Class II; and 
trilineage mesenchymal differentiation into adipocytes, chondrocytes and 
osteocytes (Dominici et al., 2006). Conversely, although adherence and 
trilineage differentiation are characteristics of murine MSCs, the surface marker 
phenotype is not so well characterised, and variations might apply. 
This chapter will focus on assessing the cells isolated from the bone marrow, 
islets of Langerhans and adipose tissue of mice to compare their phenotypes to 
ISCT criteria for human MSCs. Therefore, their morphology, surface molecule 
phenotype and differentiation potential were assessed in a standardised manner. 
The overall aim of this study was to determine the potential roles of MSCs within 
clinical settings, which are often inflammatory settings. For this reason, the 
morphology and surface molecule phenotype of MSCs from the three sources 
were assessed after 24 hours of inflammatory stimulation with a cocktail of 
inflammatory mediators containing a combination of IFN-γ, TNF-α and IL-1β, 
LPS, LTA or Poly I:C. Therefore, the aim of this chapter was to fully characterise 
cells isolated from the bone marrow, adipose tissue and islets of Langerhans for 
MSC criteria and to understand the effect of tissue origin and inflammation on 
their phenotype. For this results chapter, and the ones that follow, a colour 
code has been used for all data sets, which is outlined in Figure 3-1.  
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Figure 3-1. Schematic representation of the colour scheme used in all figures throughout 
this study. 
The above diagram illustrates the colour scheme throughout this thesis, linking a specific tissue 
source of MSCs to a particular colour. When data are graphed, BM MSCs will always be 
represented in yellow, Is MSCs in blue and Ad MSCs in red. Under resting conditions data will be 
graphed as bars without a filling pattern, while different filling patterns will be used if cells have 
been under inflammatory conditions. Cytokine-mediated stimulation of cells will be represented by 
a grey checks filling; while LPS-, LTA- and Poly I:C-mediated stimulation of cells will be 
represented by grey squares, grey bricks and grey dots respectively.  
 
Results 
 
3.2 Physical morphology of MSCs 
To assess the plastic adherence criteria established by the ISCT, after isolation 
of the cells from the bone marrow and adipose tissue, cells were seeded into 100 
mm sterile Petri dishes and 5 days later were transferred into culture flasks and 
left to grow. Islets of Langerhans were directly plated in culture flasks. In all 
cases, once cells were seeded into culture flasks it was considered passage 1 
(P1). Cells were grown up to passage 3 and their morphology was observed and 
monitored using a light-phase microscope. At P1, cells isolated from the bone 
marrow and adipose tissues showed a spindle-shaped morphology that was 
maintained through passage. However, cells grown from the islets of Langerhans 
111 
 
showed a cluster of small spherical cells where the islet was seeded, surrounded 
by spindle-shaped cells and transitioning cells in between these two populations 
with different morphologies. However, at passage 2 and 3 the only cells present 
in the flask showed a spindle–like morphology. It is unclear whether the small 
spherical cells were an epithelial population unable to proliferate or more likely, 
if an epithelial to mesenchymal transition was leading to the generation of MSCs. 
As shown in Figure 3-2, cells from all sources (excluding P1 in the cells isolated 
from the islets of Langerhans) were similar in size and shape. This satisfies the 
ISCT criteria of MSCs being plastic-adherent and spindle-shaped cells in standard 
culture conditions.   
 
Figure 3-2. MSCs isolated from all tissue sources exhibit an MSC spindle-like morphology. 
MSCs were isolated from mice and grown until P3. Their morphology was observed and monitored 
using a light-phase microscope. All MSCs were adherent to plastic and possessed the typical 
spindle-like morphology.  
 
3.3 Surface molecule phenotype of MSCs 
Flow cytometry was used to assess the surface phenotype of the cells isolated 
from the BM, Ad and Is at P3. The cocktail of antibodies used included the 
markers established by the ISCT to determine if cells are MSCs: CD90, CD105, 
CD73, MHC Class II, CD45, CD11b, CD19 and CD34. CD64 was used to further 
exclude monocytes/ macrophages, the most likely haematopoietic cell to be 
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found in an MSC culture. Due to the lack of standardised protocols to isolate 
murine MSCs from these tissues, successful isolation of the cells from the 
different sources was obtained at different stages of the project and therefore, 
were analysed when available. For this reason, different controls, voltage and 
compensation settings were used for the analysis of the cells isolated from each 
tissue, which explains the gating differences among tissues. However, in all the 
cases, fluorescence minus one (FMO) controls allowed the accurate 
identification of positive and negative populations in full stained samples.  
As shown in Figure 3-3 A and B, cells isolated from all three tissues are positive 
for the MSC markers CD90, CD105 and CD73. The percentage of live cells positive 
for each marker is graphed (Figure 3-3, F-N) to assess the effect on the tissue 
source on the surface phenotype of these cells. ~100% of the cells were positive 
for the MSC markers regardless of the tissue of origin. CD90, a 
glycophosphatidylinositol anchored conserved cell surface protein also known as 
Thy–1 cell surface antigen, was positively expressed by ~100% of the cells 
irrespectively of the tissue of origin (F). CD105, a type 1 membrane glycoprotein 
also known as endoglin, was also expressed by >98% of the cells with no 
significant differences in the percentage of positive cells when compared among 
tissue source (G). Similarly, CD73, an enzyme that converts adenosine 
monophosphate to adenosine, also known as ecto-5'-nucleotidase, was also very 
highly expressed (>98%) by cells from every tissue source (H).  
According to the ISCT, MSCs must not only express specific surface markers but 
have to lack the expression of others. All the cells were negative for the MHC 
Class II surface marker regardless of the tissue of origin (Figure 3-3, I). The 
percentage of live cells positive for the haematopoietic marker CD45 was <2% for 
cells isolated from the Ad, while it was ~30% for the cells isolated from the islets 
of Langerhans and ~85% for the cells isolated from the bone marrow (J). These 
numbers correlate quite nicely with the percentage of cells expressing the 
integrin CD11b as it was barely expressed by the cells isolated from the adipose 
tissue (<2%) while ~25% for the cells isolated from the islets of Langerhans and 
~85% for the cells isolated from the bone marrow expressed it (K). Regarding the 
expression of the B-lymphocyte antigen CD19, all the cells were negative (‹2%) 
for this marker regardless of the tissue of origin (L). Similarly, <2% of the cells 
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from the three tissue sources stained positive for the primitive haematopoietic 
progenitor marker CD34 (M). Due to the positive staining for CD45 and CD11b 
surface markers, cells from the three tissues were further characterised for the 
expression of CD64, an integral membrane glycoprotein that is constitutively 
found on macrophages and monocytes, and it was observed that the expression 
of this marker was minimal in the cells isolated from the three sources (N), 
suggesting that the isolated cells were not of myeloid origin.  
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Figure 3-3. Cells isolated from all tissues express MSC Markers. 
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. MSCs were then 
stained with a cocktail of antibodies to allow characterisation of MSCs by flow cytometry.  
As explained in Chapter 2, FSC and SSC were used to gate on cells of correct size and granularity, 
doublets were excluded, and live cells were selected in all samples before assessing surface 
phenotype (A-E). Use of FMOs allowed the accurate identification of positive and negative 
populations in full stained samples. The% of live MSCs which stained positive for each of the 
tested markers is graphed to compare expression between MSC tissue sources (F-N). Each bar 
represents an n of 3 independent experiments and is graphed as mean ± SEM. ONE WAY ANOVA 
with Tukey’s multiple comparison post-test analysis was used for statistical assessment of 
differences between MSC sources. p = 0.05 was considered the limit for statistical significance; * p 
< 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.  
 
3.4 Differentiation potential of MSCs 
To determine the trilineage differentiation potential of the cells isolated from 
the BM, Is and Ad, cells were cultured with appropriate differentiation factors to 
guide them through a specific differentiation pathway.  
Cells isolated from the BM (Figure 3-4, A.i), Is (Figure 3-4, B.i) and Ad (Figure 
3-4, C.i) were able to differentiate into adipocytes as the majority of the cells 
stained positive for fatty acid binding protein 4 (FABP4). Undifferentiated 
control samples were stained with anti-FABP4 to ensure that cells were not 
expressing FABP4 prior to differentiation (A.iv, B.iv, C.iv). As a control for 
positive staining, isotype controls (A.ii, B.ii, C.ii) and no-primary antibody 
controls (A.iii, B.iii, C.iii) were used. The lack of fluorescence in the isotype and 
no-primary controls and in the undifferentiated cells suggests that positive 
staining was specific for differentiation induced FABP4 expression and that cells 
isolated from the BM, Is and Ad were fully capable of adipogenic differentiation.  
Cells isolated from the BM (Figure 3-5, A.i), Is (Figure 3-5, B.i) and Ad (Figure 
3-5, C.i) were able to differentiate into chondrocytes as most of the cells 
stained positive for collagen II. Undifferentiated control samples were stained 
with anti-collagen II antibody to ensure that cells were not expressing collagen II 
prior to differentiation (A.iv, B.iv, C.iv). As a control for positive staining, 
isotype controls (A.ii, B.ii, C.ii) and no-primary antibody controls (A.iii, B.iii, 
C.iii) were used. The lack of fluorescence in the isotype and no-primary controls 
and in the undifferentiated cells suggests that positive staining was specific for 
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differentiation-induced collagen II expression and that cells isolated from the 
BM, Is and Ad were fully capable of differentiating into chondrocytes.  
Similarly to adipogenic differentiation, cells isolated from the BM (Figure 3-6, 
A.i), Is (Figure 3-6, B.i) and Ad (Figure 3-6, C.i) were able to differentiate into 
osteocytes as the majority of the cells stained positive for osteopontin. 
Undifferentiated control samples were stained with anti–osteopontin antibody to 
ensure that cells were not expressing osteopontin prior to differentiation (A.iv, 
B.iv, C.iv). As a control for positive staining, isotype controls (A.ii, B.ii, C.ii) and 
no–primary antibody controls (A.iii, B.iii, C.iii) were used. The lack of 
fluorescence in the isotype and no–primary controls and in the undifferentiated 
cells suggests that positive staining was specific for differentiation induced 
osteopontin expression and that cells isolated from the BM, Is and Ad were fully 
capable of differentiating into adipocytes.  
Cells isolated from the BM, Is and Ad could differentiate into adipocytes, 
chondrocytes and osteocytes as confirmed by positive staining of specific tissue 
markers. This satisfies the trilineage differentiation potential established by the 
ISCT.  
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Figure 3-4. MSCs can successfully differentiate into adipocytes. 
For adipogenesis, BM (A.i), Is (B.i) and Ad (C.i) MSCs were seeded at 2.1x104 per cm2 and grown 
in 4-well Nunc™ Lab-Tek™ Chamber Slides. When MSCs reached 100% confluency, 
differentiation factors were added every 2-3 days for 14-21 days. Undifferentiated control samples 
(A.iv, B.iv, C.iv) were maintained in medium without differentiation factors. After 14-21 days of 
differentiation, cells were stained with anti-FABP4 (RED), except for isotype controls (A.ii, B.ii, C.ii) 
and no-primary controls (A.iii, B.iii, C.iii). All samples were stained with specific fluorescent 
secondary antibodies. DAPI (BLUE) marks the cell nuclei.  
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Figure 3-5. MSCs can successfully differentiate into chondrocytes. 
For chondrogenesis, BM (A.i), Is (B.i) and Ad (C.i) MSCs were seeded at 2.5x105 per cm2, spun 
down in a 15 mL falcon tube and left culturing in spherical balls within the falcon in differentiation 
medium. Differentiation medium was changed every 2-3 days. Undifferentiated control samples 
(A.iv, B.iv, C.iv) were maintained in medium without differentiation factors. After 14-21 days of 
differentiation, cells were stained with anti-Collagen II (RED), except for isotype controls (A.ii, B.ii, 
C.ii) and no-primary controls (A.iii, B.iii, C.iii). All samples were stained with specific fluorescent 
secondary antibodies. DAPI (BLUE) marks the cell nuclei. 
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Figure 3-6. MSCs can successfully differentiate into osteocytes. 
For osteogenesis, cells were seeded at 4.2x103 per cm2 and grown in 4-well Nunc™ Lab-Tek™ 
Chamber Slides. When MSCs reached 100% confluency, differentiation factors were added every 
2-3 days for 14-21 days. Undifferentiated control samples (A.iv, B.iv, C.iv) were maintained in 
medium without differentiation factors. After 14-21 days of differentiation, cells were stained with 
anti-osteopontin (RED), except for isotype controls (A.ii, B.ii, C.ii) and no-primary controls (A.iii, 
B.iii, C.iii). All samples were stained with specific fluorescent secondary antibodies. DAPI (BLUE) 
marks the cell nuclei. 
 
3.5 Validation of CD45 expression in Islet derived MSCs 
As observed in Figure 3-3, ~30% of the Is MSCs and ~85% of the BM MSCs are CD45 
positive. According to the ISCT, in order to consider a human cell population as 
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MSCs, cells must be CD45 negative; however, surface marker phenotype is not 
well characterised in the mouse. Induction of CD45 expression on murine BM 
MSCs has been described (Yeh et al., 2006); anyhow, this event has not been 
documented in Is MSCs. For this reason, further analysis of the CD45 positive and 
negative populations within the Is MSCs was required, as well as validation of the 
CD45 expression in case the positive staining was an artefact. 
To assess and compare the morphology, size and granularity of these two 
populations CD45 MACS MicroBeads were used. CD45 positive and negative cells 
were separated and distributed into new flasks at a 3500 cells/ cm2 
concentration and left growing. As a control, CD45 positive and negative cells 
were put back together in a 25:75 (1:3) proportion to assess the effect of the 
isolation on the cells. Cell morphology was observed and monitored using a light-
phase microscope and both populations possessed the typical spindle-like 
morphology (Figure 3-7). 
 
Figure 3-7. CD45 positive and negative Is MSCs exhibit MSC spindle-like morphology. 
MSCs were isolated from mice and grown until P2. CD45 microbeads were then used to isolate the 
CD45 positive cells. After isolation, CD45 positive and negative cells were distributed into new 
flasks at a 3500 cells/ cm2 concentration and left growing. As a control, CD45 positive and negative 
cells were put back together in a 25:75 proportion to assess the effect of the isolation on the cells. 
Cell morphology was observed and monitored using a light-phase microscope. Both populations 
were adherent to plastic and possessed the typical spindle-like morphology. 
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Using flow cytometry, the parameters forward scatter (FSC) and side scatter 
(SSC) were used to measure the size and granularity (respectively) of both 
populations. The size of a cell is measured by the amount of laser light that can 
pass around the cell, while granularity is measured by the amount of light that 
bounces off particles within the cell. This way, size and complexity of a cell are 
easily measured. CD45 negative cells had a larger FSC (Figure 3-8, A) and SSC 
(Figure 3-8, B) compared to the CD45 positive population. To assess the effect of 
CD45 depletion on size and granularity, isolated CD45 positive and negative 
populations were compared to un-depleted populations. These results suggest 
that there are two different populations with different size and granularity. In 
order to perform statistical analysis and clarify the plotted data in histograms, 
mean fluorescent intensities of FSC (Figure 3-8 C) and SSC (Figure 3-8 D) values 
were graphed.  
 
Figure 3-8. CD45 positive and negative Is MSCs differ in size and granularity.  
Following the experimental set up of Figure 3-18, flow cytometry was used to measure FSC and 
SSC to assess size (A and C) and granularity (B and D) of CD45 positive and negative Is MSCs. 
Each bar represents an n of 3 independent experiments and is graphed as mean ± SEM. ONE 
WAY ANOVA with Tukey’s multiple comparison post-test analysis was used for statistical 
assessment of differences between MSC sources. p = 0.05 was considered the limit for statistical 
significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.  
 
Therefore, the next question to address was whether the CD45 positive cells 
were MSCs or a contaminating population able to express MSC markers. To 
address this, isolated CD45 positive and negative populations were differentiated 
in to all three lineages to assess their potential. As shown in Figure 3-9, both 
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islet-derived cell populations can successfully differentiate into adipocytes, 
chondrocytes and osteocytes, which suggests that both populations can be 
considered MSCs. 
 
Figure 3-9. Both Is derived MSC populations can successfully differentiate into adipocytes, 
chondrocytes and osteocytes.  
The experiment set up for adipogenesis is identical as the one in Figure 3-4, the experiment set up 
for chondrogenesis is explained in Figure 3-5 while the osteogenic differentiation is explained in 
Figure 3-6. All samples were stained with specific unlabelled primary antibodies and fluorescent 
secondary antibodies. DAPI (BLUE) marks the cell nuclei. 
 
Lastly, validation of CD45 positive staining was performed to ensure that the 
antibodies were truly interacting with CD45 and that the positive staining was 
not an artefact. CD45 RNA (Figure 3-10, A) and protein (Figure 3-10, B) levels 
were measured in CD45 negative and positive populations. As a negative control 
3T3 mouse embryo fibroblasts were used while splenocytes were considered as 
positive control for CD45 expression at both RNA and protein levels. These 
findings confirm that there is an islet derived MSC population that expresses 
CD45.  
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Figure 3-10. Validation of the expression of CD45 protein in Is MSCs.  
MSCs were isolated from mice and grown until P2. CD45 microbeads were then used to isolate the 
CD45 positive cells. After isolation, CD45 positive and negative cells were distributed into new 
flasks at a 3500 cells/ square2 concentration and left growing. Once 80% confluence was reached, 
cells were harvested and prepared for RNA (A) and protein analysis (B). As a negative control of 
CD45 expression 3T3 mouse embryo fibroblasts were used while splenocytes were used as 
positive control.  
 
3.6 Analysis of the epithelial origin of islet derived MSCs 
The origin of MSCs isolated from pancreatic exocrine tissue remains unclear and 
the epithelial to mesenchymal transition process is one of the possible 
mechanisms suggested to explain the origin of these cells. This process is based 
on the decrease in the expression of the adhesion molecules between epithelial 
cells, EpCAM among others, followed by an increase in the mesenchymal 
markers, such as vimentin. As observed in Figure 3-2, cells grown from the islets 
of Langerhans showed a cluster of small spherical cells where the islet was 
seeded surrounded by spindle–shaped cells, with transitioning cells in between 
these two populations with different morphologies. However, at later passages 
the only cells present in the flask showed a spindle–like morphology. For this 
reason, it was important to determine if the small spherical cells were an 
epithelial population unable to proliferate or more likely, if an epithelial to 
mesenchymal transition was leading to the generation of MSCs. 
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3.6.1 Co-expression of epithelial and mesenchymal markers 
through passage 
Islets of Langerhans were isolated and between 10 to 20 islets or the cells 
obtained by the disaggregation of 10 to 20 islets were seeded in 4–well Nunc™ 
Lab-Tek™ Chamber Slides and left growing for 10 days. Cells were then fixed, 
permeabilised and stained for epithelial (EpCAM) and mesenchymal (vimentin) 
specific markers (Figure 3-11). As a control for positive staining, isotype controls 
for both EpCAM and vimentin were used. All slides were imaged with a Zeiss 
epifluorescence microscope using the appropriate fluorescent channels and 
magnifications. The lack of fluorescence in the isotype controls suggests that 
positive staining was specific for EpCAM and vimentin expression and that cells 
isolated from the islets of Langerhans co-express epithelial and mesenchymal 
traits.  
 
Figure 3-11. Cells isolated from the islets of Langerhans co-express epithelial and 
mesenchymal markers. 
Between 10 and 20 islets or the cells obtained from the disaggregation of 10 to 20 islets were 
seeded in 4-well Nunc™ Lab-Tek™ Chamber Slides and left growing for 10 days. Cells were then 
stained with EpCAM (GREEN) and Vimentin (RED), except for isotype controls (Vimentin control 
and EpCAM control). All samples were stained with specific fluorescent secondary antibodies. 
DAPI (BLUE) marks the cell nuclei. All slides were imaged with a Zeiss epifluorescence 
microscope using the appropriate fluorescent channels and magnifications. Images were prepared 
using Zen software. 
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Co–expression of mesenchymal antigens by epithelial cells within the pancreas 
has been described as an artefact of cell culture (Seeberger et al., 2009), for 
this reason, islets of Langerhans were isolated, disaggregated and stained with a 
cocktail of antibodies to study their epithelial origin by flow cytometry. After 
viability exclusion, two populations of different size were observed. The smaller 
population was highly positive for EpCAM and negative for vimentin while the 
larger co-expressed both markers (Figure 3-12, A). ~80% of the cells were only 
expressing EpCAM while no cells were just vimentin positive (Figure 3-12, B). In 
addition, from the cells expressing EpCAM, ~20% of the cells were vimentin 
positive (Figure 3-12, C).  
 
Figure 3-12. Cells isolated from the islets of Langerhans co-express epithelial and 
mesenchymal markers. 
Islets of Langerhans were disaggregated and stained with a cocktail of antibodies to study their 
epithelial origin by flow cytometry. After viability exclusion, two populations were observed which 
were analysed for EpCAM and Vimentin expression (A). The% of live cells which stained positive 
for each of the tested markers is graphed (B) and represented as pie-charts (C).  
 
As observed in Section 3.2, epithelial like cells were only observed at P1. For 
that reason, we wanted to determine if cells would still be expressing EpCAM at 
passage 3. Is MSCs were grown in 4-well Nunc™ Lab-Tek™ Chamber Slides and left 
growing for 10 days. Cells were then fixed, permeabilised and stained for EpCAM 
and vimentin specific markers (Figure 3-13). As a control for positive staining, 
isotype controls for both EpCAM and vimentin were used. All slides were imaged 
with a Zeiss epifluorescence microscope using the appropriate fluorescence 
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channels and magnifications. The lack of fluorescence in the isotype controls 
suggests that positive staining was specific for EpCAM and vimentin expression 
and that passage 3 Is MSCs co–express epithelial and mesenchymal traits.  
 
Figure 3-13. Is MCS co-express epithelial and mesenchymal markers at P3. 
Is MSCs were grown in 4-well Nunc™ Lab-Tek™ Chamber Slides and left growing until 80% 
confluence was reached. Cells were then stained with EpCAM (GREEN) and Vimentin (RED), 
except for isotype controls (Vimentin control and EpCAM control). All samples were stained with 
specific fluorescent secondary antibodies. DAPI (BLUE) marks the cell nuclei. All slides were 
imaged with a Zeiss epifluorescence microscope using the appropriate fluorescent channels and 
magnifications. Images were prepared using Zen software. 
 
3.6.2 Co-expression of CD45 and epithelial markers 
As determined in Section 3.5, there is a CD45 positive population within the Is 
MSCs. For this reason, we wanted to determine if there was a correlation 
between the epithelial origin of these MSCs and the CD45 expression. Islet of 
Langerhans were disaggregated and stained with a cocktail of antibodies to 
study their EpCAM and CD45 status by flow cytometry. After viability exclusion, 
cells were gated according to their EpCAM and vimentin expression as before, 
and those populations were gated for CD45 expression (Figure 3-14, A). ~90% of 
the cells were expressing CD45 (Figure 3-14, B). In addition, CD45 was co-
expressed with both EpCAM and vimentin, with ~20% of the cells co-expressing 
EpCAM, vimentin and CD45 (Figure 3-14, C).  
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Figure 3-14. ~90% of the cells isolated from the islets of Langerhans are CD45 positive and 
co-express EpCAM.  
Islets of Langerhans were disaggregated and stained with a cocktail of antibodies to study their 
epithelial origin by flow cytometry. After viability exclusion, cells were assessed for CD45, EpCAM 
and Vimentin expression (A). The% of live cells which stained positive for each of the tested 
markers (B) and the co-expression of them (C) has been graphed.  
 
As stated in Section 3.3, ~30% of the cells were CD45 positive at passage 3. To 
correlate CD45 expression with EpCAM expression, P3 Is MSCs were stained with 
a cocktail of antibodies. ~99% of the cells were CD73 positive, even the ~20% 
that was still EpCAM positive. EpCAM positive and negative cells were gated and 
their CD45 expression was studied (Figure 3-15, A). ~95% of the EpCAM negative 
cells were CD45 negative while ~93% of the EpCAM positive cells were CD45 cells 
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(Figure 3-15, B), suggesting an unknown correlation between the epithelial to 
mesenchymal transition process and CD45 levels in the islets of Langerhans.  
 
Figure 3-15. CD45 positive Is MSC population expresses the epithelial marker EpCAM at P3. 
Is MSCs were grown in culture until P3. MSCs were then stained with a cocktail of antibodies, to 
allow characterisation of MSCs by flow cytometry (A). The% of live cells which stained positive for 
each of the tested markers has been represented as pie-charts (B). 
 
Disaggregation of the islets of Langerhans showed that ~95% of the cells within 
the islets were CD45 positive, while after culture of those cells, more precisely 
at P3, ~30% of the cells were CD45 positive. To explain this, Ki67 proliferation 
marker was studied. Ki67 is a nuclear protein that is involved in ribosomal RNA 
transcription and therefore, can be used as a proliferation marker. P3 Is MSCs 
were stained with a cocktail of antibodies, viable cells were gated and live cells 
were analysed for their CD45 and Ki67 levels (Figure 3-16, A). To appropriately 
gate the Ki67 negative cells an isotype control was used (Figure 3-16, B). As 
shown in Figure 3-16, CD45 positive cells are not proliferating in culture 
efficiently as their Ki67 levels are barely detectable (Figure 3-16, C). 
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Figure 3-16. CD45 positive population is replication-defective.  
Is MSCs were grown in culture until P3. MSCs were then stained with a cocktail of antibodies, to 
allow characterisation of MSCs by flow cytometry (A). Positive staining was measured using 
isotype controls and gates were drawn appropriately (B). Percentage of proliferative cells in each 
population was determined and graphed (C). Each bar represents an n of 3 independent 
experiments and is graphed as mean ± SEM. Mann-Whitney test analysis was used for statistical 
assessment. p = 0.05 was considered the limit for statistical significance; * p < 0.05; ** p < 0.01; *** 
p < 0.001; **** p < 0.0001.  
 
3.7 Phenotype of MSCs during Inflammation 
MSCs are able to modulate the activity of the host immune responses, which 
makes them a very promising cell therapy in the treatment of chronic 
inflammatory diseases. As MSCs are going to be infused into pre–existing 
inflammatory environments, it is extremely important to understand the effect 
of inflammation on the phenotype of MSCs. Different inflammatory agents elicit 
different patterns of responses in the cells of the immune system; therefore, 
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seems reasonable to suppose that different inflammatory agents could lead to 
differences in the morphology and surface molecule phenotype of licensed MSCs. 
Thus, MSCs were stimulated in four different ways; MSCs isolated from one 
mouse donor were grown until P2 and split into 5 flasks and allowed to grow 
until 80% confluence was reached. Cells were then stimulated with a cocktail of 
cytokines involved in systemic inflammation (40ng/ml of TNF-α, IL-1β and IFN-ϒ), 
100 ng/mL LPS, 100 ng/mL LTA or 4 µg/mL Poly I:C for 24 hours. Even if 
homeostasis is hard to mimic in vitro, as control one flask was maintained in MSC 
culture medium and this is referred as resting MSCs, while stimulated MSCs are 
considered licensed MSCs- this terminology will be used throughout.  
3.7.1 Size and granularity of MSCs in resting vs inflammatory 
conditions 
Using flow cytometry, forward scatter (FSC) and side scatter (SSC) parameters 
were used to measure the size and granularity (respectively) of BM, Is and Ad 
MSCs under resting and inflammatory conditions (Figure 3-17). When MSCs were 
under non-stimulatory conditions, BM MSCs were significantly smaller than Is and 
Ad MSCs (BM = 103.75 [±2.47], Is = 120.33 [±2.05], Ad = 114.00 [±3.26]) (Figure 
3-17, A). Inflammatory stimulation did not influence the size except in LTA-
mediated stimulation of Is MSCs, where the FSC decreased from 120.33 (±2.05) 
to 106.33 (±2.86). Tissue origin and inflammation both influenced MSC 
granularity as the differences in granularity were statistically significant among 
the three different tissue derived MSCs in resting conditions (BM = 231.00 
[±4.32], Is = 133.33 [±2.86], Ad = 121.00 [±2.94]) (Figure 3-17, B). Cytokine-
mediated stimulation produced a statistically significant decrease of granularity 
in Ad MSCs, from 121.00 (±2.94) to 100.66 (±2.49). LPS-mediated stimulation 
produced a decrease in granularity in both BM and Is MSCs as SSC values from 
231.00 (±4.32) to 214.00 (±4.54) and from 133.33 (±2.86) to 111.33 (±2.05), 
respectively. LTA and Poly I:C-mediated stimulation produced no significant 
changes in the granularity of the cells from any tissue (compared to the control). 
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Figure 3-17. Size and granularity of MSCs under inflammatory stimulation.  
Following the experimental set up of Figure 3-18, flow cytometry was used to measure FSC and 
SSC to assess size (A) and granularity (B) of MSCs during resting and inflammatory conditions. 
Each bar represents an n of 3 independent experiments and is graphed as mean ± SEM. ONE 
WAY ANOVA with Tukey’s multiple comparison post-test analysis was used for statistical 
assessment of differences between MSC sources and licensing agent. Significant differences are 
marked with the appropriate number of asterisks. p = 0.05 was considered the limit for statistical 
significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.  
 
3.7.2 Surface molecule phenotype of MSCs in resting vs 
inflammatory conditions  
Representative dot plots illustrate the percentage of Is MSCs expressing the 
markers CD73, CD146, CD166, CD271 and MHC Class I and MHC Class II during 
resting and inflammatory conditions (Figure 3-18, A). Positive staining was 
determined by the use of fluorescent minus one controls. The percentage of live 
BM, Is and Ad MSCs expressing these markers under resting and licensed 
conditions are graphed in Figure 3-18, B-G. 
Tissue source and licensing did not affect the number of live cells expressing 
CD73 as >97% of live cells were CD73 positive irrespective of tissue source or 
licensing condition. Under resting conditions, 98.80% (± 0.70) of BM MSCs, 98.53% 
(± 0.57) of Is MSCs and 99.16% (± 0.33) of Ad MSCs stained positive for CD73 
(Figure 3-18, B). The percentage of CD73 positive MSCs increased in a non-
significant manner after cytokine-mediated licensing in the BM (98.80% [± 0.70] 
to 99.14% [± 0.22]), Is (98.53% [± 0.57] to 99.00% [± 0.41]) and Ad MSCs (99.16% 
[± 0.33] to 99.46% [± 0.47]). Licensing with LPS (BM = 98.47% [± 0.49], Is = 
98.61% [± 0.54], Ad = 98.83% [± 0.30]), LTA (BM = 98.38% [± 0.58], Is = 98.90% [± 
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0.49], Ad = 98.96% [± 0.20]), and Poly I:C (BM = 98.60% [± 0.32], Is = 98.9% [± 
0.35], Ad = 98.40% [± 0.24]), led to a non-significant decrease in the number of 
CD73 positive MSCs. Median fluorescence intensity (MFI) was used to describe the 
median intensity and level of anti-CD73 antibody binding (Figure 3-19, A). Tissue 
source of MSCs did not affect the level of CD73 expression as under resting 
conditions the MFIs were as following: BM MSCs = 43 (± 3.26); Is MSCs = 44.66 (± 
2.05) and Ad MSCs = 38.86 (± 2.21). No statistically significant differences in the 
expression levels of CD73 were observed comparing resting to licensed BM 
(Cytokines = 48 [± 1.20], LPS = 45.66 [± 4.98], LTA = 43 [± 4.54], Poly I:C = 40.33 
[± 3.29]), Is (Cytokines = 44.33 [± 3.39], LPS = 49.66 [± 5.24], LTA = 45 [± 2.94], 
Poly I:C = 47.66 [± 4.10]) or Ad MSCs (Cytokines = 38.86 [± 3.72], LPS = 34.35 [± 
2.21], LTA = 34.08 [± 2.58], Poly I:C = 34.12 [± 1.65]).  
The cell surface glycoprotein CD146 is another marker commonly used for MSC 
identification (Junker et al., 2010). Even if >92.6% of MSCs from the three 
sources were positive for CD146, tissue source had an effect on the number of 
live cells expressing CD146 as BM MSCs had significantly fewer cells expressing 
this marker compared to Is and Ad MSCs (BM = 92.64% [± 1.44], Is = 98.21% [± 
0.74], Ad = 94.73% [± 2.73]) (Figure 3-18, C). Licensing of BM MSCs led to an 
increase of the percentage of CD146 expressing cells (Cytokines = 93.06% [± 
1.20], LPS = 95.20% [± 1.02], LTA = 93.53% [± 0.96], Poly I:C = 93.13% [± 1.23]) 
while licensing of Ad MSCs led to a decrease of the percentage of CD146 
expressing cells (Cytokines = 81.16% [± 1.62], LPS = 91.63% [± 1.32], LTA = 
86.53% [± 0.38], Poly I:C = 86.70% [± 4.98]). In the case of Is MSCs, cytokine-
mediated stimulation led to an increase of the percentage of CD146 expressing 
cells (Is = 98.21% [± 0.74] to 98.40% [± 0.53]) while LPS (96.20% [± 0.82]), LTA 
(98.15% [± 0.26]) and Poly I:C (97.38% [± 0.89]) licensing led to a decrease. 
These differences in percentage of live cells expressing CD146 were further 
confirmed by MFI analysis (Figure 3-19, B) of CD146. Under resting conditions, 
differences in the expression levels of CD146 were significant among MSCs from 
the three tissues (BM = 21.33 [± 3.29], Is = 44 [± 3.74], Ad = 78.33 [± 2.05]). 
Licensing of BM MSCs led to an increase of the level of CD146 expression in all 
the cases but when licensed with the cytokine cocktail (Cytokines = 20.66 [± 
1.69], LPS = 27.33 [± 2.86], LTA = 22.33 [± 2.86], Poly I:C = 24.5 [± 2.27]). 
Licensing of Is (Cytokines = 34.66 [± 3.29], LPS = 35.33 [± 2.86], LTA = 38.66 [± 
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2.05], Poly I:C = 40.33 [± 2.49]) and Ad MSCs (Cytokines = 57 [± 2.16], LPS = 
69.66 [± 2.86], LTA = 64 [± 2.44], Poly I:C = 70.66 [± 2.86]) led to a decrease in 
the median fluorescence intensity of CD146. Licensing only produced significant 
differences in Ad MSCs at both percentage of live cells expressing CD146 and 
CD146 expression levels.  
The membrane glycoprotein ALCAM, also known as CD166, is also a marker of 
MSCs, however, its expression levels are significantly variable. The percentage of 
ALCAM positive MSCs in resting conditions showed high variations from source to 
source with Ad MSCs expressing the highest number of live positive cells (35.56% 
[± 1.90]), followed by BM MSCs (22.82% [± 0.72]) and a very low number of cells 
expressing this marker in Is MSCs (0.47% [± 0.07]) (Figure 3-18, D). Cytokine 
licensing led to a decrease in the percentage of CD166 expressing MSCs from the 
BM (20.55% [± 0.52]), Is (0.39% [± 0.14]) and Ad (27.9% [± 2.90]), as well as LPS 
(BM = 17.99% [± 0.87], Is = 0.36% [± 0.15], Ad = 26.43% [± 3.21]) and Poly I:C (BM 
= 21.34% [± 1.78], Is = 0.39% [± 0.10], Ad = 31.76% [± 2.82]) licensing. LTA 
licensing produced an increase in the percentage of BM MSCs expressing CD166 
(from 22.82% [± 0.72] to 25.15% [± 1.86]), while it produced a decrease in the 
percentage of Is (from 0.47% [± 0.07] to 0.39% [± 0.13]) and Ad (from 35.56% [± 
1.90] to 29.36% [± 3.44]) MSCs expressing this marker. These differences in 
percentage of live cells expressing CD166 among tissue of origin and 
inflammatory agent were further confirmed by MFI analysis of CD166 (Figure 
3-19, C). Under resting conditions, differences in the expression levels of CD146 
were statistically significant among MSCs from all three tissues (BM = 15.76 [± 
2.15], Is = 3.86 [± 0.99], Ad = 1.63 [± 0.34]). Cytokine and Poly I:C licensing led 
to a decrease in the expression levels of CD166 in MSCs from the BM (Cytokine = 
15.06 [± 2.34]; Poly I:C = 14.86 [± 1.48]), Is (Cytokine = 3.68 [± 0.91]; Poly I:C = 
3.46 [± 0.44]) and Ad (Cytokine = 1.50 [± 0.14]; Poly I:C = 1.2 [± 0.29]). LPS and 
LTA licensing led to an increase in the expression levels of CD166 in MSCs from 
the BM (LPS = 16.56 [± 2.47]; LTA = 17.36 [± 3.02]), Is (LPS = 4.13 [± 1.16]; LTA = 
3.46 [± 0.53]) and Ad (LPS = 4.09 [± 3.61]; LTA = 1.25 [± 0.27]). Licensing 
produced statistically no significant differences in MSCs from any tissue source 
at both percentage of life cells expressing CD166 and CD166 levels.  
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The low-affinity nerve growth factor receptor, also known as CD271, is a marker 
of bone marrow MSCs with enhanced differentiation capacity for bone repair; it 
is expressed at variable levels in MSCs from different sources (Kohli et al., 2019). 
The percentage of CD271 positive MSCs in resting conditions showed very high 
and statistically significant variations from source to source where BM MSCs had 
the highest number of positive cells (40.21% [± 2.79]), followed by Ad MSCs, 
which had a low number of cells expressing this marker (3.71% [± 0.67]) and a 
very low number of Is MSCs positive for the expression of CD271 (0.41% [± 0.02]) 
(Figure 3-18, E). MSC licensing produced no significant differences in the 
percentage of MSCs positive for this marker from any tissue source except for BM 
MSCs after 24 hours of cytokine cocktail, LPS or LTA licensing, but not Poly I:C 
licensing. Licensing of BM MSCs with cytokines (39.9% [± 1.95]), LPS (33.36% [± 
2.50]) and Poly I:C (38.73% [± 4.45]) produced a decrease of the percentage of 
positive cells expressing this marker, while LTA licensing produced an increase 
(from 40.21% [± 2.79] to 41.09% [± 2.57]). Licensing of the Is MSCs produced an 
increase of the CD271 positive cells percentage (Cytokines = 0.52% [± 0.05], LPS 
= 0.51% [± 0.01], LTA = 0.57% [± 0.02], Poly I:C = 0.55% [± 0.07]) while Ad MSCs 
licensing produced a decrease of CD271 positive cells percentage (Cytokines = 
3.01% [± 0.40], LPS = 1.71% [± 0.17], LTA = 1.33% [± 0.10], Poly I:C = 2.83% [± 
0.71]). These differences in percentage of live cells expressing CD271 among 
tissue of origin and inflammatory agent were further confirmed by MFI analysis 
(Figure 3-19, D) of CD271. Under resting conditions, BM MSCs had significantly 
higher expression levels of CD271 compared to Is and Ad MSCs (BM = 15.76 [± 
2.15], Is = 3.86 [± 0.99], Ad = 1.63 [± 0.34]). MSC licensing had no effect in the 
expression levels of CD271 in Is (Cytokines = 4.29 [± 1.18], LPS = 4.75 [± 1.19], 
LTA = 4.63 [± 1.06], Poly I:C = 4.4 [± 0.29]) and Ad MSCs (Cytokines = 1.1 [± 
0.24], LPS = 1.11 [± 0.13], LTA = 1.08 [± 0.19], Poly I:C = 1.55 [± 0.22]) and only 
had a significant effect in LPS-mediated licensing in BM MSCs (Cytokines = 42.66 
[± 2.49], LPS = 39.16 [± 1.43], LTA = 41.56 [± 4.37], Poly I:C = 42.33 [± 3.39]).  
Under resting conditions, <2% of the MSCs isolated from the three tissues were 
positive for MHC Class II. Despite the low number of cells expressing this marker, 
tissue source had an effect on the number of live cells expressing MHC Class II as 
Is MSCs (0.24% [± 0.07]) had significantly fewer positive cells for this marker 
compared to BM (1.64% [± 0.39]) and Ad MSCs (1.94% [± 0.38]) (Figure 3-18, F). 
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BM MSC licensing by cytokines, LTA and Poly I:C led to an increase of the 
percentage of cells expressing MHC Class II (from 1.64% [± 0.39] to 5.14% [± 
0.28], 2.02% [± 0.24] and 1.85% [± 0.18] respectively), while LPS licensing led to 
a decrease of the percentage of cells expressing MHC Class II, from 1.64% (± 
0.39) to 1.54% (± 0.28); only cytokine-mediated licensing produced a statistically 
significant change in the percentage of BM MSCs expressing this marker. 
Licensing of Is MSCs led to a statistically non-significant decrease of the 
percentage of cells expressing MHC Class II (Cytokines = 0.19% [± 0.06], LPS = 
0.12% [± 0.03], LTA = 0.16% [± 0.04], Poly I:C = 0.12% [± 0.02]). In the case of Ad 
MSCs, licensing of these cells led to a statistically non-significant decrease of the 
percentage of cells expressing MHC Class II when stimulated with cytokines (from 
1.94% [± 0.38] to 1.36% [±0.28]), while LPS, LTA and Poly I:C licensing led to a 
statistically non-significant increase of the percentage of cells expressing MHC 
Class II (LPS = 1.97% [± 0.30], LTA = 1.53% [± 0.33], Poly I:C = 1.76% [± 0.28]). 
These differences in percentage of live cells expressing MHC Class II among 
tissue of origin and inflammatory agent were further confirmed by MFI analysis 
(Figure 3-19, E). Under resting conditions, tissue source of origin had no 
significant effect on the expression levels of MHC Class II (BM = 2.63 [± 0.77], Is = 
2.4 [± 0.37], Ad = 1.15 [± 0.09]). Licensing of MSCs produced no significant 
alteration on the median fluorescence intensity of the MHC Class II antibody in 
MSCs isolated from the BM (Cytokines = 6.56 [± 0.56], LPS = 3.52 [± 0.69], LTA = 
3.17 [± 0.50], Poly I:C = 3.36 [± 0.60]), Is (Cytokines = 2.7 [± 3.38], LPS = 3.38 [± 
0.53], LTA = 2.72 [± 0.49], Poly I:C = 2.16 [± 0.24]) and Ad (Cytokines = 1.20 [± 
0.29], LPS = 1.33 [± 0.27], LTA = 1.56 [± 0.14], Poly I:C = 1.23 [± 0.21]) with the 
exception of cytokine-mediated licensing in BM MSCs (from 2.63 [± 0.77] to 6.56 
[± 0.56]).  
Under resting conditions, the percentage of MHC Class I positive MSCs showed 
high variations from source to source with BM MSCs expressing the highest 
number of live positive cells (25.21% [± 2.15]), followed by Is MSCs (10.01% [± 
1.14]) and almost an inexistent number of cells expressing this marker in Ad 
MSCs (0.68% [± 0.02]) (Figure 3-18, G). All the licensing agents were able to 
produce a statistically significant increase in the percentage of positive cells for 
MHC Class I in the BM MSCs; this increase was highest when cells were treated 
with LPS (Cytokines = 48.5% [± 1.96], LPS = 78.95% [± 2.43], LTA = 28.49% [± 
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1.34], Poly I:C = 30.73% [± 1.82]). Within the Is MSCs, all the stimulatory agents 
were able to produce a statistically significant increase in the percentage of 
cells expressing this marker (Cytokines = 80.34% [± 2.93], LPS = 24.073% [± 2.27], 
LTA = 11.376% [± 1.39], Poly I:C = 13.56% [± 2.07]. Very few cells within the Ad 
MSCs were positive for MHC Class I and only cytokine produced licensing 
increased this percentage in a statistically significant manner, from 0.68% 
(±0.02) to 23.9% (±3.52); LPS-mediated licensing led to a 0.76% [± 0.10] of the 
cells expressing the marker while LTA and Poly I:C produced a slight decrease of 
the percentage of cells expressing the marker (LTA = 0.66% [±0.11], Poly I:C = 
0.56% [±0.08]). These differences in percentage of live cells expressing MHC 
Class I among tissue of origin and inflammatory agent were further confirmed by 
MFI analysis (Figure 3-19, F). Despite the high variation in the percentage of 
MSCs positive for MHC Class I among tissue source, under resting conditions 
tissue source of origin had no significant effect on the expression levels of MHC 
Class I (BM = 24.93 [± 2.80], Is = 19.42 [± 2.99], Ad = 16 [± 0.81]). Cytokine and 
LPS-mediated licensing produced a statistically significant increase in the 
expression levels of MHC Class I in BM MSCs (Cytokines = 41.97 [± 4.52], LPS = 
71.27 [± 6.50], LTA = 33.27 [± 4.00], Poly I:C = 30.73 [± 1.82]). In the case of Is 
MSCs, only cytokine-mediated licensing produced a statistically significant 
increase in the expression levels of anti-MHC Class I (Cytokines = 46.03 [± 4.00], 
LPS = 22.68 [± 3.48], LTA = 18.54 [± 5.12], Poly I:C = 17.56 [± 4.44]). On the 
other hand, licensing of Ad MSCs produced no effect in the expression levels of 
MHC Class I (Cytokines = 21 [± 1.63], LPS = 16 [± 0.81], LTA = 14.33 [± 1.24], Poly 
I:C = 15 [± 2.44]).
  
 
 
Figure 3-18. Surface molecule phenotype of MSCs following inflammatory stimulation.  
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with either a cocktail of cytokines (40 ng/mL of IFN-
ϒ, TNF-α and IL-1β), 100 ng/mL LPS, 100 ng/mL LTA or 4µg/mL Poly I:C. Unstimulated cells were 
left growing in MSC culture medium as a control. 24 hours after stimulation, MSCs were stained 
with a cocktail of antibodies, to allow characterisation of MSCs by flow cytometry (A). The% of live 
MSCs which stained positive for each of the tested markers is graphed to compare expression 
between MSC tissue sources (B-G). Each bar represents an n of 3 independent experiments and is 
graphed as mean ± SEM. ONE WAY ANOVA with Tukey’s multiple comparison post-test analysis 
was used for statistical assessment of differences between MSC sources and licensing agent. 
Significant differences are marked with the appropriate number of asterisks. p = 0.05 was 
considered the limit for statistical significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.  
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Figure 3-19. MFI of surface molecules expressed on MSCs following inflammatory 
stimulation. 
Data shown in Figure 3-18 has been represented as mean fluorescence intensity (A-F). Each bar 
represents an n of 3 independent experiments and is graphed as mean ± SEM. ONE WAY ANOVA 
with Tukey’s multiple comparison post-test analysis was used for statistical assessment of 
differences between MSC sources and licensing agent. Significant differences are marked with the 
appropriate number of asterisks. p = 0.05 was considered the limit for statistical significance; * p < 
0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.  
 
In summary, CD73 surface marker staining detected the highest percentage of 
positive cells (> 97%) of all markers tested and there was no significant change in 
its expression after 24 hours of stimulation. CD146 staining detected a high 
percentage of positive cells (>92.6%) by MSCs from every tissue source, where Is 
MSCs had highest percentage of cells staining positive for this marker and Ad 
MSCs had the highest expression levels of CD146. 24 hours of stimulation did not 
produce any significant effect on the percentage of cells expressing CD146 in BM 
and Is MSCs but produced a decrease in the percentage of cells expressing this 
marker on Ad MSCs. CD166 and CD271 showed tissue specific expression levels, 
where BM MSCs had the highest percentage of positive cells and Ad MSCs the 
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lowest percentage of cells expressing these markers; inflammatory stimulation 
had little effect on these markers as it produced no change in the percentage of 
cells expressing this marker in Is MSCs and very subtle changes in BM and Ad 
MSCs after 24 hours cytokine- and LPS-mediated inflammation. Despite MHC 
Class II expression levels being very low in MSCs from every source, there were 
statistically significant differences in the percentage of positive cells among 
tissue sources. 24 hours of stimulation with the different licensing agents 
produced no statistically significant variations except for cytokine-mediated 
stimulation in BM MSCs. The percentage of positive cells for MHC Class I was 
affected by tissue source; however, this percentage increased in MSCs from the 
three tissues after cytokine stimulation and in BM and Is MSCs after LPS 
stimulation. LPS-mediated licensing produced the highest increase in the 
percentage of positive cells for MHC Class I in BM MSCs while Is MSCs responded 
better to cytokine-mediated stimulation.  
 
3.8 Discussion and conclusions 
During the past decades, MSCs have been extensively investigated both in basic 
and clinical research; however, there is a lot of inconsistency and controversy in 
this topic. Despite the efforts of the ISCT to establish minimum requirements for 
what constitutes a mesenchymal stromal cell in humans, there are still 
significant sources of variability during the manufacture of these cells, including 
isolation protocols, culture conditions and the intrinsic variability among source 
material. In order to reduce manipulation and contamination risk and to create a 
cellular product for clinical applications that could comply with Good 
Manufacturing Practice (GMP) standards, the aim of this thesis was to establish a 
standardised easily reproducible methodology for isolation and culture of murine 
MSCs that produced consistent results. A further aim of this chapter was to 
determine if the developed methodologies for murine MSC isolation and culture 
produced cells that satisfied the minimal criteria established by the ISCT to be 
considered MSCs. It is important to mention that ISCT criteria were established 
for the identification of human MSCs and although adherence and trilineage 
differentiation are characteristics of murine MSCs, the surface marker phenotype 
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of murine MSCs is not well characterised. In fact, induction of CD45 expression 
on murine BM MSCs has already been described (Yeh et al., 2006). 
Moreover, we aimed to determine if tissue of origin could influence the 
phenotype of mouse MSCs. Finally, as the ultimate aim is to use MSCs as cellular 
therapeutics where they would most likely be infused in inflammatory 
environments, and as pro-inflammatory stimulation leads to the production of 
immunomodulatory factors by MSCs, the phenotype of MSCs was also assessed 
under different inflammatory conditions (Krampera, 2011).  
Since their discovery in 1976, MSCs have been described as plastic adherent, 
spindle-shaped cells; therefore, the ISCT established this morphology as their 
first criteria for defining MSCs (Horwitz et al., 2005). BM and Ad MSCs satisfied 
this criterion from isolation to later passage (P3), while Is MSCs did not show this 
morphology until P2. Is MSCs were isolated from islets of Langerhans. Islets of 
Langerhans are clusters of 5 mixed populations of endocrine cells, more 
precisely, -cells, -cells, -cells, ε-cells and γ-cells, which produce glucagon, 
insulin, somatostatin, ghrelin and pancreatic polypeptide respectively. β-cells 
have been described to undergo an EMT process when expanded in monolayer 
culture, giving rise to MSCs (Moreno-Amador et al., 2018), which would explain 
the mixture of morphologically distinct populations observed at P1.  
ISCT states that these spindle–shaped cells must be able to differentiate into 
adipocytes, chondrocytes and osteocytes (Dominici et al., 2006), criterion that 
was fulfilled by cells isolated from all three tissues.  
Lastly, in order to qualify as MSCs, multipotent spindle–shaped cells must 
express an array of mesenchymal markers including CD90, CD105, CD73 and lack 
the B cell marker CD19, the primitive haematopoietic progenitor marker CD34, 
the pan–leukocyte marker CD45 and the monocyte/ macrophage marker CD11b. 
It is important to keep in mind that ISCT criteria were established for human 
MSCs; thus, variations might apply, and have been described, for murine MSCs. 
Sca-1 is the most recognised haematopoietic stem cell marker in mice but for 
consistency reasons with the ISCT criteria CD34 primitive haematopoietic 
progenitor marker was used for haematopoietic contamination exclusion. 
Ideally, these three criteria should be enough to identify MSCs; however, 
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fibroblasts are plastic adherent spindle-shaped cells that are positive for the 
expression of the surface markers CD73, CD90 and CD105 and that have proven 
tripotency (Haniffa et al., 2009). For this reason, other markers are often used 
to identify MSCs such as CD146, which has weak expression on fibroblasts and 
high for MSCs (Lv et al., 2014), CD166 and CD271. However, the expression of 
these markers is not consistent among tissue source and the percentage of 
positive cells expressing these surface markers fluctuate through passage (Kang 
et al., 2016, Maleki et al., 2014).  
CD90, also known as Thy-1, is a glycophosphatidylinositol-anchored protein that 
was first discovered in mouse T cells but is predominantly expressed on subsets 
of fibroblast, lymphocytes and stem cells (Sauzay et al., 2019). As a cell surface 
glycoprotein, its role is related to cell-cell and cell-matrix interactions within an 
inflammatory and wound healing context (Leyton and Hagood, 2014). MSCs 
isolated from the BM, Is and Ad expressed very high levels of CD90 with more 
than 98% of the cells being positive for this marker regardless of tissue source. 
CD105, also known as Endoglin, is a component of the TGF-β receptor complex 
expressed in endothelial cells, haematopoietic stem cells and MSCs, which is 
involved in blood vessel development, erythropoiesis and myelopoiesis (Cho et 
al., 2001) and neovascularisation (Fonsatti et al., 2003).  
Human MSCs have been stated to be CD105 positive, however, there are 
discrepancies regarding the CD105 phenotype in murine MSCs. Anderson et al. 
stated that CD105 is induced in a subpopulation of murine MSCs early upon in 
vitro culture giving rise to CD105+ and CD105- populations of MSCs that have 
almost identical surface marker phenotypes (CD29+CD44+Sca1+MHC Class I+ and 
CD45-CD11b-CD31-) but which vary in their differentiation and immunoregulatory 
properties (Anderson et al., 2013). In addition, culture medium influences 
expression levels of CD105; serum-supplemented media contains TGF-β, which 
induces CD105 expression leading to the downregulation of its surface expression 
(Mark et al., 2013). Despite MSCs having been described to have variable levels 
of CD105, tissue source of origin was not found to produce a change in the 
surface expression of CD105 as more than 98% of BM, Is and Ad MSCs stained 
positive for this marker.  
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Similarly, CD73 was also expressed by cells from every tissue source with more 
than 98% of the cells expressing this marker. CD73, an enzyme that converts 
adenosine monophosphate to adenosine, has been linked to the regulatory 
phenotypes of T and NK cells, as well as to MSCs. Extracellular ATP acts on many 
immune cells to promote inflammation while the ATP metabolite adenosine is 
mostly an anti-inflammatory molecule, which makes CD73 essential for the 
modulation of the immune response (Regateiro et al., 2013). In addition, CD73 is 
involved in tissue injury (Ryzhov et al., 2019), lymphocytes adhesion to the 
epithelium (Linden and Cekic, 2012) and is a key regulatory molecule for cancer 
cell proliferation, migration and invasion in vitro and tumour angiogenesis and 
immune escape in vivo (Chen et al., 2019). The high number of positive cells for 
CD90, CD105 and CD73 in MSCs from all three tissue sources suggests an 
immunomodulatory role within the context of inflammation.  
Even if the positive expression of these markers enables the characterisation of 
MSCs, the expression of these markers is not MSC exclusive, and it is essential to 
ensure that they lack other cell-type associated markers. As CD90, CD105 and 
CD73 are all present in haematopoietic stem cells, ensuring that MSCs lack the 
primitive haematopoietic progenitor marker CD34, a transmembrane 
phosphoglycoprotein expressed by haematopoietic stem cells, was essential. B 
cells might adhere to MSCs during isolation and remain viable in culture; 
therefore, B cell exclusion was done by CD19 B cell marker analysis. CD73 is 
expressed by T cells and macrophages and monocytes which are the cell types 
most likely to be found in MSC cultures. Thus, the pan-leukocyte marker CD45 
and the monocyte and macrophage marker CD11b are essential for exclusion of 
these cells.  
The percentage of live cells positive for CD45 was <2% for Ad MSCs, ~30% for Is 
MSCs and ~85% BM MSCs while the percentage of cells positive for CD11b was ‹2% 
for Ad MSCs, ~25% for Is MSCs and ~85% for BM MSCs. Although induction of CD45 
expression on murine BM MSCs had already been described (Yeh et al., 2006), 
cells in the current study were further characterised for expression of CD64, 
which is only expressed in macrophages and monocytes, and it was observed that 
the expression of this marker was minimal in the cells isolated from the three 
sources. Thus, it may be concluded that the isolated cells were not of myeloid 
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origin. In addition, macrophages and other leukocytes lack the trilineage 
potential, which further confirms that these cells were not from myeloid origin. 
MSCs are similar to fibroblasts as they have a similar morphology and are plastic 
adherent (Haniffa et al., 2009). Moreover, human dermal fibroblasts have also 
been shown to have tripotency (Junker et al., 2010) and immunoregulatory 
functions similar to MSCs (Haniffa et al., 2007) and to express most MSC markers 
such as CD105, CD73 and CD90 (Schwab et al., 2008). Fibroblast contamination is 
a potential impediment for regenerative medicine due to their senescence and 
transformation upon long-term expansion (Zhou et al., 2006); which makes 
proper MSC isolation essential. CD146 expression has found to be weak for 
fibroblasts and high for MSCs (Lv et al., 2014) and can therefore be used for 
discrimination between these two cell types. BM, Is and Ad MSCs all had a very 
high percentage of positive cells for CD146 (BM = 92.64% [±1.44], Is = 98.21% 
[±0.74], Ad = 94.73% [±2.73]), which definitely shows that the cells isolated from 
these tissue sources can be considered MSCs. 
Isolation of murine MSCs from exocrine pancreatic culture has been reported in 
the literature; however, to my knowledge, no studies have reported isolation of 
murine MSCs from adult islets of Langerhans. Human Is MSCs have previously 
been isolated and characterised but CD45 expression had not been characterised 
in Is MSCs before. Analysis of the CD45 positive cells isolated from the islets of 
Langerhans confirmed the presence of a CD45 positive population, which was 
smaller in size, and less complex in granularity, than the CD45 negative Is MSCs, 
and which had the potential to differentiate into adipocytes, chondrocytes and 
osteoblasts.  
There is controversy regarding the origin of Is MSCs. BM MSCs were suggested to 
migrate to the pancreas contributing to pancreatic regeneration and turnover 
(Song et al., 2013). However, after transplantation of green fluorescent protein 
(GFP) positive, sex-mismatched bone marrow into mice, no GFP positive β-cells 
were found, which challenged this hypothesis (Lechner et al., 2004). Epithelial 
to mesenchymal transition, a process in which epithelial cells change their 
phenotype to become mesenchymal cells, has been suggested as a mechanism 
leading to the generation of MSCs from cultured endocrine pancreas (Moreno-
Amador et al., 2018, Gershengorn et al., 2004). EMT would explain the different 
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morphologies observed when assessing the cell morphology of Is MSCs at P1. The 
small, polarised, epithelial cells start decreasing the expression of the adhesion 
molecules between epithelial cells, losing their apical-basal polarity and 
becoming spindle in shape while an increase in the mesenchymal markers takes 
place. During EMT, cells do not necessarily exist in “pure” epithelial or 
mesenchymal states; there are hybrid populations that share mixed features, 
which are termed as the intermediate cell states (ICSs). At P1, polarised and 
spindle shaped cells could be observed, while at later passages only the spindle 
shaped cells were present. Immunocytochemistry and flow cytometry analysis 
confirmed that soon after isolation these cells were positive for EpCAM and that 
only a small percentage, ~20% of the cells, were co-expressing vimentin, the 
mesenchymal marker. However, at P3, most of the cells had completed the EMT 
process with only ~20% of ICSs co-expressing EpCAM and vimentin, which 
confirms the hypothesis of pancreatic MSCs having an EMT origin. While the 
exact functions of ICSs are unclear, they have important roles in embryogenesis, 
tissue development, and pathological processes such as cancer metastasis. In 
addition, ICSs have been described to have greater potency/ stemness than 
“pure” mesenchymal cells, which makes them better for reprogramming (Sha et 
al., 2019).  
MSCs are being evaluated as cellular therapeutics for inflammatory conditions 
and diseases, for this reason, understanding their phenotype under these 
conditions is of significance importance as it could provide preferential tissue 
sources for MSC isolation for cell therapeutics (Galipeau, 2016).  
T cells are able to eliminate infected cells by closely interacting with other cells 
and discriminating the ones that have been affected by a pathogenic threat. 
Antigen presentation is crucial for discrimination and is carried by the major 
histocompatibility complex, which displays on the cell surface information about 
the different antigens that the cells are processing or have ingested. On the one 
hand, endogenous antigens, which can be self or foreign, are presented to 
cytotoxic T lymphocytes as peptides bound to MHC Class I molecules, which is 
expressed on all nucleated cells; while antigens engulfed into endocytic 
compartments are presented to helper T cells (CD4) as peptides bound to MHC 
Class II molecules, which are expressed in antigen presenting cells such as B 
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cells, monocytes, macrophages and dendritic cells and on epithelial cells 
following inflammatory signals. In this way, T cells can interact with these 
presented peptides to identify and eliminate cells expressing microbial genes, 
mutant sequences or foreign polymorphic genes from transplants. As nucleated 
cells, MSCs express MHC Class I molecules, however, they trigger a very weak 
cellular and humoral allogenic immune response due to their minimal expression 
of MHC Class II and the absence of co-stimulatory molecules CD40, CD40 ligand, 
CD80 and CD86 (Ryan et al., 2005). In line with the literature, BM, Is and Ad 
MSCs express MHC Class I under resting conditions which was upregulated after 
MSC licensing (Schu et al., 2012). In addition, the expression of MHC Class II on 
BM, Is and Ad MSCs was very low under resting conditions but as expected 
(Griffin et al., 2013), was slightly upregulated after MSC licensing. Nevertheless, 
MHC Class II levels were still low, which suggests an ability to escape 
alloreactive CD4+ T cells recognition. 
CD73 expression levels were not affected by licensing or tissue source and were 
very high. One study suggests that the role of CD73 in MSCs is related to 
attenuating CCR2+ macrophage infiltration and upregulating several anti-
inflammatory genes producing a pronounced anti-inflammatory activity (Tan et 
al., 2019).  
Regarding CD146, MCAM, is a commonly used MSC marker with reported variable 
expression depending on MSC tissue of origin (Kang et al., 2016). However, here 
we found little variation, as all MSC sources showed very high expression of 
CD146, Ad MSCs having the highest expression and BM MSCs the lowest. 
Considering the percentage of live cells expressing this marker, MSC licensing 
slightly increased CD146 expression in BM MSCs while the overall trend in Is and 
Ad MSCs was a decrease of expression of this marker after licensing. One study 
suggests that CD146 is involved in MSC trans-endothelial migration, therefore the 
lower the levels of CD146 the easier it could be for the cells to be retained 
within the inflammatory site and immunomodulate it (Ode et al., 2011).  
Like CD146, CD166 is a marker of MSCs described to have very variable levels 
among MSCs (Szepesi et al., 2016). In line with the literature, the percentage of 
MSCs positive for CD166 under resting conditions showed extensive variation 
from source to source with Ad MSCs expressing the highest levels among the 
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compared sources of MSCs. This large variation was exaggerated when MSCs were 
maintained under inflammatory conditions, however the overall trend of MSC 
CD166 expression was to downregulate when stimulated. CD166, also known as 
activated leukocyte cell adhesion molecule, is involved in cell adhesion and 
migration so as with CD146, its downregulation could be a mechanism used by 
MSCs to minimise their migration and be retained within the inflammatory site 
to fulfil their immunomodulatory role (Swart, 2002).  
CD271 is a universal marker for MSCs; however, its expression has been linked 
with a specific subpopulation of trabecular bone-associated MSCs (Attar et al., 
2013), which correlates with the fact of BM MSCs express significantly high levels 
of this marker and very low expression of CD271 by Ad and Is MSCs. BM and Ad 
MSCs downregulated CD271 expression after stimulatory licensing while Is MSCs 
slightly upregulated their almost inexistent CD271 levels. CD271 is a marker of 
interest as it is involved in cell growth and differentiation; CD271+ cells have 
increased multipotency therefore methodologies to induce its expression in 
MSCs, as MSC co-culture with endothelial cells, are being developed, 
(Bellagamba et al., 2018).  
One of the routes of delivery of MSCs into patients is intravenous infusion, but 
tracking of the cells shows that only a small percentage of the cells home and 
remain in the target tissue which could be due to MSC trapping in the lung after 
intravenous delivery (Fischer et al., 2009, Schrepfer et al., 2007). However, 
MSCs are able to exert their anti-inflammatory role without homing to target 
inflammatory sites in significant numbers and despite the fact that the cells 
disappear within short periods of time (Kurtz, 2008). The size of the cells could 
be an essential factor involved in the lung trapping, for this reason, the size of 
MSCs was compared among tissue sources and after licensing. BM MSCs are 
slightly smaller than Is and Ad MSCs, which suggests that they could be a better 
source of MSC for intravenous delivery. Inflammatory licensed MSCs have been 
described to exhibit an increased immunomodulation in inflammatory 
environments due to upregulation of anti-inflammatory molecule expression 
(Cassano et al., 2018). Some of these molecules are stored in granules, for this 
reason, we compared the granularity of MSCs from different tissues before and 
after stimulation. Under resting conditions, BM MSCs were the most granular 
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cells. Stimulation of MSCs produced little variation or decreased the granularity 
of MSCs from every tissue. 
3.8.1 Conclusions  
Altogether, the expression of the widely used MSC markers CD90, CD105 and 
CD73 remained constant among tissue source and inflammatory stimulus. Cells 
isolated from the bone marrow and islets of Langerhans were CD45+ CD11b+ and, 
for this reason, did not meet ISCT criteria. However, fibroblast and monocyte/ 
macrophage contamination were excluded from all the cultures. ISCT criteria 
were established for the identification of human MSCs and the surface marker 
phenotype of murine MSCs is not so well characterised. For this reason, based on 
plastic adherence, trilineage differentiation potential and CD90, CD105 and 
CD73 expression, we determined that cells isolated from the bone marrow, islets 
of Langerhans and adipose tissue were MSCs regardless of CD45 and CD11b 
expression. Moreover, specific criteria to enable the identification of murine 
MSCs should be established. CD146, CD166 and CD271 levels varied among tissue 
source, which suggests that MSC tissue of origin has an effect on migratory and 
differentiation potential. More importantly, MHC Class I and II molecules were 
upregulated under inflammatory licensing, with BM MSCs having the highest MHC 
Class II levels and Is MSCs having the highest MHC Class I levels after stimulation. 
Regarding the use of MSC as cellular therapeutics, these results might have 
implications in selection of tissue source of origin for treatment. In respect of 
size and granularity, BM MSCs are the smallest and most granular among the 
compared MSCs, which makes them, so far, the best candidates for cell therapy.
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4 Profiling of MSC chemokine and chemokine 
receptor expression at the transcript and protein 
level  
4.1 Introduction and aims 
In Chapter 3, thorough characterisation determined that cells isolated from 
adipose tissue satisfied the criteria of the ISCT and can therefore be considered 
MSCs. Cell isolated from the bone marrow and islets of Langerhans retain the 
haematopoietic markers CD45 and CD11b, and thus, do not meet ISCT criteria for 
human MSCs, but nonetheless, are MSCs. The overall aim of this thesis was to 
study the behaviour of BM, Is and Ad MSCs by studying their interaction with the 
immune system in order to better understand their regenerative and 
immunomodulatory potential to be used as cellular therapeutics. According to 
the United States National Library of Medicine, as of 26th of July of 2019, MSCs 
have received nine cell therapy approvals and one tissue engineering approval 
and 8133 studies are being carried out examining their efficacy in a variety of 
clinical applications such as bone, myocardium, kidney and liver repair and co–
transplantation with haematopoietic stem cells among others (Horwitz et al., 
1999, Baron et al., 2010, Mao et al., 2017, Ezquer et al., 2017, Saberi et al., 
2019).  
One critical aspect of MSC use as cellular therapeutics is related to the delivery 
method. The optimal method should provide the highest regenerative benefit 
with the lowest side effects. The most used routes of MSC administration, 
outside tissue–engineering-based methods, are direct injection into the tissue of 
interest and systemic infusion, both intravenously or intra–arterially. Systemic 
infusion is much less invasive than direct administration while direct injection 
should have the advantage of a much more precise localization of the cells. 
However, an engraftment study using three different administration methods in 
cardiac disease showed that only 1 to 5% of delivered cells engraft within the 
target site regardless of the delivery route (Freyman et al., 2006). In addition of 
being less invasive, systemic infusion enables easy access to oxygen and 
nutrients, which is why systemic infusion is often the preferred method for MSC 
delivery (Sarkar et al., 2011). Systemic infusion of MSCs leads to engraftment of 
MSCs mostly in the lungs, which is likely generated by the small capillary size, 
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the large size of the cells and their strong adhesion properties. However, MSCs 
can also be found in the spleen, liver, bone marrow, thymus, kidney and skin, 
seconds or minutes after IV injection, but, it is still unknown if MSCs migrate 
specifically to these organs or if they just get trapped (Devine et al., 2003, 
Fischer et al., 2009, Freyman et al., 2006, Schrepfer et al., 2007).  
MSC entrapment represents a major bottleneck to reach the full therapeutic 
potential of MSC-based therapies. In order to improve this situation, better 
understanding of in vivo migration to target tissues and cell persistence within 
them is essential. In the presence of inflammation, 1 to 5% of delivered cells are 
able to escape the lung entrapment and migrate and home within the target 
site, which suggests that chemotactic stimuli could be guiding infused MSCs to 
sites of inflammation (Rustad and Gurtner, 2012). Chemokines are master 
regulators in immune cell trafficking under resting and inflammatory conditions; 
for this reason, we hypothesised that chemokines and their receptors should be 
involved in the homing of these cells to, and persistence at, sites of 
inflammation. Human and murine MSCs have been described to constitutively 
express chemokines and their receptors. CCR1, CCR7, CXCR2, CXCR4, CXCR6 and 
CX3CR1 are all important in the context of homing but the expression of these 
markers varies among reports in the literature due to tissue source of the cells, 
cell culture methods and passage number of the cells. Murine BM MSCs have 
been described to express CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR9, 
CCR10, CXCR3, CXCR4 and CXCR7 and to have functional CCR3, CCR4, CCR5, 
CCR7, CCR10 and CXCR4 (Alexeev et al., 2013). Ad MSCs have higher CXCR4 
expression and migration capacity than BM MSCs and more interestingly, the 
chemokine receptor profile is sensitive to time in culture as the expression of 
chemokine receptors CCR1, CCR7, CXCR1, CXCR2, CXCR4 and CX3CR1 was 
decreased after passage (Heirani-Tabasi et al., 2017). In addition, expression of 
chemokine receptors and ligands can be upregulated by cytokine-mediated 
stimulation (Croitoru-Lamoury et al., 2007). All this together suggests that the 
tissue source of origin of the MSCs is associated with differential chemokine 
receptor expression and therefore, different homing potential to sites of 
inflammation, which could be of relevance when used as cellular therapeutics.  
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In a similar way, in vitro cultured MSCs have been proven to secrete a wide 
range of chemokines, such as CCL2, CCL3, CCL4, CCL5, CCL20, CXCL1, CXCL2, 
CXCL5, CXCL8, CXCL12 and CX3CL1, and to recruit cells from the immune 
system; for this reason, we consider that understanding MSC chemokine 
secretion will enable us to predict the interaction of these cells with the 
immune system and therefore, their immunomodulatory potential in an in vivo 
setting (Chen et al., 2008, Ren et al., 2008, Meirelles Lda et al., 2009). 
As chemokine receptors seem to be involved in MSC homing to sites of 
inflammation, and chemokine ligands attract leukocytes towards them, we 
hypothesised that chemokines could have an extremely important role in the 
immunomodulatory potential of MSCs as they have the potential to orchestrate 
the migration and positioning of immune cells within the tissues. Therefore, the 
aims of this chapter were to i) characterise chemokine and chemokine receptor 
transcript and protein levels in MSCs, ii) identify the effect of MSC tissue source 
of origin in the expression of these molecules and iii) study how MSC licensing 
alters MSC chemokine and chemokine receptor transcription and expression.  
 
Results 
Throughout this results section, the transcription and expression profile of 
chemokines and their receptors is described in detail in each section under 
resting and inflammatory conditions. Transcriptional profiling enabled the 
identification of the chemokines that had undergone the most significant 
variations at transcriptional level upon stimulation. The secretion profile of 
those chemokines by MSCs from the three sources was then analysed under 
resting and stimulatory conditions.  
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4.2 Analysis of the effect of a single inflammatory 
stimulus on the transcription of chemokines and 
chemokine receptors  
To understand the mechanisms involved in MSC migration and 
immunomodulation, it was important to understand their chemokine and 
chemokine receptor expression. To do this, the most relevant chemokines and 
their receptors in the MSCs context were selected based on previous work 
carried out by Dr Kayleigh Thirlwell on human MSCs (Thirlwell, 2018), and their 
transcription was assessed. BM, Is and Ad MSCs were transcriptionally assessed 
under resting and inflammatory (40 ng/ mL of TNF-α, IL-1β and IFN-ϒ) conditions 
to determine the effect of tissue source and/ or inflammatory conditions on the 
MSC chemokine and chemokine receptor transcriptional profile.  
Transcription data were normalised to the house keeping gene beta-2 
microglobulin (B2M) to consider variations in RNA quality and quantity. As this 
study did not have a reference sample, data are represented as 2(-ΔCT), which 
enables the visualization of expression levels of specific genes normalised to B2M 
for each sample. Due to the nature of normalisation, genes that generated a CT 
of 35 or above resulted in 2(-ΔCT) less than or equivalent to ~0.0001 and are 
marked with a red box on the following graphs and are likely not transcribed at 
meaningful levels by MSCs (Thirlwell, 2018).  
4.2.1 Transcription of CC chemokines under resting and 
inflammatory conditions 
Under resting conditions, BM, Is and Ad MSCs transcribed very few, if any, CC 
chemokines with the exception of CCL2, which was transcribed by all tissue 
source MSCs at similar levels (Figure 4-1, A), and CCL7, which was very highly 
expressed by BM MSCs (E). A pattern of transcriptional upregulation after 
stimulation was observed in CCL2 (A), CCL3 (B), CCL5 (D), CCL7 (E), CCL11 (G), 
CCL19 (H) and CCL20 (I). However, these chemokines were upregulated 
differentially in MSCs according to their tissue of origin. CCL9 (F) was the only 
chemokine that was downregulated after 24-hour cytokine-mediated 
stimulation. Fold changes of transcriptional regulation upon cytokine-mediated 
licensing of MSCs are specified in Table 4-1.  
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BM MSCs expressed the highest levels of CCL2 under resting and inflammatory 
conditions, while Is MSCs had the highest levels of CCL3 under resting and 
inflammatory conditions. Inflammatory stimulation resulted in a substantial and 
significant upregulation of both CCL2 and CCL3 transcripts in MSCs from all 
sources. MSCs from every source did not show any statistically significant 
variation in their CCL4 levels after stimulation; these levels were much more 
consistent (at a low level) in the BM MSCs (C). CCL5 transcript levels were very 
low under resting conditions but inflammatory stimulation led to a marked 
increase in expression levels in BM and Is MSCs. As previously mentioned, CCL7 
was expressed at very substantial levels under resting conditions in all MSCs; 
however, tissue of origin of MSCs had an effect in the transcript levels as BM 
MSCs expressed much higher levels than Is and Ad MSCs. Inflammatory 
stimulation led to a substantial and significant upregulation of CCL7 transcripts 
by BM, Is and Ad MSCs. CCL9 transcripts were the highest in BM MSCs and CCL9 
was the only chemokine in which transcript levels decreased after inflammatory 
stimulation. CCL11 and CCL19 had similar levels of transcription under resting 
conditions and inflammatory stimulation produced an upregulation of these 
chemokines in MSCs from all sources; however, stimulated BM MSCs had the 
highest transcript levels of CCL11, while CCL19 was expressed in higher amounts 
by licensed Is MSCs. CCL20 showed a similar pattern of transcriptional regulation 
to CCL5, with very low levels of transcript under resting conditions and 
substantial levels after stimulation. BM MSCs had the highest levels of CCL20 
transcription, closely followed by Ad MSCs, while Is MSCs had much lower levels.  
To sum up, MSCs from all sources expressed a variety of CCL chemokines, which 
could be involved in the recruitment of immune cells such as monocytes, 
macrophages, NK cells, eosinophils and B cells. Under resting conditions, MSCs 
transcribed very low levels of CCLs, except for CCL2 and CCL7; however, 
inflammatory stimulation resulted in a marked upregulation of CCL chemokine 
transcription by all tissue sources of MSCs except CCL9, which was 
downregulated. 
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Figure 4-1. Inflammation and MSC tissue origin impacts CC chemokine transcript levels in 
MSCs. 
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with a cocktail of cytokines, 40 ng/ mL of IFN-ϒ, 
TNF-α and IL-1β, for 24 hours. Unstimulated cells were left growing in MSC culture medium as a 
control. Quantitative reverse transcription PCR (qRT-PCR) was performed to evaluate CCL 
transcripts in BM, Is and Ad MSCs under resting and inflammatory conditions. Each bar represents 
an n of 3 independent experiments and is graphed as mean ± SEM. Data are normalised to the 
housekeeping gene B2M and expressed as 2(-ΔCT). Appropriate statistical analysis was performed 
and includes Students paired T test between one MSC tissue source (Resting vs Inflammatory 
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Conditions) and One Way ANOVA with Tukey’s multiple comparisons post-test to compare all MSC 
sources. Statistically significant differences are marked with the appropriate number of asterisks. p 
= 0.05 was considered the limit for statistical significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** 
p < 0.0001. 
 
Table 4-1. Fold change in CC chemokine transcript levels of cytokine-mediated licensed BM, 
Is and Ad MSCs compared to unstimulated cells from the same source.  
Following the experimental set up explained in Figure 4-1, fold change in transcript levels of CC 
chemokine is represented as mean of fold change ± standard deviation. Statistically significant 
differences are marked with a colour code, where p < 0.05 is represented by green, p < 0.01 is 
represented by orange, p < 0.001 is represented by blue and p < 0.0001 is represented by red.  
Gene BM MSCs Is MSCs Ad MSCs 
CCL2 10.30 ± 2.11 5.71 ± 0.97 10.32 ± 2.23 
CCL3 11.71 ± 12.16 5.44 ± 0.86 9.98 ± 12.59 
CCL4 0.65 ± 0.54 0.11 ± 0.09 13.47 ± 9.79 
CCL5 438.68 ± 60.22 33.15 ± 3.06 20.46 ± 5.93 
CCL7 2.20 ± 0.41 4.91 ± 1.13 5.69 ± 1.98 
CCL9 0.54 ± 0.10 0.59 ± 0.07 0.08 ± 0.05 
CCL11 5.91 ± 3.71 2.31 ± 0.25 10.04 ± 16.53 
CCL19 4.27 ± 2.11 9.89 ± 3.94 0.20 ± 0.14 
CCL20 631.34 ± 148.34 19.27 ± 2.37 1443.42 ± 1440.99 
 
4.2.2 Transcription of CXC chemokines under resting and 
inflammatory conditions  
Under resting conditions, BM, Is and Ad MSCs transcribed very few, if any, CXC 
chemokines with the exception of CXCL1, which was highly transcribed by BM 
MSCs (Figure 4-2, A). A pattern of transcriptional upregulation was observed in 
CXCL1 (A), CXCL2 (B), CXCL5 (C), CXCL10 (D) and CXCL16 (G). However, these 
chemokines were upregulated differentially in MSCs according to their tissue of 
origin. CXCL12 (E) and CXCL13 (F) were the only chemokines that were 
downregulated after 24-hour cytokine-mediated stimulation. Fold changes of 
transcript upon cytokine-mediated licensing of MSCs are shown in Table 4-2. BM 
MSCs expressed high levels of CXCL1 transcript under resting conditions while Is 
and Ad MSCs barely expressed any transcript; however, inflammatory stimulation 
of the cells produced a marked upregulation of CXCL1 in cells from all tissues, 
with BM MSCs expressing very high levels of CXCL1. Expression of CXCL2 was 
almost undetectable during resting conditions but inflammatory stimulation 
produced a significant upregulation in BM and Is MSCs; Ad MSCs upregulated their 
CXCL2 transcript levels even if it was in a statistically non-significant way. CXCL5 
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levels were almost undetectable under resting conditions in cells from all the 
tissue sources. Inflammatory stimulation produced 45 times higher levels of 
CXCL5 transcript levels, generating 5.91 times more expression of CXCL5 than 
the housekeeping gene B2M. CXCL10 levels were very low in MSCs from all the 
tissue sources under resting conditions, and inflammatory stimulation only 
produced an increase in the amount of transcript in Is and Ad MSCs; Is MSCs were 
able to generate the highest levels of CXCL10. Regarding CXCL12, during resting 
conditions, BM MSCs were able to produce significantly higher transcript levels 
than Is and Ad MSCs, which produced very little. After inflammatory stimulation, 
MSCs isolated from the three tissue sources produced lower levels of CXCL12 
transcript, where this downregulation was only significant in BM MSCs. CXCL13 
levels were very low under both resting and inflammatory conditions in BM, Is 
and MSCs and is likely not transcribed in MSCs. Lastly, CXCL16 transcripts were 
barely detectable in MSCs during resting conditions but inflammatory licensing 
led to a pattern of upregulation of this transcript, with Ad MSCs being the cells 
expressing the highest levels and the only MSCs in which upregulation was 
statistically significant. 
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Figure 4-2. Inflammation and MSC tissue origin impacts CXC chemokine transcript levels in 
MSCs. 
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with a cocktail of cytokines, 40 ng/ mL of IFN-ϒ, 
TNF-α and IL-1β, for 24 hours. Unstimulated cells were left growing in MSC culture medium as a 
control. Quantitative reverse transcription PCR (qRT-PCR) was performed to evaluate CXCL 
transcripts in BM, Is and Ad MSCs under resting and inflammatory conditions. Each bar represents 
an n of 3 independent experiments and is graphed as mean ± SEM. Data are normalised to the 
housekeeping gene B2M and expressed as 2(-ΔCT). Appropriate statistical analysis was performed 
and includes Students paired T test between one MSC tissue source (Resting vs Inflammatory 
Conditions) and One Way ANOVA with Tukey’s multiple comparisons post-test to compare all MSC 
sources. Statistically significant differences are marked with the appropriate number of asterisks. p 
= 0.05 was considered the limit for statistical significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** 
p < 0.0001. 
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Table 4-2. Fold change in CXC chemokine transcript levels of cytokine-mediated licensed 
BM, Is and Ad MSCs compared to unstimulated cells from the same source.  
Following the experimental set up explained in Figure 4-2, fold change in transcript levels of CXC 
chemokine is represented as mean of fold change ± standard deviation. Statistically significant 
differences are marked with a colour code, where p < 0.05 is represented by green, p < 0.01 is 
represented by orange, p < 0.001 is represented by blue and p < 0.0001 is represented by red. 
 
Gene BM MSCs Is MSCs Ad MSCs 
CXCL1 15.14 ± 7.11 27.31 ± 3.28 33.65 ± 12.33 
CXCL2 197.83 ± 66.14 89.07 ± 12.03 31.85 ± 12.57 
CXCL5 45.52 ± 8.46 28.30 ± 13.55 38.20 ± 16.28 
CXCL10 5.44 ± 5.06 25.92 ± 15.32 34.32 ± 15.31 
CXCL12 0.65 ± 0.10 0.15 ± 0.05 1.91 ± 1.21 
CXCL13 6.74 ± 9.51 0.09 ± 0.06 0.01 ± 0.01 
CXCL16 6.78 ± 1.15 3.80 ± 0.47 14.66 ± 6.23 
 
 
4.2.3 Transcription of CC chemokine receptor expression under 
resting and inflammatory conditions 
Under resting conditions, BM, Is and Ad MSCs do not appear to be transcribing CC 
chemokine receptors except for CCR1 (Figure 4-3, A) and CCR5 (Figure 4-3, E). 
CCR2 (B), CCR3 (C), CCR4 (D), CCR6 (F), CCR7 (G), CCR8 (H), CCR9 (I) and CCR10 
(J) generated a CT of 35 or above, resulting in 2(-ΔCT) less than or equivalent to 
~0.0001, which suggests that are likely not transcribed at meaningful levels by 
MSCs and are marked with a red box on the following graphs. Fold changes in 
transcript levels upon cytokine-mediated licensing of MSCs are specified in Table 
4-3. 
CCR1 expression was very low in BM and Ad MSCs during resting conditions and 
transcript levels did not increase after inflammatory stimulation (Figure 4-3, A). 
Is MSCs, on average, showed higher CCR1 transcript levels during resting 
conditions but extensive variations were seen among the samples. However, 
after inflammatory stimulation, Is MSCs expressed higher transcript levels than 
MSCs isolated from other tissues. Similarly, CCR5 transcript levels were very low 
in BM and Ad MSCs under resting conditions while Is MSCs had higher levels but 
with a bigger deviation among samples. Inflammatory stimulation produced a 
small upregulation of CCR5 transcript levels in Is MSCs, but again, due to large 
variation this increase was not significant, and the expression levels were still 
quite low, which may not translate into any biological effect.  
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Figure 4-3. Inflammation and MSC tissue origin does not have a big impact on CC 
chemokine receptor transcript levels in MSCs. 
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with a cocktail of cytokines, 40 ng/ mL of IFN-ϒ, 
TNF-α and IL-1β, for 24 hours. Unstimulated cells were left growing in MSC culture medium as a 
control. Quantitative reverse transcription PCR (qRT-PCR) was performed to evaluate CCR 
transcripts in BM, Is and Ad MSCs under resting and inflammatory conditions. Each bar represents 
an n of 3 independent experiments and is graphed as mean ± SEM. Data are normalised to the 
housekeeping gene B2M and expressed as 2(-ΔCT). Appropriate statistical analysis was performed 
and includes Students paired T test between one MSC tissue source (Resting vs Inflammatory 
Conditions) and One Way ANOVA with Tukey’s multiple comparisons post-test to compare all MSC 
sources. Statistically significant differences are marked with the appropriate number of asterisks. p 
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= 0.05 was considered the limit for statistical significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** 
p < 0.0001. 
 
Table 4-3. Fold change in CC chemokine receptor transcript levels of cytokine-mediated 
licensed BM, Is and Ad MSCs compared to unstimulated cells from the same source.  
Following the experimental set up explained in Figure 4-3, fold change in transcript levels of CC 
chemokine receptors is represented as mean of fold change ± standard deviation. Statistically 
significant differences are marked with a colour code, where p < 0.05 is represented by green, p < 
0.01 is represented by orange, p < 0.001 is represented by blue and p < 0.0001 is represented by 
red. 
Gene BM MSCs Is MSCs Ad MSCs 
CCR1 1.38 ± 0.35 3.12 ± 3.77 0.42 ± 0.56 
CCR2 0.58 ± 0.35 1.34 ± 1.05 0.34 ± 0.24 
CCR3 0.58 ± 0.26 5.25 ± 6.04 0.18 ± 0.22 
CCR4 0.37 ± 0.26 5.79 ± 5.67 0.14 ± 0.20 
CCR5 0.38 ± 0.11 5.84 ± 6.92 0.05 ± 0.05 
CCR6 0.19 ± 0.16 19.89 ± 19.64 0.09 ± 0.05 
CCR7 0.15 ± 0.03 0.39 ± 0.31 0.05 ± 0.05 
CCR8 0.15 ± 0.16 29.07 ± 26.60 47.15 ± 81.36 
CCR9 0.22 ± 0.11 0.88 ± 0.74 2.14 ± 1.24 
CCR10 1.17 ± 0.40 0.25 ± 0.15 0.22 ± 0.16 
 
4.2.4 Transcription of CXC chemokine receptors expression 
under resting and inflammatory conditions 
As described for CC chemokine receptors, BM, Is and Ad MSCs do not appear to 
be transcribing CXC chemokine receptors except for CXCR6 (Figure 4-4, F). 
CXCR1 (A), CXCR2 (B), CCR3 (C), CXCR4 (D) and CXCR5 (E) generated a CT of 35 
or above, resulting in 2(-ΔCT) less than or equivalent to ~0.0001, which suggests 
that are likely not transcribed at meaningful levels by MSCs and are marked with 
a red box on the following graphs. Fold changes of transcript levels upon 
cytokine-mediated licensing of MSCs are detailed in Table 4-4.  
Under resting conditions, BM MSCs have the highest transcript levels of CXCR6 
and Is MSCs the lowest (Figure 4-4, F). Inflammatory stimulation produced a 
downregulation of CXCR6 transcript in BM and Is MSCs, while Ad MSCs did not 
show a clear pattern due to the big variation among samples.  
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Figure 4-4. Inflammation and MSC tissue origin does not have a big impact on CXC 
chemokine receptor transcript levels in MSCs. 
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with a cocktail of cytokines, 40 ng/ mL of IFN-ϒ, 
TNF-α and IL-1β, for 24 hours. Unstimulated cells were left growing in MSC culture medium as a 
control. Quantitative reverse transcription PCR (qRT-PCR) was performed to evaluate CXCR 
transcripts in BM, Is and Ad MSCs under resting and inflammatory conditions. Each bar represents 
an n of 3 independent experiments and is graphed as mean ± SEM. Data are normalised to the 
housekeeping gene B2M and expressed as 2(-ΔCT). Appropriate statistical analysis was performed 
and includes Students paired T test between one MSC tissue source (Resting vs Inflammatory 
Conditions) and One Way ANOVA with Tukey’s multiple comparisons post-test to compare all MSC 
sources. Statistically significant differences are marked with the appropriate number of asterisks. p 
= 0.05 was considered the limit for statistical significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** 
p < 0.0001. 
 
Table 4-4. Fold change in CXC chemokine receptor transcript levels of cytokine-mediated 
licensed BM, Is and Ad MSCs compared to unstimulated cells from the same source.  
Following the experimental set up explained in Figure 4-4, fold change in transcript levels of CXC 
chemokine receptors is represented as mean of fold change ± standard deviation. Statistically 
significant differences are marked with a colour code, where p < 0.05 is represented by green, p < 
0.01 is represented by orange, p < 0.001 is represented by blue and p < 0.0001 is represented by 
red. 
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Gene BM MSCs Is MSCs Ad MSCs 
CXCR1 3.20 ± 3.07 0.79 ± 0.32 0.36 ± 0.34 
CXCR2 2.57 ± 1.88 13.00 ± 18.19 3.92 ± 3.63 
CXCR3 2.62 ± 3.47 0.12 ± 0.13 1.00 ± 0.00 
CXCR4 0.06 ± 0.01 6.44 ± 7.50 3.05 ± 3.65 
CXCR5 1.35 ± 1.92 2.42 ± 2.30 3.39 ± 4.35 
CXCR6 0.17 ± 0.04 0.61 ± 0.65 1.51 ± 1.33 
 
4.2.5 Transcription of atypical chemokine receptor expression 
under resting and inflammatory conditions 
BM, Is and Ad MSCs do not appear to be transcribing ACKR2 (Figure 4-5, B) and 
ACKR3 (Figure 4-5, C) as they generated a CT of 35 or above, resulting in 2(-ΔCT) 
less than or equivalent to ~0.0001, which suggests that are likely not transcribed 
at meaningful levels by MSCs and are marked with a red box on the following 
graphs. Fold changes of transcript levels upon cytokine-mediated licensing of 
MSCs are specified in Table 4-5. 
Under resting conditions, no significant differences were found in the transcript 
levels of ACKR1 among the MSCs isolated from the three different sources and 
inflammatory stimulation did not produce a clear pattern of down or 
upregulation, which is quite likely to be due to the large variation among 
samples (Figure 4-5, A). During resting conditions, ACKR4 transcript levels were 
significantly higher in the MSCs isolated from the BM compared to Is and Ad 
MSCs. Inflammatory stimulation produced a significant downregulation in BM 
MSCs and no effect in Is and Ad MSCs (D).  
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Figure 4-5. Inflammation and MSC tissue origin impacts ACKR4 transcript levels in MSCs. 
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with a cocktail of cytokines, 40 ng/mL of IFN-ϒ, 
TNF-α and IL-1β, for 24 hours. Unstimulated cells were left growing in MSC culture medium as a 
control. Quantitative reverse transcription PCR (qRT-PCR) was performed to evaluate ACKR 
transcripts in BM, Is and Ad MSCs under restingand inflammatory conditions. Each bar represents 
an n of 3 independent experiments and is graphed as mean ± SEM. Data are normalised to the 
housekeeping gene B2M and expressed as 2(-ΔCT). Appropriate statistical analysis was performed 
and includes Students paired T test between one MSC tissue source (Resting vs Inflammatory 
Conditions) and One Way ANOVA with Tukey’s multiple comparisons post-test to compare all MSC 
sources. Statistically significant differences are marked with the appropriate number of asterisks. p 
= 0.05 was considered the limit for statistical significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** 
p < 0.0001. 
 
Table 4-5. Fold change in ACKR transcript levels of cytokine-mediated licensed BM, Is and 
Ad MSCs compared to unstimulated cells from the same source.  
Following the experimental set up explained in Figure 4-5, fold change in transcript levels of 
ACKRs is represented as mean of fold change ± standard deviation. Statistically significant 
differences are marked with a colour code, where p < 0.05 is represented by green, p < 0.01 is 
represented by orange, p < 0.001 is represented by blue and p < 0.0001 is represented by red. 
Gene BM MSCs Is MSCs Ad MSCs 
ACKR1 0.21 ± 0.08 21.39 ± 22.02 1.60 ± 1.66 
ACKR2 1.46 ± 2.39 9.87 ± 15.63 272.83 ± 278.35 
ACKR3 19.85 ± 31.88 19.31 ± 25.31 74.91 ± 108.19 
ACKR4 0.06 ± 0.01 0.97 ± 1.32 0.12 ± 0.04 
 
4.2.6 Transcription of XCL and CX3C chemokine expression, their 
receptors and the receptors for the stimulatory agents 
under resting and inflammatory conditions 
CX3CL1 transcript level variations were not detected in the MSCs isolated from 
the different sources under resting conditions; however, tissue of origin did 
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affect the transcript levels after inflammatory stimulation. BM MSC showed an 
upregulation of CX3CL1 even if it was not statistically significant, Is MSCs 
transcript levels showed no variation after stimulation and lastly, CX3CL1 
transcript levels were upregulated by Ad MSC in a statistically significant manner 
after inflammatory stimulation (Figure 4-6, A). The chemokine receptors CX3CR1 
(Figure 4-6, B) and XCR1 (Figure 4-6, C) generated a CT of 35 or above, resulting 
in 2(-ΔCT) less than or equivalent to ~0.0001, which suggests that they are likely 
not transcribed by MSCs at meaningful levels and are therefore marked with a 
red box on the following graphs. Fold changes of transcript levels upon cytokine-
mediated licensing of MSCs are specified in Table 4-6. 
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Figure 4-6. Inflammation and MSC tissue origin impacts CX3CL1 transcript levels in MSCs. 
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with a cocktail of cytokines, 40 ng/ mL of IFN-ϒ, 
TNF-α and IL-1β, for 24 hours. Unstimulated cells were left growing in MSC culture medium as a 
control. Quantitative reverse transcription PCR (qRT-PCR) was performed to evaluate transcripts in 
BM, Is and Ad MSCs under resting and inflammatory conditions. Each bar represents an n of 3 
independent experiments and is graphed as mean ± SEM. Data are normalised to the 
housekeeping gene B2M and expressed as 2(-ΔCT). Appropriate statistical analysis was performed 
and includes Students paired T test between one MSC tissue source (Resting vs Inflammatory 
Conditions) and One Way ANOVA with Tukey’s multiple comparisons post-test to compare all MSC 
sources. Statistically significant differences are marked with the appropriate number of asterisks. p 
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= 0.05 was considered the limit for statistical significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** 
p < 0.0001. 
 
Table 4-6. Fold change in XCL and CX3C chemokines, their receptors and the receptors of 
the stimulatory agents’ transcript levels of cytokine-mediated licensed BM, Is and Ad MSCs 
compared to unstimulated cells from the same source.  
Following the experimental set up explained in Figure 4-6 fold change in transcript levels of XCL 
and CX3C, their receptors and the receptors of the stimulatory agents is represented as mean of 
fold change ± standard deviation. Statistically significant differences are marked with a colour code, 
where p < 0.05 is represented by green, p < 0.01 is represented by orange, p < 0.001 is 
represented by blue and p < 0.0001 is represented by red. 
 
Gene BM MSCs Is MSCs Ad MSCs 
CX3CL1 2.35 ± 0.43 1.60 ± 1.19 5.31 ± 3.21 
CX3CR1 0.12 ± 0.01 0.57 ± 0.68 0.41 ± 0.29 
XCR1 6.89 ± 6.33 74.70 ± 128.32 0.69 ± 0.91 
IL1R1 0.18 ± 0.11 0.04 ± 0.02 1.99 ± 1.00 
IL1R2 0.19 ± 0.17 0.10 ± 0.09 25.20 ± 38.61 
TNFR1a 0.74 ± 0.49 0.35 ± 0.13 0.89 ± 0.09 
TNFR1b 0.48 ± 0.15 0.24 ± 0.08 0.68 ± 0.09 
IFNGR1 0.12 ± 0.11 0.15 ± 0.06 0.52 ± 0.49 
IFNGR2 0.78 ± 0.56 0.88 ± 0.27 2.71 ± 0.81 
 
It was essential to ensure that MSCs from the three tissues were capable of 
responding to inflammatory stimuli, for this reason, transcript levels of the 
receptors for the stimulatory molecules, IL-1β, TNF-α and IFN-ϒ, were assessed. 
In response to increased activation by a ligand, a cell’s sensitivity to that 
specific ligand commonly transiently reduces by decreasing the expression of the 
specific receptor interacting with the ligand (Heldin et al., 2016). This is called 
negative feedback and was used to determine activation of MSCs after 
inflammatory stimulation.  
IL-1β is recognised by IL1R1 and IL1R2. Under resting conditions, Is MSCs 
expressed the highest levels of IL1R1 (Figure 4-6, D) and IL1R2 (Figure 4-6, E) 
followed by the BM MSCs and lastly by Ad MSCs. After inflammatory stimulation, 
MSCs isolated from the BM and Is had downregulated the transcript levels of both 
receptors; Ad MSCs were slightly higher but the standard deviation was much 
higher in these samples. TNF-α is recognised by TNFR1a and TNFR1b, and as 
observed in Figure 4-6, F and G, under resting conditions MSCs from all sources 
expressed similar levels of transcripts for these receptors. After 24 hours of 
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inflammatory stimulation TNFR1a and TNFR1b transcript levels were 
downregulated in MSCs from every tissue, where Is MSCs had the highest 
downregulation, followed by BM MSCs and lastly Ad MSCs. Lastly, IFN-ϒ is 
recognised by IFNGR1 and IFNGR2. Tissue of origin influenced the expression of 
these receptors as during resting conditions BM MSCs expressed significantly 
higher levels of IFNGR1 than Ad MSCs and Is MSCs showed higher transcript levels 
of IFNGR2 than Ad MSCs. After inflammatory stimulus, IFNGR1 transcript levels 
were downregulated in MSCs isolated from the three tissues while IFNGR2 was 
only downregulated in cells isolated from the BM and Is. Overall, Ad MSCs 
downregulated their receptors to a lesser extent than BM or Is MSCs after 
inflammatory stimulation.  
 
4.3 Analysis of the effect of a double inflammatory 
stimulus over time on the transcription of 
chemokines and chemokine receptors 
Several reports in the literature suggest that the immunomodulatory activities of 
MSCs are not spontaneous, that priming by inflammatory cytokines is essential 
for MSC–mediated immunosuppression, irrespective of the species of origin (Ren 
et al., 2009). Within a clinical setting, MSCs are usually infused within an 
inflammatory environment, which provides the required licensing for increasing 
the immunomodulatory properties of MSCs. When the anti–inflammatory 
properties of MSCs are studied in vitro, this licensing is mimicked in an in vitro 
culture with the addition of pro-inflammatory cytokines; in this specific case 
with 40 ng/ mL of IFN-ϒ, TNF-α and IL-1β.  
As previously discussed, pro-inflammatory cytokine-mediated MSC licensing 
produced a transcriptional upregulation of chemokines, which could explain why 
MSCs are more immunosuppressive upon activation. Within clinical settings, it 
has been reported that pre-treatment of MSCs with inflammatory cytokines prior 
to administration within animal models of inflammatory diseases boosts the 
therapeutic effect of MSCs (Duijvestein et al., 2011, Noronha et al., 2019). For 
this reason, we wondered if pre-licensing the MSCs prior to exposing them to an 
inflammatory environment would lead to even bigger changes in chemokine 
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transcriptional levels and therefore, in enhanced therapeutic potential. To study 
this, cells were pre-licensed for 48 hours, after which cells were washed twice 
with PBS and stimulated again for another 24 hours. The first stimulation primes 
the MSCs while the second stimulation would mimic the inflammatory 
environment MSCs would face when infused into a patient with an inflammatory 
disorder. Figure 4-7 illustrates the time points at which supplemented medium 
was added. Culture medium was removed at the time cells were harvested and 
was kept for analysis.  
Two different control conditions were used. In the first one, cells were 
stimulated for 48 hours, after which cells were washed twice with PBS and fresh 
culture medium was added; cells were harvested 24 hours later. In the second 
condition, cells were washed twice with PBS, the culture medium was replaced 
with fresh medium and the cells were left growing for 48 hours. Cells were then 
washed twice with PBS, the culture medium was replaced with supplemented 
medium and the cells were harvested 24 hours later. There is an extensive 
literature about how cytokine-mediated licensing enhances the potential 
therapeutic efficacy of MSCs; however, little is known about the role of TLR 
ligand-mediated activation on the secretion of chemotactic cytokines by MSCs. 
For this reason, 100 ng/ mL lipopolysaccharide (LPS), 100 ng/mL lipoteichoic 
acid (LTA) and 4 mg/ ml polyinosinic-polycytidylic acid (poly I:C), as well as the 
previously described cytokine cocktail, was used for MSC licensing.  
 
Figure 4-7. Diagrammatic illustration of the time course of the MSC licensing. 
 
172 
 
On the basis of the results described in Section 4.2, the genes that showed 
alterations in their transcript levels in a statistically significant manner upon 
stimulation were selected and their transcriptional levels were assessed after 
licensing with different inflammatory molecules and different inflammatory 
conditions.  
It is important to bear in mind that in the experiments in Section 4.3, the 
influence of four different inflammatory agents (cytokine cocktail with TNF-α, 
IL-1β and IFN-ϒ, LPS, LTA and Poly I:C) at three different time points (72 hours, 
24 hours and double stimulation) on 22 different genes was studied, and an 
untreated sample was used as control. This study was performed in MSCs 
isolated from three different sources (BM, Is and Ad MSCs), which gave a total of 
858 data points per experiment ([4 inflammatory agents × 3 time points + 1 
control] × 22 genes × 3 MSC sources).  
Among all the licensing molecules tested, the combination of 40 ng/ mL of TNF-
α, IL-1β and IFN-ϒ led to the biggest variations in chemokine receptor and ligand 
expression and among all the conditions tested, harvesting the cells 24 hours 
after the inflammatory stimulation led to the most significant results. These 
condition has already been discussed in Section 4.2, for this reason, due to the 
huge amount of data presented in this chapter, we decided to move the less 
relevant results to the Appendix. Thus, this results section will only display the 
fold changes of transcript levels upon licensing of MSCs in tables, while the 
explanatory text and figures will be displayed in Section 8.1.  
4.3.1 Transcription of CC chemokines under resting and 
inflammatory conditions 
As outlined in Section 4.2.1, under resting conditions, BM, Is and Ad MSCs 
transcribed very few, if any, CC chemokines with the exception of CCL2, which 
was transcribed by all tissue sources of MSCs at similar levels, and CCL7, which 
was very highly expressed by BM MSCs. A pattern of transcriptional upregulation 
was observed in CCL2, CCL3, CCL5, CCL7 and CCL20 genes after licensing in 
every condition; however, these chemokines were upregulated differentially in 
MSCs according to their tissue of origin and licensing agent (Section 8.1). CC 
chemokine transcript levels 24 hours after stimulation (Condition 2) increased in 
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MSCs from every tissue source; however, this upregulation was not sustained, as 
cells harvested 72 hours after licensing (Condition 1) showed a decrease in the 
transcript levels of CC chemokines. A second stimulation 48 hours after the first 
stimulation (Condition 3) was able to induce the transcription of CC chemokines 
in MSCs from the three sources; however, the second stimulation was not able to 
match the transcript levels of CC chemokines found in Condition 2 in MSCs from 
every source with the exception of Ad MSCs after cytokine-mediated stimulation, 
where these cells massively increased the transcript levels of CC chemokine 
ligands. Fold changes of transcriptional regulation upon licensing of MSCs are 
specified in Table 4-7.  
 
Table 4-7. Fold change in CC chemokine transcript levels of cytokine, LPS, LTA or Poly I:C-
mediated licensed BM, Is and Ad MSCs compared to unstimulated cells from the same 
source.  
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with either a cocktail of cytokines (40 ng/ mL of 
IFN-ϒ, TNF-α and IL-1β), 100 ng/ mL LPS, 100 ng/ mL LTA or 4 µg/ mL Poly I:C. Unstimulated 
cells were left growing in MSC culture medium as a control. Three different licensing conditions 
were tested. In the first one, cells were stimulated for 48 hours, after which cells were washed twice 
with PBS and fresh culture medium was added; cells were harvested 24 hours later. In the second 
condition, cells were washed twice with PBS, the culture medium was replaced with fresh one and 
the cells were left growing for 48 hours. Cells were then washed twice with PBS, the culture 
medium was replaced with supplemented one and the cells were harvested 24 hours later. In the 
last condition, cells were stimulated for 48 hours, after which cells were washed twice with PBS 
and were stimulated again for another 24 hours. Figure 4-7 illustrates the time points at which 
supplemented medium was added. Quantitative reverse transcription PCR (qRT-PCR) was 
performed to evaluate CCL transcripts in BM, Is and Ad MSCs under resting and inflammatory 
conditions. Data are normalised to the housekeeping gene B2M and expressed as 2(-ΔCT). Fold 
change in transcript levels of CC chemokines is represented as mean of fold change ± standard 
deviation. One Way ANOVA with Tukey’s multiple comparisons post-test was performed to 
compare all MSC sources and the different conditions. Statistically significant differences are 
marked with a colour code, where p < 0.05 is represented by green, p < 0.01 is represented by 
orange, p < 0.001 is represented by blue and p < 0.0001 is represented by red. 
Gene Condition Licensing BM MSCs Is MSCs Ad MSCs 
CCL2 
1 
Cyt 1.84 ± 1.43 8.07 ± 1.77 0.51 ± 0.11 
LPS 0.71 ± 0.56 4.58 ± 2.60 1.21 ± 1.04 
LTA 0.75 ± 0.15 2.67 ± 1.79 0.56 ± 0.06 
Poly I:C 0.89 ± 0.33 2.66 ± 0.62 0.41 ± 0.03 
2 
Cyt 4.24 ± 1.14 22.93 ± 5.23 6.77 ± 1.70 
LPS 0.98 ± 0.29 10.01 ± 3.32 6.71 ± 1.76 
LTA 1.32 ± 0.36 1.02 ± 0.15 3.21 ± 0.60 
Poly I:C 5.39 ± 1.85 10.97 ± 5.25 2.88 ± 0.56 
3 
Cyt 1.38 ± 0.77 5.02 ± 1.31 202.76 ± 51.81 
LPS 1.26 ± 0.51 3.19 ± 1.18 11.66 ± 2.49 
LTA 0.82 ± 0.53 0.80 ± 0.09 5.01 ± 1.65 
Poly I:C 2.28 ± 0.79 4.96 ± 1.86 4.47 ± 1.76 
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Gene Condition Licensing BM MSCs Is MSCs Ad MSCs 
CCL3 
1 
Cyt 0.27 ± 0.07 1.02 ± 0.24 1.26 ± 0.45 
LPS 0.50 ± 0.03 1.03 ± 0.75 0.76 ± 0.31 
LTA 0.89 ± 0.14 0.24 ± 0.04 0.73 ± 0.19 
Poly I:C 0.22 ± 0.03 0.27 ± 0.07 0.30 ± 0.10 
2 
Cyt 1.23 ± 0.50 3.57 ± 1.01 0.36 ± 0.06 
LPS 0.88 ± 0.16 3.06 ± 0.97 0.56 ± 0.16 
LTA 1.04 ± 0.27 0.45 ± 0.21 0.51 ± 0.08 
Poly I:C 0.61 ± 0.33 0.82 ± 0.25 0.32 ± 0.06 
3 
Cyt 0.64 ± 0.35 1.21 ± 0.30 2.88 ± 0.69 
LPS 1.14 ± 0.14 1.18 ± 0.43 0.57 ± 0.15 
LTA 1.16 ± 0.37 1.22 ± 1.37 0.70 ± 0.22 
Poly I:C 1.13 ± 0.13 0.52 ± 0.12 0.84 ± 0.52 
CCL5 
1 
Cyt 11.59 ± 10.85 7.35 ± 2.09 10.95 ± 3.50 
LPS 4.58 ± 4.07 96.57 ± 22.51 2.63 ± 0.41 
LTA 0.25 ± 0.20 0.70 ± 0.30 0.46 ± 0.20 
Poly I:C 107.27 ± 97.50 5.82 ± 1.15 7.86 ± 2.49 
2 
Cyt 48.22 ± 45.00 29.01 ± 11.82 9.58 ± 1.87 
LPS 70.79 ± 63.95 29.90 ± 10.46 16.00 ± 5.69 
LTA 1.61 ± 1.53 0.35 ± 0.07 104.45 ± 33.37 
Poly I:C 138.31 ± 134.11 177.83 ± 38.71 52.32 ± 16.60 
3 
Cyt 10.25 ± 8.63 5.92 ± 1.49 419.49 ± 93.64 
LPS 10.17 ± 9.13 13.12 ± 6.50 2.83 ± 1.06 
LTA 1.22 ± 1.18 0.64 ± 0.55 0.56 ± 0.26 
Poly I:C 208.49 ± 195.87 117.21 ± 39.74 23.07 ± 23.86 
CCL7 
1 
Cyt 0.39 ± 0.30 1.82 ± 2.02 1.62 ± 0.86 
LPS 0.23 ± 0.14 4.56 ± 5.13 0.90 ± 0.47 
LTA 0.22 ± 0.10 2.30 ± 2.68 0.95 ± 0.46 
Poly I:C 0.33 ± 0.22 0.73 ± 0.49 0.66 ± 0.32 
2 
Cyt 1.29 ± 0.70 5.27 ± 5.15 3.77 ± 2.14 
LPS 1.14 ± 0.20 7.54 ± 6.36 6.60 ± 2.51 
LTA 0.87 ± 0.08 1.85 ± 2.26 4.59 ± 2.26 
Poly I:C 0.88 ± 0.68 13.03 ± 17.73 3.38 ± 1.83 
3 
Cyt 0.55 ± 0.07 2.87 ± 3.03 30.78 ± 15.81 
LPS 1.72 ± 0.72 6.00 ± 7.25 2.53 ± 1.32 
LTA 0.86 ± 0.67 3.06 ± 3.48 0.92 ± 0.48 
Poly I:C 1.58 ± 0.91 5.10 ± 5.83 0.09 ± 0.04 
CCL20 
1 
Cyt 4.23 ± 0.74 8.74 ± 7.80 0.18 ± 0.14 
LPS 2.45 ± 1.14 28.10 ± 13.76 2.13 ± 1.91 
LTA 1.17 ± 0.63 0.35 ± 0.25 0.02 ± 0.01 
Poly I:C 2.19 ± 0.50 0.68 ± 0.47 0.59 ± 0.57 
2 
Cyt 631.34 ± 148.34 19.27 ± 2.37 470.60 ± 222.05 
LPS 42.76 ± 42.62 7.47 ± 2.27 14.68 ± 6.22 
LTA 64.25 ± 66.43 0.57 ± 0.25 13.20 ± 4.91 
Poly I:C 45.35 ± 26.57 8.32 ± 6.09 5.25 ± 2.10 
3 
Cyt 27.91 ± 26.21 5.21 ± 0.89 298.33 ± 107.66 
LPS 87.39 ± 80.84 4.40 ± 1.63 5.93 ± 2.20 
175 
 
Gene Condition Licensing BM MSCs Is MSCs Ad MSCs 
LTA 8.18 ± 7.03 0.12 ± 0.15 1.01 ± 0.35 
Poly I:C 36.44 ± 30.10 5.21 ± 2.65 0.00 ± 0.00 
 
4.3.2 Transcription of CXC chemokines under resting and 
inflammatory conditions 
As outlined in Section 4.2.2, under resting conditions, BM, Is and Ad MSCs 
transcribed very few, if any, CXC chemokines with the exception of CXCL1, 
which was transcribed by BM MSCs. A pattern of transcriptional upregulation was 
observed in CXCL1, CXCL2, CXCL5, CXCL10 and CXCL16 after licensing in every 
condition, while stimulation of MSCs led to the downregulation of CXCL12 
(Section 8.1). However, these chemokines were regulated differentially in MSCs 
according to their tissue of origin and licensing agent. CXCL1, CXCL5, CXCL10 
and CXCL16 chemokine transcript levels increased after 24 hours of stimulation 
(Condition 2) in MSCs from every tissue source; however, this upregulation was 
not sustained, as cells harvested 72 hours after licensing (Condition 1) showed a 
decrease in the transcript levels of CC chemokines. CXCL2 transcript levels 
increased after 24 hours stimulation (Condition 2) in MSCs from every tissue 
source; however, while this upregulation was promptly reversed in BM and Is 
MSCs, Ad MSCs expressed higher amounts of CXCL2 transcript levels 72 hours 
after licensing (Condition 1). A second stimulation, 48 hours after the first 
stimulation (Condition 3), was able to induce the transcription of CXCL1, CXCL2, 
CXCL5, CXCL10 and CXCL16 chemokines in MSCs from the three sources. 
However, the second stimulation was not able to match the transcript levels of 
CXC chemokines found in Condition 2 in MSCs from every source except for Ad 
MSCs after cytokine-mediated stimulation, where these cells massively increased 
the transcript levels of CXC chemokine ligands. CXCL12 transcript levels were 
very dependent on MSC source and licensing agent; cytokine-mediated licensing 
produced a downregulation of the transcript levels in every condition in BM and 
Is MSCs, while it produced an upregulation in Ad MSCs. LPS-mediated licensing 
produced a downregulation of CXCL12 levels in BM and Ad MSCs, while it was 
able to induce the transcription levels in Is MSCs after 72 hours stimulation 
(Condition 1). LTA licensing led to a trend of upregulation in BM MSCs while it 
produced no statistically significant effect on Is and Ad MSCs. Lastly, Poly I:C 
stimulation produced a downregulation in BM MSCs, no variation in Is MSCs and a 
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downregulation in Ad MSCs which was overcome after a double stimulation 
(Condition 3). Fold changes of transcript levels upon licensing of MSCs are 
specified in Table 4-8.  
Table 4-8. Fold change in CXC chemokine transcript levels of cytokine, LPS, LTA or Poly 
I:C-mediated licensed BM, Is and Ad MSCs compared to unstimulated cells from the same 
source.  
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with either a cocktail of cytokines (40 ng/ mL of 
IFN-ϒ, TNF-α and IL-1β), 100 ng/ mL LPS, 100 ng/ mL LTA or 4 µg/ mL Poly I:C. Unstimulated 
cells were left growing in MSC culture medium as a control. Three different licensing conditions 
were tested. In the first one, cells were stimulated for 48 hours, after which cells were washed twice 
with PBS and fresh culture medium was added; cells were harvested 24 hours later. In the second 
condition, cells were washed twice with PBS, the culture medium was replaced with fresh one and 
the cells were left growing for 48 hours. Cells were then washed twice with PBS, the culture 
medium was replaced with supplemented one and the cells were harvested 24 hours later. In the 
last condition, cells were stimulated for 48 hours, after which cells were washed twice with PBS 
and were stimulated again for another 24 hours. Figure 4-7 illustrates the time points at which 
supplemented medium was added. Quantitative reverse transcription PCR (qRT-PCR) was 
performed to evaluate CXCL transcripts in BM, Is and Ad MSCs under resting and inflammatory 
conditions. Data are normalised to the housekeeping gene B2M and expressed as 2(-ΔCT). Fold 
change in transcript levels of CXC chemokines is represented as mean of fold change ± standard 
deviation. One Way ANOVA with Tukey’s multiple comparisons post-test was performed to 
compare all MSC sources and the different conditions. Statistically significant differences are 
marked with a colour code, where p < 0.05 is represented by green, p < 0.01 is represented by 
orange, p < 0.001 is represented by blue and p < 0.0001 is represented by red. 
Gene Condition Licensing BM MSCs Is MSCs Ad MSCs 
CXCL1 
1 
Cyt 3.70 ± 3.41 3.04 ± 3.73 0.09 ± 0.06 
LPS 0.35 ± 0.25 0.78 ± 0.87 0.23 ± 0.06 
LTA 0.09 ± 0.07 1.94 ± 2.28 0.11 ± 0.04 
Poly I:C 0.06 ± 0.05 2.11 ± 2.17 0.13 ± 0.03 
2 
Cyt 13.66 ± 10.35 7.77 ± 7.58 2.56 ± 0.23 
LPS 1.78 ± 0.56 5.05 ± 5.82 1.96 ± 0.41 
LTA 0.62 ± 0.10 0.93 ± 0.64 0.95 ± 0.06 
Poly I:C 1.01 ± 0.77 1.21 ± 1.20 0.91 ± 0.12 
3 
Cyt 2.49 ± 0.30 3.19 ± 2.58 57.55 ± 4.31 
LPS 2.25 ± 1.25 1.20 ± 0.63 1.58 ± 0.09 
LTA 0.18 ± 0.11 2.41 ± 2.56 0.89 ± 0.19 
Poly I:C 0.16 ± 0.08 0.44 ± 0.29 1.45 ± 0.22 
CXCL2 
1 
Cyt 0.95 ± 0.20 0.70 ± 0.41 64.35 ± 10.64 
LPS 3.24 ± 0.66 13.12 ± 12.57 0.52 ± 0.17 
LTA 1.01 ± 0.13 0.61 ± 0.22 0.33 ± 0.21 
Poly I:C 0.69 ± 0.28 0.40 ± 0.15 0.19 ± 0.08 
2 
Cyt 7.14 ± 1.15 10.04 ± 3.51 3.18 ± 0.49 
LPS 15.99 ± 4.05 8.70 ± 2.38 3.63 ± 1.65 
LTA 3.03 ± 0.65 0.98 ± 0.71 2.70 ± 0.89 
Poly I:C 2.56 ± 1.19 2.91 ± 0.50 1.40 ± 0.46 
3 
Cyt 2.21 ± 0.95 5.49 ± 1.02 110.74 ± 34.09 
LPS 12.61 ± 2.99 1.95 ± 0.49 1.34 ± 0.53 
LTA 2.05 ± 1.16 0.52 ± 0.50 0.97 ± 0.42 
Poly I:C 1.20 ± 0.14 1.86 ± 0.44 3.12 ± 1.31 
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Gene Condition Licensing BM MSCs Is MSCs Ad MSCs 
CXCL5 
1 
Cyt 0.41 ± 0.15 27.08 ± 24.87 0.97 ± 0.50 
LPS 0.05 ± 0.01 5.60 ± 4.80 4.38 ± 0.98 
LTA 0.01 ± 0.00 0.40 ± 0.17 0.51 ± 0.09 
Poly I:C 0.01 ± 0.00 0.89 ± 0.62 0.51 ± 0.12 
2 
Cyt 6.86 ± 1.60 182.44 ± 101.70 26.79 ± 4.95 
LPS 2.27 ± 2.22 13.58 ± 4.69 28.05 ± 10.42 
LTA 1.09 ± 1.06 1.40 ± 1.15 2.96 ± 0.48 
Poly I:C 0.02 ± 0.00 1.46 ± 1.33 2.30 ± 0.46 
3 
Cyt 2.22 ± 1.94 108.75 ± 37.36 402.41 ± 86.69 
LPS 1.85 ± 1.62 14.43 ± 6.41 19.12 ± 4.38 
LTA 0.14 ± 0.13 0.10 ± 0.05 0.65 ± 0.20 
Poly I:C 0.13 ± 0.10 1.68 ± 1.53 26.34 ± 6.16 
CXCL10 
1 
Cyt 0.11 ± 0.06 0.19 ± 0.15 1.02 ± 0.63 
LPS 0.43 ± 0.31 11.88 ± 15.22 0.31 ± 0.08 
LTA 0.50 ± 0.21 1.42 ± 1.21 0.48 ± 0.18 
Poly I:C 0.69 ± 0.23 0.62 ± 0.50 0.91 ± 0.46 
2 
Cyt 10.16 ± 5.26 19.21 ± 10.64 45.62 ± 21.79 
LPS 1.64 ± 0.46 1.23 ± 1.06 3.65 ± 1.84 
LTA 0.99 ± 0.47 1.14 ± 0.63 12.40 ± 6.16 
Poly I:C 97.19 ± 36.00 3.61 ± 2.02 6.92 ± 2.85 
3 
Cyt 4.09 ± 2.34 6.51 ± 5.88 913.91 ± 470.61 
LPS 1.07 ± 0.69 1.21 ± 0.58 0.64 ± 0.25 
LTA 0.80 ± 0.38 2.73 ± 3.09 1.62 ± 1.12 
Poly I:C 30.72 ± 14.62 2.58 ± 1.92 0.15 ± 0.04 
CXCL12 
1 
Cyt 0.13 ± 0.09 0.87 ± 0.90 2.87 ± 1.41 
LPS 0.27 ± 0.11 5.88 ± 1.89 0.66 ± 0.23 
LTA 1.15 ± 0.92 5.47 ± 4.99 1.02 ± 0.46 
Poly I:C 0.17 ± 0.14 2.68 ± 1.59 0.41 ± 0.23 
2 
Cyt 0.16 ± 0.12 0.36 ± 0.30 2.09 ± 0.86 
LPS 0.39 ± 0.18 1.48 ± 1.62 1.54 ± 0.60 
LTA 1.98 ± 1.13 1.43 ± 0.75 1.14 ± 0.83 
Poly I:C 0.61 ± 0.39 2.69 ± 2.03 1.04 ± 0.57 
3 
Cyt 0.22 ± 0.19 0.81 ± 0.59 5.50 ± 2.08 
LPS 0.63 ± 0.38 1.70 ± 0.41 0.53 ± 0.27 
LTA 1.88 ± 1.43 0.44 ± 0.38 2.20 ± 1.04 
Poly I:C 0.32 ± 0.23 1.95 ± 1.89 3.01 ± 1.13 
CXCL16 
1 
Cyt 2.95 ± 0.24 0.35 ± 0.23 1.81 ± 0.92 
LPS 5.07 ± 2.20 1.15 ± 0.47 0.70 ± 0.31 
LTA 8.30 ± 2.33 0.52 ± 0.42 0.81 ± 0.50 
Poly I:C 1.20 ± 0.47 0.31 ± 0.12 0.46 ± 0.23 
2 
Cyt 7.59 ± 1.34 5.13 ± 2.00 43.11 ± 16.81 
LPS 4.20 ± 0.62 1.52 ± 0.90 4.96 ± 3.71 
LTA 10.53 ± 3.08 0.54 ± 0.31 1.89 ± 0.97 
Poly I:C 3.25 ± 2.57 1.87 ± 1.42 1.57 ± 0.75 
3 
Cyt 5.30 ± 1.62 5.01 ± 3.71 62.89 ± 24.29 
LPS 7.48 ± 2.10 0.74 ± 0.44 1.57 ± 0.61 
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Gene Condition Licensing BM MSCs Is MSCs Ad MSCs 
LTA 13.80 ± 1.23 2.68 ± 3.20 1.29 ± 0.66 
Poly I:C 2.26 ± 0.14 1.04 ± 0.59 2.33 ± 1.11 
 
4.3.3 Transcription of CX3CL1 chemokine and atypical chemokine 
receptor ACKR4 under resting and inflammatory conditions  
As outlined in Section 4.2.6, under resting conditions, BM, Is and Ad MSCs 
transcribed very little, if any, CX3CL1 while ACKR4 was transcribed at higher 
rates, but in both cases transcript level variations were not observed among the 
MSCs isolated from the different sources under resting conditions. However, in 
both cases tissue of origin and licensing agent did have an influence on the 
transcript levels after inflammatory stimulation (Section 8.1). CX3CL1 showed a 
pattern of transcriptional upregulation after licensing while ACKR4 showed a 
pattern of transcriptional downregulation. With a few exceptions, CX3CL1 
transcript levels increased after a 24 hours stimulation (Condition 2) in MSCs 
from every tissue source; however, this upregulation was not sustained, as cells 
harvested 72 hours after licensing (Condition 1) showed a decrease in the 
transcript levels of CX3CL1 compared to Condition 2. A second stimulation 48 
hours after the first stimulation (Condition 3) was able to induce transcription of 
CX3CL1 in MSCs from the three sources, however, the second stimulation was 
not able to match the transcript levels observed in Condition 2. Overall, ACKR4 
transcript levels decrease after a 24 hour stimulation (Condition 2) in MSCs from 
every tissue source; however, this downregulation was not sustained, as even if 
the downregulation was still notable, cells harvested 72 hours after licensing 
(Condition 1) showed higher transcript levels than the ones observed 24 hours 
after licensing. A second stimulation 48 hours after the first stimulation 
(Condition 3) was able to slow down the reversion of the downregulation in MSCs 
from the three sources as ACKR4 transcript levels were like the ones observed 24 
hours after licensing. Fold changes of transcriptional regulation upon licensing of 
MSCs are specified in Table 4-9. 
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Table 4-9. Fold change in CX3CL1 and ACKR4 transcript levels of cytokine, LPS, LTA or 
Poly I:C-mediated licensed BM, Is and Ad MSCs compared to unstimulated cells from the 
same source.  
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with either a cocktail of cytokines (40 ng/ mL of 
IFN-ϒ, TNF-α and IL-1β), 100 ng/ mL LPS, 100 ng/ mL LTA or 4µg/ mL Poly I:C. Unstimulated cells 
were left growing in MSC culture medium as a control. Three different licensing conditions were 
tested. In the first one, cells were stimulated for 48 hours, after which cells were washed twice with 
PBS and fresh culture medium was added; cells were harvested 24 hours later. In the second 
condition, cells were washed twice with PBS, the culture medium was replaced with fresh one and 
the cells were left growing for 48 hours. Cells were then washed twice with PBS, the culture 
medium was replaced with supplemented one and the cells were harvested 24 hours later. In the 
last condition, cells were stimulated for 48 hours, after which cells were washed twice with PBS 
and stimulated again for another 24 hours. Figure 4-7 illustrates the time points at which 
supplemented medium was added. Quantitative reverse transcription PCR (qRT-PCR) was 
performed to evaluate CX3CL1 and ACKR4 transcripts in BM, Is and Ad MSCs under resting and 
inflammatory conditions. Data are normalised to the housekeeping gene B2M and expressed as 2(-
ΔCT). Fold change in transcript levels of CX3CL1 and ACKR4 is represented as mean of fold change 
± standard deviation. One Way ANOVA with Tukey’s multiple comparisons post-test was 
performed to compare all MSC sources and the different conditions. Statistically significant 
differences are marked with a colour code, where p < 0.05 is represented by green, p < 0.01 is 
represented by orange, p < 0.001 is represented by blue and p < 0.0001 is represented by red. 
Gene Condition Licensing BM MSCs Is MSCs Ad MSCs 
CX3CL1 
1 
Cyt 2.39 ± 0.51 2.34 ± 2.02 2.19 ± 0.73 
LPS 1.40 ± 0.10 7.44 ± 3.38 0.29 ± 0.12 
LTA 5.13 ± 3.48 2.84 ± 1.46 1.09 ± 0.75 
Poly I:C 0.49 ± 0.32 5.71 ± 1.25 0.28 ± 0.14 
2 
Cyt 7.07 ± 3.78 4.82 ± 4.06 23.71 ± 5.55 
LPS 0.61 ± 0.16 1.01 ± 0.88 0.15 ± 0.04 
LTA 2.40 ± 0.65 2.38 ± 2.75 0.24 ± 0.05 
Poly I:C 1.74 ± 1.62 4.29 ± 3.14 0.30 ± 0.09 
3 
Cyt 1.24 ± 0.96 1.17 ± 0.80 12.29 ± 2.38 
LPS 0.73 ± 0.27 0.77 ± 0.75 0.42 ± 0.11 
LTA 1.20 ± 0.79 4.24 ± 2.95 5.63 ± 1.68 
Poly I:C 0.32 ± 0.20 1.92 ± 1.60 1.99 ± 0.43 
ACKR4 
1 
Cyt 0.02 ± 0.02 0.01 ± 0.00 1.66 ± 1.30 
LPS 0.07 ± 0.01 0.18 ± 0.09 0.85 ± 0.30 
LTA 0.16 ± 0.05 0.23 ± 0.04 0.80 ± 0.49 
Poly I:C 0.01 ± 0.00 0.82 ± 0.57 0.52 ± 0.16 
2 
Cyt 0.02 ± 0.01 0.01 ± 0.00 0.26 ± 0.14 
LPS 0.05 ± 0.02 0.08 ± 0.02 0.12 ± 0.09 
LTA 0.26 ± 0.11 0.47 ± 0.23 0.31 ± 0.18 
Poly I:C 0.03 ± 0.01 0.13 ± 0.03 0.19 ± 0.05 
3 
Cyt 0.01 ± 0.00 0.01 ± 0.00 0.29 ± 0.12 
LPS 0.18 ± 0.08 0.17 ± 0.18 0.18 ± 0.04 
LTA 0.11 ± 0.04 0.60 ± 0.11 3.15 ± 0.66 
Poly I:C 0.00 ± 0.00 0.13 ± 0.14 0.50 ± 0.16 
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4.3.4 Transcription of the receptors for the stimulatory agents 
under resting and inflammatory conditions 
Under resting conditions, BM, Is and Ad MSCs transcribed very little, if any, 
IL1R1, IL1R2, IFNGR2, TLR2, TLR3 and TLR4, while TNFR1a, TNFR1b and IFNGR1 
were transcribed at higher rates (Section 8.1). In all the cases, transcript level 
variations were not observed among the MSCs isolated from the different sources 
under resting conditions. However, tissue of origin did influence the 
transcriptional regulation upon exposure to the different licensing agents and 
the different conditions. Fold changes of transcriptional regulation upon 
licensing of MSCs are summarised in Table 4-10. 
Briefly, cytokine-mediated stimulation led to the downregulation of the cytokine 
receptors (IL1R1, IL1R2, TNFR1a, TNFR1b, IFNGR1 and IFNGR2) in BM and Is MSCs 
under all conditions. Cytokine-mediated stimulation downregulated the cytokine 
receptors in Ad MSCs too; however, this downregulation was not sustained 72 
hours after stimulation and, in some cases, even led to the upregulation of the 
receptors. LPS and LTA were able to upregulate the cytokine receptor transcript 
levels in certain conditions in MSCs from the three sources. The effects of Poly 
I:C in the regulation of the cytokine receptor transcription levels was tissue 
specific; Poly I:C stimulation of BM MSCs led to the downregulation of all the 
cytokine receptors but IFNGR2 in all the conditions tested. Poly I:C was able to 
downregulate the transcription of all the cytokine receptors but IFNGR2 in Is 
MSCs; however, 24 hours after the stimulation the downregulation started 
getting reversed and the transcript levels started increasing. The effect of Poly 
I:C stimulation in Ad MSCs was gene dependent and the effect it produced in 
each of the genes at the established time points will be described later. LPS-
mediated stimulation downregulated its receptor, TLR4, after 24 hours licensing 
in BM MSCs; however, 24 hours after the stimulation the downregulation started 
to reverse, and the transcript levels started increasing. LPS produced no 
variation in TLR4 transcript levels after a single stimulation in Is MSCs; however, 
a second stimulation 48 hours after the first one downregulated the receptor 
transcript levels.  
Overall, LPS-mediated licensing produced no variation in TLR4 transcript levels 
in Ad MSCs under any condition. Cytokine and Poly I:C-mediated licensing were 
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associated with downregulation of the transcription of TLR4 in BM and Is MSCs; 
while cytokines upregulated its transcription in every condition and Poly I:C was 
able to upregulate the transcription of TLR4 after a double stimulation. LTA-
mediated stimulation produced an upregulation of TLR4 transcript levels in BM 
MSCs, a downregulation that was reversed after 72 hours in Is MSCs and was only 
able to upregulate the transcription after a double stimulation in Ad MSCs.  
LTA-mediated stimulation upregulated its receptor, TLR2, in BM MSCs under 
every condition, while it produced no variation in Is MSCs and a small 
downregulation in Ad MSCs after a single stimulation but no variation after a 
double stimulation. All the licensing agents were able to increase the transcript 
levels of TLR2 in BM MSCs. LPS and Poly I:C produced no variation on TLR2 
transcript levels in Is and Ad MSCs while cytokine-mediated licensing produced 
an upregulation in 24 hours in Is MSCs which was not sustained and Ad MSCs 
required a double stimulation to upregulate TLR2 transcript levels.  
Poly I:C-mediated stimulation downregulated its receptor, TLR3, in MSCs from 
the three sources under every condition tested. All the licensing agents were 
able to decrease the transcript levels of TLR3 in BM MSCs. Cytokine-mediated 
licensing downregulated TLR3 transcript levels in Is MSCs under every condition, 
while it produced an upregulation in Ad MSCs. LPS or LTA-mediated stimulation 
produced a decrease in the transcript levels 24 hours after the first or second 
stimulation, while they produced an upregulation 72 hours later in Is MSCs. In 
contrast, Ad MSCs responded to LPS or LTA licensing by downregulating TLR3, 
but this downregulation was brief as transcript level started increasing after 24 
hours.  
 
Table 4-10. Fold change in the receptors of the stimulatory agents’ transcript levels of 
cytokine, LPS, LTA or Poly I:C-mediated licensed BM, Is and Ad MSCs compared to 
unstimulated cells from the same source.  
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with either a cocktail of cytokines (40 ng/ mL of 
IFN-ϒ, TNF-α and IL-1β), 100 ng/ mL LPS, 100 ng/ mL LTA or 4 µg/ mL Poly I:C. Unstimulated 
cells were left growing in MSC culture medium as a control. Three different licensing conditions 
were tested. In the first one, cells were stimulated for 48 hours, after which cells were washed twice 
with PBS and fresh culture medium was added; cells were harvested 24 hours later. In the second 
condition, cells were washed twice with PBS, the culture medium was replaced with fresh one and 
the cells were left growing for 48 hours. Cells were then washed twice with PBS, the culture 
medium was replaced with supplemented one and the cells were harvested 24 hours later. In the 
last condition, cells were stimulated for 48 hours, after which cells were washed twice with PBS 
and were stimulated again for another 24 hours. Figure 4-7 illustrates the time points at which 
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supplemented medium was added. Quantitative reverse transcription PCR (qRT-PCR) was 
performed to evaluate transcript levels of the receptors of the stimulatory agents in BM, Is and Ad 
MSCs under resting and inflammatory conditions. Data are normalised to the housekeeping gene 
B2M and expressed as 2(-ΔCT). Fold change in transcript levels of the receptors of the stimulatory 
agents is represented as mean of fold change ± standard deviation. One Way ANOVA with Tukey’s 
multiple comparisons post-test was performed to compare all MSC sources and the different 
conditions. Statistically significant differences are marked with a colour code, where p < 0.05 is 
represented by green, p < 0.01 is represented by orange, p < 0.001 is represented by blue and p < 
0.0001 is represented by red. 
Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
IL1R1 
1 
Cyt 0.07 ± 0.04 0.22 ± 0.13 3.20 ± 2.13 
LPS 0.20 ± 0.07 3.47 ± 1.35 3.27 ± 2.77 
LTA 0.25 ± 0.06 3.62 ± 2.31 2.03 ± 1.11 
Poly I:C 0.05 ± 0.02 1.88 ± 1.82 1.04 ± 0.58 
2 
Cyt 0.18 ± 0.11 0.04 ± 0.02 1.99 ± 1.00 
LPS 0.48 ± 0.39 0.54 ± 0.25 0.73 ± 0.35 
LTA 1.61 ± 1.53 0.64 ± 0.29 0.73 ± 0.48 
Poly I:C 0.14 ± 0.09 0.56 ± 0.28 0.93 ± 0.39 
3 
Cyt 0.19 ± 0.14 0.03 ± 0.01 0.01 ± 0.01 
LPS 0.59 ± 0.41 0.53 ± 0.13 0.83 ± 0.61 
LTA 0.92 ± 1.01 1.38 ± 0.40 5.59 ± 3.74 
Poly I:C 0.05 ± 0.04 0.33 ± 0.26 0.00 ± 0.00 
IL1R2 
1 
Cyt 0.07 ± 0.07 0.86 ± 1.27 13476.79 ± 13682.54 
LPS 2.30 ± 1.21 8.66 ± 12.92 1.72 ± 1.91 
LTA 1.95 ± 1.48 4.04 ± 1.76 5.11 ± 4.66 
Poly I:C 0.52 ± 0.46 3.34 ± 3.13 4.72 ± 7.66 
2 
Cyt 0.19 ± 0.17 0.10 ± 0.09 25.20 ± 38.61 
LPS 0.99 ± 1.11 0.71 ± 0.48 1.79 ± 0.79 
LTA 2.88 ± 3.17 2.50 ± 2.97 1.39 ± 1.48 
Poly I:C 0.53 ± 0.28 0.86 ± 0.31 1.70 ± 2.57 
3 
Cyt 0.57 ± 0.64 0.47 ± 0.43 17.83 ± 18.07 
LPS 0.96 ± 0.31 0.77 ± 0.76 4.54 ± 6.34 
LTA 0.96 ± 0.46 5.51 ± 6.58 34.53 ± 53.66 
Poly I:C 0.17 ± 0.14 9.71 ± 14.87 2.13 ± 2.64 
TNFR1a 
1 
Cyt 0.69 ± 0.30 0.29 ± 0.18 0.80 ± 0.31 
LPS 0.76 ± 0.10 1.52 ± 0.60 0.47 ± 0.11 
LTA 2.65 ± 1.39 1.53 ± 1.58 0.78 ± 0.24 
Poly I:C 0.39 ± 0.20 0.95 ± 0.65 0.47 ± 0.06 
2 
Cyt 0.74 ± 0.49 0.44 ± 0.31 0.89 ± 0.09 
LPS 0.32 ± 0.07 0.84 ± 0.30 0.32 ± 0.06 
LTA 1.71 ± 0.81 0.54 ± 0.54 0.17 ± 0.03 
Poly I:C 0.48 ± 0.08 0.82 ± 0.78 0.32 ± 0.04 
3 
Cyt 0.36 ± 0.26 0.08 ± 0.05 5.92 ± 0.68 
LPS 0.62 ± 0.38 0.38 ± 0.14 2.95 ± 0.32 
LTA 1.64 ± 1.36 0.69 ± 0.89 7.05 ± 1.26 
Poly I:C 0.20 ± 0.15 0.17 ± 0.02 2.63 ± 0.50 
TNFR1b 1 
Cyt 0.32 ± 0.04 0.12 ± 0.08 0.65 ± 0.35 
LPS 0.53 ± 0.11 0.43 ± 0.05 0.45 ± 0.06 
LTA 1.13 ± 0.16 0.69 ± 0.25 0.88 ± 0.19 
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Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
Poly I:C 0.19 ± 0.05 0.34 ± 0.21 0.44 ± 0.06 
2 
Cyt 0.47 ± 0.11 0.24 ± 0.08 0.68 ± 0.09 
LPS 0.71 ± 0.07 0.55 ± 0.04 0.63 ± 0.19 
LTA 1.06 ± 0.25 0.50 ± 0.19 0.28 ± 0.03 
Poly I:C 0.34 ± 0.03 0.30 ± 0.09 0.38 ± 0.09 
3 
Cyt 0.41 ± 0.06 0.19 ± 0.01 2.81 ± 0.17 
LPS 0.84 ± 0.16 0.55 ± 0.06 1.01 ± 0.03 
LTA 1.25 ± 0.18 0.67 ± 0.36 0.99 ± 0.19 
Poly I:C 0.20 ± 0.01 0.45 ± 0.04 4.07 ± 0.66 
IFNGR1 
1 
Cyt 0.10 ± 0.10 0.12 ± 0.07 1.18 ± 0.44 
LPS 0.23 ± 0.12 0.68 ± 0.14 0.32 ± 0.28 
LTA 1.01 ± 0.17 1.13 ± 0.12 0.63 ± 0.07 
Poly I:C 0.10 ± 0.01 0.37 ± 0.26 0.42 ± 0.24 
2 
Cyt 0.10 ± 0.09 0.15 ± 0.06 0.52 ± 0.49 
LPS 0.10 ± 0.07 0.60 ± 0.19 0.40 ± 0.38 
LTA 0.97 ± 0.22 0.72 ± 0.24 0.38 ± 0.03 
Poly I:C 0.16 ± 0.05 0.48 ± 0.27 0.57 ± 0.10 
3 
Cyt 0.06 ± 0.05 0.07 ± 0.03 1.18 ± 0.98 
LPS 0.16 ± 0.10 0.52 ± 0.11 1.04 ± 0.73 
LTA 0.95 ± 0.26 0.88 ± 0.40 2.25 ± 0.40 
Poly I:C 0.07 ± 0.02 0.26 ± 0.12 0.53 ± 0.13 
IFNGR2 
1 
Cyt 0.99 ± 0.27 0.69 ± 0.61 4.84 ± 1.61 
LPS 1.37 ± 0.19 5.73 ± 2.99 1.90 ± 0.70 
LTA 5.81 ± 3.38 6.09 ± 2.63 2.92 ± 0.88 
Poly I:C 0.93 ± 0.63 4.10 ± 2.21 0.85 ± 0.34 
2 
Cyt 0.68 ± 0.29 0.84 ± 0.11 2.71 ± 0.81 
LPS 0.59 ± 0.27 2.12 ± 0.90 1.73 ± 0.40 
LTA 2.43 ± 1.26 0.84 ± 0.11 1.11 ± 0.21 
Poly I:C 2.81 ± 1.70 2.38 ± 0.88 1.02 ± 0.21 
3 
Cyt 0.39 ± 0.28 0.26 ± 0.29 19.05 ± 5.19 
LPS 0.78 ± 0.22 0.58 ± 0.30 3.51 ± 1.54 
LTA 2.04 ± 1.50 2.08 ± 1.77 10.72 ± 2.57 
Poly I:C 0.28 ± 0.21 2.12 ± 0.90 9.77 ± 2.59 
TLR2 
1 
Cyt 1.44 ± 0.83 0.42 ± 0.19 0.97 ± 0.62 
LPS 4.34 ± 2.29 1.16 ± 0.44 0.41 ± 0.13 
LTA 5.60 ± 2.63 1.56 ± 1.05 0.79 ± 0.21 
Poly I:C 1.30 ± 0.83 0.79 ± 0.19 0.32 ± 0.09 
2 
Cyt 4.42 ± 0.83 2.68 ± 0.32 0.32 ± 0.28 
LPS 4.16 ± 2.60 1.41 ± 0.13 0.47 ± 0.10 
LTA 6.85 ± 1.86 1.71 ± 0.84 0.46 ± 0.11 
Poly I:C 5.60 ± 2.41 1.69 ± 0.26 0.20 ± 0.20 
3 
Cyt 3.63 ± 1.06 0.82 ± 0.22 22.83 ± 4.59 
LPS 10.22 ± 0.53 2.64 ± 1.42 0.97 ± 0.15 
LTA 8.72 ± 1.01 2.03 ± 0.89 1.13 ± 0.34 
Poly I:C 3.40 ± 0.98 3.07 ± 1.70 1.51 ± 0.14 
TLR3 1 Cyt 0.87 ± 0.74 0.45 ± 0.25 5.50 ± 5.82 
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LPS 1.00 ± 0.38 3.16 ± 2.25 1.40 ± 1.06 
LTA 2.07 ± 0.92 3.61 ± 2.06 2.73 ± 1.04 
Poly I:C 1.14 ± 0.39 2.01 ± 2.33 0.37 ± 0.23 
2 
Cyt 2.23 ± 1.21 1.77 ± 0.67 1.01 ± 0.44 
LPS 0.92 ± 0.29 1.07 ± 0.45 0.49 ± 0.31 
LTA 2.09 ± 0.82 1.24 ± 0.47 0.83 ± 0.51 
Poly I:C 1.48 ± 0.95 3.16 ± 1.01 0.82 ± 0.62 
3 
Cyt 0.73 ± 0.40 0.41 ± 0.12 13.84 ± 9.93 
LPS 0.97 ± 0.45 0.40 ± 0.11 1.01 ± 0.72 
LTA 1.42 ± 0.62 1.22 ± 0.57 1.75 ± 0.93 
Poly I:C 1.70 ± 0.99 1.36 ± 1.44 2.19 ± 1.65 
TLR4 
1 
Cyt 0.53 ± 0.22 0.20 ± 0.16 2.31 ± 0.61 
LPS 0.73 ± 0.20 2.20 ± 0.77 1.19 ± 0.21 
LTA 2.01 ± 0.81 3.11 ± 1.21 1.27 ± 0.43 
Poly I:C 0.51 ± 0.22 0.98 ± 0.44 0.60 ± 0.12 
2 
Cyt 0.80 ± 0.43 0.52 ± 0.25 1.17 ± 0.26 
LPS 0.43 ± 0.14 0.82 ± 0.41 0.91 ± 0.38 
LTA 2.23 ± 1.29 0.52 ± 0.25 0.44 ± 0.08 
Poly I:C 0.49 ± 0.08 1.19 ± 0.30 0.60 ± 0.20 
3 
Cyt 0.60 ± 0.36 0.13 ± 0.06 5.64 ± 1.31 
LPS 0.76 ± 0.25 0.36 ± 0.15 1.12 ± 0.26 
LTA 1.86 ± 1.15 0.82 ± 0.26 3.54 ± 1.36 
Poly I:C 0.29 ± 0.18 0.37 ± 0.20 2.82 ± 1.17 
 
4.4 Analysis of the chemokine secretion profile by MSCs 
under resting and inflammatory conditions 
4.4.1 Analysis of CC chemokine secretion under resting and 
inflammatory conditions  
Under resting conditions, BM, Is and Ad MSCs secreted less than 0.35 pg of CC 
chemokines per mg of total protein (Figure 4-8). A pattern of upregulation was 
observed in CCL2 (A), CCL5 (B) and CCL7 (C) upon licensing. However, these 
chemokines were upregulated differentially in MSCs according to their tissue of 
origin. Analysis of the CC chemokine protein levels 24 hours after stimulation 
(Condition 2) resulted in upregulated secretion in MSCs from every tissue source; 
however, this upregulation was not sustained as supernatant harvested 72 hours 
after licensing (Condition 1) showed a decrease in the secretion of CC 
chemokines. A second stimulation 48 hours after the first stimulation (Condition 
3) was able to induce the production of CC chemokines in MSCs from the three 
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sources; however, this second stimulation was not able to mimic the secretion 
level of CC chemokines found in Condition 2. Fold changes in CC chemokine 
secretion upon cytokine-mediated licensing of MSCs are shown in Table 4-11.  
MSCs isolated from the three tissues were producing CCL2 under resting 
conditions but Is MSCs secreted the highest levels of CCL2 (BM = 0.29 pg/ mg; Is 
= 0.32 pg/ mg; Ad = 0.16 pg/ mg) (Figure 4-8, A). Cytokine-mediated licensing 
produced an upregulation of the secretion in all the conditions tested in MSCs of 
the three tissue sources. After 72 hours of stimulation (Condition 1), CCL2 
secretion was upregulated in MSCs from the three tissues but was only 
statistically significant in Is MSCs. However, 24 hours of stimulation (Condition 2) 
produced a statistically significant upregulation of CCL2 secretion in BM, Is and 
Ad MSCs, where Is MSCs were secreting 13 pg of CCL2 per mg of total protein. A 
second cytokine-mediated stimulation 48 hours after the first one (Condition 3) 
led to a higher secretion of CCL2 compared to unstimulated MSCs or Condition 1 
in MSCs from every tissue source, suggesting that cells were responsive to the 
second stimulation. However, CCL2 levels were lower than 24 hours after a 
single stimulation. The lower limit of quantification for CCL2 in the Mouse 
Magnetic Luminex Assay was 210.58 pg/ mL and all the analysed samples were 
above this value.  
Secretion of CCL5 under resting conditions was low in every source of MSCs; 
however, BM MSCs secreted statistically significant higher amounts of CCL5 than 
Is and Ad MSCs (BM = 0.039 pg/ mg; Is = 0.010 pg/ mg; Ad = 0.013 pg/ mg) 
(Figure 4-8, B). Cytokine-mediated licensing produced an upregulation of the 
secretion of CCL5 in all the conditions tested in MSCs from the three tissue 
sources. After 72 hours of stimulation (Condition 1), CCL5 secretion was 
significantly upregulated in MSCs from the three tissues; however, despite the 
highest secretion under resting conditions, BM MSCs had secreted the least CCL5 
and Ad MSCs the most. 24 hours after stimulation (Condition 2) BM and Is MSCs 
had secreted statistically significantly higher amounts of CCL5 compared to 
control or Condition 2; however, these levels were much higher in Is MSCs as 
they had secreted 1.56 pg of CCL5 per mg of total protein. After 24 hours of 
licensing, Ad MSCs had significantly upregulated the secretion of CCL5 compared 
to unstimulated conditions but no variations were observed when compared with 
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Condition 1, suggesting that Ad MSC licensing had a more prolonged effect than 
the one generated on BM or Is MSCs. A second cytokine-mediated stimulation 48 
hours after the first one (Condition 3) led to a higher secretion of CCL2 
compared to unstimulated MSCs or Condition 1 in BM and Is MSCs, suggesting that 
cells were responsive to the second stimulation but not able to replicate the 
effect achieved after 24 hours of licensing; however, despite the upregulation in 
the production of CCL5 compared to the control, no variations were observed in 
the production of CCL5 by Ad MSCs compared to Condition 1 or 2. The lower 
limit of quantification for CCL5 in the Mouse Magnetic Luminex Assay was 73.42 
pg/ mL and all the analysed samples were above this value. 
MSCs isolated from the three tissues were producing CCL7 under resting 
conditions but Is MSCs secreted the highest levels of CCL7 (BM = 0.13 pg/ mg; Is 
= 0.14 pg/ mg; Ad = 0.08 pg/ mg) (Figure 4-8, C). Cytokine-mediated licensing 
produced an upregulation in the secretion in all the conditions tested in MSCs of 
the three tissue sources. After 72 hours of stimulation (Condition 1), CCL7 
secretion was upregulated in the MSCs from the three tissues but was only 
statistically significant in Is and Ad MSCs. 24 hours of stimulation (Condition 2) 
produced an upregulation of CCL7 secretion in BM, Is and Ad MSCs; however, this 
upregulation was only statistically significant in Is and Ad MSCs. A second 
cytokine-mediated stimulation 48 hours after the first one (Condition 3) led to a 
higher secretion of CCL2 compared to unstimulated MSCs or Condition 1 in Is and 
Ad MSCs from every tissue source, suggesting that cells were responsive to the 
second stimulation; however, CCL2 levels were lower than 24 hours after a 
single stimulation. BM MSCs had the highest CCL7 protein levels in Condition 3; 
however, the amount of protein secreted was not statistically significantly 
different to the levels of secreted protein in Conditions 1 or 2. The lower limit of 
quantification for CCL7 in the Mouse Magnetic Luminex Assay was 5.6 pg/mL and 
all the analysed samples were above this value. 
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Figure 4-8. Cytokine-mediated stimulation, repetitive stimulus and MSC tissue origin 
impacts CC chemokine secretion in MSCs.  
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with a cocktail of cytokines (40 ng/ mL of IFN-ϒ, 
TNF-α and IL-1β). Unstimulated cells were left growing in MSC culture medium as a control. Three 
different licensing conditions were tested. In the first one, cells were stimulated for 48 hours, after 
which cells were washed twice with PBS and fresh culture medium was added; cells were 
harvested 24 hours later. In the second condition, cells were washed twice with PBS, the culture 
medium was replaced with fresh one and the cells were left growing for 48 hours. Cells were then 
washed twice with PBS, the culture medium was replaced with supplemented one and the cells 
were harvested 24 hours later. In the last condition, cells were stimulated for 48 hours, after which 
cells were washed twice with PBS and were stimulated again for another 24 hours. Figure 4-7 
illustrates the time points at which supplemented medium was added. Luminex was performed to 
evaluate protein secretion in BM, Is and Ad MSCs under resting and inflammatory conditions. Each 
bar represents an n of 3 independent experiments and is graphed as mean ± SEM. Data are 
normalised to total amount of protein in medium and expressed as picograms of protein of interest 
per mg of total protein. Appropriate statistical analysis was performed and includes Students paired 
T test between one MSC tissue source (Resting vs Inflammatory Conditions) and One Way 
ANOVA with Tukey’s multiple comparisons post-test to compare all MSC sources. Statistically 
significant differences are marked with the appropriate number of asterisks. p = 0.05 was 
considered the limit for statistical significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
Table 4-11. Fold change in CC chemokine secretion of cytokine-mediated licensed BM, Is 
and Ad MSCs compared to unstimulated cells from the same source.  
Following the experimental set up explained in Figure 4-8, fold change in CC chemokine protein 
levels is represented as mean of fold change ± standard deviation. Statistically significant 
differences are marked with a colour code, where p < 0.05 is represented by green, p < 0.01 is 
represented by orange, p < 0.001 is represented by blue and p < 0.0001 is represented by red. 
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Protein Condition BM MSCs Is MSCs Ad MSCs 
CCL2 
1 3.00 ± 2.10 6.72 ± 0.79 22.91 ± 5.90 
2 18.38 ± 16.43 41.47 ± 4.27 44.54 ± 19.65 
3 15.84 ± 14.63 12.63 ± 1.52 24.39 ± 2.55 
CCL5 
1 3.20 ± 0.04 28.80 ± 11.61 73.27 ± 22.14 
2 14.69 ± 0.64 206.50 ± 86.46 65.53 ± 37.30 
3 7.19 ± 0.39 39.83 ± 19.56 59.72 ± 15.70 
CCL7 
1 1.84 ± 1.14 2.61 ± 0.12 4.56 ± 0.70 
2 3.60 ± 2.50 4.45 ± 0.48 5.57 ± 1.43 
3 3.99 ± 2.95 3.01 ± 0.23 4.52 ± 0.09 
 
4.4.2 Analysis of CXC chemokine secretion under resting and 
inflammatory conditions  
Under resting conditions, BM, Is and Ad MSCs secreted less than 0.5 pg of CXC 
chemokines per mg of total protein (Figure 4-9). A pattern of upregulation was 
observed in CXCL1 (A), CXCL2 (B) and CXCL10 (C), while CXCL12 (D) presented a 
pattern of downregulation after licensing. However, these chemokines were 
regulated differentially in MSCs according to their tissue of origin. Analysis of the 
CXC chemokine protein levels 24 hours after stimulation (Condition 2) 
demonstrated a marked upregulation of the secretion of CXCL1, CXCL2 and 
CXCL10 in MSCs from every tissue source; however, this upregulation was not 
sustained as supernatant harvested 72 hours after licensing (Condition 1) showed 
a decrease in the secretion of CXC chemokines. A second stimulation 48 hours 
after the first stimulation (Condition 3) was able to induce the production of CXC 
chemokines in MSCs from the three sources, however, the second stimulation 
was not able to mimic the secretion level of CC chemokines found in Condition 
2. Regarding CXCL12, 24 hours of stimulation (Condition 2) produced no effect in 
BM and Ad MSCs while it produced a downregulation in Is MSCs. Condition 1 and 3 
produced a downregulation in the secretion of CXCL12 from MSCs of every 
source. Fold changes in CXC chemokine secretion upon cytokine-mediated 
licensing of MSCs are specified in Table 4-12.  
MSCs isolated from the three tissues were producing very little CXCL1 under 
resting conditions but BM MSCs secreted the highest levels of CXCL1 (BM = 0.07 
pg/ mg; Is = 0.02 pg/ mg; Ad = 0.01 pg/ mg) (Figure 4-9, A). Cytokine-mediated 
licensing produced an upregulation of the secretion in all the conditions tested 
in MSCs of the three tissue sources. After 72 hours of stimulation (Condition 1), 
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CXCL1 secretion was upregulated in MSCs from the three tissues but was only 
statistically significant in BM MSCs. However, 24 hours of stimulation (Condition 
2) produced a statistically significant upregulation of CXCL1 secretion in Is and 
Ad MSCs, where Is MSCs were secreting 8 pg of CXCL1 per mg of total protein. A 
second cytokine-mediated stimulation 48 hours after the first one (Condition 3) 
led to a statistically significant higher secretion of CXCL1 compared to 
unstimulated MSCs or Condition 1 in Is and Ad MSCs, suggesting that cells were 
responsive to the second stimulation; however, CXCL1 levels were lower than 24 
hours after a single stimulation. The lower limit of quantification for CXCL1 in 
the Mouse Magnetic Luminex Assay was 33.83 pg/ mL and all the analysed 
samples were above this value.  
MSCs isolated from the three tissues were producing very little CXCL2 under 
resting conditions but BM MSCs secreted the highest levels of CXCL2 (BM = 0.012 
pg/ mg; Is = 0.0007 pg/ mg; Ad = 0.0001 pg/ mg) (Figure 4-9, B). Cytokine-
mediated licensing produced an upregulation of the secretion in all the 
conditions tested in MSCs of the three tissue sources. After 72 hours of 
stimulation (Condition 1), CXCL2 secretion was upregulated in MSCs from the 
three tissues but was only statistically significant in Ad MSCs. However, 24 hours 
of stimulation (Condition 2) produced a statistically significant upregulation of 
CXCL2 secretion in MSCs from every source, with BM MSCs secreting 0.31 pg of 
CXCL2 per mg of total protein. A second cytokine-mediated stimulation 48 hours 
after the first one (Condition 3) led to a statistically significant higher secretion 
of CXCL2 compared to unstimulated MSCs or Condition 1 in MSCs from every 
source, suggesting that cells are responsive to the second stimulation; however, 
CXCL2 levels were lower than 24 hours after a single stimulation. The lower limit 
of quantification for CXCL2 in the Mouse Magnetic Luminex Assay was 5.14 pg/ 
mL and all the analysed samples were above this value.  
MSCs isolated from the three tissues were producing very little CXCL10 under 
resting conditions but BM MSCs secreted the highest levels of CXCL10 (BM = 0.011 
pg/ mg; Is = 0.010 pg/ mg; Ad = 0.009 pg/ mg) (Figure 4-9, C). Cytokine-
mediated licensing produced an upregulation of the secretion in all the 
conditions tested in MSCs of the three tissue sources. After 72 hours of 
stimulation (Condition 1), CXCL10 secretion was upregulated in a statistically 
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significant manner in MSCs from the three tissues. However, 24 hours of 
stimulation (Condition 2) produced an even greater upregulation of CXCL10 
secretion in MSCs from every source, with Is MSCs secreting 2.4 pg of CXCL10 per 
mg of total protein. A second cytokine-mediated stimulation 48 hours after the 
first one (Condition 3) led to a statistically significant higher secretion of CXCL10 
compared to unstimulated MSCs or Condition 1 in all sources of MSCs, suggesting 
that cells were responsive to the second stimulation; however, CXCL10 levels 
were lower than 24 hours after a single stimulation. The lower limit of 
quantification for CXCL10 in the Mouse Magnetic Luminex Assay was 59.51 pg/ 
mL and all the analysed samples were above this value. 
MSCs isolated from the three tissues were producing CXCL12 under resting 
conditions but BM MSCs secreted the highest levels of this CXC chemokine (BM = 
0.56 pg/ mg; Is = 0.25 pg/ mg; Ad = 0.16 pg/ mg) (Figure 4-9, D). Cytokine-
mediated licensing produced no statistically significant effect on the secretion 
of CXCL12 in any of the conditions tested in BM and Ad MSCs, while it produced a 
downregulation in the secretion of CXCL12 by Is MSCs. After 72 hours of 
stimulation (Condition 1), CXCL12 secretion was downregulated in MSCs from the 
three tissues, even if it was only statistically significant in Is MSCs. 24 hours of 
stimulation (Condition 2) produced a downregulation of the same level as 
Condition 1 in Is MSCs, while it produced no effect in BM and Ad MSCs. A second 
cytokine-mediated stimulation 48 hours after the first one (Condition 3) led to a 
greater downregulation in the secretion of CXCL12 by Is MSCs compared to 
unstimulated MSCs or Condition 1 and 2. Condition 3 led to a statistically non–
significant downregulation of CXCL12 secretion by BM and Ad MSCs. The lower 
limit of quantification for CXCL12 in the Mouse Magnetic Luminex Assay was 
319.88 pg/ mL and all the analysed samples were above this value. 
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Figure 4-9. Cytokine-mediated stimulation, repetitive stimulus and MSC tissue origin 
impacts CXC chemokine secretion in MSCs.  
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with a cocktail of cytokines (40 ng/ mL of IFN-ϒ, 
TNF-α and IL-1β). Unstimulated cells were left growing in MSC culture medium as a control. Three 
different licensing conditions were tested. In the first one, cells were stimulated for 48 hours, after 
which cells were washed twice with PBS and fresh culture medium was added; cells were 
harvested 24 hours later. In the second condition, cells were washed twice with PBS, the culture 
medium was replaced with fresh one and the cells were left growing for 48 hours. Cells were then 
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washed twice with PBS, the culture medium was replaced with supplemented one and the cells 
were harvested 24 hours later. In the last condition, cells were stimulated for 48 hours, after which 
cells were washed twice with PBS and were stimulated again for another 24 hours. Figure 4-7 
illustrates the time points at which supplemented medium was added. Luminex was performed to 
evaluate protein secretion in BM, Is and Ad MSCs under resting and inflammatory conditions. Each 
bar represents an n of 3 independent experiments and is graphed as mean ± SEM. Data are 
normalised total amount of protein in medium and expressed as picograms of protein of interest per 
mg of total protein. Appropriate statistical analysis was performed and includes Students paired T 
test between one MSC tissue source (Resting vs Inflammatory Conditions) and One Way ANOVA 
with Tukey’s multiple comparisons post-test to compare all MSC sources. Statistically significant 
differences are marked with the appropriate number of asterisks. p = 0.05 was considered the limit 
for statistical significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
Table 4-12. Fold change in CXC chemokine secretion of cytokine-mediated licensed BM, Is 
and Ad MSCs compared to unstimulated cells from the same source.  
Following the experimental set up explained in Figure 4-8, fold change in CXC chemokine protein 
levels is represented as mean of fold change ± standard deviation. Statistically significant 
differences are marked with a colour code, where p < 0.05 is represented by green, p < 0.01 is 
represented by orange, p < 0.001 is represented by blue and p < 0.0001 is represented by red. 
Protein Condition BM MSCs Is MSCs Ad MSCs 
CXCL1 
1 17.30 ± 15.64 47.59 ± 8.98 178.92 ± 35.55 
2 112.58 ± 124.64 401.24 ± 151.04 451.60 ± 161.68 
3 0.31 ± 0.16 106.12 ± 22.97 194.01 ± 20.36 
CXCL2 
1 3.96 ± 1.38 67.94 ± 26.72 961.84 ± 195.65 
2 28.06 ± 11.58 384.46 ± 78.04 1792.17 ± 262.76 
3 0.31 ± 0.16 175.15 ± 74.87 1184.16 ± 222.43 
CXCL10 
1 15.24 ± 1.38 37.43 ± 4.38 52.76 ± 11.24 
2 69.18 ± 8.45 229.39 ± 26.36 111.16 ± 31.80 
3 44.58 ± 2.40 103.07 ± 17.41 92.26 ± 9.59 
CXCL12 
1 0.22 ± 0.14 0.57 ± 0.06 0.61 ± 0.03 
2 1.34 ± 0.91 0.68 ± 0.10 1.03 ± 0.35 
3 0.31 ± 0.16 0.37 ± 0.02 0.64 ± 0.02 
 
 
4.5 Discussion and conclusions  
The establishment of standardised MSC isolation and culture protocols described 
in Chapter 3 enabled an objective comparison of the transcriptional and protein 
profile of BM, Is and Ad MSCs. For this reason, the aim of this chapter was to 
study the transcriptional profile of chemokines and chemokines receptors by BM, 
Is and Ad MSCs under resting and inflammatory conditions, which is summarised 
in Figure 4-10. Moreover, careful analysis of the transcript data enabled the 
identification of genes of interest to be targeted for protein assays. The 
chemokine secretion of BM, Is and Ad MSCs under resting and inflammatory 
conditions is summarised in Figure 4-11.  
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The use of different inflammatory agents, as well as the different conditions in 
which MSCs were stimulated with the same inflammatory agent, did not show a 
clear trend of up or down regulation of genes that could suggest a better 
inflammatory agent for MSC licensing. For these reasons, instead of discussing 
the results per condition, we have decided to discuss the results by gene of 
interest, focusing on the results obtained harvesting the cells 24 hours after 
licensing with 40 ng/ml of TNF-α, IL-1β and IFN-ϒ (Condition 2). In this manner, 
it is possible to compare the expression of all the genes analysed in this study in 
Section 4.2, which is summarised in Figure 4-10. More importantly, careful 
analysis of the transcript data enabled the identification of genes of interest to 
be targeted for protein assays; the secretion of chemokines by BM, Is and Ad 
MSCs under resting and inflammatory conditions is summarised in Figure 4-11. 
Moreover, the role of the chemokines and their receptors will be discussed, and 
the clinical implications of the expression and regulation upon inflammatory 
stimulus of these molecules will be examined.  
 
196 
 
 
197 
 
Figure 4-10. Heat map representing the transcriptional expression of CC and CXC 
chemokine ligands and receptors by MSCs from different sources under resting and 
inflammatory conditions.  
Data from Figure 4-1, Figure 4-2, Figure 4-3, Figure 4-4, Figure 4-5 and Figure 4-6 are combined 
and presented as a heat map to illustrate the chemokine and chemokine receptor transcriptional 
profile of MSCs maintained under resting and inflammatory conditions. The heat map summarises 
each tissue source of MSC highest and lowest transcribed genes under resting conditions and 
inflammatory stimulation. Genes with low 2(-ΔCT) values are highlighted in blue, genes with 
intermediate 2(-ΔCT) values are highlighted in grey and genes with high 2(-ΔCT) values are highlighted 
in yellow. 
 
4.5.1 Chemokine receptor expression by MSCs 
As previously described, one of the most critical aspects of MSC use as cellular 
therapeutics is related to MSC homing and engraftment within the target tissue 
following their administration. MSC homing encompasses both non–systemic, 
where MSCs are transplanted locally at the target tissue and are then guided to 
the site of injury, and systemic homing, where MSCs are administered intra-
venously or intra-arterially and the cells must exit the circulation and migrate to 
the site of injury (Nitzsche et al., 2017). In both cases, chemokine receptors 
have been described to be relevant for this process, in combination with other 
molecules as selectins and integrins (Xiao Ling et al., 2016, Liu et al., 2018a). 
Under resting conditions, BM, Is and Ad MSCs were most likely not transcribing 
CC chemokine receptors, except for CCR1 (Figure 4-3, A) and CCR5 (Figure 4-3, 
E), CXC chemokine receptors, except for CXCR6 (Figure 4-4, F) and atypical 
chemokine receptors, except for ACKR1 (Figure 4-5, A) and ACKR4 (Figure 4-5, 
D). These results correlate with the literature as BM MSCs have been reported to 
have essentially undetectable chemokine receptor transcripts and low levels of 
these transcripts have been observed in Ad MSCs. However, mRNA levels do not 
always correlate with protein levels, and in this specific case, with surface 
chemokine receptor expression and functionality (Ahmadian Kia et al., 2011, 
Bidkhori et al., 2016). Under resting conditions, little variation was observed in 
the transcription of these receptors among MSC sources. BM MSCs transcribed 
significantly higher levels of CCR7, CXCR6 and ACKR4; Is MSCs transcribed 
significantly higher levels of CCR1, CCR10 and CXCR3, while Ad MSCs transcribed 
significantly higher levels of CCR3. Altogether, these findings suggest that 
chemokine receptor expression by MSCs depends on MSC tissue of origin. 
Chemokine receptors are G protein-coupled receptors and they all share a very 
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similar structure which makes it very difficult to generate specific antibodies 
towards them that do not generate high non–specific background. For this 
reason, due to the lack of specific mouse antibodies, analysis of protein 
expression of chemokine receptors could not be performed.  
Differential surface expression of chemokine receptors by MSCs could lead to 
MSCs migrating towards different organs. The expression of CCR1 in macrophages 
and neutrophils led to kidney infiltration in renal ischemia-reperfusion injury 
(Furuichi et al., 2008); CCR5 directs CD8+ T cells towards the brain (Martin-
Blondel et al., 2016); CCR7 programs naïve T cells and B cells to migrate to the 
spleen and lymph nodes (Bjorkdahl et al., 2003); CCR3, CCR4 and CCR10 are 
highly expressed by T cells in skin (Fujimoto et al., 2008, Ma et al., 2002); 
CXCR3 mediates T cell recruitment into the kidney (Panzer et al., 2007); CXCR4 
expression is increased on the surface of extravascular neutrophils in the lung 
and the bone marrow (30); CXCR6 is highly expressed by liver-infiltrating CD8+ T 
cells (Sato et al., 2005b). If specific chemokines can target immune cells into 
specific tissues, the expression of these chemokines should be able to target 
MSCs into those tissues. In fact, CCR7 targets MSCs to secondary lymphoid organs 
(Li et al., 2014, Ma et al., 2016), CXCR3-deficient MSCs fail to infiltrate into the 
nephritic kidney (Lee et al., 2018) and CXCR4 receptor overexpression in MSCs 
improves treatment of acute lung injury (Yang et al., 2015). Taking all this into 
account, we could hypothesise that CCR7 and CXCR6 expression would direct BM 
MSCs towards lymphoid organs as the spleen, the lymph nodes and the liver; Is 
MSCs would migrate towards the kidneys due to their CCR1 and CXCR3 
expression; and Ad MSCs could have the potential to migrate towards the skin 
and bone marrow.  
Unlike conventional chemokine receptors, ACKRs interact with chemokines 
without inducing cell migration but rather regulate chemokine gradients by 
interacting with chemokines from the environment. ACKR1 can interact, with 
high affinity, with both CC and CXC chemokines and it is not believed to have 
ligand-scavenging properties, just ligand presentation on the cell surface 
(Pruenster et al., 2009); ACKR2 binds, internalises and degrades CC chemokines 
(Fra et al., 2003); ACKR3 interacts and scavenges two chemokines, CXCL12, the 
ligand of CXCR4, and CXCL11, one of the ligands of CXCR3 (Burns et al., 2006); 
199 
 
and ACKR4 binds the homeostatic chemokines CCL19, CCL21, CCL25, and 
CXCL13. As ACKRs do not induce cell migration and there is little literature on 
MSCs and ACKRs, it is hard to determine the clinical relevance of the expression 
of these molecules by MSCs, however it suggests that ACKRs in MSCs would be 
involved in regulating the availability of chemokine ligands. MSCs from the three 
sources would have the potential to regulate CC and CXC chemokines due to 
their similar transcript levels of ACKR1; however, BM MSCs transcribed 
significantly higher ACKR4 transcript levels, suggesting a better regulation of the 
homeostatic chemokines CCL19, CCL21, CCL25 and CXCL13 (Hughes and Nibbs, 
2018). 
The degree of difficulty understanding the role of chemokine receptors in MSCs 
increases when we consider the effect of inflammatory stimulation, as it 
produced a downregulation of the transcription of the receptors which was 
tissue specific. Cytokine-mediated stimulation decreased the transcription of 
CCR7, CXCR6 and ACKR4 in BM MSCs, which would make the cells less prone to 
migrate towards lymphoid organs (Ma et al., 2016) and would reduce the 
scavenging potential for homeostatic chemokines, which could help to dampen 
inflammation in a more efficient manner. Cytokine-mediated licensing 
decreased CXCR3 transcript levels, making it more difficult for these cells to 
migrate towards the kidney, even if CCR1 expression was not altered. Lastly, 
cytokine-mediated stimulation decreased CCR3 transcript levels in Ad MSCs, 
which could stop the migration of MSCs towards the skin or epithelial tissues.  
Altogether, BM, Is and Ad MSCs expressed low levels of chemokine receptor 
transcripts and few significant differences between MSC populations were 
observed; CCR7, CXCR6 and ACKR4 were specific to BM MSCs; CCR1, CCR10 and 
CXCR3 were specific to Is MSCs; while CCR3 was specific to Ad MSCs, suggesting 
that the tissue of origin of MSCs influences the chemokine receptor expression 
and therefore, could affect their in vivo migratory capacity. Overall, Ad MSCs 
downregulated their receptors to a lesser extent than BM or Is MSCs after 
inflammatory stimulation, which is likely explained by the higher resistance of 
Ad MSCs to stress (El-Badawy et al., 2016). These standardised comparison of 
MSCs isolated from different sources provides evidence to support further 
investigation into the expression and function of chemokine receptors by MSCs 
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from different sources to analyse the impact tissue of origin has on the in vivo 
migratory capacity and therefore, on the clinical outcome.  
4.5.2 Chemokine secretion by MSCs 
As previously described, in vitro cultured MSCs have been shown to secrete a 
wide range of chemokines, including CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, 
CXCL1, CXCL2, CXCL5, CXCL10, CXCL12 and CX3CL1 (Chen et al., 2008, Ren et 
al., 2008, Meirelles Lda et al., 2009). However, the lack of standardised isolation 
and culture methods has led to very few studies regarding the comparison of 
chemokines secreted by MSCs isolated from different tissues in human (Thirlwell, 
2018) and none for mouse MSCs. The aforementioned chemokines have the 
ability to recruit towards MSCs cells from the immune system including 
macrophages, neutrophils, monocytes, eosinophils, DCs, T Cells, B cells and NK 
cells (Deshmane et al., 2009, De Filippo et al., 2013, Dwinell et al., 2001). For 
this reason, we consider that understanding MSC chemokine secretion will 
enable prediction of the interaction of these cells with the immune system and 
therefore, their immunomodulatory potential in an in vivo setting (Chen et al., 
2008, Ren et al., 2008, Meirelles Lda et al., 2009). Therefore, standardised 
comparison of the chemokine secretion of MSCs isolated from different sources 
could lead to the identification of MSCs that could be more relevant in specific 
clinical settings. The chemokine secretion of BM, Is and Ad MSCs under resting 
and inflammatory conditions is summarised in Figure 4-11. 
In the current study, under resting conditions, BM, Is and Ad MSCs transcribed 
and secreted low levels of CC chemokines, with the exception of CCL2 and CCL7 
(Figure 4-8, A and C), which were both expressed at similar levels in MSCs from 
every source; and CXC chemokines, with the exception of CXCL1 and CXCL12, 
which were all secreted by all tissue source MSCs at similar levels (Figure 4-9, A 
and D). These chemokines are strong chemoattractants for monocytes (CCL2 and 
CCL7), neutrophils (CXCL1) and lymphocytes (CXCL12). Under inflammatory 
stimulation, BM, Is and Ad MSCs upregulated the transcription and secretion of 
the previously mentioned chemokines, whilst also inducing the transcription and 
secretion of CCL5, CXCL2 and CXCL10. Inflammatory stimulation produced no 
effect in the transcription and secretion of CXCL12. After inflammatory 
stimulation, Is MSCs were able to secrete the highest amounts of every 
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chemokine aforementioned. Even if the transcriptional level of many 
chemokines has been analysed under different conditions, this discussion section 
is going to focus on the chemokines that were secreted at high level under 
resting and inflammatory conditions (CCL2, CCL5, CCL7, CXCL1, CXCL2, CXCL10 
and CXCL12) and the specific immune cells that MSCs could attract due to the 
secretion of those chemokines. It is important to mention that the secretion of 
CCL2, CCL5, CCL7, CXCL1, CXCL10 and CXCL12 by MSCs has previously been 
reported (Kyurkchiev et al., 2014, Thirlwell, 2018, Lee et al., 2012, Kimura et 
al., 2014); but to my knowledge, differences in chemokine transcription, 
secretion and leukocyte recruitment by murine MSCs isolated from different 
tissue sources has not been documented. 
 
Figure 4-11. Heat map representing the secretion of CC and CXC chemokine ligands by 
MSCs from different sources under resting and inflammatory conditions.  
Data from Figure 4-8 and Figure 4-9 are combined and presented as a heat map to illustrate the 
chemokine secretion profile of MSCs maintained under resting and inflammatory conditions. The 
heat map summarises each tissue source of MSC highest and lowest secreted chemokines under 
resting conditions and inflammatory stimulation. Proteins with low secretion are highlighted in blue, 
proteins with intermediate secretion are highlighted in grey and proteins with high secretion are 
highlighted in yellow. 
 
202 
 
CCL2, also known as the monocyte chemoattractant protein 1 (MCP–1), is 
secreted by many cell types including endothelial cells, fibroblasts, epithelial 
cells and smooth muscle cells, but monocytes and macrophages have been 
identified as the major source of CCL2 (Deshmane et al., 2009, Yoshimura et al., 
1989). On the one hand, CCL2 is involved in the regulation of the migration and 
infiltration of monocytes, memory T cells and NK cells and is involved in the 
development of inflammatory disorders including rheumatoid arthritis 
(Hayashida et al., 2001), multiple sclerosis (Sørensen et al., 2004) and insulin-
resistant diabetes (Sartipy and Loskutoff, 2003). On the other hand, CCL2 is 
involved in angiogenesis and neovascularisation (Daly and Rollins, 2003, Rose et 
al., 2003). BM, Is and Ad MSCs transcribed (Figure 4-1, A) and secreted (Figure 
4-8, A) substantial levels of CCL2 under resting conditions. These transcriptional 
and protein levels were significantly upregulated after inflammatory stimulation 
by MSCs isolated from all tissue sources. BM MSCs had the highest CCL2 
expression levels while, at protein level, Is MSCs secreted the highest levels of 
CCL2 under cytokine-mediated inflammatory stimulation, suggesting the 
involvement of post-transcriptional mechanisms in the expression of CCL2. 
Moreover, Is MSCs could have the potential to attract more monocytes than BM 
and Ad MSCs. Secretion of CCL2 by human BM, Is and Ad MSCs has previously 
been reported (Thirlwell, 2018) but to my knowledge, differences in CCL2 
transcription, secretion and monocyte and T cell chemoattraction by mouse 
MSCs isolated from different tissue sources have not been documented.  
CCL5, also known as “regulated upon activation normal T cell expressed and 
secreted” (RANTES), is expressed by T lymphocytes, macrophages, platelets, 
synovial fibroblasts, tubular epithelium, and certain types of tumour cells and is 
involved in the recruitment of T cells, eosinophils and basophils predominantly 
but also NK cells, DCs and MCs (Marques et al., 2013). CCL5 is a key pro-
inflammatory chemokine involved in viral (Glass et al., 2003) and helminth 
(Souza et al., 2011) infections and enhancing inflammation in diseases such as 
asthma (Lukacs, 2001) or atherosclerosis; however, CCL5 is also involved in 
angiogenesis (Suffee et al., 2011). BM, Is and Ad MSCs transcribed (Figure 4-1, D) 
and secreted (Figure 4-8, B) little CCL5 under resting conditions. However, 
inflammatory stimulation significantly upregulated CCL5 transcript and protein 
levels in MSCs isolated from all tissue sources. At the transcriptional level, BM 
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MSC were expressing the highest CCL5 transcript levels, while at protein level, Is 
MSCs secreted the most CCL5 after cytokine-mediated inflammatory stimulation, 
suggesting the involvement of post-transcriptional mechanisms in the expression 
and secretion of CCL5. Moreover, under inflammatory conditions Is MSCs could 
have the potential to recruit the most leukocytes.  
 
CCL7, previously known as monocyte chemoattractant protein 3 (MCP3), is 
expressed in fibroblasts, epithelial cells, and endothelial cells and it specifically 
attracts monocytes, eosinophils, basophils, DCs, NK cells and activated T 
lymphocytes (Liu et al., 2018b). CCL7 is involved in antiviral, antibacterial and 
antifungal immunity due to the monocyte mobilization from the bone marrow 
towards sites of inflammation; moreover, CCL7 is the only member of the CC 
chemokine family that can induce the migration of neutrophils (Fioretti et al., 
1998). However, an excess of CCL7 is involved in several diseases including 
psoriasis (Brunner et al., 2015), acquired immunodeficiency syndrome (Atluri et 
al., 2016) and acute neutrophilic lung inflammation and pulmonary fibrosis 
(Mercer et al., 2014). BM, Is and Ad MSCs transcribed (Figure 4-1, E) and 
secreted (Figure 4-8, C) little CCL7 under resting conditions. However, 
inflammatory stimulation significantly upregulated CCL7 transcript and protein 
levels in MSCs isolated from all tissue sources. At transcriptional level, BM MSC 
were expressing the highest CCL7 transcript levels, while at protein level, Is 
MSCs secreted the most CCL7 after cytokine-mediated inflammatory stimulation, 
suggesting the involvement of post-transcriptional mechanisms in the expression 
and secretion of CCL7. Moreover, under inflammatory conditions Is MSCs could 
have the potential to recruit more monocytes than BM and Ad MSCs.  
CXCL1, also known as keratinocyte chemoattractant (KC), and CXCL2, also 
known as macrophage inflammatory protein 2 (MIP2), are the functional 
homologs of human CXCL8 (Hol et al., 2010). CXCL1 is expressed by 
keratinocytes, endothelial cells, monocytes and macrophages while CXCL2 is 
expressed by endothelial cells and megakaryocytes (Shea-Donohue et al., 2008). 
Despite CXCL1 and 2 not being the direct homologues of CXCL8, they both 
belong to the same major cluster of CXC chemokines and they are both involved 
in neutrophil recruitment via CXCR2 (Zlotnik and Yoshie, 2000b), which is why 
they are going to be discussed together. However, their role is not redundant; 
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CXCL1 is critical for luminal and subendothelial cell neutrophil crawling, while 
CXCL2 is involved in the correct breaching of endothelial junctions (Girbl et al., 
2018), but they are both involved in angiogenesis, tumorigenesis, wound healing 
and inflammation (Gillitzer and Goebeler, 2001, Kolaczkowska and Kubes, 2013, 
De Filippo et al., 2013). However, they are also involved in the development and 
maintenance of the inflammation in autoimmune diseases as rheumatoid 
arthritis (Udalova et al., 2016), multiple sclerosis (Grist et al., 2018) and 
psoriasis (Lowes et al., 2014) among others. BM, Is and Ad MSCs transcribed 
(Figure 4-2, A and B) and secreted (Figure 4-9, A and B) little CXCL1 and CXCL2 
under resting conditions. However, inflammatory stimulation significantly 
upregulated CXCL1 and CXCL2 transcriptional and protein levels in MSCs isolated 
from all tissue sources. At the transcript level, BM and Is MSCs expressed the 
highest CXCL1 and CXCL2 transcript levels respectively, while at the protein 
level, Is MSCs secreted the most CXCL1 and CXCL2 after cytokine-mediated 
inflammatory stimulation, suggesting the involvement of post-transcriptional 
mechanisms in the expression and secretion of CXCL1 and CXCL2. Moreover, 
under inflammatory conditions Is MSCs could have the potential to recruit more 
neutrophils than BM and Ad MSCs. 
CXCL10, also known as interferon–γ-inducible protein 10 (IP-10), is produced by a 
wide range of cell types including monocytes, neutrophils, endothelial cells, 
keratinocytes, fibroblasts, MSCs, DCs, hepatocytes and astrocytes (Vazirinejad et 
al., 2014). The CXCL10/ CXCR3 axis is involved in the chemoattraction of 
macrophages, monocytes and activated T and NK cells (Crow et al., 2001). 
Moreover, CXCL10 is involved in the modulation of T cell development and 
function as well as being an inhibitor of neovascularization, even in a tumoral 
environment (Vazirinejad et al., 2014). Due to the pro-inflammatory role of 
CXCL10, this CXC chemokine is involved in several pathologies including multiple 
sclerosis, rheumatoid arthritis, systemic lupus erythematosus and idiopathic 
inflammatory myopathy among others (Lee et al., 2009). BM, Is and Ad MSCs 
transcribed (Figure 4-2, D) and secreted (Figure 4-9, C) little CXCL10 under 
resting conditions. However, inflammatory stimulation significantly upregulated 
CXCL10 transcript and protein levels in MSCs isolated from all tissue sources. 
Under cytokine-mediated inflammatory stimulation, Is MSCs transcribed and 
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secreted the most CXCL10, suggesting that Is MSCs could attract more monocytes 
than BM and Ad MSCs.  
CXCL12, also known as stromal-derived factor 1α (SDF-1α), is constitutively 
secreted by stromal cells in the bone marrow, lymph nodes, liver and lungs 
(Ieranò et al., 2019). CXCL12 induces the migration of haematopoietic progenitor 
and stem cells as well as being a very strong chemoattractant for endothelial 
cells and several leukocytes including pre-B cells, T cells and monocytes (Askari 
et al., 2003, Janssens et al., 2018). CXCL12 interacts with its receptors CXCR4 
and ACKR3 to fulfil extremely important physiological processes, including 
embryogenesis, haematopoiesis, angiogenesis and inflammation (Janssens et al., 
2018). Despite its homeostatic functions, increased expression of CXCL12 is 
involved in cancer progression, inflammatory bowel disease, rheumatoid 
arthritis, asthma and amyotrophic lateral sclerosis among others (Mousavi, 
2020). BM, Is and Ad MSCs transcribed (Figure 4-2, E) and secreted (Figure 4-9, 
C) little CXCL12 under resting conditions. Opposite to the other mentioned 
chemokines, inflammatory stimulation did not lead to an upregulation of CXCL10 
transcript and protein levels in MSCs isolated from any of the tissue sources. 
Under homeostatic or cytokine-mediated inflammatory stimulation, BM MSCs 
transcribed and secreted the most CXCL12, suggesting that BM MSCs could 
attract more progenitor and stem cells than Is and Ad MSCs.  
Altogether, inflammatory stimulation led to the secretion of substantial levels of 
CCL2, CCL5, CCL7, CXCL1, CXCL2, CXCL10 and CXCL12, which could potentially 
induce the recruitment of all sorts of leukocytes but more predominantly, 
neutrophils, monocytes/ macrophages, NK cells and T cells (Deshmane et al., 
2009, De Filippo et al., 2013, Dwinell et al., 2001). The recruitment of these 
cells by these chemokines could be considered detrimental within a clinical 
setting due to their role in triggering alloimmunity and graft rejection by 
recognizing allogenic nonself antigens (Lakkis and Li, 2018, Oberbarnscheidt et 
al., 2014, Choi et al., 2007). However, it is essential to bear in mind that MSCs 
are well known for their immunomodulatory potential producing a switch from 
pro-inflammatory environments towards anti–inflammatory ones. 
The CCL2/ CCR2 axis promotes the differentiation of monocytes towards anti–
inflammatory phenotypes, which are involved in the regulation of the resolution 
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phase of inflammation and the repair of damaged tissues and would therefore 
promote graft survival (Sierra-Filardi et al., 2014). In addition, secreted CCL2 by 
MSCs is not only relevant for monocyte attraction, but for T cells too as the 
CCL2/ CCR2 axis is crucial for the suppression of autoreactive T cells by MSCs 
(Lee et al., 2017a). Autoreactive T cells are present in pancreatic islets of T1DM 
patients and are able to mediate cross-reactive alloreactivity in T1DM that 
receive pancreas transplant (Burrack et al., 2018).  
CCL5 expression has been proven to supress the anti–tumour immunity in triple 
negative breast cancer due to the chemoattraction of T cells, NK cells and 
macrophages (Araujo et al., 2018). The CCL5/ CCR1 and CXCL10/ CXCR3 axis 
have been described to modulate allogeneic T cell responses contributing to the 
development of GVHD following allogeneic stem cell transplantation (Choi et al., 
2007, Piper et al., 2007); however, GVHD can be treated by infusion of MSCs, 
which leads to long–term graft function (Le Blanc et al., 2008). Little is known 
about the role of CCL7 in transplantation as CCL7 can induce chemotaxis of both 
pro-inflammatory and anti–inflammatory macrophages (Xuan et al., 2015). 
Galleu et al. described the essential role of cytotoxic cells to initiate MSC–
mediated immunosuppression in a murine model of GvHD; MSCs need to be 
targeted by cytotoxic T cells to undergo apoptosis so they can then be engulfed 
by macrophages and produce indoleamine 2,3 dioxygenase (IDO) (Galleu et al., 
2017). In addition, impaired expression of CCL5 in Ad MSCs leads to delayed 
repair of the vasculature of ischemic regions (Kimura et al., 2014). Moreover, 
CCL5 mediated recruitment of NK cells could be essential for alloimmunity and 
tolerance as NK cells can produce IL–10 and other anti–inflammatory cytokines 
(Benichou et al., 2011).  
Regarding neutrophil recruitment, CXCL1 mediated neutrophil infiltration has 
been shown to be essential for the recruitment of allospecific CD4+ T cells into 
the graft and is therefore associated with low survival rates of the allografts 
(Amescua et al., 2008). CXCL1 and CXCL2 mediated neutrophil infiltrates are 
involved in the ischemia and reperfusion injury after transplantation that leads 
to the onset and persistence of acute rejection in cardiac allografts (Shimizu and 
Mitchell, 2008). However, neutrophils could also inhibit graft inflammation and 
its subsequent rejection by enhancing wound and tissue repair coupled with 
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neovascularization (Christoffersson et al., 2012). Moreover, apoptosis of 
neutrophils is anti–inflammatory and pro–resolution of the inflammation process 
itself as it reduces the secretion of pro–inflammatory molecules by phagocytic 
cells (Byrne and Reen, 2002).  
Lastly, the presence of CXCL12 within a graft leads to progenitor cell and stem 
cell recruitment, angiogenesis and tissue regeneration after lung transplantation 
(Gomperts et al., 2006). Moreover, the addition of CXCL12 has been shown to 
increase the long-term survival of microencapsulated auto-, allo- and xenogeneic 
islets in murine models of diabetes without systemic immune suppression 
(Sremac et al., 2019). For these reasons, the overexpression of CXCL12 in MSCs 
would be therapeutically beneficial within a clinical setting.  
 
4.5.3 Conclusions 
To summarise and conclude, this chapter aimed to determine if murine MSCs 
isolated from different tissues had a specific pattern of chemokine and 
chemokine receptor expression at transcript, and most importantly, protein 
level. BM, Is and Ad MSCs all had very low transcript levels of chemokine 
receptors under resting and stimulatory chemokines, which suggests that homing 
into specific tissues is unlikely but if transplanted locally at the target tissue, 
MSCs would be unlikely to migrate away from the graft site. Due to the lack of 
specific antibodies towards murine chemokine receptors, protein analysis could 
not be performed. For this reason, to understand the functionality of receptors 
expressed by MSC, migration assays towards chemokines would have to be 
performed. Moreover, this chapter aimed to assay chemokine secretion by BM, Is 
and Ad MSCs and to understand if tissue of origin of MSCs led to a differential 
chemokine secretion under resting and inflammatory conditions. MSCs were able 
to produce large quantities of CCL2, CCL5, CXCL1 and CXCL10 at differential 
levels depending on MSC source of origin under inflammatory conditions, with Is 
MSCs secreting the most, which could induce the migration of large amounts of 
monocytes/ macrophages and neutrophils and NK cells and T cells in a smaller 
amount. This chapter showed differential chemoattraction potential of MSCs 
depending on their tissue of origin and suggests that MSCs isolated from various 
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tissues would act differentially in vivo. For this reason, determining the immune 
cell attraction in vivo would be essential to have a better understanding of the 
potential behaviour of MSCs from different sources within a clinical setting. 
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5 Defining the immune cell recruitment profile of 
MSCs in vivo  
5.1 Introduction and aims 
In Chapter 4 we determined that MSCs isolated from the bone marrow, islets of 
Langerhans and adipose tissue expressed overall low levels of chemokine 
receptor transcripts and that tissue of origin determines a specific pattern of 
chemokine transcription. BM, Is and Ad MSCs secreted CCL2, CCL7, CXCL1 and 
CXCL12 under resting conditions at similar levels, suggesting that MSCs have the 
potential to attract monocytes, neutrophils and lymphocytes. In addition, 
inflammatory licensing led to a substantial upregulation in the secretion of the 
aforementioned chemokines, whilst also inducing the transcription and secretion 
of CCL5, CXCL2 and CXCL10 by MSCs from all sources. Therefore, we 
hypothesised that inflammatory stimulation would lead to an increased 
recruitment of leukocytes by MSCs, with a predominance of neutrophils and 
monocytes/ macrophages.  
MSCs have been described to have stronger immunomodulatory and anti-
inflammatory properties after licensing with TNF-α, IL-1β and IFN-γ (Krampera 
et al., 2006, Krampera et al., 2007, Di Nicola et al., 2002, Beyth et al., 2005); 
which may be at odds with an increased secretion of chemokines with the ability 
to recruit leukocytes. It is essential to determine the immune recruitment 
potential of MSCs and its outcome, as infusion of MSCs into a patient with an 
existing inflammatory condition could lead to the recruitment of leukocytes and 
exacerbate inflammation. Monocytes and neutrophils are essential cell 
populations in early stages of acute inflammation and may be regarded as 
monofunctional pro-inflammatory cells. However, there is a relatively new body 
of literature surrounding the existence of pro-inflammatory and anti-
inflammatory or pro-angiogenic subsets of monocytes/ macrophages and 
neutrophils. Neutrophils are a heterogenic population and distinct neutrophil 
subsets with different roles have been identified based on their cell surface 
receptor expression. As an example, CD11b+/ Gr-1+ neutrophils are recruited to 
grafts where they are involved in the re-vascularization of the transplanted 
tissue (Christoffersson et al., 2012). More importantly, this subset of neutrophils 
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is CXCR4 high and would therefore be able to respond to the CXCL12 secretion 
by MSCs.  
Macrophages can be categorised in two major subsets, pro-inflammatory 
macrophages also known as M1 macrophages, and anti-inflammatory 
macrophages, known as M2 macrophages. The interaction between apoptotic 
neutrophils and macrophages promotes type 2 macrophage polarization (Marwick 
et al., 2018), leading to an anti-inflammatory environment. In the same way, 
MSC infusions induce a switch from pro-inflammatory to anti-inflammatory 
macrophages, driving alleviation of myocardial injury and restoration of cardiac 
function (Jin et al., 2019). Moreover, CXCL12 production has been described to 
modulate the differentiation of monocytes towards a distinctive pro-angiogenic 
and immunosuppressive phenotype (Sánchez-Martín et al., 2011). Taking all this 
into account, increased secretion of chemokine ligands and the subsequent 
recruitment of immune cells by licensed MSCs could have the potential to 
exacerbate inflammation or, in contrast, promote an anti-inflammatory milieu 
after infusion into a patient. Thus, the phenotype of the recruited immune cells 
would determine if MSCs could be beneficial or detrimental to tissue 
regeneration in a clinical setting.  
Having have showed in the previous chapter differential chemoattraction 
potential of MSCs depending on their tissue of origin, determining the immune 
cell attraction in vivo was the next logical step in this study to allow a better 
understanding of the potential behaviour of MSCs from different sources within a 
clinical setting. To do this, the murine air pouch model was used, which is a 
well-established model to study immune infiltration into an artificially created 
air pouch on the back of mice (Dyer et al., 2019). This model has already been 
used to assess the immune cell infiltration in response to licensed human Is MSC 
infusion into the air pouch of mice (Thirlwell, 2018, Dyer et al., 2019). For this 
reason, the air pouch was used as an in vivo environment to study the immune 
cell infiltration in response to resting and licensed BM, Is and Ad MSCs. Licensing 
of MSCs was carried out with 40 ng/ ml of TNF-α, IL-1β and IFN-ϒ for 24 hours. 
MSCs were thoroughly washed prior to infusion into the air pouch to avoid non-
specific immune cell attraction by the inflammatory cytokines.  
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Therefore, this chapter aimed to assess; i) the in vivo immune cell attraction 
profile of resting and licensed mouse MSCs, ii) the phenotype of infiltrated 
immune cells and iii) the fate of MSCs after infusion.  
 
Results 
5.2 Flow cytometry gating strategies 
Subcutaneous injection of sterile air into the intracapsular area of the mouse 
creates a hollow pocket of air, where MSCs are infused, surrounded by a 
membrane. Flow cytometry was used to analyse the immune cell infiltration into 
the air pouch fluid and membrane of C57BL/6 female mice 24 hours after MSC 
infusion into the air pouch.  
An array of cell markers (CD45, CD11b, Ly6g, F480, Siglec F, Ly6c and CD11c) 
coupled with a specific gating strategy (Figure 5-1) was used to identify 
neutrophils (Figure 5-1, D.i), macrophages (Figure 5-1, E.i), eosinophils (Figure 
5-1, F.i), monocytes (Figure 5-1, G.i) and CD11b high CD11c+ myeloid cells 
(Figure 5-1, I). CD11b and CD11c are co-expressed in myeloid-lineage DCs, while 
they are absent in lymphoid-lineage plasmacytoid DCs (Musumeci et al., 2019, 
Donaghy et al., 2001). CD11b is expressed on a variety of leukocytes, while 
CD11c is usually expressed by DCs. However, the expression of these markers 
can be upregulated on activated cells irrespective of their naïve expression 
status, which makes it impossible to confirm that the CD11b high CD11c+ 
population are DCs without the addition of other DC markers such as CD24 or 
MHC Class II.  
An additional array of mouse cell markers was used to analyse the infiltration of 
NK cells (Figure 5-2, D.i), CD8+ (Figure 5-2, E.i) and CD4+ T cells (Figure 5-2, E.ii) 
and B cells (Figure 5-2, F.i) into the air pouch fluid and membrane (Figure 5-2). 
CD73 was used to enumerate infused MSCs. 
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Figure 5-1. Flow cytometry gating strategy to identify various mouse innate immune cells in 
the air pouch of C57BL/6 mice. 
Flow cytometry was used to assess and identify the immune cell infiltration into the air pouches of 
C57BL/6 mice. Black arrows highlight the gating pathway and red arrows highlight gated cell 
populations. Cells were selected based on forward versus side scatter (A) and viable cells were 
selected (B). CD45+ cells were selected (C) and CD11b+, Ly6g+ cells were considered neutrophils 
after doublet exclusion (D.i). Remaining cells were assessed for their expression of F480. F480+, 
CD11b+ cells were considered macrophages after doublet exclusion (E.i). The remaining 
population of cells were assessed for Siglec F expression. Siglec F+ cells were considered 
eosinophils after doublet exclusion (F.i). CD11b+ Ly6c+ cells were considered monocytes after 
doublet exclusion (G.i). The remaining cells were assessed for the expression of CD11c. CD11b 
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high CD11c+ were classified as CD11b+ CD11c+ myeloid cells after doublets exclusion and 
ensuring they were a single population (I).  
 
 
Figure 5-2. Flow cytometry gating strategy to identify various mouse adaptive immune cells 
in the air pouch of C57BL/6 mice. 
Flow cytometry was used to assess and identify the immune cell infiltration into the air pouches of 
C57BL/6 mice. Black arrows highlight the gating pathway. Red arrows highlight the gated cell 
population. Cells were selected based on forward versus side scatter (A) and viable cells were 
selected (B). CD45+ cells were selected (C) and assessed for their expression of NK1.1, CD8, CD4 
and B220. NK1.1 positive cells were considered NK cells after doublet exclusion (D.i) and the 
remaining cells were assessed for the expression of CD8 and CD4 (E) and considered CD8+ T 
cells (E.i) or CD4+ T cells (E.ii), respectively after doublet exclusion. Cells negative for CD4 and 
CD8 were assessed for their expression of B220 and positive cells were considered B cells (F.i).  
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5.3 Analysis of the cellular infiltration into the air 
pouches 
Using flow cytometry, the total number of CD45 positive cells that had 
infiltrated into the air pouches was assessed. All the data are expressed as 
number of cells per mL of fluid extracted from the air pouch.  
5.3.1 PBS only Controls  
First, the immune cell infiltration produced by the generation of the air pouch 
itself and injection of PBS was assessed (Figure 5-3). Minimal migration of CD45+ 
cells into control air pouches was observed, which showed that the creation of 
the air pouch, or PBS injection, did not lead to the generation of an 
inflammatory site with subsequent immune cell infiltration. Macrophages and NK 
cells were the predominant immune cells present in the air pouches of control 
mice, followed by smaller numbers of neutrophils, monocytes and eosinophils.  
 
Figure 5-3. Generation of the air pouch on C57BL/6 mice and injection of PBS into the air 
pouch led to minimal migration of CD45+ cells.  
Air pouches were created on the dorsal of 8-week C57BL/6 female mice as explained in Section 
2.4.2.1. The sixth day mice received a sterile PBS injection and mice were sacrificed, and tissues 
were harvested 24 hours later. Flow cytometry was used to assess the immune cell infiltration into 
the air pouches of mice, and it is expressed as number of cells per mL of fluid extracted from the 
air pouch. The total number of CD45+, F480+ macrophages, Ly6g+ neutrophils, CD11b+ CD11c+ 
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myeloid cells, Ly6c+ monocytes and Siglec F+ eosinophils that had infiltrated into the air pouches of 
mice was determined and graphed, as well as the total number of NK1.1+ NK cells, CD8+ T cells, 
CD4+ T cells and B220+ B cells that had infiltrated into the air pouches of mice. Each bar group 
represents 5 mice ± SEM.  
 
Next, immune cell infiltration needed to be tested after the infusion of MSCs 
from three different sources, BM, Is and Ad MSCs, in two different conditions, 
resting and after licensing, which meant a large number of mice to work with. 
For this reason, this experiment was performed for MSCs from each tissue 
independently. Data were therefore normalised to the PBS control infiltrates in 
each individual set of experiments in order to be able to compare the data from 
different experiments and replicates.  
5.3.2 Administration of BM, Is and Ad MSCs  
As shown in Figure 5-4 and Figure 5-5, migration of innate or adaptive immune 
cells towards resting BM (A and B), Is (C and D) and Ad MSCs (E and F) was 
observed and there was no statistically significant variation in the number of 
CD45+ cells, F4/80+ macrophages, Ly6g+ neutrophils, CD11b+ CD11c+ myeloid 
cells, Ly6c+ monocytes, SiglecF+ eosinophils, NK1.1+ NK cells, CD4+ T cells, CD8+ 
T cells and B220+ B cells recruited per mL of fluid extracted when compared to 
the control PBS mice.  
Conversely, infusion of licensed MSCs into the air pouch of mice resulted in an at 
least 2-fold increase in infiltrating CD45+ cells compared to PBS control mice 
regardless of the MSCs tissue of origin. However, the immune cells recruited and 
the numbers of these cells within the air pouch was MSC source of origin 
dependent. Stimulated MSCs from every source were able to produce a 
statistically significant increased recruitment of F4/80+ macrophages compared 
to resting MSCs, with Ad MSCs recruiting the most. Regarding Ly6g+ neutrophils, 
stimulation of MSCs led to a statistically significant increase in the recruitment 
of these cells; however, BM MSCs did not recruit as many Ly6g+ neutrophils as Is 
and Ad MSCs. The recruitment of CD11b+ CD11c+ myeloid cells was statistically 
significantly higher in stimulated MSCs from every source compared to resting 
MSCs, and all the licensed MSCs recruited CD11b+ CD11c+ myeloid cells at similar 
levels. Stimulated MSCs from every source were able to produce a statistically 
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significant increased recruitment of Ly6c+ monocytes compared to resting MSCs, 
with Ad MSCs recruiting the most. The recruitment of SiglecF+ eosinophils was 
statistically significantly higher in stimulated MSCs from every source compared 
to resting MSCs, and all the licensed MSCs recruited SiglecF+ eosinophils at 
similar levels. Stimulated Ad were the only MSCs able to produce a statistically 
significant increase in the recruitment of NK1.1+ NK cells and CD4+ T cells 
compared to resting MSCs. Stimulated Is and Ad MSCs were both able to produce 
a statistically significant increase in the recruitment of CD8+ T cells compared to 
resting conditions, while the number of CD8+ T cells recruited from stimulated 
BM MSCs did not differ with respect to the number of CD8+ T cells recruited by 
unstimulated BM MSCs; stimulated Ad MSCs were able to recruit significantly 
more CD8+ T cells than stimulated Is MSCs. Regarding B220+ B cells, no 
statistically significant differences in the number of recruited B220+ B cells were 
found between stimulated MSCs and resting MSCs regardless of the tissue of 
origin.  
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Figure 5-4. Immune infiltration into the air pouch of C57BL/6 female mice.  
Air pouches were created on the dorsal of 8-week C57BL/6 female mice as explained in Section 
2.4.2.1. The sixth day mice received an injection of either 1x106 resting or stimulated MSCs in 1 mL 
of sterile PBS or sterile PBS alone after which mice were sacrificed, and tissues were harvested 24 
hours later. Flow cytometry was used to assess the immune cell infiltration into the air pouches of 
mice, and it is expressed as number of cells per mL of fluid extracted from the air pouch. Data was 
then normalised to the PBS control. The total number of CD45+, F480+ macrophages, Ly6g+ 
neutrophils, CD11b+ CD11c+ myeloid cells, Ly6c+ monocytes and Siglec F+ eosinophils that had 
infiltrated into air pouches of mice was determined and are graphed in A, C and E. The total 
number of NK1.1+ NK cells, CD8+ T cells, CD4+ T cells and B220+ B cells that had infiltrated into 
the air pouches of mice are graphed in B, D and F. To assess if MSC tissue of origin influenced the 
immune cell infiltrate, BM (A and B), Is (C and D) and Ad MSCs (E and F) were injected into the air 
pouches of mice. One Way ANOVA with Tukey’s multiple comparisons was used to compare the 
immune cell infiltration among PBS control, resting and stimulated MSCs. Statistically significant 
differences are marked with the appropriate number of asterisks in Table 5-1.  
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Table 5-1. Statistical analysis of the immune infiltration produced by PBS, resting and 
licensed MSCs into the air pouch of C57BL/6 female mice. 
Following the experimental set up explained in Figure 5-4, One Way ANOVA with Tukey’s multiple 
comparisons was used to compare the immune cell infiltrate among PBS control, resting and 
stimulated MSCs. Significant differences are marked with the appropriate number of asterisks. p = 
0.05 was considered the limit for statistical significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p 
< 0.0001. 
 
Immune cell 
PBS Control vs  
Resting MSCs 
PBS Control vs 
Stimulated MSCs 
Resting MSCs vs 
Stimulated MSCs 
B
M
 M
SC
s 
CD45+ ns ** *** 
F4/80+ Macrophages ns ns * 
Ly6g+ Neutrophils ns ** *** 
CD11c+ Myeloid cells ns * ** 
Ly6c+ Monocytes ns ns * 
SiglecF+ Eosinophils ns ** ** 
NK1.1+ NK cells ns ns ns 
CD4+ T cells ns ns ns 
CD8+ T cells ns ns ns 
B220+ B cells ns ns ns 
Is
 M
SC
s 
CD45+ ns **** **** 
F4/80+ Macrophages ns ** ** 
Ly6g+ Neutrophils ns **** **** 
CD11c+ Myeloid cells ns ** * 
Ly6c+ Monocytes ns *** ** 
SiglecF+ Eosinophils ns **** *** 
NK1.1+ NK cells ns * ns 
CD4+ T cells ns *** ns 
CD8+ T cells ns * * 
B220+ B cells ns ns ns 
A
d
 M
SC
s 
CD45+ ns ** *** 
F4/80+ Macrophages ns ns * 
Ly6g+ Neutrophils ns ** *** 
CD11c+ Myeloid cells ns ** * 
Ly6c+ Monocytes ns ns * 
SiglecF+ Eosinophils ns ** ** 
NK1.1+ NK cells ns **** **** 
CD4+ T cells ns **** **** 
CD8+ T cells ns **** **** 
B220+ B cells ns ns ns 
 
It is important to examine if MSCs from different sources not only recruited 
different types of immune cells, but also recruited them in statistically 
significant different amounts. For this reason, for an easier comparison of the 
immune cell recruitment produced by each source of MSCs, fold changes in the 
recruitment of immune cells by resting and stimulated BM, Is and Ad MSCs is 
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represented in Figure 5-5 and the significant differences in the recruitment by 
these cells is detailed in Table 5-2. 
 
 
Figure 5-5. Comparison of the immune attraction profile among MSCs from different 
sources under resting and stimulated conditions in the air pouch.  
Following the experimental set up explained in Figure 5-4, PBS control mice were used as a control 
to normalise all the data and the infiltration of immune cells in the air pouches (A and B) was 
compared among MSCs from different sources. One Way ANOVA with Tukey’s multiple 
comparisons was used to compare the immune cell infiltrate originated by resting and stimulated 
MSCs from the different sources. Statistically significant differences are marked with the 
appropriate number of asterisks in Table 5-2. 
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Table 5-2. Statistical analysis of the immunoreactivity of resting and stimulated BM, Is and 
Ad MSCs into the air pouches and air pouch membranes of C57BL/6 female mice. 
Following the experimental set up explained in Figure 5-5, One Way ANOVA with Tukey’s multiple 
comparisons was used to compare the immune cell infiltrate among resting and stimulated BM, Is 
and Ad MSCs. Statistically significant differences are marked with the appropriate number of 
asterisks. p = 0.05 was considered the limit for statistical significance; * p < 0.05; ** p < 0.01; *** p 
< 0.001; **** p < 0.0001. 
Tissue Immune cell 
Stim. BM MSCs 
vs Stim. Is MSCs 
Stim. BM MSCs 
vs Stim. Ad 
MSCs 
Stim. Is MSCs vs 
Stim. Ad MSCs 
AIR POUCH 
CD45+ ns ** ** 
F4/80+ Macrophages ns ** ** 
Ly6g+ Neutrophils ns *** ns 
CD11c+ Myeloid cells ns ns ns 
Ly6c+ Monocytes ns * * 
SiglecF+ Eosinophils ns ns ns 
NK1.1+ NK cells ns ** ** 
CD4+ T cells ns *** * 
CD8+ T cells ns ** ** 
B220+ B cells ns ns ns 
+++ No statistically significant differences were found among BM, Is and Ad resting MSCs. 
 
5.4 Analysis of the cellular infiltration into the air pouch 
membrane 
Using flow cytometry, the total numbers of CD45 positive cells that had 
infiltrated into the membrane of the air pouches was assessed. All the data are 
expressed as number of cells per mg of membrane.  
5.4.1 PBS only Controls  
First, the immune cell infiltration produced by the generation of the air pouch 
itself and introduction of PBS was assessed (Figure 5-6). Minimal migration of 
CD45+ cells into control air pouch membranes was observed, which proved that 
the creation of the air pouch or PBS injection itself, did not lead to the 
generation of an inflammatory site with subsequent immune cell infiltration. 
Macrophages and NK cells were the predominant immune cell present in the 
membranes of air pouches of control mice, followed by smaller numbers of 
neutrophils, monocytes and eosinophils. 
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Figure 5-6. Generation of the air pouch on C57BL/6 mice and injection of PBS into the air 
pouch led to minimal migration of CD45+ cells towards the air pouch membrane.  
Air pouches were created on the dorsal of 8-week C57BL/6 female mice as explained in Section 
2.4.2.1. The sixth day mice received a sterile PBS injection and mice were sacrificed, and tissues 
were harvested 24 hours later. Flow cytometry was used to assess the immune cell infiltration into 
the membrane of the air pouches of mice and it is expressed as number of cells per mg of 
membrane. The total number of CD45+, F480+ macrophages, Ly6g+ neutrophils, CD11b+ CD11c+ 
myeloid cells, Ly6c+ monocytes and Siglec F+ eosinophils that had infiltrated into the membrane of 
the air pouches of mice was determined and graphed, as well as the total number of NK1.1+ NK 
cells, CD8+ T cells, CD4+ T cells and B220+ B cells that had infiltrated into the membrane of the air 
pouches of mice. Each bar group represents 5 mice ± SEM.  
 
Next, immune cell infiltration needed to be tested after the infusion of MSCs 
from the three different sources, BM, Is and Ad MSCs, in two different 
conditions, resting and after licensing, which meant a large number of mice to 
work with. For this reason, this experiment was performed for MSCs from each 
tissue independently. Data were therefore normalised to the PBS control 
infiltrates in each individual set of experiments in order to be able to compare 
the data from the different experiments and replicates.  
5.4.2 Administration of BM, Is and Ad MSCs  
As shown in Figure 5-7, under resting conditions, minimal infiltration of innate or 
adaptive immune cells was observed in the air pouch membranes of the mice 
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infused with BM (A and B), Is (C and D) and Ad MSCs (E and F) and no statistically 
significant variation was seen in the number of CD45+ cells, F4/80+ macrophages, 
Ly6g+ neutrophils, CD11b+ CD11c+ myeloid cells, Ly6c+ monocytes, SiglecF+ 
eosinophils, NK1.1+ NK cells, CD4+ T cells, CD8+ T cells and B220+ B cells 
recruited per mg of membrane harvested when compared to the control PBS 
mice was observed.  
Infusion of licensed MSCs into the air pouch resulted in a small increase in the 
number of CD45+ cells infiltrates compared to PBS control mice; however, this 
increase in the number of CD45+ cells was only statistically significant in BM 
MSCs. Despite the small variation in the overall number of CD45+ cells, the 
infusion of stimulated MSCs from each source led to some statistically significant 
variations in the population analysed using flow cytometry. Infusion of 
stimulated MSCs from any source produced no effect on the number of 
infiltrated F4/80+ macrophages, SiglecF+ eosinophils and CD4+ T cells in the 
membrane of the air pouch. The number of Ly6g+ neutrophils was increased in a 
statistically significant manner after the infusion of stimulated Is MSCs, while 
stimulated BM and Ad MSCs did not produce an infiltration of these cells in the 
membrane of the air pouch compared to the infusion of unstimulated MSCs or 
the PBS control mice. Resting BM MSCs were the only MSCs able to trigger the 
infiltration of CD11b+ CD11c+ myeloid cells in the membrane of the air pouch 
after infusion and this recruitment by BM MSCs was maintained after stimulation 
of the cells prior to infusion into the air pouch. This increased recruitment of 
CD11b+ CD11c+ myeloid cells was not statistically significant when compared to 
the PBS control mice; however, stimulated BM MSCs recruited statistically 
significantly more CD11b+ CD11c+ myeloid cells into the membrane of the air 
pouch than stimulated Is and Ad MSCs. Stimulated BM MSCs were the only MSCs 
able to trigger the infiltration of Ly6c+ monocytes into the membrane of the air 
pouch after infusion. The infiltration of NK1.1+ NK cells was statistically 
significantly higher in stimulated BM and Is MSCs compared to resting MSCs or 
PBS control mice, while licensing of Ad MSCs produced no change in the number 
of NK1.1+ NK cells recruited. Stimulated Is MSCs were the only MSCs able to 
produce a statistically significant increase in the infiltration of CD8+ T cells and 
B220+ B cells in the membrane of the air pouch.  
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Figure 5-7. Immune infiltration into the air pouch membrane of C57BL/6 female mice.  
Air pouches were created on the dorsal of 8-week C57BL/6 female mice as explained in Section 
2.4.2.1. The sixth day mice received an injection of either 1x106 resting or stimulated MSCs in 1 mL 
of sterile PBS or sterile PBS alone and mice were sacrificed, and tissues were harvested 24 hours 
later. Flow cytometry was used to assess the immune cell infiltration into the membrane of the air 
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pouches of mice and it is expressed as number of cells per mg of membrane. Data was then 
normalised to the PBS control. The total number of CD45+, F480+ macrophages, Ly6g+ neutrophils, 
CD11b+ CD11c+ myeloid cells, Ly6c+ monocytes and Siglec F+ eosinophils that had infiltrated into 
the membrane of air pouches of mice was determined and are graphed in A, C and E. The total 
number of NK1.1+ NK cells, CD8+ T cells, CD4+ T cells and B220+ B cells that had infiltrated into 
the membrane of the air pouches of mice are graphed in B, D and F. To assess if MSC tissue of 
origin influenced the immune cell infiltrate, BM (A and B), Is (C and D) and Ad MSCs (E and F) 
were injected into the air pouches of mice. One Way ANOVA with Tukey’s multiple comparisons 
was used to compare the immune cell infiltrate among PBS control, resting and stimulated MSCs. 
Statistically significant differences are marked with the appropriate number of asterisks in Table 
5-3.  
 
Table 5-3. Statistical analysis of the immune infiltration produced by PBS, resting and 
licensed MSCs into the membrane of the air pouch of C57BL/6 female mice. 
Following the experimental set up explained in Figure 5-7, One Way ANOVA with Tukey’s multiple 
comparisons was used to compare the immune cell infiltrate among PBS control, resting and 
stimulated MSCs. Statistically significant differences are marked with the appropriate number of 
asterisks. p = 0.05 was considered the limit for statistical significance; * p < 0.05; ** p < 0.01; *** p 
< 0.001; **** p < 0.0001. 
  
Immune cell 
PBS Control vs  
Resting MSCs 
PBS Control vs 
Stimulated MSCs 
Resting MSCs vs 
Stimulated MSCs 
B
M
 M
S
C
s
 
CD45+ ns * * 
F4/80+ Macrophages ns ns ns 
Ly6g+ Neutrophils ns ns ns 
CD11c+ Myeloid cells ns ns ns 
Ly6c+ Monocytes ns *** ns 
SiglecF+ Eosinophils ns ns ns 
NK1.1+ NK cells ns *** ** 
CD4+ T cells ns ns ns 
CD8+ T cells ns ns ns 
B220+ B cells ns * ns 
Is
 M
S
C
s
 
CD45+ ns ns ns 
F4/80+ Macrophages ns ns ns 
Ly6g+ Neutrophils ns *** *** 
CD11c+ Myeloid cells ns ns ns 
Ly6c+ Monocytes ns ns * 
SiglecF+ Eosinophils ns ns ns 
NK1.1+ NK cells ns **** ** 
CD4+ T cells ns * ns 
CD8+ T cells ns **** * 
B220+ B cells ns **** ** 
A
d
 M
S
C
s
 
CD45+ ns ns ns 
F4/80+ Macrophages ns ns ns 
Ly6g+ Neutrophils ns ns ns 
CD11c+ Myeloid cells ns ns ns 
Ly6c+ Monocytes ns ns * 
SiglecF+ Eosinophils ns ns ns 
NK1.1+ NK cells ns ns * 
CD4+ T cells ns ns ns 
CD8+ T cells ns ns ns 
B220+ B cells ns ns ns 
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It is important to examine if MSCs from different sources not only recruited 
different types of immune cells, but also recruited them in statistically 
significant different amounts. For this reason, for an easier comparison of the 
immune cell recruitment produced by each source of MSCs, fold changes in the 
recruitment of immune cells by resting and stimulated BM, Is and Ad MSCs is 
represented in Figure 5-8 and the significant differences in the recruitment by 
these cells is detailed in Table 5-4. 
 
 
Figure 5-8. Comparison of the immune attraction profile among MSCs from different 
sources under resting and stimulated conditions in the air pouch membrane.  
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Following the experimental set up explained in Figure 5-7, PBS control mice were used as a control 
to normalise all the data and the infiltration of immune cells in the air pouches (A and B) was 
compared among MSCs from different sources. One Way ANOVA with Tukey’s multiple 
comparisons was used to compare the immune cell infiltrate originated by resting and stimulated 
MSCs from the different sources. Statistically significant differences are marked with the 
appropriate number of asterisks in Table 5-4. 
 
Table 5-4. Statistical analysis of the immunoreactivity of resting and stimulated BM, Is and 
Ad MSCs into the air pouches and air pouch membranes of C57BL/6 female mice. 
Following the experimental set up explained in Figure 5-8, One Way ANOVA with Tukey’s multiple 
comparisons was used to compare the immune cell infiltrate among resting and stimulated BM, Is 
and Ad MSCs. Significant differences are marked with the appropriate number of asterisks. p = 
0.05 was considered the limit for statistical significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p 
< 0.0001. 
Tissue Immune cell 
Stim. BM MSCs 
vs Stim. Is MSCs 
Stim. BM MSCs 
vs Stim. Ad 
MSCs 
Stim. Is MSCs vs 
Stim. Ad MSCs 
MEMBRANE 
CD45+ ns ns ns 
F4/80+ Macrophages ns ns ns 
Ly6g+ Neutrophils ns ns ns 
CD11c+ Myeloid cells * * ns 
Ly6c+ Monocytes *** ** ns 
SiglecF+ Eosinophils ns ns ns 
NK1.1+ NK cells * * **** 
CD4+ T cells ns ns ns 
CD8+ T cells *** ns **** 
B220+ B cells ns ns *** 
+++ No statistically significant differences were found among BM, Is and Ad resting MSCs. 
 
5.5 Distribution of MSCs within the air pouch 
To determine the fate of the MSCs injected into the air pouch, an MSC marker 
was included into the antibody cocktail for easy and quantifiable detection of 
MSCs. As shown in Chapter 3, BM, Is and Ad MSCs all express very high levels of 
CD73, therefore, an anti-CD73 antibody was included into the flow cytometry 
panel, which in combination with the CD45- expression of MSCs provided an easy 
strategy to identify MSCs (Figure 5-9).  
Firstly, the CD45 negative population was gated in both the air pouches (Figure 
5-9, A) and membranes of mice (B). CD45 negative cells were then assessed for 
their CD73 expression in both the air pouch (D) and the membrane (F). CD73 
FMOs were used for the identification of CD73 positive expression (C and E). 
MSCs were not found in the air pouches or membranes of the mice. To rule out 
the possibility of the cells being dead, the dead cell gate was removed and both 
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the air pouches (G) and the membranes (H) were assessed for the presence of 
CD73 positive cells. Live or dead CD73+ cells were not detected in the air 
pouches or membrane of mice. 
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Figure 5-9. Assessment of the CD45 negative infiltration into the air pouches and 
membranes of C57BL/6 female mice. 
Air pouches were created on the dorsal of 8-week C57BL/6 female mice as explained in Section 
2.4.2.1. The sixth day mice received an injection of either 1x106 resting or stimulated MSCs in 1 mL 
of sterile PBS or sterile PBS alone and mice were sacrificed, and tissues were harvested 24 hours 
later. Flow cytometry was used to assess de presence of CD73 positive cells. First, CD45 negative 
population was gated in the air pouches (A) and membranes (B) of mice. CD45 negative cells were 
then assessed for their CD73 expression in both the air pouch (D) and the membrane (F). CD73 
FMOs were used for the identification of CD73 positive expression (C and E). Dead cell gate was 
removed and both the air pouches (G) and the membranes (H) were assessed for the presence of 
CD73 positive cells.  
 
5.6 Assessment and validation of the immune-reactivity 
of the Cell-Tracker Green CMFDA 
Necrotic and apoptotic cell death involves the disruption of the plasma 
membrane, which could explain the lack of detection of the CD73 protein on the 
surface of cells. In addition, MSCs could have undergone an engulfment process 
by the recruited phagocytic cells and therefore the anti-CD73 would not be able 
to interact with the CD73 surface protein. For these reasons, due to the lack of 
detection of CD73 positive cells within the air pouches and membranes of 
C57BL/6 female mice, we decided to use a cell tracker to determine the fate of 
the injected MSCs.  
CellTracker™ Green CMFDA (5-chloromethylfluorescein diacetate) is a 
fluorescent dye that passes through the cell membrane, where it remains as cell 
membrane-impermeant reaction products. It is retained in living cells and it is 
transferred to daughter cells, but not to close cells in a population, which would 
therefore enable the detection of the cell tracker if the cell has divided or 
differentiated. Despite its low toxicity, it was essential to determine that the 
cell tracker would not affect the immune-reactivity of the MSCs stained with it 
(Figure 5-10). Staining of resting MSCs with the cell tracker lead to no variation 
in the immune cell attraction profile of MSCs as no statistically significant 
differences were found in the number of cells found in the air pouches (Figure 
5-10, A) and membranes (B) of mice injected with the Green CMFDA stained 
MSCs compared to the control unstained MSCs. Similarly, the staining of 
stimulated MSCs with the cell tracker produced no variation in the immune cell 
attraction profile of MSCs, proved by the lack of statistically significant 
differences between the number of cells found in the air pouches (C) and 
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membranes (D) of mice injected with the Green CMFDA stained stimulated MSCs 
compared to the control unstained stimulated MSCs.  
 
 
235 
 
 
Figure 5-10. Staining with the Cell-tracker Green CMFDA did not produce a variation on the 
immune attraction profile of MSCs injected into C57BL/6 female mice. 
Air pouches were created on the dorsal of 8-week C57BL/6 female mice as explained in Section 
2.4.2.1. The sixth day mice received an injection of either resting or stimulated MSCs in 1 mL of 
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sterile PBS or resting or stimulated MSCs pre-stained with the Cell-tracker Green CMFDA in 1 mL 
of sterile PBS. Mice were sacrificed and tissues were harvested 24 hours later. Flow cytometry was 
used to assess the immune cell infiltration into the air pouches of mice, and it is expressed as 
number of cells per mL of fluid extracted from the air pouch (A and B) or per mg of membrane (C 
and D). Each bar group represents 5 mice ± SEM. Students (unpaired) T test was used to assess 
statistical differences between mice injected with unstained and Green CMFDA-stained MSCs.  
 
Despite the previous lack of CD73 positive staining, we looked for the double 
staining of cell tracker and CD73. Once again, the CD45 negative population was 
gated out (Figure 5-11, A) and cells were gated for Green CMFDA and CD73. Cells 
from control mice injected with PBS were used as a negative control for CD73 
and Green CMFDA due to the lack of infused MSCs on those samples (B). As 
observed in Figure 5-11, C, there was a small detection of Green CMFDA stained 
cells but those cells lacked the CD73 positive staining observed in cultured MSCs 
stained with the Green CMFDA cell tracker (D).  
 
Figure 5-11. Lack of CD73 and cell tracker Green CMFDA double positive expression on the 
air pouches and membranes of the mice injected with Green CMFDA stained MSCs.  
Air pouches were created on the dorsal of 8-week C57BL/6 female mice as explained in Section 
2.4.2.1. The sixth day mice received an injection of either resting or stimulated MSCs in 1 mL of 
sterile PBS, resting or stimulated MSCs pre-stained with the Cell-tracker Green CMFDA in 1 mL of 
sterile PBS or sterile PBS alone. Mice were sacrificed, and tissues were harvested 24 hours later. 
Flow cytometry was used to assess de presence of CD73 and Green CMFDA positive cells. First, 
the CD45 negative population was gated in (A). CD45 negative cells were then assessed for their 
CD73 and Green CMFDA expression. Due to the lack of mouse MSCs on those samples, cells 
from control mice injected with PBS were used as a negative double stain for MSCs (B). Cells from 
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mice injected with Green CMFDA stained MSCs were analysed for their CD73 and Green CMFDA 
levels (C). Cultured MSCs stained with the cell tracker were used as a positive control of Green 
CMFDA and CD73 staining (D).  
 
As there was no positive signal for the MSC marker CD73, we then focused on 
searching Green CMFDA signal within the air pouch and membrane samples. 
When we removed the dead gate within the CD45 negative population we were 
able to detect Green CMFDA signal in both dead and live cells (Figure 5-12, A), 
however, as shown in Figure 5-11, these cells were not MSCs. Due to the 
presence of Green CMFDA signal within the death gate, we wanted to see if we 
could find Green CMFDA signal in immune cells, which would suggest an 
interaction between the membrane of MSCs and the immune cells. Green CMFDA 
positive signal was found in F4/80+ macrophages, NK1.1+ NK cells and CD8+ T 
cells (Figure 5-12, B).  
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Figure 5-12. Identification of Green CMFDA positive staining from the air pouches and 
membranes of mice injected with Green CMFDA stained MSCs.  
Air pouches were created on the dorsal of 8-week C57BL/6 female mice as explained in Section 
2.4.2.1. The sixth day mice received an injection of pre-stained MSCs with the Cell-tracker Green 
CMFDA in 1 mL of sterile PBS or 1 mL sterile PBS. Mice were sacrificed and tissues were 
harvested 24 hours later. Flow cytometry was used to assess the immune cell infiltration into the air 
pouches of mice. CD45 negative population was studied for its Green CMFDA levels and its 
distribution between live and dead cells was assessed (A). The expression of Green CMFDA was 
assessed in F480+ macrophages, NK1.1+ NK cells and CD8+ T cells (B). PBS injected mice were 
used as a negative control to determine the Green CMFDA positive staining.  
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5.7 Discussion and conclusions  
Using the air pouch model on C57BL/6 female mice, this chapter aimed to 
identify and examine the in vivo immune cell attraction profile of resting and 
pre-stimulated MSCs isolated from the bone marrow, Islets of Langerhans and 
adipose tissue via flow cytometry and to determine if tissue of origin influences 
the phenotype of the recruited cells.  
As previously mentioned, MSCs have been shown to recruit immune cells but the 
mechanism by which this takes place is still not understood. It is important to 
point out that there are few studies that examine the immunogenicity of MSCs in 
vivo and to my knowledge, none that compares the immune attraction profile of 
MSCs isolated from different sources in a standardised manner. In addition, many 
of those studies have been conducted with human MSCs (Thirlwell, 2018) which 
usually lack a control for mismatched major histocompatibility complex 
molecule expression. Moreover, studies that did have a control for MHC 
expression determined that infusion of MHC-mismatched MSCs into an 
inflammatory environment led to both cell-mediated and humoral immune 
responses (Eliopoulos et al., 2005, Joswig et al., 2017). All these reasons made it 
essential to use autologous MSCs to study and compare the immune reactivity of 
MSCs from different sources. Allogenic stem cell-transplant and transplantation 
itself are heavily influenced by the sex of the donor and the recipient as sex-
mismatched transplantation is linked to increased GVHD and even mortality 
(Nakasone et al., 2015, Kim et al., 2016). This is due to the mismatched minor 
histocompatibility antigens present on Y chromosome (H-Y) in males, increasing 
the rejection chances when the donor is male and the recipient is female, 
compared to female donor and male recipient (Kongtim et al., 2015). To avoid 
any kind of mismatch and study the immune attraction profile of MSCs in a highly 
controlled environment, MSCs were isolated from C57BL/6 female mice and 
infused into C57BL/6 female mice.  
The current study found that resting BM, Is and Ad MSCs produced no immune 
cell infiltration into the air pouch, as the small number of immune cells present 
on it were the result of the creation of the air pouch itself, as demonstrated by 
the sterile PBS control mice (Figure 5-4 and Figure 5-7). However, licensing of 
MSCs with 40 ng/ mL of IFN-γ, TNF-α and IL-β for 24 hours produced an 
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infiltration of CD45 positive cells, with a predominance for neutrophils, followed 
by macrophages and smaller numbers of eosinophils and monocytes regardless of 
the source of origin of the MSC. Moreover, on top of those immune cells, Is MSCs 
were also able to recruit CD8+ T cells, while Ad MSCs were able to recruit CD4+ 
and CD8+ T cells and NK cells. Due to the lack of immune infiltration after the 
infusion of the resting MSCs into the air pouch, we can say with confidence that 
immune infiltration takes place as a result of the licensing of the cells and that 
the differences in the recruitment of immune cells by the different MSCs can 
only be explained as being related to the tissue of origin of MSCs. It is important 
to point out that the air pouch model had already been used to study the 
immune attraction profile of human stimulated Is MSCs (Thirlwell, 2018, 
Thirlwell et al., 2020). These cells produced a large infiltration of CD45 positive 
cells that consisted mostly of neutrophils, followed by macrophages and smaller 
numbers of monocytes and eosinophils. The much larger infiltration towards 
human MSCs in terms of cell number is likely explained by the mismatched major 
histocompatibility complex molecule expression.  
It is important to mention that MSCs from different sources not only recruited 
different types of immune cells, but also recruited them in statistically 
significant different amounts. For this reason, the aim of this discussion will be 
focused on the mechanism by which the recruited cells could be detrimental or 
beneficial in a clinical setting and the relationship with the chemokine patterns 
described in Chapter 4. 
5.7.1 MSCs and their in vivo attraction of neutrophils  
Murine neutrophils express high levels of CXCR2 which is a receptor for several 
chemokines, mostly CXCL1 and CXCL2, but also CXCL3, CXCL5 and CXCL7, that 
lead to neutrophil recruitment and migration into target tissues (Futosi et al., 
2013, Girbl et al., 2018). BM, Is and Ad MSCs were tested for the transcription of 
CXCL1, CXCL2 and CXCL5 and CXCL1 and CXCL2 protein levels. CXCL1 and CXCL2 
were secreted at low levels under homeostatic conditions but their secretion 
was markedly upregulated upon MSC licensing in MSCs from every source, with Is 
MSCs secreting the most CXCL1 and Is and BM MSCs secreting the most CXCL2. As 
predicted by the increase of CXCL chemokine secretion, licensing of MSCs of 
every source led to a big neutrophil infiltration. Moreover, the role of human 
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CXCL8 (CXCL1 and CXCL2 in mouse) in neutrophil migration towards human MSCs 
has already been described; infusion of resting human Is MSCs produced a small 
neutrophil recruitment using the air pouch model, but this neutrophil 
recruitment was massively upregulated after stimulation of MSCs, which was 
correlated with increased secretion of CXCL8 (Joel et al., 2019, Thirlwell, 2018). 
However, despite the higher secretion of CXCL1 and CXCL2 by Is MSCs, no 
statistically significant differences were found when compared to the neutrophil 
recruitment by Is MSCs to BM and Ad MSCs (Figure 5-8 and Table 5-4). This 
finding suggests that even if CXCL1 and CXCL2 are strong neutrophil 
chemoattractants, there are other molecules involved in neutrophil migration or 
that only a low level of CXCL1 and CXCL2 is needed to induce neutrophil 
migration and once that is reached increased secretion will not further increase 
neutrophil recruitment.  
Traditionally, the recruitment of neutrophils towards MSCs within a clinical 
setting could be considered to be detrimental due to the association of 
neutrophils with inflammatory diseases such as atherosclerosis, 
glomerulonephritis or rheumatoid arthritis, as well as being a marker for acute 
injury and transplant rejection (Prame Kumar et al., 2018). Neutrophils are fast 
responders to inflammatory signals and can exert their inflammatory role in 
three different manners: phagocytosis, degranulation and the formation of 
neutrophil extracellular traps (NETs). Neutrophils not only modulate the innate 
response but also the adaptive immune response as they produce and secrete 
several inflammatory factors that enable the recruitment of alloreactive CD8+ T 
cells (Jones et al., 2010) and induce the expression of the pro-inflammatory 
cytokine IL-12 in DCs (Kreisel et al., 2011). However, in the last two decades the 
concept of neutrophil heterogeneity and plasticity has evolved, which suggests 
that once the neutrophils leave the bone marrow and infiltrate into 
inflammatory target sites, they can differentiate into discrete subsets with 
specific phenotypes and roles and can exert anti-inflammatory and pro-
angiogenic functions (Rosales, 2018).  
On the one hand, apoptosis of neutrophils is anti-inflammatory and pro-
resolution not only because it avoids the secretion of proteolytic and oxidative 
mediators, but also because of the response it produces in phagocytic cells. 
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Phagocytosis of apoptotic neutrophils reduces IL-23 production and secretion by 
macrophages, which leads to a reduction in granulopoiesis and disabling of 
neutrophil degranulation within tissues (Stark et al., 2005). Moreover, 
phagocytosis of apoptotic neutrophils also results in the production and 
secretion of the anti-inflammatory mediators prostaglandin E2, TGF-β, IL-10 and 
a novel class of lipid mediators called specialised pro-resolving mediators (Kasagi 
et al., 2014, Greenlee-Wacker, 2016, Serhan et al., 2015), which not only 
dampen the expression of inflammatory genes but also enforce tolerance 
through CD4+ T cells (Kasagi et al., 2014). Furthermore, apoptotic neutrophils do 
not need to be phagocytosed to exert their anti-inflammatory effects, contact 
with monocytes is enough to suppress the production and secretion of pro-
inflammatory cytokines and to increase the production of TGF-β and IL-10 (Byrne 
and Reen, 2002).  
Neutrophils could also inhibit graft inflammation and its subsequent rejection by 
enhancing wound and tissue repair coupled with neovascularization. Neutrophils 
generate barrier like dense clusters around necrotised tissues to prevent 
spreading and damaging of the healthy tissue surrounding it (Lammermann et 
al., 2013). Moreover, Pillay et al. described how the interaction between 
CD16bright CD62low neutrophil subset with T cells resulted in the suppression of 
proliferation (Pillay et al., 2012). In addition, Christoffersson et al. identified a 
CD11b+/ Gr-1+/ CXCR4high murine neutrophil subset that was recruited by VEGF-a 
into the site of islet engraftment that lead to the revascularization of 
transplanted islets (Christoffersson et al., 2012). As previously mentioned, this 
subset of neutrophils would be able to respond to the CXCL12 secretion by MSCs 
and they would be beneficial within a clinical setting. More importantly, this 
neutrophil subset produced matrix metallopeptidase 9 (MMP9) and the 
revascularization of transplanted islets was MMP9 dependent and CD11b+/ Gr-1+/ 
CXCR4high dependent, as MMP9 deficient mice were unable to revascularise the 
graft and the revascularization of the graft required the presence of neutrophils. 
MMP9 is most likely required for revascularization due to its role in increasing 
vascular density and blood flow (Christoffersson et al., 2010, Christoffersson et 
al., 2012).  
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Lastly, activated neutrophils are able to prevent T cell activation, and 
therefore, alloimmunity, by the release of the serine proteases cathepsin G and 
neutrophil elastase which cleave, and inactivate, the pro-inflammatory 
cytokines IL-2 and IL-6 (Bank et al., 1999).  
Taking all this into account, we can conclude that the outcome of neutrophil 
infiltration into a site of inflammation could most likely be environment 
dependent and determining if they would be beneficial or detrimental within a 
clinical setting is not possible without the appropriate disease model. However, 
it is important to consider that granulocytic myeloid derived suppressor cells 
(GMDSCs) are anti-inflammatory immune cells that share surface marker 
expression with neutrophils. In fact, there is an ongoing debate on whether they 
are a neutrophil subset or a completely distinct cell or even if all suppressive 
neutrophils subsets should be considered GMDSCs. GMDSCs are able to suppress 
effector T cell responses and their function needs to be tightly regulated as they 
can lead to the development of chronic infection and tumour progression (Zilio 
and Serafini, 2016). Therefore, GMDSCs would most likely be beneficial within a 
transplant setting.  
5.7.2 MSCs and their in vivo attraction of monocytes and 
macrophages 
Murine monocytes and macrophages express high levels of CCR2 which is the 
receptor for several chemokines including CCL2, CCL7, CCL8, CCL12 and CCL13, 
that lead to extravasation and transmigration of monocytes and migration into 
target tissues (Chu et al., 2014). BM, Is and Ad MSCs were tested for the 
transcriptional and protein levels of CCL2 and CCL7. CCL2 and CCL7 were 
secreted at low levels under homeostatic conditions but their secretion was 
markedly upregulated upon MSC licensing in MSCs from every source, with Is 
MSCs secreting the most CCL2 and CCL7. As predicted by CCL chemokine 
secretion, licensed MSCs of every source induced a monocyte and macrophage 
infiltration into the air pouches. However, despite the higher secretion of CCL2 
and CCL5 by Is MSCs, Ad MSCs produced a statistically significant higher 
monocyte and macrophage infiltration compared to BM and Is MSCs (Figure 5-8 
and Table 5-4). This finding suggests that even if CCL2 and CCL5 are strong 
monocyte and macrophage chemoattractants, there are other molecules 
244 
 
involved in monocyte and macrophage migration or that only a low level of CCL2 
and CCL5 is needed to induce monocyte and macrophage migration and once 
that amount is reached, an increased secretion will not produce an increment in 
monocyte and macrophage recruitment. 
Like neutrophils, the recruitment of monocytes and macrophages towards MSCs 
within a clinical setting could be considered as detrimental due to the well-
known association of monocytes and macrophages with inflammatory diseases 
such as systemic lupus erythematosus, systemic sclerosis and rheumatoid 
arthritis among others (Ma et al., 2019). However, within a transplant setting, 
the state of activation and macrophage phenotype may lead to a completely 
different outcome, from graft rejection due to tissue injury to tissue 
remodelling and anti-inflammatory effects. Macrophages are phagocytic immune 
cells essential in host defence and tissue homeostasis and like neutrophils, 
monocytes can differentiate into pro-inflammatory or anti-inflammatory 
macrophages depending on micro-environmental signals. Macrophages are 
classified as M1 and M2 macrophages. On the one hand, M1 macrophages are 
pro-inflammatory and are able to mediate transplant rejection by producing pro-
inflammatory cytokines, such as IL-1, IL-12, IL-18, IL-6, IL-23, TNF-α, and IFN-γ, 
reactive oxygen species and reactive nitrogen species, which all together lead to 
acute rejection (Li et al., 2019a). On the other hand, M2 macrophages, are anti-
inflammatory and are involved in tissue repair due to their roles in wound 
healing, angiogenesis, phagocytosis, fibrosis, and the resolution of inflammation 
(Li et al., 2019a). On top of this regulatory macrophages, a subset of 
macrophages that does not express most markers shared by M1 and M2 
macrophages, are able to suppress allogeneic T cells by an inducible nitric oxide 
synthase (iNOS) dependent mechanism while promoting the expansion of CD4+ 
Foxp3+ regulatory T cells, thereby enabling graft tolerance (Conde et al., 2015, 
Riquelme et al., 2013).  
However, it is important to mention that the infusion of bone marrow derived 
macrophages in a murine model of liver fibrosis led to the chemokine mediated 
recruitment of endogenous macrophages and neutrophils, which secreted MMP9 
and IL-10, leading to the apoptosis of scar producing myofibroblasts and 
therefore, to reduced fibrosis (Thomas et al., 2011). Moreover, infusion of in 
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vitro differentiated CD14+ monocytes isolated from cirrhotic patients into a 
murine liver fibrosis model led to the decrease of liver injury markers and to the 
increase of liver regeneration markers and, therefore, to reduced fibrosis (Moore 
et al., 2015).  
Macrophages seem to be essential for liver repair however, to determine the 
outcome of macrophage infiltration within a clinical setting further 
characterisation of the recruited macrophages would be essential. The 
phenotype of macrophages will most likely be environment-dependent and 
determining if they would be beneficial or detrimental within a clinical setting is 
not possible without the appropriate disease model. Thorough analysis of gene 
signatures and flow cytometry validation enable a distinction to be made 
between M1 and M2 macrophages based on CD38/ Egr2 expression. M1 
macrophages express CD38, Gpr18 and Fpr2 while Egr2 and c-Myc are exclusively 
expressed by M2 macrophages (Jablonski et al., 2015). DHRS9 has been 
established as human regulatory macrophage marker; however, DHRS9 is not 
upregulated in murine regulatory macrophages and therefore, can’t be used to 
exclude other monocyte–derived cells (Riquelme et al., 2017).  
5.7.3 MSCs and their in vivo attraction of eosinophils 
Murine eosinophils express high levels of CCR3, which is the receptor for CCL2, 
CCL3, CCL4, CCL5, CCL11, CCL13, CCL14 and CCL16, that leads to migration into 
target tissues and degranulation (Chu et al., 2014, Nagase et al., 2001). BM, Is 
and Ad MSCs were tested for their transcription of CCL3, CCL4, CCL5 and CCL11 
and protein levels of CCL2, CCL5 and CCL7. CCL2, CCL5 and CCL7 were secreted 
at low levels under homeostatic conditions. MSC licensing increased the 
production and secretion of the three CCLs but produced the largest 
upregulation in CCL2 in MSCs from the three sources. As predicted by the 
increase of CCL chemokine secretion, licensing of MSCs of every source led to a 
small upregulation of eosinophil infiltration. However, despite the higher 
secretion of CCL2, CCL5 and CCL7 by Is MSCs, Ad MSCs produced a statistically 
significant increased eosinophil infiltration compared to BM and Is MSCs (Figure 
5-8 and Table 5-4), suggesting that even if CCL2, CCL5 and CCL7 are eosinophil 
chemoattractants, there are other factors involved in their migration.  
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The recruitment of eosinophils towards MSCs within a clinical setting could be 
considered as potentially detrimental due to their roles in allergic reactions. 
Eosinophils are involved in the secretion of pro-inflammatory molecules such as 
major basic protein (MBP), MBP2, eosinophil cationic protein (ECP), eosinophil 
peroxidase (EPO), and β-glucuronidase. Moreover, they are also able to secrete 
cytokines (IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, IL-16 and IL-18) and chemokines 
(CCL3, CCL5 and CL11), leading to the upregulation of the vascular adhesion 
system as well as to the increase of vascular permeability, enabling the 
recruitment of immune cells (Kita, 2011).  
Eosinophilic infiltrates are a specific marker of rejection in liver allografts after 
discovering that successful treatment of acute rejection was correlated with a 
decrease on the number of infiltrated eosinophils (Nagral et al., 1998). In renal 
allografts eosinophilia is also a marker of graft damage and poor graft prognosis 
(Vanikar et al., 2017). However, Goldman et al. showed that the disappearance 
of the eosinophilic infiltrate did not stop the rejection of pig pancreatic islets in 
mice, suggesting that eosinophils could be bystanders in transplant rejection 
(Goldman et al., 2001). Although eosinophils can be found in the blood of 
patients transplanted with haematopoietic stem cells (Cromvik et al., 2014), 
eosinophilia after stem cell transplantation has been suggested to be a marker 
for a favourable outcome as the survival rate of patients with haematological 
disorders treated with stem cell transplantation was higher in those with 
eosinophilia compared to those without it (88.7 vs 43.0%) (Sato et al., 2005a). 
For these reasons, we hypothesised that eosinophilic infiltration produced by 
MSCs could be beneficial in a clinical setting, but an appropriate transplant 
model would be required to confirm this.  
5.7.4 MSCs and their in vivo attraction of DCs  
As previously described, CD11b and CD11c are co-expressed in myeloid-lineage 
DCs but these markers can be upregulated on activated cells irrespective of their 
naïve expression status. For this reason, despite the identification of a CD11b 
high CD11c+ population the subset was not identified as DCs due to the lack of 
CD24 or other DC markers in the panel that would enable the exclusion of 
activated cells. However, we know that the CD11b high CD11c+ myeloid contains, 
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among others, DCs and for this reason the role of DCs within a clinical setting is 
included in this discussion.  
Immature murine DCs express high levels of CCR1, CCR2, CCR5, and CCR6, as 
well as CXCR3 and CXCR4; however, upon inflammatory stimulation they 
downregulate these receptors except for CXCR4 and CCR7, which are 
upregulated. CXCR4 interacts with CXCL12, while CCR7 interacts with CCL19 and 
CCL21 (Ricart et al., 2011). BM, Is and Ad MSCs were tested for transcription of 
CCL19 and CXCL12 and CXCL12 protein levels. CXCL12 was secreted at medium 
levels in BM and Is MSCs and at low levels in Ad MSCs under homeostatic 
conditions but its secretion was downregulated upon MSC licensing in MSCs from 
every source, with BM MSCs secreting the most CXCL12. Despite the decrease of 
CXCL12 secretion, licensing of MSCs from every source led to an increase in 
CD11b high CD11c+ myeloid cells infiltration. However, despite the higher 
secretion of CXCL12 by BM MSCs, Ad MSCs recruited more CD11b high CD11c+ 
myeloid cells upon stimulation (Figure 5-8 and Table 5-4); suggesting that even if 
CXCL12 is a strong CD11b high CD11c+ myeloid cell chemoattractant, there are 
other molecules involved in their migration.  
The recruitment of DCs towards MSCs in a clinical setting could be considered 
detrimental due to their role linking the innate and adaptive immune responses. 
Dendritic cells are mononuclear professional phagocytes that, unlike neutrophils 
and macrophages, do not digest the phagocytosed material but process it into 
peptide fragments and present self and nonself antigens to CD4+ and CD8+ T cells 
using MHC Class I and MHC Class II molecules respectively. In this way, DCs can 
activate the adaptive immune response; therefore, they connect the innate and 
the adaptive immune responses (Steinman, 2006). However, different DC subsets 
enable the balance between tolerance in the steady state and the induction of 
innate and adaptive immunity. DCs can initiate GVHD by activation of recipient T 
cells, for this reason removal of recipients DCs reduces the presence of effector 
T cells in the graft; thus, subsequently reducing rejection in solid organ 
transplantation (Zhuang et al., 2016). However, DCs are radioresistant, 
therefore they survive to the irradiation that precedes stem cell transplantation 
and can initiate GVHD by activation of recipient T cells (Duffner et al., 2004).  
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The absence of functional DCs lead to survival of iPSCs transplanted under the 
kidney capsule in a syngeneic C57BL/6 mouse stem cell transplantation model, 
whilst when iPSCs were co-transplanted with mature DCs immune rejection took 
place (Todorova et al., 2016). Moreover, prevention of DC migration towards the 
lymph nodes, inhibition of the maturation of DCs and downregulation of co-
stimulatory molecules required for T cell activation, has been shown to alleviate 
GVHD. However, semi-mature DCs are able to decrease the CD4+ T cell 
infiltration, prolonging survival of transplanted cells; and tolerogenic DCs induce 
regulatory T cells, promoting immune tolerance (Zhang et al., 2017). Taking all 
this into account, we cannot conclude that DC migration towards MSCs would be 
beneficial or detrimental within a clinical setting.  
5.7.5 MSCs and their in vivo attraction of T cells 
T cells express most of the CC and CXC chemokine receptors at different levels 
according to their state of differentiation, as an example, T cells can express 
high levels of CCR4, CCR5, CCR7, CCR9 and CCR10, as well as CXCR3 and CXCR4 
and respond to CCL5, CCL17, CCL19, CCL21, CCL25, CCL27, CCL28 and CXCL9, 
CXCL10 and CXCL12, which shows the complex regulation of T cell migration 
(Nolz et al., 2011). BM, Is and Ad MSCs were tested for transcription of CCL5, 
CCL19, CXCL10 and CXCL12 and CCL5, CXCL10 and CXCL12 protein levels. CCL5 
and CXCL12 were secreted at medium levels under homeostatic conditions, while 
CXCL10 was secreted at lower levels. However, their secretion was upregulated 
upon MSC licensing in MSCs from every source, with BM MSCs secreting the most 
CCL5 and CXCL12 and Is MSCs secreting the most CXCL10. This increase in the 
secretion of CCL5, CXCL10 and CXCL12 was associated with increased T cell 
migration towards MSCs from all sources. However, despite the higher secretion 
of CCL5 and CXCL12 by BM MSCs and CXCL10 by Is MSCs, Ad MSCs recruited the 
most CD8+ and CD4+ T cells upon stimulation, followed by Is MSCs, while BM MSCs 
did not produce a CD8+ and CD4+ T cell infiltration (Figure 5-8 and Table 5-4).  
The recruitment of CD4+ and CD8+ T cells towards MSCs within a clinical setting 
could be considered detrimental due to the role of CD4+ T cells in activation and 
proliferation of CD8+ T cells, which have cytotoxic and inflammatory functions.  
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As previously mentioned, T cell mediated graft rejection starts with the 
recognition and presentation of antigens by DCs, leading to the stimulation of T 
cells and to the subsequent secretion of cytotoxic molecules, such as perforin 
and granzyme-B by CD8+ T cells, as well as pro-inflammatory cytokines, such as 
IFN-γ and IL–2 by CD4+ and CD8+ T cells to induce an increased immune response. 
Th1 cells produce IL-2, promoting the proliferation of cytotoxic CD8+ T cells and 
CD8+ T cells secrete IFN-γ, acting as positive feedback as it promotes Th1 
responses. Bishop et al. found high number of CD8+ T cells within the rejected 
grafts in a murine cardiac allograft model. However, depletion of CD8+ T cells 
did not resolve rejection as it led to Th1 and Th2 mediated rejection, proving 
that both CD4+ and CD8+ T cells are involved in graft rejection (Chan et al., 
1995). In addition, memory CD8+ T cells need to be depleted to be able to 
induce tolerance towards the graft. On the contrary, CD8+ regulatory T cell 
populations are able to suppress the function of effector CD8+ T cells promoting 
tolerance and avoiding graft rejection in a rat liver transplantation model (Liu et 
al., 2007). CD4+ regulatory T cells secrete IL-9, which recruits mast cells 
mediating immune tolerance in a skin graft model (Lu et al., 2006). Moreover, 
the presence of CD8+ T cells in a BM graft promoted engraftment of the 
haematopoietic and progenitor cells via a poorly understood mechanism, as CD8+ 
T cells also increased the risk for acute and chronic GVHD (Martin et al., 1999). 
Anyhow, recipient cytotoxic cells are essential to initiate MSC-mediated 
immunosuppression in a murine model of GVHD as MSCs need to be targeted by 
cytotoxic T cells to undergo apoptosis to be engulfed by macrophages and 
produce indoleamine 2,3-dioxygenase (IDO) (Galleu et al., 2017). For this 
reason, we conclude that T cell migration towards MSCs may be beneficial within 
a clinical setting. 
5.7.6 MSCs and their in vivo attraction of NK cells  
NK cells express CXCR1, CXCR3, CXCR4 and different NK cell subsets also express 
CCR1, CCR4, CCR5, CCR6, CCR9, CXCR5 and CXCR6; for this reason NK cells are 
able to interact with a wide range of chemokines including CCL2, CCL5, CCL7, 
CCL19, CCL21 and CXCL10, CXCL11 and CXCL12 among others (Berahovich et al., 
2006). BM, Is and Ad MSCs were tested for transcription of CCL5, CCL19, CXCL10 
and CXCL12 and CCL5, CXCL10 and CXCL12 protein levels. CCL5 and CXCL12 were 
secreted at medium levels under homeostatic conditions, while CXCL10 was 
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secreted at lower levels. However, their secretion was upregulated upon MSC 
licensing in MSCs from every source, with BM MSCs secreting the most CCL5 and 
CXCL12 and Is MSCs secreting the most CXCL10. This increase in the secretion of 
CCL5, CXCL10 and CXCL12 led to an increase of NK cell infiltration by MSCs from 
all sources. However, despite the higher secretion of CCL5 and CXCL12 by BM 
MSCs and CXCL10 by Is MSCs, Ad MSCs recruited the most NK cells upon 
stimulation, followed by Is MSCs, while BM MSCs did not produce a NK cell 
infiltration (Figure 5-8 and Table 5-4).  
NK cells interact with MHC Class I molecules and promote self-tolerance when a 
self-antigen is recognised; however, recognition of nonself-antigen leads to 
activation of NK cells and subsequent cytotoxicity due to the secretion of 
cytoplasmic granules containing perforins and granzymes (Warren and Smyth, 
1999). For this reason, the recruitment of NK cells towards MSCs within a clinical 
setting could be considered detrimental. NK cell infiltration is considered 
detrimental in kidney and lung transplants due to the production of granzyme A 
and B along with IFN-γ, leading to cytotoxic T cell recruitment and GVHD 
(Tötterman et al., 1989). However, not only the NK cells from the recipient 
itself can lead to graft rejection, but also the NK cells within the graft as they 
could recognise the recipient as nonself, leading to graft rejection. To support 
this, Espinoza et al. showed that NK cell response was ameliorated in recipients 
in which the graft was HLA matching (Peraldi et al., 2015). On the other side, NK 
cells are associated with better prognosis in patients with haematological 
malignancies that have received stem cell transplantation as they promote graft 
versus leukaemia instead of GVHD (Cooley et al., 2018).  
Despite its cytotoxic effector functions, NK cells are also able to secrete 
cytokines that can modulate the immune response. As an example, a subset of 
IL-10 secreting NK cells has been described to suppress T cell proliferation and 
secretion of IFN-γ and other pro-inflammatory cytokines in vitro (Deniz et al., 
2008). Moreover, there is growing evidence suggesting that NK cells can interact 
with myeloid cells and lymphocytes supressing alloimmunity and promoting 
tolerance. NK cells can interact and promote perforin mediated death of donor 
allogeneic DCs in the lymph nodes; therefore, avoiding the activation of T cells 
and promoting skin graft survival (Laffont et al., 2008). In addition, Beilke et al. 
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showed that perforins secreted by NK cells are essential for islet allograft 
tolerance as perforin competent NK cells were able to restore graft tolerance in 
perforin-recipient recipients (Beilke et al., 2005). Taking all this into account, 
we cannot conclude whether NK cell migration towards MSCs would be beneficial 
or detrimental within a clinical setting. 
5.7.7 Conclusions 
To summarise and conclude, this chapter aimed to determine the in vivo 
immune cell attraction profile of resting and licensed BM, Is and Ad MSCs to 
determine the effect of the differential chemokine secretion on the 
immunoreactivity of MSCs. Under resting conditions MSCs did not produce many 
chemokines which predicted, if any, a small infiltrate of leukocytes, while MSC 
licensing led to the production of large quantities of CCL2, CCL5, CXCL1 and 
CXCL10, which predicted the migration of large amounts of monocytes/ 
macrophages and neutrophils. Despite Is MSCs secreting the most chemokines, 
Ad MSCs produced the biggest infiltrate, suggesting that there are more 
elements involved in the immune attraction profile of MSCs. As an example, 
MSCs could induce a secondary response in the surrounding tissues resulting in 
chemokine production. MSCs were not only able to recruit large numbers of 
neutrophils and macrophages, but also eosinophils, monocytes and DCs and in 
some cases, CD4+ and CD8+ T cells and NK cells. These cells have been shown to 
have a dual role promoting inflammation but also graft tolerance, which makes 
difficult to determine whether immune cell migration towards MSCs would be 
detrimental or beneficial in a clinical setting.  
It is important to bear in mind that MSCs are well known for their 
immunomodulatory properties, which suggests that MSCs could recruit these 
leukocytes and use their immunomodulatory properties to exert an anti-
inflammatory phenotype. Secretion of IDO, iNOS in mouse, PGE2 and tumour 
necrosis factor-inducible gene 6 (TSG-6), by IFN-γ mediated licensed MSCs, 
promoted the switch of monocytes and macrophages towards an anti-
inflammatory phenotype (Choi et al., 2011, Chiossone et al., 2016, Németh et 
al., 2009) and IDO has also been shown to restrain the proliferation, IFN-γ 
secretion and cytotoxic activity of NK cells (Spaggiari et al., 2008). Licensing of 
MSCs with TNF-α has been described to induce cyclooxygenase 2 (COX2), which is 
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essential for the synthesis of PGE2 and promotes M2 macrophage polarization as 
COX2 inhibition promotes the M1 phenotype (Francois et al., 2012). MSCs are 
also able to supress the immune response by regulating DCs. Co-culture of MSCs 
and DCs promotes the secretion of the anti-inflammatory cytokine IL-10 by DCs 
while decreasing the production of TNF-α by these cells (Aggarwal and Pittenger, 
2005). Moreover, MSCs suppress maturation and the antigen presentation 
potential of DCs, reducing CD4+ T cell proliferation (Aggarwal and Pittenger, 
2005). Regarding their role in neutrophils, MSCs enhance their migration and 
phagocytosis potential while suppressing the production of nitric oxide and 
hydrogen peroxide by active neutrophils, thereby diminishing their inflammatory 
potential and neutrophil extracellular trap formation (Joel et al., 2019, Jiang et 
al., 2016). 
Another important aspect relates to the absence of detection of MSCs after 
administration into the air pouch. Inability to detect MSCs after administration 
has already been described and understanding the fate of these cells is essential 
to assess their immunoregulatory potential (Thirlwell, 2018, Galleu et al., 2017). 
Uptake of the Green CMFDA cell-tracker by macrophages, NK cells and CD8+ T 
cells suggests an uptake of MSCs. MSCs have been described to not only alter the 
activation of immune cells via active mechanisms such as the secretion of 
molecules, but also by passive mechanisms. A murine model of GVHD 
demonstrated that recipient’s cytotoxic cells must target MSCs promoting their 
perforin-dependent apoptosis in order to initiate immunosuppression. This 
hypothesis was confirmed when it was shown that after MSC infusion, only 
patients that had high toxicity responded to the treatment (Galleu et al., 2017). 
Phagocytosis of MSCs by macrophages increases the production of IL-10 and IDO 
while decreasing the production of IL-6 (Braza et al., 2016). Phinney et al. also 
showed that MSCs undergo mitophagy, which is the degradation of mitochondria 
by autophagy, enabling the macrophages to engulf the mitochondria and the 
secretion of exosomes containing miRNA that activate NF-κB signalling pathway 
increasing the production of IL-1β, PGE2, TNF-α and IL-10 by macrophages 
(Phinney et al., 2015).  
 
Taking all this into account, we have shown the ability of licensed MSCs to 
induce leukocyte migration and we have observed interactions between MSCs, 
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cytotoxic cells and macrophages, which may explain the rapid clearance of 
infused MSCs within the air pouch. However, we have not been able to explain 
the mechanism by which the MSCs could benefit from the leukocyte recruitment. 
For this reason, determining the secretion of immunomodulatory mediators 
potentially involved in this process by MSCs would provide a better 
understanding of their role in a clinical setting. 
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6 Profiling of MSC toll-like receptors, complement 
system and other immunoregulatory and anti-
inflammatory molecules expression at transcript 
and protein level 
6.1 Introduction and aims 
In Chapter 5, we demonstrated that licensing of BM, Is and Ad MSC with 40 ng/ 
mL of TNF-α, IL-1β and IFN-ϒ lead to the recruitment of not only neutrophils and 
macrophages, but also eosinophils, monocytes and DCs and in some cases CD4+ 
and CD8+ T cells and NK cells in vivo. These immune cells have been shown to 
have a dual role promoting inflammation but also graft tolerance, which makes 
it difficult to determine whether MSC-mediated immune cell infiltration would 
be detrimental or beneficial in a clinical setting. But MSCs are well described for 
their tissue repairing and immunomodulatory properties. As an example, in the 
presence of IFN-γ and inflammatory cytokines such as TNF-α, IL-1α or IL-1β, 
MSCs have been shown to increase the expression of adhesion molecules and the 
secretion of chemokines and nitric oxide (NO), producing an immune cell 
infiltrate and enhancing their immunosuppressive activity (Ren et al., 2010, Ren 
et al., 2008). However, low NO production by MSCs leads to enhanced immune 
responses by the recruited immune cells promoting inflammation. For this 
reason, it has been proposed that the immunomodulatory properties of MSCs 
might depend on the level of inflammation surrounding them as well as their 
tissue of origin (Li et al., 2012).  
Toll-like receptors (TLRs) are essential in the regulation of the cross talk 
between the innate and adaptive immune response; TLRs can recognise damage-
associated molecular pattern molecules (DAMPs) leading to the expression of 
pro-inflammatory genes involved in the innate immune response and at the same 
time, TLRs promote the secretion of cytokines involved in the recruitment and 
maturation of the adaptive immune response. TLRs are expressed on progenitor 
cells and they have been described to be involved in proliferation, 
differentiation, self-renewal and immunomodulation (Sallustio et al., 2019). TLR 
signalling by MSCs has been described to promote the production of both pro- 
and anti-inflammatory cytokines by MSCs and TLR expression and the subsequent 
immune response appear to have a strong association with tissue of origin of the 
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MSCs. The expression of TLR3 and TLR4 has been associated with the 
immunosuppressive properties of human BM MSCs by suppressing T cell 
proliferation (Opitz et al., 2009), while other studies show that expression of 
these TLRs decrease the ability to suppress T cell proliferation (Liotta et al., 
2008). TLR4 expression has been linked with the secretion of the pro-
inflammatory mediators IL-6 and CXCL8, while TLR3 expression has been 
associated with the secretion of the anti-inflammatory molecules IL-4, IDO and 
PGE2 by human MSCs (Shirjang et al., 2017).  
The complement system is a component of the innate immune system and it is 
involved in the amplification of the immune system through synergy in 
collaboration with TLRs. Interaction of MSCs with the complement system has 
been described but it is not fully understood. Infusion of MSCs leads to 
complement activation after their contact with serum (Li and Lin, 2012), but at 
the same time, licensing of MSCs with TNF-α and IFN–γ leads to the secretion of 
complement factor H, which inhibits the activation of the complement system 
and its subsequent inflammation (Tu et al., 2010a). Moreover, BM MSCs can 
secrete C3 protein, inhibiting immunoglobulin production by B cells (Lee et al., 
2014).  
The overall aim of this thesis was to gain understanding of the in vivo behaviour 
of MSCs by studying which immune cells MSCs attract and to gain understanding 
of the anti-inflammatory and immunomodulatory effects of MSCs on recruited 
immune cells. Thus, the expression of TLRs, the complement system and several 
immunomodulatory and anti-inflammatory genes were assessed at a 
transcriptional level, including IL-6, IL-10, TSG-6, iNOS, COX2, hepatocyte 
growth factor (HGF), MMP9 and granulocyte-macrophage colony-stimulating 
factor (GMCSF) among others. All in all, the aims of this chapter were to i) 
characterise the transcriptional levels of TLRs, complement system and other 
relevant immunomodulatory molecules in murine MSCs, ii) identify the effect of 
MSC tissue source of origin on the expression of these molecules and iii) study 
how MSC licensing alters the expression of these molecules.  
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Results 
Throughout this results section, the transcription and expression profile of toll-
like receptors, complement system and other immunoregulatory and anti-
inflammatory molecules are described in detail in each section under resting and 
inflammatory conditions. Transcriptional profiling enabled the identification of 
the molecules that had undergone the most significant variations at 
transcriptional level upon stimulation. The secretion profile of those molecules 
by MSCs from the three sources was then analysed under resting and stimulatory 
conditions. 
6.2 Analysis of the effect of a single inflammatory 
stimulus on the transcription of toll-like receptors, 
complement system and other immunoregulatory and 
anti-inflammatory molecules  
To understand the mechanisms involved in MSC-mediated immunomodulation 
and tissue repair, it was important to study the expression of the TLRs, the 
complement system and other immunomodulatory genes by MSCs. To do this, 
TLRs, the complement system and a selection of the most studied 
immunomodulatory molecules were chosen, and their transcript analysis was 
carried out. BM, Is and Ad MSCs were transcriptionally assessed under resting and 
inflammatory conditions (40 ng/mL of TNF-α, IL-1β and IFN-ϒ), to determine the 
effect of tissue source and/or inflammatory conditions in the transcriptional 
profile of these molecules my MSCs.  
As explained in Chapter 4, transcriptional data were normalised to the house 
keeping gene beta-2 microglobulin (B2M) to control for variations in RNA quality 
and quantity. As this study did not have a reference sample, data were 
represented as 2(-ΔCT), which enables the visualization of expression levels of 
specific genes normalised to B2M for each sample. Due to the nature of 
normalisation, genes that generated a CT of 35 or above resulted in 2(-ΔCT) less 
than, or equivalent to ~0.0001. Genes with 2(-ΔCT) values similar to ~0.0001 are 
marked with a red box on the following graphs and are likely not transcribed at 
meaningful levels by MSCs (Thirlwell, 2018).  
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6.2.1 Transcription of toll-like receptors under homeostatic and 
inflammatory conditions  
Under resting conditions, BM, Is and Ad MSCs transcribed very few, if any, TLRs 
(Figure 6-1). No clear pattern of transcriptional regulation was observed upon 
MSC licensing and the outcome of licensing was not affected by tissue of origin 
of MSCs. The expression of TLR1 (A), TLR4 (D), TLR6 (F) and TRL7 (G) was 
downregulated after 24-hour cytokine-mediated stimulation in MSCs isolated 
from all sources, TLR2 (B) expression was upregulated in BM, Is and Ad MSCs 
after 24–hour cytokine-mediated stimulation, while cytokine-mediated 
stimulation produced no effect on the expression of TLR3 (C), TLR5 (E), TLR8 
(H), TLR9 (I), TLR11 (J), TLR12 (K) and TLR13. Fold transcript changes upon 
cytokine-mediated licensing of MSCs are detailed in Table 6-1.  
BM MSCs expressed the highest levels of TLR1 (A) under resting conditions and 
inflammatory stimulation resulted in TLR1 downregulation in MSCs from every 
source, with BM and Ad MSCs showing the biggest fold change. BM MSCs 
expressed the highest levels of TLR2 (B) under resting and stimulatory 
conditions; TLR2 was the only TLR that was downregulated after cytokine-
mediated licensing in MSCs from the three sources. BM MSCs expressed the 
highest levels of TLR3 (C), TLR5 (E) and TLR12 (K) under resting conditions and 
inflammatory stimulation did not significantly alter the expression of these 
receptors. BM MSCs expressed the highest levels of TLR4 (D) and TLR6 (F) under 
resting conditions and inflammatory stimulation resulted in reduction of these 
transcript levels in MSCs from every source, with BM MSCs showing the biggest 
fold change. Is MSCs expressed the highest levels of TLR7 (G) under resting 
conditions and inflammatory stimulation resulted in downregulation in MSCs 
from every source, but this downregulation was statistically significant only in Is 
MSCs. TLR8 (H), TLR9 (I), TLR11 (J) and TLR13 (L) were expressed at very low 
levels by MSCs from all sources and 24-hour cytokine-mediated stimulation 
produced no alteration in the expression of these TLRs.  
 
259 
 
 
Figure 6-1. Inflammation and MSC tissue origin impacts TLR transcript levels in MSCs. 
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MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with a cocktail of cytokines, 40 ng/ mL of IFN-ϒ, 
TNF-α and IL-1β, for 24 hours. Unstimulated cells were left growing in MSC culture medium as a 
control. Quantitative reverse transcription PCR (qRT-PCR) was performed to evaluate TLR 
transcripts in BM, Is and Ad MSCs under homeostatic and inflammatory conditions. Each bar 
represents an n of 3 independent experiments and is graphed as mean ± SEM. Data are 
normalised to the housekeeping gene B2M and expressed as 2(-ΔCT). Appropriate statistical 
analysis was performed and includes Students paired T test between one MSC tissue source 
(Resting vs Inflammatory Conditions) and One Way ANOVA with Tukey’s multiple comparisons 
post-test to compare all MSC sources. Statistically significant differences are marked with the 
appropriate number of asterisks. p = 0.05 was considered the limit for statistical significance; * p < 
0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
Table 6-1. Fold change in TLR transcript levels of cytokine-mediated licensed BM, Is and Ad 
MSCs compared to unstimulated cells from the same source.  
Following the experimental set up explained in Figure 6-1, fold change in transcript levels of TLR is 
represented as mean of fold change ± standard deviation. Statistically significant differences are 
marked with a colour code, where p < 0.05 is represented by green, p < 0.01 is represented by 
orange, p < 0.001 is represented by blue and p < 0.0001 is represented by red. 
Gene BM MSCs Is MSCs Ad MSCs 
TLR1 0.09 ± 0.02 0.44 ± 0.16 0.01 ± 0.00 
TLR2 4.10 ± 0.66 3.28 ± 0.44 1.14 ± 0.27 
TLR3 0.43 ± 0.10 1.28 ± 0.34 2.18 ± 0.81 
TLR4 0.25 ± 0.06 0.53 ± 0.18 0.58 ± 0.16 
TLR5 0.21 ± 0.06 0.62 ± 0.38 3.20 ± 4.10 
TLR6 0.12 ± 0.03 0.35 ± 0.06 0.99 ± 0.44 
TLR7 0.21 ± 0.04 0.57 ± 0.17 0.52 ± 0.27 
TLR8 0.21 ± 0.06 0.37 ± 0.04 0.37 ± 0.50 
TLR9 0.23 ± 0.08 0.49 ± 0.36 1.04 ± 1.11 
TLR11 0.22 ± 0.08 0.44 ± 0.28 1443.42 ± 1440.99 
TLR12 0.21 ± 0.05 2.20 ± 1.39 0.23 ± 0.11 
TLR13 0.51 ± 0.55 0.22 ± 0.00 0.78 ± 0.27 
 
6.2.2 Transcription of the complement system under homeostatic 
and inflammatory conditions  
Under resting conditions, BM, Is and Ad MSCs transcribed very few, if any, 
elements of the complement system with the exception of CFH (Figure 6-2, E), 
which was transcribed at higher levels by BM MSCs, and C1Qc, which was 
expressed at higher levels by Is MSCs (Figure 6-2, M). A pattern of transcriptional 
downregulation was observed in CFD (D), CFH (E), CFI (G), CR1 (J), C5 (T) and 
C5AR1 (U) after 24-hour cytokine-mediated stimulation while cytokine-mediated 
stimulation did not produce a statistically significant effect in the expression of 
CD46 (A), CD59 (B), CFB (C), CFHR1 (F), CFP (H), CR1L (I), C1Qa (K), C1Qb (L), 
C1Qc (M), C1R (N), C1Sa (O), C2 (P), C3 (Q), C3AR1 (R), C4 (S), C6 (V), C7 (W), 
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C8a (X), C8b (Y) and C8g (Z). Fold transcript upon cytokine-mediated licensing of 
MSCs are detailed in Table 6-2.  
CD46 (Figure 6-2, A), CFB (C), CFHR1 (F), CFP (H), CR1 (J), C1Qa (K), C1Qb (L), 
C1R (N), C1Sa (O), C2 (P), C4 (S), C6 (V), C8a (X), C8b (Y) and C8g (Z) were 
expressed at very low levels by MSCs from all sources and 24-hour cytokine-
mediated stimulation produced no variation in the levels of these elements of 
the complement system. BM MSCs expressed the highest levels of CD59 (B) under 
resting and inflammatory conditions and inflammatory stimulation resulted in 
downregulation in MSCs from every source, with Is and Ad MSCs showing the 
biggest fold change. CFD and CFI were expressed at very low levels by MSCs from 
all sources but Ad MSCs expressed statistically significant higher levels of CFD (D) 
and CFI transcripts (G). BM MSCs expressed the highest levels of CFH (E) under 
resting and stimulatory conditions and inflammatory stimulation resulted in 
downregulation in MSCs from every source. BM MSCs expressed the highest levels 
of CR1L (I) under resting and inflammatory conditions and inflammatory 
stimulation resulted in downregulation in MSCs from every source. Is MSCs 
expressed the highest levels of C1Qc (M) and C5AR1 (U) under resting and 
inflammatory conditions and inflammatory stimulation resulted in 
downregulation of these transcript levels in MSCs from every source except Ad 
MSCs, where cytokine-mediated stimulation increased the expression of C1Qc. Is 
MSCs expressed the highest transcript levels of C3 (Q) under resting conditions 
but the effect of cytokine-mediated stimulation depended on the tissue of origin 
of MSCs; BM and Ad MSCs increased their C3 transcript levels after stimulation 
while Is MSCs decreased their transcript levels. Ad MSCs expressed the highest 
levels of C3AR1 (R) and C5 (T) under resting and inflammatory conditions and 
inflammatory stimulation resulted in downregulation in MSCs from every source. 
Under resting conditions C7 (W) was expressed at very low levels but BM MSCs 
expressed the highest levels; inflammatory stimulation led to a reduction of C7 
transcript levels in BM MSCs while producing an upregulation of transcript levels 
in Is and Ad MSCs.  
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Figure 6-2. Inflammation and MSC tissue origin impacts complement system molecules 
transcript levels in MSCs. 
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with a cocktail of cytokines, 40 ng/ mL of IFN-ϒ, 
TNF-α and IL-1β, for 24 hours. Unstimulated cells were left growing in MSC culture medium as a 
control. Quantitative reverse transcription PCR (qRT-PCR) was performed to evaluate complement 
system transcripts in BM, Is and Ad MSCs under homeostatic and inflammatory conditions. Each 
bar represents an n of 3 independent experiments and is graphed as mean ± SEM. Data are 
normalised to the housekeeping gene B2M and expressed as 2(-ΔCT). Appropriate statistical 
analysis was performed and includes Students paired T test between one MSC tissue source 
(Resting vs Inflammatory Conditions) and One Way ANOVA with Tukey’s multiple comparisons 
post-test to compare all MSC sources. Statistically significant differences are marked with the 
appropriate number of asterisks. p = 0.05 was considered the limit for statistical significance; * p < 
0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
Table 6-2. Fold change in the complement system molecules transcript levels of cytokine-
mediated licensed BM, Is and Ad MSCs compared to unstimulated cells from the same 
source.  
Following the experimental set up explained in Figure 6-2, fold change in transcript levels of the 
complement system molecules is represented as mean of fold change ± standard deviation. 
Statistically significant differences are marked with a colour code, where p < 0.05 is represented by 
green, p < 0.01 is represented by orange, p < 0.001 is represented by blue and p < 0.0001 is 
represented by red. 
Gene BM MSCs Is MSCs Ad MSCs 
CD46 0.24 ± 0.20 0.16 ± 0.07 0.82 ± 0.30 
CD59 0.13 ± 0.06 0.10 ± 0.02 0.07 ± 0.03 
CFB 2.62 ± 1.29 1.99 ± 0.66 1.31 ± 0.35 
CFD 0.05 ± 0.04 0.14 ± 0.04 0.00 ± 0.00 
CFH 0.27 ± 0.09 0.16 ± 0.01 0.14 ± 0.03 
CFHR1 0.46 ± 0.27 0.27 ± 0.21 10.31 ± 4.12 
CFI 0.30 ± 0.38 0.19 ± 0.12 0.04 ± 0.07 
CFP 0.13 ± 0.04 0.27 ± 0.07 0.00 ± 0.00 
CR1L 0.32 ± 0.15 0.14 ± 0.08 0.78 ± 0.17 
CR1 0.23 ± 0.15 0.21 ± 0.20 0.78 ± 0.92 
C1Qa 0.43 ± 0.07 0.23 ± 0.03 0.04 ± 0.02 
C1Qb 0.63 ± 0.43 0.17 ± 0.00 0.13 ± 0.13 
C1Qc 0.48 ± 0.17 0.25 ± 0.05 12.36 ± 10.94 
C1R 0.72 ± 0.34 0.70 ± 0.12 0.89 ± 0.14 
C1Sa 0.91 ± 0.44 1.33 ± 0.35 0.93 ± 0.20 
C2 0.33 ± 0.17 1.99 ± 0.60 0.46 ± 0.23 
C3 12.97 ± 5.57 0.62 ± 0.05 1.68 ± 0.38 
C3AR1 0.19 ± 0.07 0.18 ± 0.05 0.67 ± 0.20 
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Gene BM MSCs Is MSCs Ad MSCs 
C4 0.26 ± 0.14 0.70 ± 0.15 0.18 ± 0.28 
C5 0.36 ± 0.20 1.20 ± 1.92 0.15 ± 0.20 
C5AR1 0.80 ± 0.40 0.30 ± 0.04 0.17 ± 0.16 
C6 0.32 ± 0.25 0.89 ± 0.34 0.04 ± 0.05 
C7 0.26 ± 0.15 8.73 ± 10.12 6.81 ± 3.71 
C8a 0.24 ± 0.19 1.09 ± 0.00 0.08 ± 0.04 
C8b 0.93 ± 0.94 0.44 ± 0.69 9.68 ± 6.53 
C8g 0.16 ± 0.07 0.20 ± 0.07 0.01 ± 0.02 
 
 
6.2.3 Transcription of other immunoregulatory and anti-
inflammatory molecules under homeostatic and 
inflammatory conditions 
Under resting conditions BM, Is and Ad MSCs transcribed very little IL-1β (Figure 
6-3, A), TNF-α (B), IL-10 (D), IFN-β (E), IDO 1 (L), IDO 2, MMP9 (S), ITGAX (U) and 
ITGB2 (V) while TGF-β (G), COX2 (O), HGF (Q) and CD142 (R) were transcribed at 
high levels. The effect of inflammatory licensing was gene, and tissue of origin, 
dependent. Fold changes in transcript levels upon cytokine-mediated licensing of 
MSCs are detailed in Table 6-3.  
IFN-β (E), IDO 1 (L), IDO 2, CD274 (P), MMP9 (S) and ITGAX (U) were expressed at 
very low levels by MSCs from all sources and 24-hour cytokine-mediated 
stimulation produced no variation in the transcript levels of these genes. BM 
MSCs expressed the highest levels of IL-1β (A) under resting conditions and 
inflammatory stimulation led to increased levels of IL-1β transcription only in Is 
MSCs. TNF-α (B) was expressed at very low levels in MSCs from every source and 
24-hour cytokine-mediated stimulation led to no effect but Is MSCs had 
statistically significant higher transcript levels than BM and Ad MSCs. BM MSCs 
expressed the highest levels of IL-6 (C) under resting and stimulatory conditions 
and inflammatory stimulation led to an upregulation of IL-6 in MSCs from every 
source, especially in BM MSCs where it produced 21–times more IL-6 transcript. 
IL-10 (D) was expressed at very low levels by MSCs from all sources but Ad MSCs 
expression was higher in a statistically significant manner and cytokine-mediated 
stimulation led to a downregulation of IL-10 transcript levels in MSCs from all 
sources. BM MSCs expressed the highest levels of TSG-6 (F), VEGFb (I), VEGFd 
(K), HGF (Q) and CD142 (R) under resting and inflammatory conditions and 24-
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hour stimulatory licensing led to the downregulation of these transcripts in MSCs 
from all sources. Ad MSCs expressed the highest levels of VEGFc (J) under resting 
and inflammatory conditions and stimulatory licensing led to the downregulation 
of VEGFc in MSCs from all sources. BM MSCs expressed the highest levels of iNOS 
(N) under resting conditions; stimulatory licensing led to no effect in BM MSCs 
while it produced a marked upregulation in Is and Ad MSCs, with Is MSCs 
expressing the highest transcript levels. Ad MSCs expressed the highest levels of 
COX2 (O) under resting and inflammatory conditions and stimulatory licensing 
led to no effect on COX2 transcript levels. Ad MSCs expressed the highest levels 
of GMCSF (T) under resting conditions; stimulatory licensing led to an 
upregulation of GMCSF transcript levels in MSCs from all sources, with Is MSCs 
showing the biggest fold change. Is MSCs expressed the highest levels of ITGB2 
(V) under resting and inflammatory conditions and stimulatory licensing led to no 
effect in BM MSCs while it produced a statistically significant downregulation in 
Is and Ad MSCs.  
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Figure 6-3. Inflammation and MSC tissue origin impacts immunomodulatory molecules 
transcript levels in MSCs. 
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with a cocktail of cytokines, 40 ng/ mL of IFN-ϒ, 
TNF-α and IL-1β, for 24 hours. Unstimulated cells were left growing in MSC culture medium as a 
control. Quantitative reverse transcription PCR (qRT-PCR) was performed to evaluate 
immunomodulatory molecule transcripts in BM, Is and Ad MSCs under homeostatic and 
inflammatory conditions. Each bar represents an n of 3 independent experiments and is graphed 
as mean ± SEM. Data are normalised to the housekeeping gene B2M and expressed as 2(-ΔCT). 
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Appropriate statistical analysis was performed and includes Students paired T test between one 
MSC tissue source (Resting vs Inflammatory Conditions) and One Way ANOVA with Tukey’s 
multiple comparisons post-test to compare all MSC sources. Statistically significant differences are 
marked with the appropriate number of asterisks. p = 0.05 was considered the limit for statistical 
significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
Table 6-3. Fold change in immunomodulatory molecules transcript levels of cytokine-
mediated licensed BM, Is and Ad MSCs compared to unstimulated cells from the same 
source.  
Following the experimental set up explained in Figure 6-3, fold change in transcript levels of 
immunomodulatory molecules represented as mean of fold change ± standard deviation. 
Statistically significant differences are marked with a colour code, where p < 0.05 is represented by 
green, p < 0.01 is represented by orange, p < 0.001 is represented by blue and p < 0.0001 is 
represented by red. 
Gene BM MSCs Is MSCs Ad MSCs 
IL-1β 1.09 ± 0.62 14.03 ± 3.49 0.95 ± 0.88 
TNF-α 2.79 ± 2.06 0.95 ± 0.11 0.42 ± 0.53 
IL-6 21.85 ± 4.62 3.56 ± 0.45 3.42 ± 1.25 
IL-10 0.27 ± 0.28 0.07 ± 0.07 0.02 ± 0.02 
IFN-β 2.73 ± 4.12 0.51 ± 0.28 0.45 ± 0.49 
TSG-6 0.17 ± 0.03 0.26 ± 0.15 0.11 ± 0.13 
TGF-β 1.66 ± 1.62 0.12 ± 0.14 65.03 ± 93.49 
VEGFa 0.53 ± 0.04 0.38 ± 0.04 0.96 ± 0.31 
VEGFb 0.17 ± 0.04 0.35 ± 0.06 0.24 ± 0.04 
VEGFc 0.27 ± 0.03 0.51 ± 0.14 0.60 ± 0.03 
VEGFd 0.10 ± 0.03 0.06 ± 0.02 0.12 ± 0.01 
IDO1 0.44 ± 0.28 1.49 ± 0.00 0.29 ± 0.20 
IDO2 0.40 ± 0.21 0.52 ± 0.28 2.97 ± 2.02 
iNOS 174.63 ± 159.27 727.41 ± 163.85 4528.28 ± 6706.77 
COX2 1.92 ± 0.53 0.76 ± 0.10 1.22 ± 0.36 
CD274 0.55 ± 0.42 6.08 ± 5.42 1.65 ± 0.64 
HGF 0.33 ± 0.06 0.70 ± 0.22 0.21 ± 0.09 
CD142 0.12 ± 0.03 0.16 ± 0.03 0.77 ± 0.10 
MMP9 21.85 ± 23.09 3.21 ± 2.39 1.73 ± 1.94 
GMCSF 16.71 ± 8.28 71.23 ± 63.81 3.98 ± 2.62 
ITGAX 0.33 ± 0.24 1.23 ± 0.68 0.09 ± 0.04 
ITGB2 1.06 ± 0.95 0.62 ± 0.04 0.04 ± 0.04 
 
6.3 Analysis of the effect of a double inflammatory 
stimulus over time on the transcription of the 
complement system and other immunoregulatory and 
anti-inflammatory molecules   
Several reports in the literature indicate that the immunomodulatory activities 
of MSCs are not spontaneous, that priming by inflammatory cytokines is essential 
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for MSC-mediated immunosuppression, irrespective of the species of origin (Ren 
et al., 2009). Within a clinical setting, MSCs are usually infused within an 
inflammatory environment, which provides the required licensing for increasing 
the immunomodulatory properties of MSCs. When the anti-inflammatory 
properties of MSCs are studied in vitro, this licensing is mimicked in an in vitro 
culture with the addition of proinflammatory cytokines; in this specific case with 
40 ng/ mL of IFN-ϒ, TNF-α and IL-1β.  
As described in the previous section, pro-inflammatory cytokine-mediated MSC 
licensing produced a transcriptional regulation of genes involved in the 
regulation of the immune response and immunomodulatory mediators, which 
could explain why MSCs are more immunosuppressive upon activation. Within 
clinical settings, it has been reported that pre-treatment of MSCs with 
inflammatory cytokines prior to administration within animal models of 
inflammatory diseases boosts the therapeutic effect of MSCs (Duijvestein et al., 
2011, Noronha et al., 2019). For this reason, we wondered if pre-licensing the 
MSCs prior to exposing them to an inflammatory environment in vitro would lead 
to even bigger variations in chemokine transcript levels and therefore, in 
enhanced therapeutic potential. Following the experimental set up explained in 
Chapter 4, cells were pre-licensed for 48 hours, after which cells were washed 
twice with PBS and stimulated again for another 24 hours. The first stimulation 
primes the MSCs while the second stimulation would mimic the inflammatory 
environment MSCs would face when infused into a patient with an inflammatory 
disorder. Figure 6-4 illustrates the time points at which supplemented medium 
was added. Culture medium was removed at the time cells were harvested and 
was kept for experimental procedures.  
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Figure 6-4. Diagrammatic illustration of the time course of the MSC licensing. 
 
Two different control conditions were used. In the first one, cells were 
stimulated for 48 hours, after which cells were washed twice with PBS and fresh 
culture medium was added; cells were harvested 24 hours later. In the second 
condition, cells were washed twice with PBS, the culture medium was replaced 
with fresh medium and the cells were left to grow for 48 hours. Cells were then 
washed twice with PBS, the culture medium was replaced with supplemented 
medium and the cells were harvested 24 hours later. There is extensive 
literature about how cytokine-mediated licensing enhances the potential 
therapeutic efficacy of MSCs however, little is known about the role of TLR 
ligand-mediated activation on the secretion of chemotactic cytokines by MSCs. 
For this reason, 100 ng/mL lipopolysaccharide (LPS), 100 ng/mL lipoteichoic acid 
(LTA) and 4 mg/ ml polyinosinic-polycytidylic acid (poly I:C), as well as the 
previously described cytokine cocktail, was used for MSC licensing.  
According to the results described in Section 6.2, the genes that regulated their 
transcript levels in a statistically significant manner upon stimulation were 
selected and their transcriptional levels were assessed after licensing with 
different inflammatory molecules and different inflammatory conditions.  
It is important to bear in mind that in this section, the influence of four 
different inflammatory agents (cytokine cocktail with TNF-α, IL-1β and IFN-ϒ, 
LPS, LTA and Poly I:C) at four different time points (control, 72 hours, 24 hours 
and double stimulation) in 14 different genes was studied. This study was 
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performed in MSCs isolated from three different sources (BM, Is and Ad MSCs), 
which gave us a total of 546 data points per experiment ([4 inflammatory agents 
× 3 time points + 1 control] × 14 genes × 3 MSC sources). 
Among all the licensing molecules tested, the combination of 40 ng/ mL of TNF-
α, IL-1β and IFN-ϒ led to the biggest change in immunomodulatory mediators and 
among all the conditions tested, harvesting the cells 24 hours after the 
inflammatory stimulation led to the most significant results. These conditions 
have already been discussed in Section 6.2, for this reason, due to the large 
amount of data presented in this chapter, we decided to move the less relevant 
results to the Appendix. Thus, this result section will only display the fold 
transcript changes upon licensing of MSCs in tables, while the explanatory text 
and figures are displayed in Section 8.2.  
6.3.1 Transcription of the complement system under homeostatic 
and inflammatory conditions  
As outlined in Section 6.2.2, under resting conditions, BM, Is and Ad MSCs 
transcribed very little, if any, of the elements of the complement system and 
only the transcription of CFH, C1Qc and C5AR1 were affected by MSC licensing in 
a statistically significant manner (Section 8.2). A pattern of transcriptional 
upregulation was observed in CFH, C1Qc and C5AR1 after cytokine, LPS and Poly 
I:C-mediated licensing while LTA licensing led to a pattern of transcriptional 
upregulation; however, these genes were upregulated differentially in MSCs 
according to their tissue of origin. Fold changes of transcriptional regulation 
upon licensing of MSCs are detailed in Table 6-4.  
Table 6-4. Fold change in complement system molecules transcript levels of cytokine, LPS, 
LTA or Poly I:C-mediated licensed BM, Is and Ad MSCs compared to unstimulated cells 
from the same source.  
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with either a cocktail of cytokines (40 ng/ mL of 
IFN-ϒ, TNF-α and IL-1β), 100 ng/ mL LPS, 100 ng/ mL LTA or 4 µg/ mL Poly I:C. Unstimulated 
cells were left growing in MSC culture medium as a control. Three different licensing conditions 
were tested. In the first one, cells were stimulated for 48 hours, after which cells were washed twice 
with PBS and fresh culture medium was added; cells were harvested 24 hours later. In the second 
condition, cells were washed twice with PBS, the culture medium was replaced with fresh one and 
the cells were left growing for 48 hours. Cells were then washed twice with PBS, the culture 
medium was replaced with supplemented one and the cells were harvested 24 hours later. In the 
last condition, cells were stimulated for 48 hours, after which cells were washed twice with PBS 
and were stimulated again for another 24 hours. Figure 6-4 illustrates the time points at which 
supplemented medium was added. Quantitative reverse transcription PCR (qRT-PCR) was 
performed to evaluate complement system molecules transcripts in BM, Is and Ad MSCs under 
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resting and inflammatory conditions. Data are normalised to the housekeeping gene B2M and 
expressed as 2(-ΔCT). Fold change in transcript levels is represented as mean of fold change ± 
standard deviation. One Way ANOVA with Tukey’s multiple comparisons post-test was performed 
to compare all MSC sources and the different conditions. Statistically significant differences are 
marked with a colour code, where p < 0.05 is represented by green, p < 0.01 is represented by 
orange, p < 0.001 is represented by blue and p < 0.0001 is represented by red. 
Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
CFH 
1 
Cyt 0.21 ± 0.07 0.10 ± 0.12 0.69 ± 0.50 
LPS 0.37 ± 0.10 0.32 ± 0.26 0.30 ± 0.04 
LTA 3.40 ± 2.12 46.04 ± 25.45 0.72 ± 0.24 
Poly I:C 0.03 ± 0.01 0.24 ± 0.23 0.46 ± 0.10 
2 
Cyt 0.38 ± 0.26 0.03 ± 0.00 0.24 ± 0.04 
LPS 0.22 ± 0.07 0.15 ± 0.11 0.17 ± 0.12 
LTA 0.91 ± 0.34 15.74 ± 7.32 0.18 ± 0.06 
Poly I:C 0.09 ± 0.01 0.08 ± 0.04 0.19 ± 0.03 
3 
Cyt 0.26 ± 0.17 0.03 ± 0.02 0.27 ± 0.07 
LPS 0.63 ± 0.37 0.20 ± 0.14 0.43 ± 0.09 
LTA 1.26 ± 0.71 149.39 ± 91.04 1.24 ± 0.35 
Poly I:C 0.03 ± 0.02 0.28 ± 0.24 0.64 ± 0.13 
C1Qc 
1 
Cyt 0.59 ± 0.25 0.15 ± 0.07 0.94 ± 0.23 
LPS 0.92 ± 0.42 0.12 ± 0.07 0.47 ± 0.05 
LTA 2.19 ± 0.86 0.50 ± 0.18 0.63 ± 0.10 
Poly I:C 0.22 ± 0.08 0.21 ± 0.18 0.35 ± 0.05 
2 
Cyt 0.52 ± 0.19 0.04 ± 0.02 0.18 ± 0.03 
LPS 0.32 ± 0.04 0.08 ± 0.05 0.27 ± 0.07 
LTA 2.04 ± 1.26 0.40 ± 0.17 0.25 ± 0.05 
Poly I:C 0.40 ± 0.17 0.08 ± 0.03 0.14 ± 0.04 
3 
Cyt 0.52 ± 0.26 0.13 ± 0.05 1.04 ± 0.18 
LPS 0.67 ± 0.33 0.21 ± 0.13 0.14 ± 0.02 
LTA 1.59 ± 0.51 2.52 ± 0.75 0.36 ± 0.08 
Poly I:C 0.39 ± 0.35 0.52 ± 0.65 0.07 ± 0.01 
C5AR1 
1 
Cyt 1.59 ± 0.26 0.09 ± 0.06 1.06 ± 0.44 
LPS 3.14 ± 0.44 0.24 ± 0.09 0.74 ± 0.14 
LTA 6.45 ± 0.57 0.40 ± 0.10 0.88 ± 0.16 
Poly I:C 0.89 ± 0.07 0.22 ± 0.12 0.46 ± 0.13 
2 
Cyt 2.71 ± 0.51 0.06 ± 0.03 0.81 ± 0.13 
LPS 2.49 ± 0.92 0.22 ± 0.04 0.48 ± 0.06 
LTA 8.17 ± 0.42 0.41 ± 0.06 0.25 ± 0.07 
Poly I:C 1.72 ± 0.70 0.13 ± 0.07 0.34 ± 0.09 
3 
Cyt 1.63 ± 0.12 0.08 ± 0.03 0.01 ± 0.01 
LPS 2.87 ± 0.24 0.40 ± 0.17 1.00 ± 0.11 
LTA 8.49 ± 1.17 1.52 ± 0.82 1.44 ± 0.38 
Poly I:C 0.61 ± 0.02 0.22 ± 0.19 0.29 ± 0.08 
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6.3.2 Transcription of other immunoregulatory and anti-
inflammatory molecules under homeostatic and 
inflammatory conditions  
As previously mentioned, under resting conditions BM, Is and Ad MSCs 
transcribed very little, if any, of the immunoregulatory and anti-inflammatory 
genes analysed in Section 6.2.3 with the exception of IL-6, VEGFa, VEGFd and 
CD142 (Section 8.2). The effect of inflammatory licensing in these genes was 
tissue of origin and stimulatory agent dependent and fold changes of 
transcriptional regulation upon licensing of MSCs are detailed in Table 6-5. 
Table 6-5. Fold change in immunomodulatory molecules transcript levels of cytokine, LPS, 
LTA or Poly I:C-mediated licensed BM, Is and Ad MSCs compared to unstimulated cells 
from the same source.  
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with either a cocktail of cytokines (40 ng/ mL of 
IFN-ϒ, TNF-α and IL-1β), 100 ng/ mL LPS, 100 ng/ mL LTA or 4 µg/ mL Poly I:C. Unstimulated 
cells were left growing in MSC culture medium as a control. Three different licensing conditions 
were tested. In the first one, cells were stimulated for 48 hours, after which cells were washed twice 
with PBS and fresh culture medium was added; cells were harvested 24 hours later. In the second 
condition, cells were washed twice with PBS, the culture medium was replaced with fresh one and 
the cells were left growing for 48 hours. Cells were then washed twice with PBS, the culture 
medium was replaced with supplemented one and the cells were harvested 24 hours later. In the 
last condition, cells were stimulated for 48 hours, after which cells were washed twice with PBS 
and were stimulated again for another 24 hours. Figure 6-4 illustrates the time points at which 
supplemented medium was added. Quantitative reverse transcription PCR (qRT-PCR) was 
performed to evaluate immunomodulatory molecule transcripts in BM, Is and Ad MSCs under 
resting and inflammatory conditions. Data are normalised to the housekeeping gene B2M and 
expressed as 2(-ΔCT). Fold change in transcript levels is represented as mean of fold change ± 
standard deviation. One Way ANOVA with Tukey’s multiple comparisons post-test was performed 
to compare all MSC sources and the different conditions. Statistically significant differences are 
marked with a colour code, where p < 0.05 is represented by green, p < 0.01 is represented by 
orange, p < 0.001 is represented by blue and p < 0.0001 is represented by red. 
Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
IL-6 
1 
Cyt 1.15 ± 0.90 1.56 ± 0.97 0.11 ± 0.05 
LPS 0.26 ± 0.22 2.35 ± 1.05 0.42 ± 0.06 
LTA 0.17 ± 0.12 1.24 ± 0.62 0.22 ± 0.02 
Poly I:C 0.15 ± 0.11 1.92 ± 1.31 0.23 ± 0.03 
2 
Cyt 53.97 ± 44.65 8.04 ± 4.83 0.65 ± 0.06 
LPS 2.02 ± 0.64 3.09 ± 1.63 0.89 ± 0.29 
LTA 0.49 ± 0.06 1.38 ± 0.51 1.07 ± 0.13 
Poly I:C 0.78 ± 0.72 1.46 ± 0.36 0.66 ± 0.11 
3 
Cyt 76.21 ± 61.41 3.41 ± 1.35 10.74 ± 1.08 
LPS 1.72 ± 0.72 2.26 ± 1.29 0.51 ± 0.02 
LTA 0.30 ± 0.20 0.88 ± 0.21 0.70 ± 0.18 
Poly I:C 0.86 ± 0.43 1.04 ± 0.79 0.80 ± 0.13 
TSG-6 1 
Cyt 0.08 ± 0.03 0.74 ± 0.14 3.98 ± 2.09 
LPS 0.13 ± 0.01 2.86 ± 0.90 0.66 ± 0.21 
LTA 0.17 ± 0.02 2.24 ± 0.34 0.54 ± 0.18 
Poly I:C 0.07 ± 0.03 1.53 ± 0.40 0.42 ± 0.21 
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Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
2 
Cyt 0.06 ± 0.03 0.62 ± 0.17 0.51 ± 0.28 
LPS 0.23 ± 0.09 2.34 ± 1.30 0.56 ± 0.17 
LTA 0.76 ± 0.36 1.40 ± 0.39 0.31 ± 0.30 
Poly I:C 0.07 ± 0.03 1.09 ± 0.25 0.37 ± 0.21 
3 
Cyt 0.13 ± 0.09 0.29 ± 0.19 1.12 ± 0.40 
LPS 0.66 ± 0.35 1.44 ± 0.36 0.51 ± 0.20 
LTA 0.54 ± 0.31 4.18 ± 1.52 1.06 ± 0.53 
Poly I:C 0.08 ± 0.05 0.82 ± 0.58 1.27 ± 0.66 
VEGFa 
1 
Cyt 0.40 ± 0.05 0.22 ± 0.10 2.43 ± 0.51 
LPS 0.54 ± 0.17 0.93 ± 0.19 0.63 ± 0.06 
LTA 1.04 ± 0.14 1.77 ± 0.57 1.16 ± 0.10 
Poly I:C 0.24 ± 0.04 0.46 ± 0.14 0.47 ± 0.05 
2 
Cyt 0.76 ± 0.12 0.37 ± 0.27 1.04 ± 0.17 
LPS 0.65 ± 0.19 0.68 ± 0.05 1.01 ± 0.35 
LTA 1.07 ± 0.26 1.14 ± 0.29 0.67 ± 0.05 
Poly I:C 0.41 ± 0.29 1.02 ± 0.31 0.46 ± 0.07 
3 
Cyt 0.49 ± 0.04 0.38 ± 0.13 3.17 ± 0.47 
LPS 0.98 ± 0.07 0.73 ± 0.17 0.80 ± 0.08 
LTA 0.92 ± 0.21 1.25 ± 0.17 1.10 ± 0.26 
Poly I:C 0.37 ± 0.02 0.83 ± 0.08 1.19 ± 0.29 
VEGFb 
1 
Cyt 0.35 ± 0.10 0.16 ± 0.06 0.61 ± 0.14 
LPS 3.30 ± 4.00 0.69 ± 0.17 0.34 ± 0.13 
LTA 2.10 ± 0.97 0.71 ± 0.22 0.48 ± 0.18 
Poly I:C 0.19 ± 0.10 0.36 ± 0.21 0.35 ± 0.04 
2 
Cyt 0.25 ± 0.11 0.21 ± 0.13 0.66 ± 0.19 
LPS 0.21 ± 0.07 0.38 ± 0.03 0.38 ± 0.11 
LTA 1.21 ± 0.66 0.82 ± 0.07 0.27 ± 0.04 
Poly I:C 0.14 ± 0.04 0.31 ± 0.29 0.34 ± 0.07 
3 
Cyt 0.19 ± 0.11 0.09 ± 0.02 4.45 ± 0.52 
LPS 0.71 ± 0.31 0.30 ± 0.12 0.75 ± 0.11 
LTA 1.45 ± 0.76 0.94 ± 0.34 1.10 ± 0.27 
Poly I:C 0.11 ± 0.06 0.28 ± 0.07 0.60 ± 0.10 
VEGFc 
1 
Cyt 0.27 ± 0.15 1.00 ± 0.28 0.29 ± 0.18 
LPS 0.56 ± 0.23 3.07 ± 0.34 0.67 ± 0.13 
LTA 0.67 ± 0.17 2.50 ± 1.14 0.56 ± 0.13 
Poly I:C 0.22 ± 0.06 1.83 ± 0.68 0.47 ± 0.10 
2 
Cyt 0.45 ± 0.05 0.96 ± 0.36 1.12 ± 0.07 
LPS 0.63 ± 0.08 1.05 ± 0.26 0.86 ± 0.31 
LTA 0.62 ± 0.22 1.64 ± 0.92 0.38 ± 0.12 
Poly I:C 0.53 ± 0.28 1.60 ± 0.71 0.54 ± 0.11 
3 
Cyt 0.20 ± 0.08 0.61 ± 0.21 7.80 ± 1.71 
LPS 0.74 ± 0.46 1.09 ± 0.51 1.05 ± 0.28 
LTA 0.65 ± 0.25 0.91 ± 0.39 1.14 ± 0.36 
Poly I:C 0.38 ± 0.10 0.65 ± 0.19 1.14 ± 0.23 
VEGFd 1 
Cyt 0.15 ± 0.04 0.05 ± 0.03 1.44 ± 0.35 
LPS 0.27 ± 0.03 0.25 ± 0.10 1.10 ± 0.41 
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Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
LTA 0.37 ± 0.07 0.42 ± 0.07 1.30 ± 0.13 
Poly I:C 0.10 ± 0.03 0.11 ± 0.10 0.66 ± 0.11 
2 
Cyt 0.16 ± 0.07 0.01 ± 0.00 0.29 ± 0.07 
LPS 0.54 ± 0.10 0.09 ± 0.03 0.20 ± 0.07 
LTA 1.15 ± 0.37 0.30 ± 0.07 0.31 ± 0.08 
Poly I:C 0.12 ± 0.03 0.13 ± 0.02 0.40 ± 0.07 
3 
Cyt 0.15 ± 0.08 0.00 ± 0.00 0.23 ± 0.03 
LPS 0.61 ± 0.08 0.16 ± 0.11 0.38 ± 0.05 
LTA 0.72 ± 0.19 0.46 ± 0.08 2.06 ± 0.41 
Poly I:C 0.10 ± 0.04 0.09 ± 0.02 0.41 ± 0.08 
iNOS 
1 
Cyt 18.43 ± 14.56 4.52 ± 3.84 4.06 ± 3.80 
LPS 5.04 ± 7.56 0.54 ± 0.40 1.99 ± 1.86 
LTA 0.09 ± 0.09 0.23 ± 0.24 1.01 ± 0.93 
Poly I:C 0.57 ± 0.40 0.16 ± 0.15 1.88 ± 1.73 
2 
Cyt 191.3 ± 171.7 170.15 ± 178.95 49.31 ± 47.41 
LPS 2.25 ± 1.86 0.20 ± 0.21 271.90 ± 239.85 
LTA 0.25 ± 0.22 0.25 ± 0.04 1.04 ± 1.13 
Poly I:C 135.1 ± 222.2 0.14 ± 0.05 22.15 ± 31.04 
3 
Cyt 77.75 ± 55.07 83.97 ± 86.59 40476 ± 37122 
LPS 4.61 ± 3.70 1.99 ± 1.83 32.53 ± 51.05 
LTA 0.22 ± 0.09 45.06 ± 53.10 28.72 ± 37.91 
Poly I:C 4.38 ± 3.46 0.15 ± 0.16 147.15 ± 153.43 
COX2 
1 
Cyt 0.85 ± 0.16 5.46 ± 1.93 2.45 ± 0.86 
LPS 1.00 ± 0.46 29.93 ± 4.88 0.46 ± 0.05 
LTA 1.39 ± 0.19 11.11 ± 7.88 0.69 ± 0.17 
Poly I:C 0.50 ± 0.07 5.41 ± 1.65 0.37 ± 0.05 
2 
Cyt 1.65 ± 0.67 5.16 ± 1.41 3.34 ± 0.19 
LPS 1.48 ± 0.67 3.96 ± 2.32 1.52 ± 0.53 
LTA 1.19 ± 0.59 6.46 ± 0.44 0.79 ± 0.06 
Poly I:C 1.31 ± 0.47 6.15 ± 4.01 0.75 ± 0.08 
3 
Cyt 0.93 ± 0.09 8.71 ± 3.77 23.83 ± 2.96 
LPS 1.57 ± 0.59 7.92 ± 5.36 1.52 ± 0.15 
LTA 0.97 ± 0.35 6.73 ± 2.58 0.89 ± 0.54 
Poly I:C 0.57 ± 0.06 4.33 ± 1.81 1.88 ± 0.27 
HGF 
1 
Cyt 0.09 ± 0.01 0.17 ± 0.06 2.48 ± 0.99 
LPS 0.17 ± 0.05 0.87 ± 0.36 1.13 ± 0.25 
LTA 0.37 ± 0.07 1.40 ± 1.24 1.68 ± 0.56 
Poly I:C 0.04 ± 0.01 1.75 ± 0.53 0.87 ± 0.19 
2 
Cyt 0.32 ± 0.24 0.48 ± 0.28 0.67 ± 0.16 
LPS 0.39 ± 0.28 1.68 ± 1.01 1.27 ± 0.74 
LTA 1.06 ± 0.69 5.03 ± 0.70 0.61 ± 0.11 
Poly I:C 0.11 ± 0.05 0.43 ± 0.08 0.33 ± 0.08 
3 
Cyt 0.22 ± 0.13 1.24 ± 1.02 2.20 ± 0.38 
LPS 0.74 ± 0.56 1.01 ± 0.63 0.52 ± 0.10 
LTA 0.97 ± 0.45 2.12 ± 0.69 0.65 ± 0.24 
Poly I:C 0.12 ± 0.07 0.35 ± 0.22 0.53 ± 0.14 
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CD142 
1 
Cyt 0.32 ± 0.03 0.11 ± 0.00 0.93 ± 0.11 
LPS 0.74 ± 0.12 0.47 ± 0.14 0.42 ± 0.05 
LTA 0.70 ± 0.12 0.79 ± 0.32 0.55 ± 0.06 
Poly I:C 0.27 ± 0.06 0.40 ± 0.18 0.35 ± 0.03 
2 
Cyt 0.45 ± 0.26 0.18 ± 0.11 0.53 ± 0.06 
LPS 0.59 ± 0.17 0.90 ± 0.37 0.39 ± 0.14 
LTA 1.19 ± 0.25 0.78 ± 0.27 0.42 ± 0.04 
Poly I:C 0.32 ± 0.05 0.18 ± 0.07 0.49 ± 0.08 
3 
Cyt 0.33 ± 0.20 0.13 ± 0.06 1.48 ± 0.15 
LPS 0.79 ± 0.21 0.27 ± 0.03 0.50 ± 0.06 
LTA 0.83 ± 0.25 0.37 ± 0.11 1.44 ± 0.40 
Poly I:C 0.55 ± 0.37 0.53 ± 0.36 0.87 ± 0.13 
GMCSF 
1 
Cyt 1.56 ± 1.30 6.07 ± 8.72 14.53 ± 12.02 
LPS 0.66 ± 0.30 13.17 ± 22.47 1.65 ± 1.05 
LTA 14.41 ± 24.03 10.08 ± 9.00 2.62 ± 1.26 
Poly I:C 145.6 ± 250.5 7.51 ± 11.31 1.07 ± 0.86 
2 
Cyt 8.85 ± 8.64 2.75 ± 2.17 1.22 ± 0.60 
LPS 0.74 ± 0.40 1.59 ± 1.77 1.98 ± 2.17 
LTA 1.31 ± 0.84 10.35 ± 16.41 1.31 ± 1.05 
Poly I:C 0.87 ± 0.75 0.78 ± 0.27 0.55 ± 0.28 
3 
Cyt 1.26 ± 0.95 8.57 ± 13.07 365.9 ± 300.6 
LPS 1.25 ± 0.67 1.59 ± 1.99 1.53 ± 1.14 
LTA 0.72 ± 0.40 8.85 ± 11.71 2.35 ± 1.37 
Poly I:C 0.74 ± 0.40 3.32 ± 5.56 4.37 ± 3.01 
 
6.4 Analysis of the immunoregulatory and anti-
inflammatory molecules secretion profile by MSCs 
under homeostatic and inflammatory conditions 
Under resting conditions, BM, Is and Ad MSCs secreted less than 0.6 pg of IL-6 
and less than 0.2 pg of VEGF per mg of total protein (Figure 6-5). A pattern of 
upregulation was observed in IL-6 (A) under every condition in MSCs from the 
three sources after cytokine-mediated licensing, while the effect mediated by 
cytokine licensing on VEGF (B) depends on condition and tissue of origin. Fold 
changes of IL-6 and VEGF secretion upon cytokine-mediated licensing of MSCs 
are specified in Table 6-6.  
MSCs isolated from the three tissues produced very little IL-6 under resting 
conditions but Ad MSCs secreted the highest levels of IL-6 (BM = 0.09 pg/ mg; Is = 
0.23 pg/ mg; Ad = 0.60 pg/ mg). Cytokine-mediated licensing produced an 
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upregulation of the secretion in all the conditions tested in MSCs of the three 
tissue sources. After 72 hours of stimulation (Condition 1), IL-6 secretion was 
upregulated in MSCs from the three tissues but was only statistically significant 
in Is and Ad MSCs. However, 24 hours of stimulation (Condition 2) produced a 
statistically significant upregulation of IL-6 secretion in MSCs from the three 
sources, with the three sources secreting close to 2 pg of IL-6 per mg of total 
protein. A second cytokine-mediated stimulation 48 hours after the first one 
(Condition 3) led to the same level of secretion of IL-6 as Condition 1 in MSCs 
from the three sources. The lower limit of quantification for IL-6 in the Mouse 
Magnetic Luminex Assay was 29.55 pg/mL and all the analysed samples were 
above this value.  
MSCs isolated from the three tissues produced very little VEGF under resting 
conditions but Ad MSCs secreted the highest levels of VEGF (BM = 0.07 pg/ mg; Is 
= 0.19 pg/ mg; Ad = 0.11 pg/ mg). 72 hours of stimulation with the cytokine 
cocktail (Condition 1) led to no effect in VEGF secretion by MSCs from the three 
sources. However, 24 hours of stimulation (Condition 2) produced a statistically 
non-significant upregulation of VEGF secretion by BM MSCs and no effect in Is 
and Ad MSCs. A second cytokine-mediated stimulation 48 hours after the first 
one (Condition 3) led to a statistically non-significant upregulation of VEGF 
secretion by BM MSCs, to a statistically significant downregulation in Is MSCs and 
to no effect in the secretion of VEGF by Ad MSCs. The lower limit of 
quantification for VEGF in the Mouse Magnetic Luminex Assay was 4.2 pg/mL and 
all the analysed samples were above this value. 
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Figure 6-5. Cytokine-mediated stimulation, repetitive stimulus and MSC tissue origin 
impacts IL-6 and VEGF secretion in MSCs.  
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with a cocktail of cytokines (40 ng/ mL of IFN-ϒ, 
TNF-α and IL-1β). Unstimulated cells were left growing in MSC culture medium as a control. Three 
different licensing conditions were tested. In the first one, cells were stimulated for 48 hours, after 
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which cells were washed twice with PBS and fresh culture medium was added; cells were 
harvested 24 hours later. In the second condition, cells were washed twice with PBS, the culture 
medium was replaced with fresh one and the cells were left growing for 48 hours. Cells were then 
washed twice with PBS, the culture medium was replaced with supplemented one and the cells 
were harvested 24 hours later. In the last condition, cells were stimulated for 48 hours, after which 
cells were washed twice with PBS and were stimulated again for another 24 hours. Figure 6-4 
illustrates the time points at which supplemented medium was added. Luminex was performed to 
evaluate protein secretion in BM, Is and Ad MSCs under homeostatic and inflammatory conditions. 
Each bar represents an n of 3 independent experiments and is graphed as mean ± SEM. Data are 
normalised total amount of protein in medium and expressed as picograms of protein of interest per 
mg of total protein. Appropriate statistical analysis was performed and includes Students paired T 
test between one MSC tissue source (Resting vs Inflammatory Conditions) and One Way ANOVA 
with Tukey’s multiple comparisons post-test to compare all MSC sources. Statistically significant 
differences are marked with the appropriate number of asterisks. p = 0.05 was considered the limit 
for statistical significance; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
Table 6-6. Fold change in IL-6 and VEGF secretion of cytokine-mediated licensed BM, Is and 
Ad MSCs compared to unstimulated cells from the same source.  
Following the experimental set up explained in Figure 6-5, fold change in IL-6 and VEGF protein 
levels is represented as mean of fold change ± standard deviation. Statistically significant 
differences are marked with a colour code, where p < 0.05 is represented by green, p < 0.01 is 
represented by orange, p < 0.001 is represented by blue and p < 0.0001 is represented by red. 
Protein Condition  BM MSCs Is MSCs Ad MSCs 
IL-6 
1 15.35 ± 15.43 9.04 ± 0.77 2.93 ± 0.68 
2 54.67 ± 57.57 8.59 ± 0.26 2.99 ± 0.49 
3 51.14 ± 55.55 8.54 ± 1.18 2.91 ± 0.25 
VEGF 
1 1.00 ± 0.15 0.65 ± 0.06 1.33 ± 0.28 
2 1.90 ± 0.60 1.12 ± 0.07 1.20 ± 0.35 
3 0.31 ± 0.16 0.77 ± 0.08 1.28 ± 0.04 
 
 
 
6.5 Discussion and conclusions  
It is largely assumed that MSCs elicit their immunomodulatory effects via the 
inhibition of lymphocyte activation and proliferation and the secretion of pro-
inflammatory cytokines, while at the same time, promoting a regulatory 
phenotype. Several molecules, including IL-6, IL-10, TGF-β, TSG-6, iNOS, COX2, 
HGF, MMP9 and GMCSF have been described to be important for their efficacy in 
the clinic but there is controversy in the literature and the immunomodulatory 
mechanism of MSCs remains unknown. For this reason, the aim of this chapter 
was to gain an understanding of the anti-inflammatory and immunomodulatory 
mechanisms of MSCs by studying the expression of TLRs, the complement system 
and several genes described in the literature to have essential roles. Transcript 
levels 24 hours after cytokine–mediated stimulation are summarised in Figure 
6-6.  
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Figure 6-6. Heat map representing the transcriptional expression of TLRs, the complement 
system and several immunomodulatory and anti-inflammatory genes by MSCs from 
different sources under resting and inflammatory conditions.  
Data from Figure 6-1, Figure 6-2 and Figure 6-3 are combined and presented as a heat map to 
illustrate the transcriptional profile of TLRs, the complement system and several 
immunomodulatory and anti-inflammatory genes by MSCs maintained under resting and 
inflammatory conditions. The heat map summarises each tissue source of MSC highest and lowest 
transcribed genes under resting conditions and inflammatory stimulation. Genes with low 2(-ΔCT) 
values are highlighted in blue, genes with intermediate 2(-ΔCT) values are highlighted in grey and 
genes with high 2(-ΔCT) values are highlighted in yellow. 
 
Priming by inflammatory cytokines has been described to be essential for MSC-
mediated immunosuppression (Ren et al., 2009), but to my knowledge, there are 
no studies comparing different inflammatory agents and their potential to 
increase the clinical efficacy of MSCs. The establishment of standardised MSC 
isolation and culture protocols (Chapter 3) enables an objective comparison of 
the transcriptional and protein profile of BM, Is and Ad MSCs. For this reason, in 
this study we decided to examine the potential of different immunostimulants, 
cytokines and TLR 2, TLR3 and TLR4 agonists, to prime MSCs and increase their 
immunomodulatory functions. However, the use of these inflammatory agents, 
as well as the different conditions in which MSCs were stimulated with the same 
inflammatory agent, did not show any trend of up or down regulation of genes 
that could suggest a better inflammatory agent for MSC licensing. For these 
reasons, instead of discussing the results per condition, we have decided to 
discuss the results by gene of interest, focusing on the results obtained 
harvesting the cells 24 hours after licensing with 40 ng/ml of TNF-α, IL-1β and 
IFN-ϒ (Condition 2). In this manner, it is possible to compare the expression of 
all the genes analysed in this study in Section 6.2, which is summarised in Figure 
6-6. More importantly, careful analysis of the transcript data enabled the 
identification of genes of interest to be targeted for protein assays; the 
secretion of IL-6 and VEGF by BM, Is and Ad MSCs under resting and inflammatory 
conditions is summarised in Figure 6-7. 
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Figure 6-7. Heat map representing the secretion of IL-6 and VEGF by MSCs from different 
sources under homeostatic and inflammatory conditions.  
Data from Figure 6-5 are combined and presented as a heat map to illustrate the IL-6 and VEGF 
secretion profile of MSCs maintained under homeostatic and inflammatory conditions. The heat 
maps summarise each tissue source of MSC highest and lowest transcribed genes under 
homeostatic conditions and inflammatory stimulation. Proteins with low secretion are highlighted in 
blue, proteins with intermediate secretion are highlighted in grey and proteins with high secretion 
are highlighted in yellow. 
 
After analysis and comparison of the transcript and protein data described in this 
thesis with other studies in the literature, this discussion will focus on 5 genes, 
IL-6, IL-10, TGF-β, VEGF, and iNOS, and the clinical implications of the 
expression and regulation upon inflammatory stimulus of these molecules will be 
examined.  
Interleukin 6 (IL-6) is a cytokine with pleiotropic effects on inflammation and 
immune response as well as regenerative processes and haematopoiesis. 
Different names, including B-cell stimulatory factor 2 and hepatocyte-
stimulating factor, were provided to this soluble factor based on all these 
distinct biological roles and it was not until the molecular cloning of these 
molecules that it was determined they were all the same and subsequently 
renamed IL-6 (Kishimoto, 1989, Tanaka et al., 2014). IL-6 is secreted after 
inflammation by most nucleated cells, including monocytes and macrophages, 
endothelial cells, T cells, B cells, granulocytes and osteoclasts among others and 
is involved in host defence through induction of acute phase responses, 
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haematopoiesis and immune reactions (Tanaka et al., 2014). IL-6 exerts its 
functions by targeting hepatocytes, leukocytes, T cells, B cells and 
haematopoietic cells (Akdis et al., 2011). Circulating IL-6 levels are upregulated 
in several chronic inflammatory disorders including rheumatoid arthritis, 
psoriasis, systemic lupus erythematosus and Crohn's disease (Gabay, 2006). BM, 
Is and Ad MSCs transcribed (Figure 6-3, C) and secreted (Figure 6-5, A) moderate 
levels of IL-6 under resting conditions. These transcript and protein levels were 
significantly upregulated after inflammatory stimulation by MSCs isolated from 
all tissue sources. BM MSCs secreted the most IL-6 after cytokine-mediated 
inflammatory stimulation. Secretion of IL-6 by human BM and Ad MSCs has 
previously been reported (Ivanova-Todorova et al., 2012, Mi and Gong, 2017), 
but to my knowledge differences in IL-6 transcription and secretion by mouse 
BM, Is and Ad MSCs has not been documented.  
It is difficult to determine whether the secretion of IL-6 by MSCs would be 
beneficial or detrimental in a clinical environment. IL-6 promotes the 
differentiation of monocytes into macrophages instead of DCs by inducing the 
expression of colony stimulating factor receptors (Chomarat et al., 2000) and at 
the same time, IL-6 modulates the DCs towards an immunosuppressive 
phenotype (Pasare and Medzhitov, 2003). IL-6 upregulates the secretion of CCL2, 
CCL4, CCL5, CCL11, CCL17 promoting the recruitment of monocytes, 
macrophages, CD4+ T cells, CD8+ T cells, NK cells and DCs, while downregulating 
the secretion of CXCL1 and CXCL8, thereby supressing neutrophil infiltration 
(McLoughlin et al., 2004, Akdis et al., 2011). IL-6 promotes anti-inflammatory 
Th2 cell differentiation (Diehl et al., 2002) and increases IL-27 secretion by 
monocytes and macrophages promoting the maturation of regulatory T cells 
(Pyle et al., 2017).  
However, IL-6 has also been described to inhibit TGF-β-induced Treg 
differentiation and to promote the differentiation of the pro-inflammatory Th17 
cells from naïve T cells, disrupting immunological tolerance and leading to 
autoimmune and chronic inflammatory diseases (Bettelli et al., 2006, Tanaka et 
al., 2014). IL-6 promotes the differentiation of CD8+ T cells into cytotoxic T cells 
(Okada et al., 1988) and induces the differentiation of activated B cells into 
antibody producing plasma cells (Okada et al., 1988, Kishimoto, 1989).  
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Within a transplant setting, IL-6 has been shown to mediate allograft rejection 
as blockage of the IL-6 axis prolonged graft survival in a mouse model of cardiac 
allograft rejection (Zhao et al., 2012). Despite its inflammatory effects, IL-6 is 
required for MSC proliferation and ‘stemness’ maintenance as it suppresses 
differentiation of MSCs, which results in loss of immune privilege and rejection 
(Pricola et al., 2009, Li et al., 2013). More importantly, IL-6 also induces the 
secretion of VEGF, enhancing angiogenesis, which is essential for the repair and 
regenerative processes required for effective engraftment after transplantation 
(Mathe et al., 2006). Taking all this into account, IL-6 secretion by MSCs would 
most likely be beneficial within a clinical setting and as BM MSCs secreted the 
most IL-6 under inflammatory conditions, BM MSCs could be a better choice than 
Is and Ad MSC to be used as cellular therapeutics.  
Interleukin 10 (IL-10), also known as cytokine synthesis inhibitory factor, is an 
anti-inflammatory cytokine involved in Th1 cell, NK cell and macrophage 
inhibition to avoid tissue damage after acute inflammation. IL-10 was first 
described to be produced by Th2 cells, but it is also secreted by macrophages, 
DCs, B cells and subsets of regulatory T cells (Li et al., 1999, Kamanaka et al., 
2006, Fiorentino et al., 1989). IL-10 inhibits the expression of MHC Class II and 
co-stimulatory molecules as well as secretion of pro-inflammatory cytokines and 
chemokines by macrophages and in this manner, it supresses T cells and NK cells 
(Couper et al., 2008). Due to its roles in resolving inflammation, IL-10 can also 
ameliorate autoimmune pathologies and its expression has been found altered in 
several autoimmune diseases including systemic lupus erythematosus and 
rheumatoid arthritis, where high levels of IL-10 correlate with low disease 
activity (Moore et al., 2001). BM, Is and Ad MSCs transcribed (Figure 6-3, D) very 
low levels of IL-10 under resting conditions and cytokine-mediated stimulation 
downregulated IL-10 transcript levels in MSCs isolated from all tissue sources. Ad 
MSCs transcribed the most IL-10 under resting and inflammatory conditions.  
Secretion of IL-10 by murine MSCs has already been described and it attenuated 
acute liver failure in a D–galactosamine–mediated acute liver failure mouse 
model. However, IL-10 secretion levels by MSCs need to be very high as infusion 
of MSCs alone into mouse and rat models of inflammatory rheumatoid arthritis 
produced no effect, while injection of IL-10 transduced MSCs significantly 
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decreased the severity of arthritis in a mouse model of antigen-induced arthritis 
(Hughes et al., 2014, Peruzzaro et al., 2019). IL-10 secretion may be highly 
beneficial in any clinical setting to dampen inflammation; thus, we could 
hypothesise that Ad MSCs could have an increased therapeutic potential 
compared to BM and Is MSCs. However, due to the very low transcript levels, IL-
10 secretion should be study as the increased transcript levels by Ad MSCs may 
not be biologically significant.  
The TGF-β family of growth factors is involved in development and homeostasis 
by tightly regulating cell proliferation, differentiation and apoptosis in most cell 
types including fibroblasts, immune cells and haematopoietic cells (Kubiczkova 
et al., 2012). The most relevant effect of TGF-β on target cells is based on its 
ability to suppress the expression and function of c-myc and cyclin-dependent 
kinases to suppress proliferation. For this reason, the TGF-β pathway, and 
sensitivity to this family of growth factors, is altered in a number of diseases 
including solid and haematopoietic tumours and psoriasis. Under these 
conditions, TGF-β switches from promoting an anti-proliferative response to 
induce proliferation, promoting tumour growth and keratinocyte 
hyperproliferation in psoriasis, thus, increasing the severity of the disease (Han 
et al., 2010, Kubiczkova et al., 2012).  
BM and Ad MSCs transcribed (Figure 6-3, G) high levels of TGF-β, while Is MSCs 
transcribed low levels of TGF-β under resting conditions. Cytokine-mediated 
stimulation upregulated TGF-β transcript levels in BM and Ad MSCs, while it led 
to a downregulation in Is MSCs. BM MSCs transcribed the highest TGF-β transcript 
levels under resting conditions, however, cytokine-mediated stimulation resulted 
in Ad MSCs transcribing the highest levels of TGF-β. Human MSCs isolated from 
the bone marrow, adipose tissue, Wharton’s jelly and placenta have already 
been described to produce and secrete TGF-β (Ryan et al., 2007, Carrillo-Galvez 
et al., 2015, Tomic et al., 2011, Zhou et al., 2011, Heo et al., 2016).  
TGF-β treatment of MSCs has been widely described to alter their in vitro and in 
vivo behaviour (Ghosh et al., 2017); however, TGF-β secreted by MSCs also plays 
an important role in the context of tissue regeneration and modulation of the 
immune responses. TGF-β is well known to inhibit T cell responses and its 
secretion by MSCs has been demonstrated to be partially involved in MSC-
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mediated T cell inhibition in vitro (Nasef et al., 2007, Gao et al., 2016). 
Moreover, MSC-secreted TGF-β induces the proliferation of regulatory T cells as 
TGF-β deficient MSCs could not generate regulatory T cells in vitro (Wang et al., 
2017). MSC-derived TGF-β promotes Th2 phenotypes while inhibiting Th17 
responses in vitro (Kong et al., 2009). To further confirm this role, infusion of 
engineered TGF-β overexpressing BM MSCs increased Th2 response in a model of 
type 1 diabetes, which resulted in increased therapeutic potential compared to 
control BM MSCs (Daneshmandi et al., 2017).  
MSC-derived TGF-β not only modulates T cells, but also macrophages as it 
promotes anti-inflammatory phenotypes. As an example, Song et al. 
demonstrated that infusion of MSCs into an experimental asthma model 
alleviated the symptoms by promoting the polarization of M2 macrophages in the 
lungs and it was TGF-β-mediated, as inhibition of TGF-β signalling abolished the 
therapeutic effect of infused MSCs (Song et al., 2015). Altogether, TGF-β 
secretion would be highly beneficial in any clinical setting to dampen 
inflammation; thus, according to the increased transcript levels by Ad MScs 
under inflammatory conditions we could again hypothesise that Ad MSCs could 
have an increased therapeutic potential compared to BM and Is MSCs. However, 
protein secretion would have to be assessed to further confirm this hypothesis.  
Vascular endothelial growth factor (VEGF), also known as vascular permeability 
factor (VPF), is secreted by most cell types including macrophages, platelets and 
keratinocytes, but usually not by endothelial cells themselves (Maharaj and 
D'Amore, 2007). VEGF was originally described to promote endothelial cell 
permeability, proliferation and angiogenesis however, its roles are not only 
associated with the vascular system but also with the formation of bone (Gerber 
et al., 1999), haematopoiesis (Ferrara et al., 1996), wound healing (Chintalgattu 
et al., 2003) and development (Reichardt and Tomaselli, 1991). However, 
upregulation of VEGF is also involved in the development of inflammatory 
diseases as rheumatoid arthritis (Lee et al., 2001), psoriasis (Detmar et al., 
1994), atherosclerosis (Zhao and Zhang, 2018) and cancer (Carmeliet, 2005).  
BM, Is and Ad MSCs transcribed high levels of VEGFa (Figure 6-3, H) and VEGFd 
(K) while they had low VEGFb (I) and VEGFc (J) transcript levels under resting 
conditions. MSCs from the three sources were secreting close to 0.1 pg of VEGF 
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per mg of total protein (Figure 6-5, B) and despite the downregulation of VEGF 
transcript levels after stimulatory licensing, 24 hour cytokine licensing led to the 
upregulation of VEGF secretion by MSCs from all sources. Is MSCs secreted the 
most VEGF under resting and stimulatory conditions. Secretion of VEGF by 
murine BM and human BM and Ad MSCs has previously been reported (Ge et al., 
2018, Lu et al., 2018, Kagiwada et al., 2008), but to my knowledge differences 
in VEGF transcription and secretion by murine BM, Is and Ad MSCs has not been 
documented.  
Secretion of VEGF by MSCs is most likely beneficial within a clinical setting due 
to its role in angiogenesis. VEGF is a key mediator of angiogenesis in cancer 
enabling development and growth of the tumour; for this reason, anti-VEGF is 
used to reduce the production of tumour vasculature and reduce the growth and 
progression potential. However, this leads to hypertension, proteinuria, 
impaired wound healing, haemorrhage and thrombosis, endocrine dysfunction 
and cardiac impairment, which shows how essential VEGF is for maintaining 
homeostasis (Kamba and McDonald, 2007).  
Liver transplantation is commonly followed by hepatic ischemia/ reperfusion 
injury, which is treated with endothelial precursor cell transplantation. 
Administration of exogenous VEGF prior to endothelial precursor cell 
transplantation significantly reduced liver transaminase levels, hepatocellular 
injury levels and hepatic apoptosis levels significantly decreasing hepatic 
ischemia/ reperfusion injury and increasing graft survival (Cao et al., 2017).  
Transfection of VEGF gene into bone MSCs led to a better therapeutic outcome 
on endometrial regeneration and endometrial receptivity compared to MSC-only 
controls in a thin endometrium rat model (Jing et al., 2018). Moreover, 
transplantation of VEGF-overexpressing BM MSCs promoted the 
neovascularization and decreased senile plaques in hippocampal specific layers 
in a murine model of Alzheimer’s disease (Garcia et al., 2014). VEGF has been 
described to promote the therapeutic efficacy of MSC derived extracellular 
vesicles against neonatal hyperoxic lung injury (Ahn et al., 2018). VEGF secreted 
by MSCs has been described to improve myocardial survival and to improve the 
engraftment of infused MSCs within infarcted hearts (Tang et al., 2011); 
moreover, VEGF is also involved in decreasing cardiac apoptosis in a rat model of 
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myocardial infarction (Song et al., 2017). For these reasons, we consider that 
expression of VEGF by MSCs could be therapeutically beneficial within a clinical 
setting and as Is MSCs secreted the most VEGF, infusion of MSCs isolated from 
the islets could have a better clinical outcome in transplantation than infusion of 
BM and Ad MSCs.  
iNOS is an inducible nitric oxide synthase expressed by macrophages, T cells and 
DCs that upon inflammatory activation produces large quantities of nitric oxide, 
an important pro-inflammatory cytotoxic agent involved in immunity. However, 
iNOS is also involved in the regulation of differentiation and function of immune 
cells and therefore, iNOS has an important immunomodulatory role. iNOS inhibits 
the production of IL-12 in DCs and macrophages and in this manner, it inhibits 
differentiation towards Th1 phenotype (Xiong et al., 2004). Moreover, iNOS 
expression by T cells also inhibits Th17 differentiation and pro-inflammatory 
phenotypes in macrophages and DCs as iNOS knock out mice exhibit increased 
Th17 subsets and pro-inflammatory macrophages and DCs (Xue et al., 2018). Due 
to its immunomodulatory role, iNOS has been described to be deregulated in 
several disease models including hepatocellular carcinoma and Parkinson’s 
disease (Calvisi et al., 2008, Koppula et al., 2012).  
BM, Is and Ad MSCs transcribed (Figure 6-3, N) low levels of iNOS under resting 
conditions and cytokine-mediated stimulation upregulated iNOS transcript levels 
in MSCs isolated from all tissue sources. Under resting conditions, BM MSCs 
transcribed higher iNOS transcript levels than Is and Ad MSCs, while Is MSCs 
transcribed the highest iNOS transcript levels after cytokine-mediated 
stimulation.  
MSC-mediated iNOS expression and secretion could be beneficial within a clinical 
setting due to its role suppressing allogeneic effector T cells as well as 
promoting the expansion of CD4+ Foxp3+ regulatory T cells (Conde et al., 2015, 
Riquelme et al., 2013). In fact, in a model of systemic sclerosis induced by 
hypochlorite in mice, MSCs isolated from iNOS knocked out mice were unable to 
exert the anti-fibrotic properties exerted by WT MSCs, and thus, did not promote 
a reduction of skin thickness and collagen deposition as compared to MSCs 
isolated from WT mice (Maria et al., 2018). Furthermore, MSCs isolated from 
iNOS KO mice were unable to suppress T cell proliferation in vitro and their co-
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administration with ovalbumin in ovalbumin-immunised mice enhanced the 
immune response compared to WT MSCs (Ren et al., 2008). It is important to 
bear in mind that there are more mechanisms involved in MSC-mediated 
immunosuppression as blocking of IDO, the human equivalent to iNOS in mouse, 
was only able to partially inhibit the immunosuppressive functions of amnion 
MSCs (Meesuk et al., 2016). However, expression of iNOS could be highly 
beneficial within a clinical setting. Is MSCs transcribed the highest levels of iNOS 
transcript levels under inflammatory conditions, however, iNOS secretion and its 
T cell proliferation potential would have to be assessed to allow us to conclude 
that Is MSCs could be a better source for MSC isolation to use as cellular 
immunomodulatory therapeutics.  
To summarise and conclude, this chapter aimed to determine if murine MSCs 
isolated from different tissues had a specific pattern of TLRs, complement 
system and other immunoregulatory molecule expression at a transcriptional, 
and most importantly, protein level.  
BM, Is and Ad MSCs all had very low transcript levels of TLRs under resting and 
stimulatory conditions, which suggests that they are not key regulators of MSC 
function. Regarding the complement system, these molecules were transcribed 
at low levels and no differences where observed except for CFH, C1Qc and 
C5AR1. BM MSCs expressed the highest CFH transcript levels while C1Qc and 
C5AR1 transcript levels were higher in Is MSCs under resting conditions. 24-hour 
cytokine-mediated licensing led to the downregulation of these transcripts in 
MSCs from every source.  
Among the immunomodulatory molecules studied, only IL-6 and VEGF were 
transcribed at high levels and were affected by MSC licensing. Under resting 
conditions Ad MSCs secreted the most IL-6 but 24-hour cytokine-mediated 
licensing led to high levels of IL-6 secretion by BM, Is and Ad MSCs. Under resting 
conditions Is MSCs secreted the most VEGF but 24-hour cytokine-mediated 
licensing led to a higher secretion by Is MSCs. This chapter showed differential 
immunoregulatory and angiogenic potential of MSCs depending on their tissue 
origin and suggests that MSCs isolated from various tissues may act differently in 
vivo. For this reason, to have a better understanding of the behaviour of MSCs 
from different sources in vivo, co-transplantation of MSCs to evaluate the fate of 
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the graft would be essential. Moreover, knocking out IL-6 and VEGF would help 
to understand the role of these molecules in a clinical setting. 
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7 General Discussion  
7.1 Introduction 
MSCs have the ability to self-renew and differentiate, have low levels of MHC 
Class I expression and lack the expression of MHC Class II and co-stimulatory 
molecules, which has raised the biologic and clinic interest in MSCs. BM MSCs 
were the first MSCs to be isolated and are therefore the most researched and 
clinically used source of MSCs. However, their isolation involves an invasive and 
painful procedure. As MSCs can be isolated from a large variety of tissues, 
alternative sources which are more easily accessible could be more suitable for 
clinical use. Adipose tissue, umbilical cord and islets of Langerhans are easily 
accessible, they are clinical waste so there is no burden on the donor and MSCs 
have an increased frequency in these sources. As an example, adipose tissue 
yields a 500-fold higher frequency of colony forming units (CFU-F) than bone 
marrow and can be obtained easily (Fraser et al., 2006); MSCs from the umbilical 
cord could also be a good choice as they are very abundant and they are 
ontogenically primitive (Choudhery et al., 2013). Different isolation, enrichment 
and culture protocols, as well as the intrinsic variability among MSCs derived 
from different donors/ tissues has led to contradictory results in the literature 
regarding their immunomodulatory and regenerative potential. In addition, MSCs 
are often infused within an inflammatory environment, which makes it essential 
to study their properties both under resting and inflammatory conditions. As a 
result of inflammatory stimulation, MSCs increase MHC Class I and MHC Class II 
expression, leading to both cell-mediated and humoral immune responses when 
human MSCs are infused in murine models, which confounds interpretation of 
results (Eliopoulos et al., 2005, Joswig et al., 2017, Thirlwell, 2018).  
Thus, considering the limitations of studies carried out with human MSCs, the 
aim of this study was to isolate, study and compare, through a stringent set of 
standardised techniques, the potential in vivo function of murine BM, Is and Ad 
MSCs under resting and inflammatory conditions. This would provide insight into 
the role of tissue source in the therapeutic potential of MSCs and would 
potentially allow the identification of a preferred tissue source for MSC isolation 
for use within the clinic, with a particular focus on the co-transplantation of 
MSCs with islets of Langerhans to treat individuals with type 1 diabetes mellitus 
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(T1DM), which is a major area of study in the SNBTS group. To address this, four 
key questions were considered: 
o Are cells isolated from murine bone marrow, islets of Langerhans 
and adipose tissue true MSCs? Do they have the same phenotype? 
o What is the migratory potential of murine MSCs when infused into a 
mouse? Does the tissue origin of MSCs impact this?  
o Are MSCs able to recruit immune cells? Does MSC microenvironment 
(stimulation) impact the recruitment capability of MSCs? Does 
tissue source of origin affect MSCs recruitment potential? 
o How do MSCs interact and immunomodulate surrounding tissues? 
Does MSC microenvironment (stimulation) and tissue origin 
influence their behaviour? 
Chapter 3 of this thesis focused on question number one and studied whether 
cells isolated from the bone marrow, islets of Langerhans and adipose tissue 
satisfied the minimum criteria outlined by the International Society of Cellular 
Therapy (ISCT) for human MSCs (Dominici et al., 2006). Although adherence and 
trilineage differentiation are characteristics of murine MSCs, the surface marker 
phenotype is not so well characterised, and variations might apply. The ability to 
adhere to plastic and the phenotypic properties of these cells was assessed 
throughout passage. As required by the ISCT, the surface molecule expression, 
size and granularity of the cells was studied under resting and stimulatory 
conditions. Moreover, trilineage differentiation potential into adipocytes, 
chondrocytes and osteocytes was assessed in cells isolated from the three 
tissues.  
Chapter 4 addressed question number two. Transcript levels of chemokine 
receptors expressed by MSCs were assessed under resting and inflammatory 
conditions to understand if MSCs possessed migratory capacity and if MSC tissue 
origin could affect their migratory potential. 
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Chapters 4 and 5 addressed question number three. An extensive assessment of 
the chemokine ligands expressed by MSCs at a transcript level under resting and 
inflammatory conditions highlighted genes of interest to be assessed at a protein 
level (Chapter 4). Chemokine secretion by MSCs was examined to predict the 
leukocyte recruitment potential of MSCs under resting and inflammatory 
conditions. After showing that MSCs transcribed and secreted a distinct set of 
chemokines under homeostatic and inflammatory conditions, chemokine function 
was studied in vivo (Chapter 5) by assessing the immune cell attraction profile of 
MSCs. 
Chapter 6 answered question number four. An extensive assessment of toll like 
receptors, complement system and anti-inflammatory and immunomodulatory 
genes expressed by MSCs at transcript level, under resting and inflammatory 
conditions, highlighted genes of interest to be assessed at the protein level. This 
knowledge provided a better understanding into how MSCs might interact with 
and immunomodulate the immune cells they recruit. The following section will 
discuss these findings and their relevance within specific areas of clinical 
relevance. 
 
7.2 The tissue origin of MSCs could impact their 
performance within the clinic  
Cells isolated from bone marrow, islets of Langerhans and adipose tissue were 
plastic adherent, expressed high levels of the widely used CD90, CD105 and CD73 
MSC markers and had trilineage differentiation potential. In contrast to human 
MSCs, cells isolated from the bone marrow and islets of Langerhans were CD45+ 
CD11b+ and, for this reason, did not meet ISCT criteria.  ISCT criteria were 
established for the identification of human MSCs and although adherence and 
trilineage differentiation potential are characteristics of murine MSCs, the 
surface marker phenotype of murine MSCs is not so well characterised. In fact, 
induction of CD45 expression on murine BM MSCs has already been described 
(Yeh et al., 2006). The lack of CD64 expression rules out a myeloid origin of 
these cells, while CD146 positive expression enables to discriminate MSCs from 
fibroblasts. Under resting conditions, MSCs from the three tissues were 
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expressing very low levels of MHC Class I and II molecules, which is essential to 
avoid recognition by the recipient’s immune system and subsequent rejection. 
Inflammatory conditions upregulated the expression of MHC Class I, which avoids 
recognition and cytotoxic activity by NK cells. Thus, based on plastic adherence, 
trilineage differentiation potential and CD90, CD105 and CD73 expression, we 
determined that cells isolated from the bone marrow, islets of Langerhans and 
adipose tissue were MSCs regardless of CD45 and CD11b expression. Moreover, 
specific criteria to enable the identification of murine MSCs should be 
established. 
MSCs are often infused within an inflammatory environment and their clinical 
performance is often monitored by the resolution of symptoms, or in the case of 
transplantation, the promotion of graft survival (Ankrum et al., 2014, English 
and Wood, 2013). The efficacy of MSCs within the clinic depends on several 
factors including the ability of MSCs to migrate into target tissues and the 
potential of MSCs to interact and immunomodulate the surrounding tissues and 
immune cells (Kean et al., 2013). One of the most critical aspects of MSC use as 
cellular therapeutics is related to MSC homing and engraftment within the target 
tissue following their administration. MSCs can be infused systemically, where 
MSCs are administered intra-venously or intra-arterially and the cells must exit 
the circulation and migrate to the site of injury, or can be administered locally 
at the target tissue and are then guided to the site of injury (Nitzsche et al., 
2017). After systemic administration, the majority of the cells are found in the 
lungs and only a small percentage of the cells home to, and remain in, the 
target tissue.  
The size of the cells could be an essential factor involved in lung trapping. For 
this reason, the size of MSCs was compared among tissue sources (Figure 3-17). 
Murine BM MSCs are smaller than Is and Ad MSCs, which suggests that they could 
be a better source of MSC if being delivered intravenously as their smaller size 
may prevent lung entrapment. However, in humans, size of MSCs does not vary 
significantly between tissue sources and thus, it is not valid interpretation for 
human therapy (Thirlwell, 2018). MSCs are well described for their anti-
inflammatory and immunomodulatory properties. Many of these molecules are 
stored in granules; BM MSC are more granular than Is and Ad MSCs, suggesting 
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more extensive storage of clinically beneficial molecules (Figure 3-17). These 
data correlate with human MSCs, as BM MSCs have previously been described to 
be more granular than Is and Ad MSCs under both resting and inflammatory 
conditions (Thirlwell, 2018).  
Specific chemokines have been shown to target immune cells to specific tissues. 
For example, CCR7 targets MSCs to secondary lymphoid organs (Li et al., 2014, 
Ma et al., 2016), CXCR3-deficient MSCs fail to infiltrate into the nephritic kidney 
(Lee et al., 2018) and CXCR4 receptor overexpression in MSCs improves 
treatment of acute lung injury (Yang et al., 2015). Moreover, the expression of 
CCR1 in macrophages and neutrophils leads to kidney infiltration in renal 
ischemia-reperfusion injury (Furuichi et al., 2008); CCR5 directs CD8+ T cells 
towards the brain (Martin-Blondel et al., 2016); CCR3, CCR4 and CCR10 are 
highly expressed by T cells in skin (Fujimoto et al., 2008, Ma et al., 2002); 
CXCR3 mediates T cell recruitment into the kidney (Panzer et al., 2007); and 
CXCR6 is highly expressed by liver-infiltrating CD8+ T cells (Sato et al., 2005b). 
Therefore, we hypothesise that the expression of these chemokines could 
potentially target MSCs into those tissues. BM MSCs transcribed significantly 
higher levels of CCR7, CXCR6 and ACKR4; Is MSCs transcribed significantly higher 
levels of CCR1, CCR10 and CXCR3, while Ad MSCs transcribed significantly higher 
levels of CCR3 (Figure 4-10). Therefore, we hypothesise that CCR7 and CXCR6 
expression would direct BM MSCs towards lymphoid organs such as the spleen, 
the lymph nodes and the liver and thus, BM MSCs would be ideal candidates for 
dampening inflammation in the liver after transplantation. Is MSCs have an 
enhanced potential to migrate towards the kidneys due to their CCR1 and CXCR3 
expression; thus, islets of Langerhans would be the best tissue source for MSC 
isolation when used as cell therapeutics to dampen inflammation within the 
kidneys. Lastly, Ad MSCs transcribed statistically significantly more CCR3 than Is 
and BM MSCs and therefore, they have a greater potential to migrate to the skin 
and to be more beneficial dampening and regulating excessive inflammation in 
psoriasis and other skin conditions. In contrast, due to the increased 
transcription of CXCR4 by Ad MSCs, if infused systemically Ad MSCs are more 
likely to remain in the lungs or to migrate towards the bone marrow. However, 
Ad MSCs transcribed the lowest levels of chemokines receptors apart from 
CXCR4, which suggests that if infused at the target tissue they are more likely to 
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remain in place. These hypotheses have been formulated from transcript 
analysis data in murine MSCs. Thus, experiments on chemokine receptor 
expression and functionality and a critical comparison with the expression of 
chemokine receptors on human MSCs would be essential to translate these 
results into human therapy. Based on chemokine receptor expression at 
transcript level, the tissue of choice to isolate MSCs to enhance migration and 
retention towards specific anatomical location is represented in Figure 7-1. 
 
Figure 7-1. Overview of chemokine receptor expression by MSCs at transcript level under 
resting and inflammatory conditions. 
Chemokine receptor expression by BM, Is and Ad MSCs were compared to each other in resting 
and inflammatory conditions to understand which tissue source of MSC expressed the highest 
levels of chemokine receptors. Colour coding highlights tissue sources that transcribed receptors at 
the highest (yellow), medium (grey) and lowest (blue) levels. BM MSCs transcribed the highest 
levels of CCR7 and CXCR6, suggesting that bone marrow might be the preferred tissue to isolate 
MSCs to enhance migration towards the lymph nodes. Conversely, Is MSCs transcribed the 
highest levels of CCR1, CXCR3 and CCR5, suggesting that islets of Langerhans might be the 
desired source of MSCs to promote trafficking towards the kidneys and brain, respectively. Ad 
MSCs, on the contrary, transcribed the highest levels of CCR3 and CXCR4, suggesting that 
adipose tissue could be the preferred tissue for MSC isolation to enhance migration towards the 
skin and the lungs and BM, respectively. Transcriptional expression does not always correlate to 
protein expression and therefore, a rigorous testing of receptors at protein level is required. 
Transcript data shown here is summarised from Chapter 4, Figure 4-3 and Figure 4-4.  
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Through the assessment of chemokine ligand expression at transcript and protein 
level this study highlighted that MSCs isolated from different tissue sources were 
able to secrete pro-inflammatory, angiogenic and angiostatic chemokines that 
have the potential to recruit and interact with the surrounding cells. Under 
resting conditions, all MSCs regardless of tissue source of origin had a similar 
chemokine secretion profile, where CCL2 was the top chemokine secreted by all 
MSC populations (Figure 4-11). Furthermore, CCL2 is also the top chemokine 
secreted by human MSCs regardless of the tissue of origin, under resting 
conditions (Thirlwell, 2018). Despite the low secretion of chemokines, infusion 
of MSCs from the three sources into the air pouch did not lead to a recruitment 
of leukocytes above control levels (Figure 5-5).  
Inflammatory stimulation of MSCs led to the upregulation of transcription and 
secretion of chemokines in MSCs from the three sources (Figure 4-11). CCL2, 
CCL5, CXCL1 and CXCL10 were the most upregulated chemokines and secretion 
levels depended on tissue source of origin. Inflammatory stimulation with a 
cytokine cocktail also resulted in increased secretion of CCL2, CXCL1 and CXCL8, 
the equivalent of CXCL1 in mice, by human BM, Is and Ad MSCs (Thirlwell, 2018). 
Is MSCs secreted the highest levels of the chemokines studied except for CXCL12, 
which was secreted at higher levels by BM MSCs. CCL2, CCL5 and CXCL1 are 
strong chemoattractants, however, despite higher secretion by Is MSCs under 
inflammatory conditions, Ad MSCs were able to recruit significantly more 
leukocytes into the air pouches of mice than BM and Is MSCs. An overview of the 
chemokines that MSCs expressed at protein level and the subsequent in vivo 
immune cell recruitment by MSCs under resting and inflammatory conditions is 
provided in Figure 7-2. More importantly, Ad MSCs were the only MSCs able to 
support the recruitment of small numbers of T cells. Recipient cytotoxic cells 
are essential to initiate MSC-mediated immunosuppression in a murine model of 
GVHD as MSCs need to be targeted by cytotoxic T cells to undergo apoptosis, be 
engulfed by macrophages and produce IDO (Galleu et al., 2017). As Ad MSCs are 
the only MSCs able to support the recruitment of T cells we could hypothesise 
that they have a greater immunosuppressive potential than BM and Is MSCs 
(Figure 5-5).  
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Figure 7-2. Summary of the CC and CXC chemokines MSCs transcribed, secreted and the 
subsequent immune cell attraction under homeostatic and inflammatory conditions.  
Colour coding highlights tissue sources that secreted chemokines at the highest (yellow), medium 
(grey) and lowest (blue) levels. The immune cells that each chemokine could potentially attract are  
highlighted by colour coded lines that match specific immune cells. The same colour coding system 
was implemented (blue-grey-yellow) based on the number of immune cells MSCs attracted in vivo 
under resting and stimulatory conditions.  
 
Chemokines do not only have the potential to recruit leukocytes but also have 
angiogenic and angiostatic roles. CXCL1, CXCL2 and CXCL12 have angiogenic 
properties, while CXCL10 has angiostatic potential. Is MSCs have the highest 
secretion of these four chemokines and it is therefore difficult to predict the 
overall effect of the secretion of the four chemokines altogether. On the one 
hand, Is MSCs have the potential to promote angiogenesis the most, while they 
have the potential to inhibit it the most compared to BM and Ad MSCs. High 
secretion of angiogenic chemokines would be of importance in transplantation to 
promote graft re-vascularization. However, if MSCs were infused within a tumour 
environment, high secretion of angiogenic chemokines would be detrimental, 
while the secretion of CXCL10 would be beneficial to suppress tumour growth.  
Chemokines are not the only molecules secreted by MSCs with the potential to 
regulate angiogenesis. VEGF, hepatocyte growth factor (HGF) and matrix 
metalloproteinases (MMP) are well-known pro-angiogenic mediators involved in 
revascularisation (Cheng et al., 2007, Golocheikine et al., 2010, Olsson et al., 
2006). Moreover, IL-6 can increase VEGF expression and can therefore, promote 
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angiogenesis (Huang et al., 2004). In Chapter 6, the transcription of IL-6, VEGF, 
HGF and MMP9 (Figure 6-3), as well as the secretion of IL-6 and VEGF (Figure 
6-7) were studied.  
IL-6 transcription levels were similar in MSCs from the three sources under 
resting conditions; inflammatory conditions upregulated the transcription in 
MSCs from every source but BM MSCs upregulated IL-6 transcription the most. 
Despite similar levels of transcription under resting conditions, Ad MSCs secreted 
the most IL-6, while inflammatory stimulation led to similar levels of secretion 
by MSCs from the three sources. Therefore, MSCs from the three sources have 
the same potential for VEGF production and secretion.  
VEGFa, VEGFb, VEGFc and VEGFd were downregulated after inflammatory 
stimulation in MSCs from the three sources. Ad MSCs transcribed the most VEGFa 
and VEGFc, while BM MSCs had the highest transcript levels of VEGFb and VEGFd. 
However, transcript levels do not correlate with protein level in this case, as Is 
MSCs secreted the most VEGF under resting and stimulatory conditions and 24-
hour cytokine-mediated stimulation increased the secretion of VEGF in MSCs 
from the three sources. The increased secretion of VEGF suggests that Is MSCs 
would be the preferential tissue source of MSC to promote angiogenesis.  
Under resting conditions, BM MSCs transcribed the highest levels of HGF and the 
transcript levels decreased after inflammatory stimulation in the three sources 
of MSCs. MMP9 was transcribed at similar levels by MSCs from the three sources 
and inflammatory stimulation did not influence its transcription. Due to the 
increased secretion of CXCL1, CXCL2 and CXCL12 as well as VEGF, we 
hypothesise that Is MSCs could have greater re-vascularisation potential.  
More importantly, MSCs not only regulate angiogenesis but also immunomodulate 
their surroundings by inhibition of effector T cell proliferation as well as 
promoting a regulatory phenotype of leukocytes via the secretion of anti-
inflammatory and immunomodulatory molecules, including IL-10, TSG-6, TGF-β, 
IDO and CD274 (Choi et al., 2008, Li et al., 2019b, Niu et al., 2017, Davies et al., 
2017, Chinnadurai et al., 2018). IL-10, and TSG-6 secretion not only suppresses  T 
cell proliferation, but also secretion of IFN-γ and other pro-inflammatory 
cytokines (Deniz et al., 2008, Choi et al., 2008, Li et al., 2019b, Chinnadurai et 
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al., 2018). Moreover, MSCs secrete TGF-β, which upon interaction with 
glycoprotein A repetitions predominant (GARP) in regulatory T cells, activates 
Tregs, which is indispensable for effector T cells suppression (Niu et al., 2017). 
Similarly, iNOS, the murine equivalent of IDO is able to suppress allogeneic T 
cells as well as to promote the expansion of CD4+ Foxp3+ regulatory T cells, 
enabling in this way graft tolerance (Conde et al., 2015, Riquelme et al., 2013). 
CD274, also known as programmed death 1 ligand, is an important regulator of T 
cell activation and in addition to MSC-surface expression, MSCs are also able to 
secrete it to mediate immunosuppression in a contact-independent manner 
(Davies et al., 2017).  
In Chapter 6, the transcription of IL-10, TSG-6, TGF-β, iNOS and CD274 was 
assessed. IL-10, TSG-6 and TGF-β transcript levels were downregulated after 
inflammatory stimulation, while iNOS and CD274 transcript levels were 
upregulated. BM MSCs transcribed the most TSG-6, Is MSCs transcribed the most 
iNOS and Ad MSCs transcribed the most IL-10, TGF-β and CD274 (Figure 6-3). 
Among all these molecules, iNOS was transcribed at the highest levels and IDO is 
at least in part, involved in the suppressive effect of MSCs on cytotoxic cell 
proliferation, and thus, immunomodulation. For this reason, Is MSCs could have 
an increased immunosuppressive potential compared to BM and Ad MSCs.  
Complement factor H is a complement regulatory protein that regulates 
complement mediated cell destruction by disrupting C3b and suppressing, in this 
way, the formation of C3 convertases. MSCs have been shown to secrete CFH 
under resting conditions and this secretion has been documented to increase 
under inflammatory conditions, where human BM MSCs were secreting 
significantly higher amounts of CFH than Is and Ad MSCs (Thirlwell, 2018). In this 
study, we showed that BM MSCs transcribed statistically significantly more CFH 
than Is and Ad MSCs under resting and stimulatory conditions; however, 
inflammatory stimulation resulted in the downregulation of CFH transcript levels 
in MSCs from every source (Figure 6-2). Despite RNA levels not always correlating 
with protein levels, if we assume that transcription levels of CFH are 
proportionately maintained at the protein level, BM MSCs would be secreting the 
most CFH. Therefore, we could hypothesise that BM MSCs would have better 
therapeutic potential than Is and Ad MSCs due to their increased potential to 
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suppress complement system activation. A summary of the expression at 
transcript and protein level of angiogenic, angiostatic and anti-inflammatory 
molecules by BM, Is and Ad MSCs under resting and inflammatory conditions is 
provided in Figure 7-3.  
 
Figure 7-3. Summary of the angiogenic, angiostatic and anti-inflammatory molecules 
transcribed and secreted by MSCs under resting and inflammatory conditions.  
Colour coding highlights tissue sources that transcribed (left hand side) and secreted (right hand 
side) angiogenic, angiostatic and anti-inflammatory molecules at the highest (yellow), medium 
(grey) and lowest (blue) levels. 
 
To summarise, the answers to the questions outlined in the introduction of this 
chapter: 
1) Are cells isolated from murine bone marrow, islets of Langerhans and 
adipose tissue MSCs? Do they have the same phenotype? Cells isolated from 
the three sources are spindle-shaped plastic-adherent cells with trilineage 
potential. However, tissue origin affects size and granularity as well as CD45 
and CD11b expression. ISCT criteria were established for the identification of 
human MSCs and the surface marker phenotype of murine MSCs is not so well 
characterised. For this reason, based on plastic adherence, trilineage 
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differentiation potential and CD90, CD105 and CD73 expression, we 
determined that cells isolated from the bone marrow, islets of Langerhans 
and adipose tissue were MSCs and that specific criteria to enable the 
identification of murine MSCs should be established. More importantly, unlike 
BM and Ad MSCs, cells isolated from the islets of Langerhans undergo an 
epithelial to mesenchymal transition to give rise to MSCs and we hypothesise 
that these cells lose the CD45 and CD11b positive expression as a result of 
this transition.  
2) What is the migratory potential of murine MSCs when infused into a 
mouse? Does the tissue origin of MSCs impact this? MSCs from the three 
sources transcribed very low levels of chemokine receptors. However, based 
on these transcripts MSCs could migrate to the lymph nodes, kidneys, brain, 
skin and lungs. More importantly, the source of MSC isolation affects the 
transcription levels of chemokine receptors suggesting that particular tissue 
sources might increase the potential to get entrapped in the lungs or to 
migrate towards specific anatomical sites. 
3) Are MSCs able to recruit immune cells? Does MSC microenvironment 
(stimulation) impact the recruitment capability of MSCs? Does tissue 
source of origin affect MSCs recruitment potential? Under resting 
conditions, all MSCs, regardless of tissue source of origin, had a similar 
chemokine secretion profile, where CCL2 was the top chemokine secreted by 
all MSC populations. CCL2 has the potential to recruit monocytes and 
macrophages with high affinity however, CCL2 secretion did not support 
leukocyte recruitment above background levels in vivo. Inflammatory 
stimulation of MSCs resulted in upregulated secretion of neutrophil and 
monocyte/ macrophage chemoattractants, which was mirrored by the 
recruitment of these cells towards MSCs from the three sources. However, 
the tissue of origin dictated the chemokine secretion levels and more 
importantly, secretion levels did not correlate with recruitment levels in 
vivo, suggesting that more factors are involved in leukocyte recruitment.  
4) How do MSCs interact and immunomodulate surrounding tissues? Does MSC 
microenvironment (stimulation) and tissue origin influence their 
behaviour? Under resting conditions, MSCs from the three sources 
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transcribed and secreted angiogenic and immunomodulatory mediators. 
However, transcription and expression levels were tissue source of origin 
dependent. Moreover, inflammatory stimulation influenced each gene and 
protein in a different manner and no trends were observed. These findings 
show the complexity of this field and suggest that MSCs isolated from specific 
tissue sources might possess greater immunomodulatory capacity on the 
immune cells they attract as well as on the tissue resident cells.  
 
Altogether, this thesis has shown that BM, Is and Ad MSCs had differential 
transcription levels of chemokine receptors that could influence their migratory 
potential, as well as differential chemokine, anti-inflammatory and angiogenic 
molecule secretion profiles. Thus, the data presented in this thesis suggest that 
MSCs isolated from specific tissues might be more beneficial than other tissue 
sources of MSCs in distinct clinical settings. For the purpose of this discussion, I 
will focus on three clinical settings, transplantation and the autoimmune 
diseases psoriasis and arthritis, and I will discuss the potential benefits of MSCs 
as a cellular therapy in these settings and whether tissue source of origin could 
influence outcome.  
7.2.1 The optimal tissue for MSC isolation to co-transplant with 
islets of Langerhans 
As T1DM results from the destruction of insulin-producing cells within the islets 
of Langerhans in the pancreas, pancreas solid organ transplantation (SOT) seems 
like a reasonable approach. However, it involves major surgery that carries 
considerable risk of complications, including organ rejection, and is therefore 
only performed with simultaneous kidney transplantation in diabetic patients in 
end-stage kidney disease who would already be administered immunosuppressive 
drugs due to the kidney graft (Chiang et al., 2014). Thus, islet transplantation is 
an attractive alternative to SOT because the transplantation of a smaller tissue 
mass makes it minimally invasive and reduces the need for immunosuppression 
after transplantation (Figliuzzi et al., 2014). The success of islet transplantation 
expressed as insulin independence 5 years after transplantation is 25% to 50% in 
international cohort studies (Barton et al., 2012, Bellin et al., 2012). Graft 
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rejection and failure of islets re-vascularisation are the causes of the low 
success rate (Ritz-Laser et al., 2002, Blondet et al., 2007, Wood and Goto, 
2012). Both innate and adaptive immune responses are involved in graft 
rejection and involve multiple processes including activation of complement 
system, antibody mediated rejection, alloantigen specific induction of T cell 
proliferation and the activation of T cell effector functions (Tjernberg et al., 
2008). The anti-inflammatory, immunomodulatory and pro-regenerative 
properties of MSCs make them a promising candidate for co-transplantation with 
islets of Langerhans to improve long-term islet transplant function by reducing 
graft rejection, whilst increasing survival. In fact, diabetic immunodeficient and 
immunocompetent mouse models support the success of this approach (Forbes et 
al., 2020).  
The liver is the favoured islet transplantation site due to its high vascularization 
and the bolus of islets is typically infused into the hepatic portal vein. However, 
islet infusion through this vein can increase the blood pressure, activating the 
endothelium and promoting leukocyte recruitment into the liver leading to 
portal vein thrombosis (Kariya et al., 2016, Lalor et al., 2002). For this reason, 
alternative sources for islet transplantation, including the kidney capsule and 
the liver surface, are being investigated in mouse models (Fujita et al., 2018, 
Rajab et al., 2008). To date, the portal vein is the primary site for clinical islet 
transplantation, for this reason, minimising the size of the graft to avoid portal 
vein thrombosis is essential. Thus, it is important to consider the size of the co-
transplanted MSCs to minimise unwanted inflammation. In the current study, 
murine BM MSCs were smaller than Is and Ad MSCs (Figure 3–17) under resting 
and inflammatory conditions, which suggests that infusion of BM MSCs would 
minimise the development of portal vein thrombosis. However, as previously 
mentioned, in humans, size of MSCs does not vary significantly between tissue 
sources and thus, it is not valid interpretation for human therapy (Thirlwell, 
2018). CCR7 transcript levels were statistically significantly higher in BM MSCs 
compared to Is and Ad MSCs under resting and inflammatory conditions (Figure 4-
3). Moreover, CXCR6 transcription levels were higher in BM MSCs compared to Is 
and Ad MSCs under resting conditions, while no variation was observed under 
inflammatory conditions (Figure 4-4). CCR7 programs naïve T cells and B cells to 
migrate to the spleen and lymph nodes (Bjorkdahl et al., 2003), while CXCR6 has 
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been reported to be involved in immune cell trafficking and retention within the 
liver as it is highly expressed by liver-infiltrating CD8+ T cells (Sato et al., 
2005b). Moreover, human BM MSCs have also been shown to express higher levels 
of CXCR6 than human Is and Ad MSCs (Thirlwell, 2018). These observations 
suggest that BM MSCs could possess enhanced migratory and retention capacity 
within the liver and could therefore deliver greater therapeutic effects than Is 
and Ad MSCs when infused with the bolus of islets into the hepatic portal vein or 
on the surface of the liver. In contrast, Is MSCs express higher CXCR3 transcript 
levels than BM and Ad MSCs; thus, Is MSCs could have better clinical outcome if 
co-transplanted with the islets in the kidney capsule (Figure 4-4).  
Once MSCs and islets are infused into the liver, islets must engraft to restore 
glycaemic awareness and MSCs must therefore avoid the rejection of the 
allogeneic islets while promoting the re-vascularisation of the islets to promote 
long-term graft survival.  
When co-transplanted into a patient, any cell could have the potential to trigger 
allospecific T cells. However, MSCs do not express the key antigens involved in 
immediate rejection-ABO blood group antigens (Moll et al., 2014). This is an 
essential factor in humans but not in mice as the murine equivalent of the ABO 
group gene is a cis-AB gene that encodes a glycosyltransferase with both A and B 
transferase activity (Yamamoto et al., 2001). Moreover, mismatched MSCs should 
not promote alloreactivity as MSCs express very low levels of MHC Class I under 
resting conditions and only inflammatory stimulation can upregulate the 
expression of this key molecule involved in graft rejection (Machado et al., 
2013). This study has shown that BM, Is and Ad MSCs express very low levels of 
MHC Class II molecules and inflammatory stimulation only increases the 
expression of this marker in BM MSCs (Figure 3-18). BM MSCs expressed the 
highest levels of MHC Class I under resting conditions, Is MSCs expressed low 
levels, while Ad MSCs barely expressed this marker (Figure 3-18). Cytokine-
mediated inflammatory stimulation increased the expression of MHC Class I, with 
Is MSCs expressing the most. This study found that Ad MSCs expressed the least 
MHC Class I, suggesting that this source could be better for co-transplantation 
than BM or Is MSCs. However, MSCs lack the expression of co-stimulatory 
molecules and they are therefore unlikely to promote activation of T cells based 
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on mismatched MHC Class I expression. For these reasons, murine MSCs isolated 
from the bone marrow, islets of Langerhans and adipose tissue will not trigger 
allospecific T cells and their role will be focused on controlling the activation 
and proliferation of immune cells generated by the infusion of islets.  
After infusion of the islets into the hepatic portal vein the host’s immune system 
can trigger rejection by several mechanisms. Firstly, infusion of islets can induce 
the activation of complement, leading to the destruction of the graft (Tjernberg 
et al., 2008, Ricordi and Strom, 2004). CFH is a complement regulatory protein 
that regulates complement mediated cell destruction by disrupting C3b and 
avoiding, in this manner, the formation of C3 convertases. CFH deficiency has 
been associated with increased graft rejection and thus, CFH secretion by MSCs 
would be a beneficial mechanism for islet survival (Mella et al., 2014, Dragon-
Durey et al., 2010). Human MSCs have been reported to secrete CFH under 
resting conditions and this secretion has been shown to increase under 
inflammatory conditions, where human BM MSCs were secreting significantly 
higher amounts of CFH than Is and Ad MSCs (Thirlwell, 2018). In this study, we 
demonstrate that BM MSCs transcribed statistically significantly more CFH than Is 
and Ad MSCs under resting and stimulatory conditions; however, inflammatory 
stimulation resulted in the downregulation of CFH transcript levels in MSCs from 
every source (Figure 6-2). Despite RNA levels not always correlating with protein 
levels, if we assume that transcription levels of CFH are proportionately 
maintained at protein level, BM MSCs would be secreting the most CFH. 
Therefore, we could hypothesise that BM MSCs would have better therapeutic 
outcome than Is and Ad MSCs due to their increased potential to avoid 
complement system activation after islet transplantation.  
Secondly, infusion of islets can induce the activation of pre-existing autoimmune 
T cells within the host as well as the proliferation and activation of allogeneic T 
cells. Autoreactive CD4+ and CD8+ T cells have the potential to recognise 
identical antigens in the graft, while auto-antibodies against β-cell antigens can 
trigger an attack on the graft leading to early graft loss (Sutherland et al., 1984, 
Jaeger et al., 1997). MSCs have been widely reported to inhibit T cell 
proliferation as well as to promote a regulatory phenotype in leukocytes via the 
secretion of anti-inflammatory and immunomodulatory molecules, including IL-
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10, TSG-6, TGF-β, IDO and CD274 (Choi et al., 2008, Li et al., 2019b, Niu et al., 
2017, Davies et al., 2017, Chinnadurai et al., 2018). Among all these molecules, 
iNOS was transcribed at the highest levels and IDO is at least in part, involved in 
the suppressive effect of MSCs on cytotoxic cell proliferation, and thus, 
immunomodulation. For this reason, Is MSCs could have an increased 
immunosuppressive potential compared to BM and Ad MSCs, which would support 
graft tolerance (Figure 6-3). It is important to bear in mind that despite T cells 
triggering graft rejection, recipient cytotoxic cells are essential to initiate MSC-
mediated immunosuppression; MSCs need to be targeted by cytotoxic T cells to 
undergo apoptosis to be engulfed by macrophages and produce IDO (Galleu et 
al., 2017). 
In addition, to supress the host’s immune system to avoid rejection, MSCs must 
promote islet survival. Islets in the pancreas receive 0% to 15% of arterial blood, 
providing a very high amount of oxygen to satisfy the metabolic demands to 
fulfil the physiological activities of the islets. The process of islet isolation 
destroys the external vasculature and the partial oxygen in the liver is much 
lower than that in the pancreas; thus, revascularization of the islets is essential 
to avoid hypoxia and to ensure survival of the graft (Komatsu et al., 2018). 
Intrahepatic co-transplantation of autologous MSC and islets has been shown to 
improve islet engraftment after transplantation in a pilot study (Wang et al., 
2018). Among the three tissue sources, Is MSCs secreted the most VEGF under 
resting and stimulatory conditions and thus we hypothesise that Is MSCs would be 
the preferential tissue source of MSC to promote angiogenesis and islet re-
vascularisation. However, increased concentrations of VEGF do not correlate 
with increased re-vascularization of islets (Carlsson and Mattsson, 2002), which 
suggests the essential role of other angiogenic mediators like HGF and MMP9.  
BM MSCs transcribed the highest levels of HGF while MMP9 was transcribed at 
similar levels by MSCs from the three sources, suggesting that BM MSCs could 
have greater re-vascularisation potential, but HGF protein secretion by MSCs 
from the three sources should be studied. CXCL8 secretion by contaminating 
duct cells within the islets are currently under study to increase islet 
engraftment after transplantation (Movahedi et al., 2008). Moreover, co-
transplantation of islets and human MSCs into a diabetic mouse model has shown 
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that IL-6 and CXCL8 secretion by human MSCs enhances vascularization and 
basement membrane formation (Takahashi et al., 2018). IL-6 was secreted at 
similar levels by MSCs from the three sources while CXCL1 and CXCL2, the 
murine equivalents of CXCL8, were secreted at higher rates by Is MSCs, 
suggesting that Is MSCs could have a greater potential to promote re-
vascularization and to therefore, promote graft survival. This hypothesis is not in 
agreement with Citro et al., as they reported that inhibition of the receptors for 
CXCL1 and CXCL2 (CXCR1 and CXCR2) enhanced pancreatic islet survival after 
transplantation (Citro et al., 2012). CXCR1 and CXCR2 blockade would lead to 
decreased neutrophil recruitment towards the graft. Neutrophils are considered 
detrimental in transplantation due to their role promoting inflammation. 
However, as discussed in Chapter 5, Christoffersson et al. identified a CD11b+/ 
Gr-1+/ CXCR4high murine neutrophil subset that was recruited by VEGF-a into the 
site of islet engraftment that lead to the revascularization of transplanted islets 
(Christoffersson et al., 2012). More importantly, this neutrophil subset produced 
MMP9 and the revascularization of transplanted islets was MMP9 dependent and 
CD11b+/ Gr-1+/ CXCR4high dependent. In Chapter 5, neutrophils were the 
predominant CD45+ cell type recruited towards MSCs in vivo. Under resting 
conditions, MSCs from any source were unable to recruit neutrophils towards the 
air pouch. However, inflammatory stimulation of MSCs prior to infusion into the 
air pouch led to a statistically significant recruitment of neutrophils by MSCs 
from every source, where Ad MSCs were able to produce the highest recruitment 
of neutrophils. Therefore, I propose that MSCs could promote graft re-
vascularization not only by the well-described VEGF and HGF secretion but by 
the extensive secretion of pro-angiogenic cytokines (IL-6), matrix 
metallopeptidases (MMP9) and chemokines (CXCL1 and CXCL2) that recruit 
neutrophils. However, this hypothesis is based on an air pouch model instead of 
an islet transplant model. Moreover, the flow panel used for neutrophil 
identification did not include specific markers for neutrophil phenotyping.  
In conclusion, BM, Is and Ad MSCs express different levels of CXCR3 and CXCR6 
which could impact MSC migration and retention within the liver. The current 
study highlights that MSCs differentially transcribed immunoregulatory mediators 
like CFH, IL-10, TSG-6, TGF-β, iNOS and CD274, suggesting differential potential 
to suppress effector T cell activation and to induce proliferation and activation 
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of regulatory T cells. Moreover, MSCs isolated from all sources secreted 
substantial amounts of CXCL1, CXCL2, VEGF, and IL-6 which could have an 
impact on the re-vascularisation of the graft. These differences among MSC 
tissue source of isolation not only have an impact on islet transplantation but in 
any transplantation setting. Additionally, as discussed in Chapter 5, the tissue 
source of MSCs leads to differences in their immune cell attraction profile, which 
could be detrimental or beneficial in an islet transplant setting, depending on 
the phenotype of the immune cells attracted.  
7.2.2 The optimal tissue for MSC isolation for potential 
therapeutic use in psoriasis  
Psoriasis is a multifactorial inflammatory disease involving the skin, joints, or 
both. It is mediated by both the innate and adaptive immune systems and 
affects around 2% of people in the UK and worldwide. Psoriasis can be triggered 
by several factors including injury and trauma, infection and medications; 
imiquimod, a TLR7 agonist, induces skin inflammation like psoriasis and is 
therefore used in murine models. Histologically, psoriasis is characterised by: 
epidermal hyperplasia, leukocyte infiltrate, and increased dermal vascularity 
(Casciano et al., 2018). Little is known about the initiation of psoriasis but 
models suggest that injury to the skin leads to AMP LL37 production by 
keratinocytes, which upon interaction with DNA or RNA activates plasmacytoid 
dendritic cells (pDCs) and myeloid DCs, leading to the secretion of IFN-α and 
IFN-β and promoting T cell activation (Lowes et al., 2014). Supporting this model 
of psoriasis initiation, neutrophil extracellular traps (NETs) and extracellular 
DNA have been found in the epidermis under inflammatory conditions (Kumar 
and Sharma, 2010). DCs secrete TNF-α and IL-23 and present self-antigens on 
their surface, leading to the activation of autoreactive CD8+ T cells and the 
polarization of CD4+ T cells towards a Th17 phenotype in the dermis. Activated T 
cells migrate to the epidermis where they recognise self-antigens, leading to the 
secretion of cytokines, including IL-22, which promote epidermal 
hyperproliferation and activation of keratinocytes, leading to the secretion of 
more inflammatory molecules that promote progression of the disease (Zaba et 
al., 2009). Once in the epidermis, activated T cells can differentiate towards 
tissue-resident memory T cells (Trm), where Trm with a pathogenic IFN-γ-IL-17A 
cytokine profile have been described as potential drivers of disease memory in 
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resolved psoriatic lesions (Matos et al., 2017, Cheuk et al., 2014). Moreover, 
Bovenschen et al. described a dysfunction of regulatory T cells in psoriasis as 
they differentiate towards IL-17 expressing Tregs, promoting in this manner 
exacerbated chronic inflammation (Bovenschen et al., 2011).  
Unfortunately, there is no fully satisfactory therapy against psoriasis yet. There 
are multiple palliative treatment options and it often depends on patient 
preferences, as treatment satisfaction is very variable among patients. Primary 
care level is based on topical agents like corticosteroids, vitamin D3 analogues 
or the combination of both, which are well tolerated and effective with mild 
psoriasis. When psoriasis is wide-spread and topical agents are not enough, they 
are usually combined with systemic therapy, mainly phototherapy and 
methotrexate. Methotrexate is a well-known inhibitor of folate biosynthesis with 
a very good record of success in psoriasis. However, it is not always tolerated or 
suitable, as it is not compatible with pregnancy, and biologic therapy has 
emerged as a strong alternative (Kim et al., 2017). Biological therapy is based on 
the use of inhibitors that specifically target a biological mediator of a 
pathophysiological process, including anti-TNF-α agonists and anti-p40 agonists, 
where p40 is a subunit shared by both IL-12 and IL-23. The formation of 
antibodies against these inhibitors has been documented and affects their long-
term efficacy (Sivamani et al., 2010). As explained in the previous section, the 
potential of MSCs to immunomodulate and suppress effector T cell activities 
provides a rationale for the clinical use of MSCs in diseases in which T cell 
hyperactivation contributes to the onset of the disease. The use of stem cells for 
the treatment of psoriasis started gathering strong support when, in 2009, a 35-
year old man with psoriasis was diagnosed with diffuse large B-cell lymphoma. 
His treatment included autologous haematopoietic stem cell transplantation and 
unexpectedly, six months later, his psoriasis had significantly resolved, twelve 
months later his skin had become essentially normal and his condition remained 
normal for 5 years (Chen et al., 2016).  
A study conducted by Lee et al. showed that psoriasis-like skin inflammation 
generated by imiquimod or IL-23 was ameliorated after MSC infusion, which 
reduced the expression of the proinflammatory cytokines IL-6 and IL-17 as well 
as the expression of chemokines such as CCL17, CCL20, and CCL27 (Lee et al., 
313 
 
2017b). Chen et al. infused umbilical cord derived MSCs into a 26-year-old 
woman once a week for three weeks and another two MSC infusions three 
months later. As a result, the psoriasis had been in remission for four years in 
2016, when the study was published (Chen et al., 2016). Intravenous infusion of 
stromal vascular fraction, a mixture of Ad MSCs, progenitor cells and other cells 
obtained from fat, into psoriasis patient demonstrated a significant alleviation of 
the symptoms (Comella et al., 2018). MSC conditioned medium accelerates skin 
wound healing in vitro in fibroblast and keratinocyte scratch assays (Walter et 
al., 2010) and the results from the first clinical report on the use of MSC 
conditioned medium demonstrates that the secretion of immunomodulatory 
molecules, cytokines and growth factors by MSCs ameliorate the symptoms of 
psoriasis (Seetharaman et al., 2019).  
Psoriasis can appear anywhere in the skin as well as in the joints, for this reason 
local administration is not an option. When delivered by systemic infusion, only 
a small percentage of the cells home and remain in the target tissue due to MSC 
trapping in the lung (Fischer et al., 2009, Schrepfer et al., 2007). CCR3, CCR4 
and CCR10 are highly expressed by T cells in skin (Fujimoto et al., 2008, Ma et 
al., 2002) while CXCR4 expression is increased on the surface of extravascular 
neutrophils in the lung and the bone marrow (30). CCR3, CCR4 and CCR10 
transcript levels were very low in MSCs from every source but CCR3 transcript 
levels were statistically significantly higher in Ad MSCs compared to BM and Is 
MSCs (Figure 4-3), suggesting that Ad MSCs could have an increased potential to 
migrate towards the skin. In contrast, CXCR4 transcript levels were highest in Ad 
MSCs, which could favour lung entrapment. These observations, combined with 
the smaller size of BM MSCs, suggest that BM MSCs would have a better chance of 
avoiding lung entrapment and migrating towards target areas despite lower CCR3 
transcript levels.  
Once MSCs are infused into the psoriasis patient, MSCs must supress effector T 
cells and activate regulatory T cells to dampen and control excessive 
inflammation. The mechanisms by which MSCs could inhibit T cell proliferation 
as well as promote a regulatory phenotype of leukocytes via the secretion of 
anti-inflammatory and immunomodulatory molecules has already been described 
in the previous sections and Is MSCs have been suggested to have increased 
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immunosuppressive potential compared to BM and Ad MSCs and could therefore, 
be more effective in regulating excessive inflammation in the skin. However, it 
is important to mention that deficiency of IL-10 and TGF-β in serum and skin are 
important elements of psoriasis pathogenesis. MSCs have been reported to 
secrete IL-10 and TGF-β, promoting the generation of immunosuppressive Treg 
subsets both in vitro and in vivo (Sah et al., 2016). In this study, MSCs from the 
three sources transcribed very low levels of IL-10 (Figure 6-3). Under resting 
conditions, MSCs from the three sources expressed substantial TGF-β transcript 
levels; inflammatory stimulation upregulated TGF-β transcript level in BM and Ad 
MSCs and Ad MSCs reached very high levels of transcription (Figure 6-3). If 
protein levels correlate with transcription, we could suggest that infusion of Ad 
MSCs would be more beneficial than infusion of BM or Is MSCs for the treatment 
of psoriasis.  
IL-6 has been associated with the pathogenesis of psoriasis and increased levels 
of this cytokine in the skin and serum is a characteristic of this disease (Arican et 
al., 2005, Neuner et al., 1991). Moreover, IL-6 levels are positively correlated 
with clinical severity and effective treatment of psoriasis results in a reduction 
of IL-6 levels (Mizutani et al., 1997). BM MSCs expressed the highest transcript 
levels of IL-6 under resting and stimulatory conditions and inflammatory 
stimulation led to an upregulation of IL-6 in MSCs from every source, especially 
in BM MSCs. At the protein level, MSCs isolated from the three tissues produced 
very little IL-6 under resting conditions (Figure 6-3); however, inflammatory 
stimulation resulted in the upregulation of IL-6 to similar levels in MSCs from the 
three sources (Figure 6-7). IL-6 promotes anti-inflammatory Th2 cell 
differentiation (Diehl et al., 2002) and increases IL-27 secretion by monocytes 
and macrophages promoting the maturation of regulatory T cells (Pyle et al., 
2017). However, IL-6 has also been reported to inhibit TGF-β-induced Treg 
differentiation and to promote the differentiation of pro-inflammatory Th17 
cells from naïve T cells, disrupting the immunological tolerance and leading to 
autoimmune and chronic inflammatory diseases (Bettelli et al., 2006, Tanaka et 
al., 2014). Due to the dual roles of IL-6 it is difficult to rationalise the role of IL-
6 secretion by MSCs and its roles in psoriasis.  
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In conclusion, BM, Is and Ad MSCs have different sizes and express different 
levels of CCR3, CCR4, CCR10 and CXCR4 which could impact lung entrapment 
and MSC migration towards the skin. The current study highlights that MSCs 
differentially transcribed IL-10 and TGF-β, suggesting differential potential to 
counteract the deficiency of IL-10 and TGF-β in serum and skin in psoriasis.  
7.2.3 The optimal tissue for MSC isolation for potential 
therapeutic use in rheumatoid arthritis 
Rheumatoid arthritis (RA) is an autoimmune disease characterised by the 
production of auto-antibodies targeting the joints and producing pain, swelling 
and even changing the joint’s shape, which can cause bone and cartilage break 
down; it affects up to 1% of the worldwide population. Rheumatoid arthritis 
flares can be triggered by several factors including overextension related injury, 
trauma and infections. The pathophysiology of RA starts with synovitis, followed 
by subsequent cartilage destruction and bone erosion leading to loss of joint 
function (Milner and Day, 2003). The aetiology, timing and anatomic site of RA is 
currently unknown. It is well established that auto-antibodies like rheumatoid 
factor and antibodies to citrullinated peptides can be increased in the serum 
years prior to the onset of the first flare of joint inflammation (Demoruelle et 
al., 2014). In addition to auto-antibodies, biomarkers of systemic inflammation 
like cytokines, chemokines and C reactive protein can also be identified in the 
serum. Evaluation of the joints during this period of high auto-antibody levels 
and no joint symptoms shows no histologic or magnetic resonance imaging (MRI) 
evidence of RA (van de Sande et al., 2011), which suggests that RA related 
autoimmunity does not initiate in the joints. There are several findings which 
suggest that RA initiates in mucosal sites including oral, lungs and gut mucosal 
sites (Demoruelle et al., 2014). Necrosis results in the release of endogenous 
nuclear material, which can be recognised by TLRs leading to the generation of 
citrullinated endogenous proteins (Makrygiannakis et al., 2006). Moreover, 
recruitment of neutrophils to mucosal sites can produce tissue citrullination, 
generating, in this manner, antibodies to citrullinated peptides (Khandpur et al., 
2013). Furthermore, mucosal inflammation has been associated with an increase 
in rheumatoid factor (Elkayam et al., 2006). Three immunologic mechanisms to 
explain the transition of autoimmunity from the mucosal sites into articular sites 
have been considered. First, immune complex formation could lead to 
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transportation and deposition in the synovium; Zhao et al. described immune 
complexes containing citrullinated fibrinogen in plasma as well as in the joint 
tissue (Zhao et al., 2008). Second, a shared antigenic target between the 
mucosal sites and the joints; to support this, Ytterberg et al. described the 
presence of a citrullinated vimentin protein both in the lungs and joint tissues of 
patients suffering from RA (Ytterberg et al., 2015). Lastly, epitope spreading and 
subsequent migration of activated T cells; Huo et al. reported that antigen-
specific T cell responses can traffic to a different organ (Huo et al., 2012). 
Altogether, these three mechanisms would explain how auto-immunity could be 
generated in the mucosal sites and trigger symptoms in a completely different 
tissue.  
As with psoriasis, there is no fully satisfactory therapy against RA. There is a 
large variety of drugs to reduce the symptoms and the progression of the disease 
to avoid the loose of joint mobility due to bone and cartilage break down. For 
this purpose, all the treatments aim to dampen inflammation including disease-
modifying anti-rheumatic drugs like methotrexate and sulfasalazine and biologic 
response modifiers. Due to the anti-inflammatory, immunomodulatory and 
regenerative properties of MSCs, infusion of these cells could contribute to the 
repair of damaged cartilage as well as dampening the inflammation and 
avoiding, in this manner, further damage. In support of this hypothesis, 
allogeneic MSC infusion and transplantation of chondrocytes differentiated from 
allogeneic MSCs were able to suppress the responses of type-II collagen reactive 
T cells in vitro (Zheng et al., 2008). Furthermore, MSC infusion into collagen-
induced arthritis mouse models reduced the severity of RA symptoms. At 
present, there are several trials that include MSCs for the treatment of RA. So 
far, the systemic infusion of BM and umbilical cord derived MSCs in a RA group 
that did not respond to other treatments lead to the decrease of anti-cyclic 
citrullinated peptide antibodies and to amelioration of symptoms (Liang et al., 
2012).  
RA can appear in any joint of the body and, as previously described, it is 
reported to initiate in mucosal sites, thus, local administration of MSCs is not an 
alternative. As already mentioned, when delivered by intravenous infusion, only 
a small percentage of the cells home and remain in the target tissue due to MSC 
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trapping in the lung (Fischer et al., 2009, Schrepfer et al., 2007). However, in 
this particular clinical scenario, as autoimmunity towards joints is initiated in 
mucosal sites, lung entrapment could be an advantage instead of an 
unfavourable circumstance. On the one hand, Is and Ad MSCs are statistically 
significantly bigger in size than BM MSCs. On the other hand, CXCR4 transcript 
levels were highest in Ad MSCs and we could therefore hypothesise that Ad MSCs 
are more likely to remain in the lungs where they could dampen mucosal 
inflammation by regulating effector T cells and at the same time, promoting a 
regulatory phenotype. As explained in Section 7.2, MSCs inhibit T cell 
proliferation and promote a regulatory phenotype of leukocytes via the secretion 
of anti-inflammatory and immunomodulatory molecules. In this study Is MSCs 
transcribe higher levels of iNOS and for this reason it has been suggested that Is 
MSCs could have increased immunosuppressive potential compared to BM and Ad 
MSCs, which suggests that Is MSCs could be more effective in regulating 
excessive inflammation in the lungs. However, it is important to mention that 
TSG-6 and IL-10 have been reported to be essential for dampening the 
autoimmune response in RA and for this reason further discussion will follow.  
TSG-6 levels have been found to be increased in the synovial fluid, in the blood 
vessel walls of inflamed synovium and to a lesser extent in serum (Wisniewski et 
al., 1993, Bayliss et al., 2001). Its presence within these locations has been 
associated with the roles of TSG-6 in cell proliferation and extracellular matrix 
remodelling (Ye et al., 1997). The use of autoimmune polyarthritis inducible 
mouse models has enabled an investigation of the roles of systemic recombinant 
TSG-6 and of TSG-6 produced locally by T cells in the arthritic joints of 
transgenic mice. In this way, it has been shown that TSG-6 was a potent inhibitor 
of inflammation which protected cartilage and bone and thus, prevented joint 
destruction (Mindrescu et al., 2000, Mindrescu et al., 2002). Moreover, 
treatment of collagen-induced arthritis in mice with TSG-6 lead to a significant 
reduction of antibodies against type II collagen (Mindrescu et al., 2002). BM MSCs 
expressed higher levels of TSG-6 (Figure 6-3), under resting and inflammatory 
conditions, than Is and Ad MSCs, and 24-hour stimulatory licensing led to the 
downregulation of these transcripts in MSCs from all sources. If transcript and 
protein levels correlate, BM MSCs could have the potential to produce increased 
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inhibition of inflammation and in that way, promote a better clinical outcome in 
the context of RA.  
IL-10 has been found in RA synovial membrane biopsies and spontaneous 
production of IL-10 in cell suspension cultures of RA synovial membranes has 
been described. Moreover, neutralization of IL-10 led to an increase of TNF-α 
and IL-1β secretion in vitro, which are strongly implicated in the pathology of 
RA. More importantly, exogenous addition of IL-10 to these cultures led to a 
significant decrease of TNF-α and IL-1β secretion and therefore, IL-10 could be 
an effective RA treatment (Katsikis et al., 1994). Systemic infusion of IL-10 had a 
negligible effect in both mouse models and clinical trials (Whalen et al., 1999, 
van Roon et al., 2003). However, efficacy increased when IL-10 was delivered 
locally or tagged to an antibody fragment specific to damaged arthritic cartilage 
(Hughes et al., 2014). Infusion of MSCs alone into mouse and rat models of 
inflammatory RA produced no effect, while injection of IL-10 transduced MSCs 
significantly decreased the severity of arthritis whilst also decreasing anti-
collagen II antibodies and T cell proliferation (Hughes et al., 2014, Peruzzaro et 
al., 2019). These results show the therapeutic relevance of high doses of IL-10. 
Ad MSCs transcribed significantly higher levels of IL-10 compared to BM and Is 
MSCs and for this reason, Ad MSCs could be a better source of MSCs for an IL-10 
mediated RA therapy.  
In conclusion, BM, Is and Ad MSCs have different sizes and express different 
levels of CXCR4 which could impact retention within the lung. The current study 
highlights that MSCs differentially transcribed TSG-6 and IL-10, suggesting 
differential potential to immunoregulate the exacerbated immune response in 
RA. 
 
7.3 Overview  
It is widely reported that MSCs have the potential to switch pro-inflammatory 
environments into anti-inflammatory and pro-regenerative environments by 
immunomodulating surrounding immune cells; for this reason, MSCs are involved 
in an increasing number of clinical trials. As previously mentioned, BM MSCs are 
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considered the gold standard MSC as they were the first MSCs isolated and used 
within the clinic; however, their yield within the bone marrow is very low and 
isolation imposes a burden on the donor. For this reason, alternative sources 
with higher frequency of MSCs within the tissue and that are isolated in a less 
invasive and harmful manner are being investigated. The variability in tissue 
sources, donors, isolation and culture procedures as well as differences in 
passage number has led to controversial results through the literature making 
the comparison of MSCs isolated from different sources nearly impossible. It is 
important to point out that there are few studies that have examined the 
immunogenicity of MSCs in vivo and many of those studies have been conducted 
with human MSCs (Thirlwell, 2018) which usually lack a control for mismatched 
major histocompatibility complex molecule expression. Infusion of MHC-
mismatched MSCs into an inflammatory environment leads to both cell-mediated 
and humoral immune responses (Eliopoulos et al., 2005, Joswig et al., 2017). For 
these reasons, the standardised methodologies throughout this study allowed 
comparative study of the potential in vivo differences of MSCs isolated from the 
bone marrow, islets of Langerhans and adipose tissue. Through the assessment of 
chemokine receptors at transcript level this study highlighted that MSCs isolated 
from different tissue sources could have differential migration potential. This is 
critical when considering which tissue source of MSC to administer when MSCs 
are being infused systemically, where high specific chemokine receptor surface 
expression could enhance homing to target tissues. In contrast, when 
administered locally, low chemokine receptor surface expression would enhance 
retention within the tissue of infusion.  
Through the assessment of chemokine ligands at transcript and protein level, 
this study highlighted that MSCs isolated from different tissue sources could have 
differential interactions with their surrounding environment when infused into a 
patient. Under resting conditions, all MSCs regardless of tissue source of origin 
had a similar chemokine secretion profile, where CCL2 was the top chemokine 
secreted by all MSC populations. Despite CCL2 and other chemokine secretion at 
lower levels, infusion of resting BM, Is and Ad MSCs did not lead to leukocyte 
recruitment above background levels. Inflammatory stimulation of MSCs resulted 
in the upregulation of CC and CXC chemokine secretion with an emphasis on 
CCL2 and CXCL1 secretion. The secretion of these chemokines was followed by 
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chemoattraction of neutrophils and macrophages towards MSCs isolated from all 
tissue sources; however, the number of cells attracted towards MSCs was tissue 
of origin dependent, where Ad MSCs attracted statistically significantly more 
leukocytes. These observations have huge clinical implications due to the 
described role of inflammatory chemokine secretion and the subsequent 
monocyte, macrophage and neutrophil recruitment in pathogenesis in several 
clinical settings.  
Furthermore, the anti-inflammatory and immunomodulatory properties of MSCs 
have been studied by thorough analysis of the complement system, TLRs and 
multiple inflammatory and extra cellular matrix remodelling mediators. The 
transcription of these molecules was MSC source dependent and inflammatory-
dependent patterns were not observed. Variability in the transcription and 
secretion of anti-inflammatory and angiogenic factors demonstrates that tissue 
source of origin could have a major impact in MSC mediated immunomodulation 
within a clinical setting.  
To sum up, the stringent set of standardised methodologies established in this 
study to objectively compare the phenotype, migration, interaction with the 
environment and immunomodulation potential demonstrates the complexity of 
the MSC field and shows the need for further studies to fully understand the role 
of each of the assessed molecules in MSC in vivo behaviour.  
 
7.4 Hypothesis 
I therefore hypothesise that the source for MSC isolation would influence the 
clinical outcome of MSC infusion via the differential expression of chemokine 
receptors and the specific secretion of chemokine ligands and anti-inflammatory 
and immunomodulatory mediators. These differences lead to differential 
recruitment of immune cells by MSCs while also affecting their interactions with 
the recruited and tissue resident cells. Furthermore, I strongly believe that 
there are other undiscovered factors involved in the differential behaviour of 
MSCs isolated from different sources, which may have a critical impact on MSC 
clinical potential.  
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7.5 Conclusions 
This study provides a highly standardised methodology for murine bone marrow, 
islet of Langerhans and adipose MSC isolation, characterisation and comparison. 
The findings detailed in this thesis show the variability of MSC behaviour 
according to the source for MSC isolation and the surrounding environment, 
resting or inflammatory.  
Differences in the transcription and expression of chemokine receptors, 
chemokines and other angiogenic and immunoregulatory molecules suggest that 
their in vivo function within a clinical setting could potentially be different and 
this could have a major impact for the choice of MSC tissue of isolation.  
 
7.6 Future directions 
This study has generated novel data that will help to further understand the 
potential use of MSCs as cellular therapeutics. However, the experiments 
described have their own limitations and this project would benefit from further 
testing to gain a better understanding of the differences among MSCs isolated 
from different sources.  
To confidently compare MSCs migratory potential, experiments on chemokine 
receptor expression by MSCs must be performed. Moreover, expression and 
functionality do not always come together, and intracellular calcium flux assays 
should be performed to study if receptors are able to recognise, interact with 
and signal in the presence of ligand. Furthermore, in vitro MSC migration assays 
would test the migratory potential of MSCs. As an example, CCL19 or CCL21, the 
two well characterised CCR7 ligands, could be used to assess and compare MSC 
migratory capacity using a transwell system with increasing concentrations of 
these chemokines or via a CCR7 blocker. In this manner, we could confidentially 
conclude which tissue source of MSCs possessed greater migratory capacity 
towards specific tissues, in this case, towards the lymph nodes. To further 
confirm this hypothesis, in vivo trafficking and retention of MSCs should be 
studied via fluorescent labelling of MSC. To rule out nonspecific migration or to 
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identify the involvement of other receptors in migration, genetically modified 
MSCs with specific chemokine receptor knock out should be used as negative 
controls.  
As previously mentioned, chemokine secretion was not correlated with leukocyte 
recruitment in vivo. As an example, Is MSCs secreted the most CXCL1 and CXCL2 
but Ad MSCs recruited the most neutrophils. These findings suggest that even if 
CXCL1 and CXCL2 are strong neutrophil chemoattractants, there are other 
molecules involved in neutrophil migration or that only a small concentration of 
CXCL1 and CXCL2 is needed to induce neutrophil migration and once that is 
reached, increased secretion will not produce an increment in neutrophil 
recruitment. Therefore, MSCs could recruit leukocytes via alternative 
mechanisms. In the case of neutrophils, the VEGF-VEGFR or GMCSF-GMCSFR axis 
could be involved. Therefore, transwell analysis with the appropriate 
chemoattractants and the appropriate receptor blockers should be performed to 
gain insight in the mechanisms used by MSCs to migrate towards specific tissues.  
The in vivo air pouch model assessed the immune cell attraction profile of MSCs 
from the three sources. However, 24 hours might not have been enough time for 
the adaptive immune cells to migrate towards the air pouch. For this reason, a 
second time point at 72 hours would allow us to better study the infiltration of 
innate and adaptive immune cells mediated by the infusion of MSCs within the 
air pouch. Furthermore, despite the fluorescent labelling of the cells we could 
not find any MSC within the air pouch. MSCs could have migrated elsewhere and 
for this reason, fluorescent labelling could be used to try find them in blood, 
bone marrow or lymph nodes, among other tissues.  
Lastly, this study would benefit from the study and comparison of MSCs isolated 
from various tissues in different clinical models such as mouse islet 
transplantation, psoriasis and RA models. In this way, we could clarify if 
differences in transcription and expression of chemokines and their receptors, as 
well as other immunoregulatory molecules, could have, as hypothesised, an 
impact in different clinical settings.  
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8 Appendices 
8.1 Analysis of the effect of a double inflammatory 
stimulus over time on the transcription of 
chemokines and chemokine receptors  
As previously discussed, pro-inflammatory cytokine-mediated MSC licensing 
produced a transcriptional regulation of chemokines, which could explain why 
MSCs are described to be more immunosuppressive upon activation. Within 
clinical settings, it has been reported that pre-treatment of MSCs with 
inflammatory cytokines prior to administration within animal models of 
inflammatory diseases boosts the therapeutic effect of MSCs (Duijvestein et al., 
2011, Noronha et al., 2019). For this reason, we wondered if pre-licensing the 
MSCs prior to expose them to an inflammatory environment in vitro would lead 
to even bigger variations in chemokines transcriptional levels and therefore, in 
enhanced therapeutic potential. To study this, cells were pre-licensed for 48 
hours, after which cells were washed twice with PBS and stimulated again for 
another 24 hours. The first stimulation primes the MSCs while the second 
stimulation would mimic the inflammatory environment MSCs would face when 
infused into a patient with an inflammatory disorder. Figure 8-1 illustrates the 
time points at which supplemented medium was added. Culture medium was 
removed at the time cells were harvested and was kept for experimental 
procedures.  
Two different control conditions were used. In the first one, cells were 
stimulated for 48 hours, after which cells were washed twice with PBS and fresh 
culture medium was added; lastly, cells were harvested 24 hours later. In the 
second condition, cells were washed twice with PBS, the culture medium was 
replaced with fresh one and the cells were left growing for 48 hours. Cells were 
then washed twice with PBS, the culture medium was replaced with 
supplemented one and the cells were harvested 24 hours later. There is wide 
literature about how cytokine-mediated licensing enhances the potential 
therapeutic efficacy of MSCs however, little is known about the role of TLR 
ligands mediated activation on the secretion of chemotactic cytokines by MSCs. 
For this reason, 100 ng/ mL LPS, 100 ng/ mL LTA and 4 mg/ mL Poly I:C, as well 
as the previously described cytokine cocktail, was used for MSC licensing.  
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Figure 8-1. Diagrammatic illustration of the time course of the MSC licensing. 
 
According to the results described in Section 4.2, the genes that regulated their 
transcript levels in a statistically significant manner upon stimulation were 
selected and their transcriptional levels were assessed after licensing with 
different inflammatory molecules and different inflammatory conditions.  
8.1.1 Transcription of CC chemokines under resting and 
inflammatory conditions  
Under resting conditions, BM, Is and Ad MSCs transcribed very little, if any, CC 
chemokines with the exception of CCL2, which was transcribed by all tissue 
sources of MSCs at similar levels (Figure 8-2, A), and CCL7, which was very highly 
expressed by BM MSCs (D).  
A pattern of transcriptional upregulation was observed in CCL2 (Figure 8-2, A), 
CCL3 (B), CCL5 (C), CCL7 (D) and CCL20 (E) genes after licensing in every 
condition; however, these chemokines were upregulated differentially in MSCs 
according to their tissue of origin and licensing agent. CC chemokine transcript 
levels 24 hours after stimulation increased (Condition 2) in MSCs from every 
tissue source; however, this upregulation was not sustained, as cells harvested 
72 hours after licensing (Condition 1) showed a decrease in the transcript levels 
of CC chemokines. A second stimulation 48 hours after the first stimulation 
(Condition 3) was able to induce the transcription of CC chemokines in MSCs 
from the three sources; however, the second stimulation was not able to match 
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the transcript levels of CC chemokines found in Condition 2 in MSCs from every 
source with the exception of Ad MSCs after cytokine-mediated stimulation, 
where these cells massively increased the transcript levels of CC chemokine 
ligands. Fold changes of transcriptional regulation upon licensing of MSCs are 
specified in Table 8-1.  
As previously described, BM MSCs had the highest CCL2 transcript levels under 
resting conditions (Figure 8-2, A). After 72 hours of stimulation (Condition 1), 
cytokine-mediated licensing led to an increase of the transcript levels in BM and 
Is MSCs and to a decrease in Ad MSCs. 24 hours after stimulation with the 
cytokine cocktail (Condition 2), MSCs from the three tissues upregulated their 
CCL2 transcript levels. A second stimulation with the cytokine cocktail 48 hours 
after the first stimulation (Condition 3) was able to induce the production of 
CCL2 in MSCs from the three sources; however, the second stimulation was not 
able to match the transcript levels of CCL2 found in Condition 2 in BM and Is 
MSCs. Ad MSCs, at the contrary, produced 202 times more CCL2 after the second 
stimulation than Ad MSCs under resting conditions or 16 times more than in 
Condition 2. After 72 hours of stimulation (Condition 1), LPS-mediated licensing 
led to an increase of CCL2 transcript levels in Is and Ad MSCs and to a decrease 
in BM MSCs, while LTA and Poly I:C-mediated licensing only produced an 
upregulation of CCL2 in Is MSCs and a downregulation in BM and Ad MSCs. After 
24 hours of stimulation (Condition 2), LPS produced no variation in CCL2 
transcript levels in BM MSCs but produced an increase of transcript levels in Is 
and Ad MSCs; LTA had no effect on Is MSCs but led to an upregulation of the 
transcript levels in BM and Ad MSCs. Lastly, Poly I:C produced an upregulation of 
CCL2 transcript levels in MSCs from every source. Double stimulation (Condition 
3) with any of the licensing agents led to higher transcript levels of CCL2 than 
cells that had been harvested 72 hours after stimulation (Condition 1), but lower 
levels than those obtained by the cells harvested 24 hours after stimulation.  
BM MSCs had the highest CCL3 transcript levels under resting conditions (Figure 
8-2, B). After 72 hours of stimulation (Condition 1), cytokine-mediated licensing 
led to a decrease in the transcript levels of CCL3 in BM MSCs, produced no effect 
in Is MSCs and led to an increase in Ad MSCs; LPS licensing led to a decrease of 
the transcript levels in BM and Ad MSCs and produced no effect in Is MSCs and 
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LTA and Poly I:C licensing produced a decrease on CCL3 transcript levels in MSCs 
from the three sources. After 24 hours of stimulation (Condition 2), cytokine-
mediated licensing led to an increase of the transcript levels in BM and Is MSCs 
and led to a decrease in Ad MSCs; LPS licensing led to a decrease of the 
transcript levels in BM and Ad MSCs and produced an increase in Is MSCs; LTA 
licensing produced no effect in BM MSCs and led to a decrease of the transcript 
levels in Is and Ad MSCs; lastly, Poly I:C led to a decrease of CCL3 transcript 
levels in MSCs from every source. Double stimulation (Condition 3) with the 
cytokine cocktail led to a decrease of the transcript levels in BM MSCs, produced 
no effect in Is MSCs and led to an increase in Ad MSCs; LPS licensing led to a 
decrease of the transcript levels in Is MSCs and had no effect in BM and Is MSCs; 
LTA licensing led to a decrease in CCL3 transcript in MSCs from every source 
while Poly I:C had no effect in BM MSCs and produced a decrease in CCL3 
transcript levels in Is and Ad MSCs.  
CCL5 transcript levels were very low under resting conditions, where BM MSCs 
had the highest levels of transcript and Ad MSCs the lowest, but inflammatory 
stimulation led to substantial levels in MSCs from the three sources (Figure 8-2, 
C). Cytokine-mediated licensing produced an upregulation of CCL5 transcript 
levels in MSCs from every source under every condition. 72 hours after 
stimulation (Condition 1) MSCs from every tissue source had undergone at least a 
7.35 fold change in CCL5 transcript levels; 24 hours after stimulation (Condition 
2) MSCs from the three tissues had higher transcript levels than in Condition 1, 
reaching significant amounts in the case of BM and Is MSCs. Double stimulation 
(Condition 3) led to the upregulation of CCL5 transcript to levels that matched 
the ones achieved in Condition 1 in BM and Is MSCs; Ad MSCs, however, had 419 
times higher amounts of transcript compared to resting conditions. 72 hours of 
LPS licensing produced an upregulation of CCL5 transcript levels in BM and Is 
MSCs and barely produced any effect in Ad MSCs; LTA licensing had no effect in 
BM MSCs, led to a small downregulation in Is MSCs and produced a hundred times 
fold change in Ad MSCs. Poly I:C-mediated stimulation led to an upregulation of 
CCL5 transcript levels in MSCs from the three sources, where this upregulation 
was the highest in BM MSCs even if Is MSCs had a higher amount of CCL5 
transcripts. Double stimulation (Condition 3) with the cytokine cocktail led to an 
increase of the transcript levels in MSCs from the three sources, but Ad MSCs 
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produced significantly higher amounts of transcript than BM and Is MSCs. LPS-
mediated licensing led to an upregulation in MSCs from the three sources and 
this upregulation was higher than the one observed in Condition 1 and smaller 
than the one in Condition 2 for BM and Ad MSCs. Is MSCs produced the highest 
CCL5 transcript levels in Condition 1 after LPS licensing. LTA-mediated 
stimulation produced no effect in BM and Is MSCs after double stimulation and 
produced a small downregulation in Ad MSCs. Poly I:C, on the contrary, produced 
a ≥117-fold change in BM and Is MSCs and a smaller upregulation in Ad MSCs.  
As previously discussed, CCL7 was expressed at very substantial levels under 
resting conditions in all MSCs; however, tissue of origin of MSCs had an effect in 
the transcript levels as BM MSCs expressed much higher transcript levels than Is 
and Ad MSCs (Figure 8-2, D). After 72 hours of stimulation (Condition 1), 
cytokine-mediated licensing led to a decrease of the transcript levels in BM 
MSCs, while it produced a small increase in Is and Ad MSCs. 24 hours after 
stimulation with the cytokine cocktail (Condition 2), MSCs from the three tissues 
upregulated their CCL7 transcript levels. A second stimulation with the cytokine 
cocktail 48 hours after the first stimulation (Condition 3) was able to induce the 
production of CCL7 in Is and Ad MSCs, however, the second stimulation was not 
able to match the transcript levels of CCL7 observed in Condition 2. BM MSCs, on 
the contrary, downregulated their CCL7 transcript levels after the double 
stimulation with the cytokine cocktail. After 72 hours of stimulation (Condition 
1), LPS and LTA-mediated licensing led to a decrease of CCL7 transcript levels in 
BM MSCs, led to an increase in Is MSCs and produce no effect in Ad MSCs. Poly 
I:C-mediated licensing produced a downregulation of CCL7 transcript levels in 
MSCs from every source after 72 hours of stimulation (Condition 1). After 24 
hours of stimulation (Condition 2), LPS produced no variation in CCL7 transcript 
levels in BM MSCs but produced an increase of transcript levels in Is and Ad MSCs; 
LTA led to a slight decrease in BM MSCs but led to an upregulation of the 
transcript levels of CCL7 in Is and Ad MSCs. Lastly, Poly I:C had no effect in BM 
MSCs but produced an upregulation of CCL7 transcript levels in Is and Ad MSCs. 
Double stimulation (Condition 3) with any of the licensing agents led to higher 
transcript levels of CCL7 in Is MSCs when compared to cells that had been 
harvested 72 hours after stimulation (Condition 1), but lower levels than those 
obtained by the cells harvested 24 hours after stimulation. Cytokine-mediated 
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double stimulation (Condition 3) led to a decrease of CCL7 transcript levels in 
BM MSCs, produced an upregulation in Is MSCs smaller than the one obtained in 
Condition 2 and produced 8 times more CCL7 transcript in Ad MSCs compared to 
Condition 2. LPS-mediated double stimulation led to an increase of CCL7 
transcript levels in MSCs from all sources, LTA-mediated double stimulation led 
to a decrease of CCL7 transcript levels in BM and Ad MSCs while it upregulated 
CCL7 transcript levels in Is MSCs. Lastly, Poly I:C-mediated double stimulation 
increased CCL7 transcript levels in BM and Is MSCs while it decreased CCL7 
transcript levels in Ad MSCs.  
CCL20 transcript levels were almost undetectable under resting conditions, with 
2(-ΔCT) ≤ 0.00059, but inflammatory stimulation led to substantial transcript 
expression levels in MSCs from the three sources (Figure 8-2, E). After 72 hours 
of stimulation (Condition 1), cytokine-mediated licensing led to an increase of 
CCL20 transcript levels in BM and Is MSCs while it produced a decrease in Ad 
MSCs. 24 hours after stimulation with the cytokine cocktail (Condition 2), MSCs 
from the three tissues massively upregulated their CCL20 transcript levels, with 
fold changes of up to 630 in BM MSCs. A second stimulation with the cytokine 
cocktail 48 hours after the first stimulation (Condition 3) was able to induce the 
transcription of CCL20 in MSCs from every source, however, the second 
stimulation was not able to match the transcript levels of CCL20 found in 
Condition 2 in BM and Is MSC, while Ad MSCs transcribed similar amounts to 
Condition 2. 72 hours LPS-mediated stimulation (Condition 1) led to the 
upregulation of the transcript levels in Is MSCs but had barely no effect in BM 
and Ad MSCs; however, 24 hours LPS-mediated stimulation (Condition 2) led to 
the upregulation of transcript levels in MSCs from the three sources. Once again, 
a second stimulation with LPS 48 hours after the first stimulation (Condition 3) 
was able to induce the production of CCL20 in MSCs from every source but the 
levels produced could not match the ones from Condition 2 except for BM MSCs. 
72 hours of LTA-mediated stimulation (Condition 1) led to no effect in BM MSCs 
and to a reduction of the transcript levels of CCL20 in Is and Ad MSCs. 24 hours 
stimulation (Condition 2), on the contrary, led to an upregulation of CCL20 
transcript in BM and Ad MSCs, while Is MSCs produced less transcript levels. 
Double stimulation of the cells (Condition3) with LTA produced a slight 
upregulation in BM MSCs, a downregulation in Is MSCs and led to no effect on the 
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transcript levels of CCL20 in Ad MSCs. 72 hours of Poly I:C-mediated stimulation 
led to a slight upregulation on BM MSCs while it had no significant effect on 
CCL20 transcript levels in Is and Ad MSCs. 24 hours stimulation (Condition 2) led 
to an upregulation in MSCs from every source while double stimulation with Poly 
I:C led to an upregulation in BM and Is MSCs that did not match the transcript 
levels produced by these cells after 24 hours of stimulation (Condition 2). Double 
stimulation with Poly I:C produced a downregulation of CCL20 transcript levels 
to almost undetectable amounts.  
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Figure 8-2. Inflammatory agent, repetitive stimulus and MSC tissue origin impacts CC 
chemokine transcript levels in MSCs. 
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with either a cocktail of cytokines (40 ng/ mL of 
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IFN-ϒ, TNF-α and IL-1β), 100 ng/ mL LPS, 100 ng/ mL LTA or 4 µg/ mL Poly I:C. Unstimulated 
cells were left growing in MSC culture medium as a control. Three different licensing conditions 
were tested. In the first one, cells were stimulated for 48 hours, after which cells were washed twice 
with PBS and fresh culture medium was added; cells were harvested 24 hours later. In the second 
condition, cells were washed twice with PBS, the culture medium was replaced with fresh one and 
the cells were left growing for 48 hours. Cells were then washed twice with PBS, the culture 
medium was replaced with supplemented one and the cells were harvested 24 hours later. In the 
last condition, cells were stimulated for 48 hours, after which cells were washed twice with PBS 
and were stimulated again for another 24 hours. Figure 4-7 illustrates the time points at which 
supplemented medium was added. Quantitative reverse transcription PCR (qRT-PCR) was 
performed to evaluate CCL transcripts in BM, Is and Ad MSCs under resting and inflammatory 
conditions. Each bar represents an n of 4 independent experiments and is graphed as mean ± 
SEM. Data are normalised to the housekeeping gene B2M and expressed as 2(-ΔCT). Statistically 
significant differences are marked with a colour code in Table 4-7.  
 
Table 8-1. Fold change in CC chemokine transcript levels of cytokine, LPS, LTA or Poly I:C-
mediated licensed BM, Is and Ad MSCs compared to unstimulated cells from the same 
source.  
Following the experimental set up explained in Figure 8-2, fold change in transcript levels of CC 
chemokines is represented as mean of fold change ± standard deviation. One Way ANOVA with 
Tukey’s multiple comparisons post-test was performed to compare all MSC sources and the 
different conditions. p = 0.05 was considered the limit for statistical significance. Statistically 
significant differences are marked with a colour code, where p < 0.05 is represented by green, p < 
0.01 is represented by orange, p < 0.001 is represented by blue and p < 0.0001 is represented by 
red. 
Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
CCL2 
1 
Cyt 1.84 ± 1.43 8.07 ± 1.77 0.51 ± 0.11 
LPS 0.71 ± 0.56 4.58 ± 2.60 1.21 ± 1.04 
LTA 0.75 ± 0.15 2.67 ± 1.79 0.56 ± 0.06 
Poly I:C 0.89 ± 0.33 2.66 ± 0.62 0.41 ± 0.03 
2 
Cyt 4.24 ± 1.14 22.93 ± 5.23 6.77 ± 1.70 
LPS 0.98 ± 0.29 10.01 ± 3.32 6.71 ± 1.76 
LTA 1.32 ± 0.36 1.02 ± 0.15 3.21 ± 0.60 
Poly I:C 5.39 ± 1.85 10.97 ± 5.25 2.88 ± 0.56 
3 
Cyt 1.38 ± 0.77 5.02 ± 1.31 202.76 ± 51.81 
LPS 1.26 ± 0.51 3.19 ± 1.18 11.66 ± 2.49 
LTA 0.82 ± 0.53 0.80 ± 0.09 5.01 ± 1.65 
Poly I:C 2.28 ± 0.79 4.96 ± 1.86 4.47 ± 1.76 
CCL3 
1 
Cyt 0.27 ± 0.07 1.02 ± 0.24 1.26 ± 0.45 
LPS 0.50 ± 0.03 1.03 ± 0.75 0.76 ± 0.31 
LTA 0.89 ± 0.14 0.24 ± 0.04 0.73 ± 0.19 
Poly I:C 0.22 ± 0.03 0.27 ± 0.07 0.30 ± 0.10 
2 
Cyt 1.23 ± 0.50 3.57 ± 1.01 0.36 ± 0.06 
LPS 0.88 ± 0.16 3.06 ± 0.97 0.56 ± 0.16 
LTA 1.04 ± 0.27 0.45 ± 0.21 0.51 ± 0.08 
Poly I:C 0.61 ± 0.33 0.82 ± 0.25 0.32 ± 0.06 
3 
Cyt 0.64 ± 0.35 1.21 ± 0.30 2.88 ± 0.69 
LPS 1.14 ± 0.14 1.18 ± 0.43 0.57 ± 0.15 
LTA 1.16 ± 0.37 1.22 ± 1.37 0.70 ± 0.22 
Poly I:C 1.13 ± 0.13 0.52 ± 0.12 0.84 ± 0.52 
CCL5 1 Cyt 11.59 ± 10.85 7.35 ± 2.09 10.95 ± 3.50 
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Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
LPS 4.58 ± 4.07 96.57 ± 22.51 2.63 ± 0.41 
LTA 0.25 ± 0.20 0.70 ± 0.30 0.46 ± 0.20 
Poly I:C 107.27 ± 97.50 5.82 ± 1.15 7.86 ± 2.49 
2 
Cyt 48.22 ± 45.00 29.01 ± 11.82 9.58 ± 1.87 
LPS 70.79 ± 63.95 29.90 ± 10.46 16.00 ± 5.69 
LTA 1.61 ± 1.53 0.35 ± 0.07 104.45 ± 33.37 
Poly I:C 138.31 ± 134.11 177.83 ± 38.71 52.32 ± 16.60 
3 
Cyt 10.25 ± 8.63 5.92 ± 1.49 419.49 ± 93.64 
LPS 10.17 ± 9.13 13.12 ± 6.50 2.83 ± 1.06 
LTA 1.22 ± 1.18 0.64 ± 0.55 0.56 ± 0.26 
Poly I:C 208.49 ± 195.87 117.21 ± 39.74 23.07 ± 23.86 
CCL7 
1 
Cyt 0.39 ± 0.30 1.82 ± 2.02 1.62 ± 0.86 
LPS 0.23 ± 0.14 4.56 ± 5.13 0.90 ± 0.47 
LTA 0.22 ± 0.10 2.30 ± 2.68 0.95 ± 0.46 
Poly I:C 0.33 ± 0.22 0.73 ± 0.49 0.66 ± 0.32 
2 
Cyt 1.29 ± 0.70 5.27 ± 5.15 3.77 ± 2.14 
LPS 1.14 ± 0.20 7.54 ± 6.36 6.60 ± 2.51 
LTA 0.87 ± 0.08 1.85 ± 2.26 4.59 ± 2.26 
Poly I:C 0.88 ± 0.68 13.03 ± 17.73 3.38 ± 1.83 
3 
Cyt 0.55 ± 0.07 2.87 ± 3.03 30.78 ± 15.81 
LPS 1.72 ± 0.72 6.00 ± 7.25 2.53 ± 1.32 
LTA 0.86 ± 0.67 3.06 ± 3.48 0.92 ± 0.48 
Poly I:C 1.58 ± 0.91 5.10 ± 5.83 0.09 ± 0.04 
CCL20 
1 
Cyt 4.23 ± 0.74 8.74 ± 7.80 0.18 ± 0.14 
LPS 2.45 ± 1.14 28.10 ± 13.76 2.13 ± 1.91 
LTA 1.17 ± 0.63 0.35 ± 0.25 0.02 ± 0.01 
Poly I:C 2.19 ± 0.50 0.68 ± 0.47 0.59 ± 0.57 
2 
Cyt 631.34 ± 148.34 19.27 ± 2.37 470.60 ± 222.05 
LPS 42.76 ± 42.62 7.47 ± 2.27 14.68 ± 6.22 
LTA 64.25 ± 66.43 0.57 ± 0.25 13.20 ± 4.91 
Poly I:C 45.35 ± 26.57 8.32 ± 6.09 5.25 ± 2.10 
3 
Cyt 27.91 ± 26.21 5.21 ± 0.89 298.33 ± 107.66 
LPS 87.39 ± 80.84 4.40 ± 1.63 5.93 ± 2.20 
LTA 8.18 ± 7.03 0.12 ± 0.15 1.01 ± 0.35 
Poly I:C 36.44 ± 30.10 5.21 ± 2.65 0.00 ± 0.00 
 
8.1.2 Transcription of CXC chemokines under resting and 
inflammatory conditions  
Under resting conditions, BM, Is and Ad MSCs transcribed very little, if any, CXC 
chemokines with the exception of CXCL1, which was transcribed by BM MSCs 
(Figure 8-3). A pattern of transcriptional upregulation was observed in CXCL1 
(Figure 8-3, A), CXCL2 (B), CXCL5 (C), CXCL10 (D) and CXCL16 (F) after licensing 
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in every condition, while stimulation of MSCs led to the downregulation of 
CXCL12 (E). However, these chemokines were differentially regulated in MSCs 
according to their tissue of origin and licensing agent.  
CXCL1, CXCL5, CXCL10 and CXCL16 chemokine transcript levels increased 24 
hours after stimulation (Condition 2) in MSCs from every tissue source; however, 
this upregulation was not sustained, as cells harvested 72 hours after licensing 
(Condition 1) showed a decrease in CC chemokines transcript levels. CXCL2 
chemokine transcript levels increased after 24 hours stimulation (Condition 2) in 
MSCs from every tissue source. However, while this upregulation was not 
sustained in BM and Is MSCs, Ad MSCs expressed higher amounts of CXCL2 
transcript levels 72 hours after licensing (Condition 1). A second stimulation 48 
hours after the first stimulation (Condition 3) was able to induce the 
transcription of CXCL1, CXCL2, CXCL5, CXCL10 and CXCL16 chemokines in MSCs 
from the three sources, however, the second stimulation was not able to match 
the transcript levels of CXC chemokines found in Condition 2 in MSCs from every 
source with the exception of Ad MSCs after cytokine-mediated stimulation, 
where these cells massively increased the transcript levels of CXC chemokine 
ligands. CXCL12 transcriptional levels were very dependent on MSC source and 
licensing agent; cytokine-mediated licensing produced a downregulation of the 
transcriptional levels in every condition in BM and Is MSCs, while it produced an 
upregulation in Ad MSCs. LPS-mediated licensing produced a downregulation of 
CXCL12 levels in BM and Ad MSCs, while it was able to induce the transcription 
levels in Is MSCs after 72 hours stimulation (Condition 1). LTA licensing led to a 
trend of upregulation in BM MSCs while it produced no statistically significant 
effect on Is and Ad MSCs. Lastly, Poly I:C stimulation produced a downregulation 
in BM MSCs, no variation in Is MSCs and a downregulation in Ad MSCs which was 
overcome after a double stimulation (Condition 3). Fold changes of 
transcriptional regulation upon licensing of MSCs are specified in Table 8-2.  
As previously described, BM MSCs had the highest CXCL1 transcript levels under 
resting conditions (Figure 8-3, A). After 72 hours of stimulation (Condition 1), 
cytokine-mediated licensing led to no variation in the transcript levels in BM 
MSCs, an increase in Is MSCs and to a decrease in Ad MSCs. 24 hours after 
stimulation with the cytokine cocktail (Condition 2), MSCs from the three tissues 
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upregulated their CXCL1 transcript levels, with Is MSCs expressing the highest 
levels. A second stimulation with the cytokine cocktail 48 hours after the first 
stimulation (Condition 3) was able to induce the production of CXCL1 in MSCs 
from the three sources; however, the second stimulation was not able to match 
the transcript levels of CXCL1 found in Condition 2 in BM and Is MSCs. Ad MSCs, 
at the contrary, produced 57 times more CXCL1 after the second stimulation 
than Ad MSCs under resting conditions or 11 times more than in Condition 2. 
After 72 hours of stimulation with LPS, LTA or Poly I: C (Condition 1), CXCL1 
levels were almost undetectable in BM and Ad MSCs, while no variation was 
observed in Is MSCs. 24 hours stimulation with LPS produced a statistically non-
significant upregulation in MSCs from every source while double stimulation 
(Condition 3) with LPS led to higher transcript levels of CXCL1 in BM and Ad MSCs 
compared to Condition 1, but lower levels than those obtained by the cells 
harvested 24 hours after stimulation. On the contrary, double stimulation of Ad 
MSCs with LPS (Condition 3) produced an increase of CXCL1 transcript levels.  
As previously described, BM MSCs had the highest CXCL2 transcript levels under 
resting conditions (Figure 8-3, B). After 72 hours of stimulation (Condition 1), 
cytokine-mediated licensing led to no variation in the transcript levels of CXCL2 
in BM MSCs, a decrease in Is MSCs and to 64 times increase in Ad MSCs. On the 
contrary, 24 hours stimulation (Condition 2) led to a transcriptional upregulation 
in MSCs from every tissue source; however, the upregulation in Ad MSCs is 18 
times lower than in the previous condition. A second stimulation with the 
cytokine cocktail 48 hours after the first stimulation (Condition 3) was able to 
induce the production of CXCL2 in MSCs from every source, but the transcript 
levels produced did not match the ones from Condition 2 for BM and Is MScs, 
while for Ad MSCs the CXCL2 transcript levels were higher than in Conditions 1 
and 2. 24 hours of LPS licensing (Condition 1) led to the increase of CXCL2 levels 
in BM and Is MSCs, while it led to a decrease in Ad MSCs. Analysis of CXCL2 
transcript levels after 72 hours of LPS licensing showed a bigger upregulation in 
BM MSCs compared to the previous condition, while Is MSCs upregulated the 
transcription of CXCL2 but could not match the expression levels achieved in 
Condition 1; Ad MSCs upregulated their CXCL2 transcript levels but these were 
still very low. After 72 hours of stimulation (Condition 1), LTA-mediated 
licensing led to no variation in the transcript levels of CXCL2 in BM MSCs and to a 
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decrease in Is and Ad MSCs, while 24 hours of licensing led to upregulation in BM 
and Ad MSCs and to no variation in Is MSCs. A second stimulation with the 
cytokine cocktail 48 hours after the first stimulation (Condition 3) led to 
upregulation in BM MSCs, to downregulation in Is MSCs and to no variation in Ad 
MSCs. 72 hours of Poly I:C stimulation (Condition 1) led to a decrease of CXCL2 
transcript levels in MSCs from every source while 24 hours of licensing (Condition 
2) led to an increase of CXCL2 transcript levels in MSCs from every source. 
Double stimulation of MSCs (Condition 3) led to no variation in BM MSCs and to a 
statistically non-significant increase in Is and Ad MSCs.  
As previously described, CXCL5 expression levels were almost undetectable 
under resting conditions in Is and Ad MSCs, while BM MSCs had the highest CXCL5 
transcript levels (Figure 8-3, C). After 72 hours of stimulation (Condition 1), 
cytokine-mediated licensing led to a decrease in BM MSCs, an increase in Is MSCs 
and no variation in Ad MSCs. 24 hours after stimulation with the cytokine 
cocktail (Condition 2), MSCs from the three tissues upregulated their CXCL5 
transcript levels, with BM MSCs expressing the highest levels. A second 
stimulation with the cytokine cocktail 48 hours after the first stimulation 
(Condition 3) was able to induce the production of CXCL5 in MSCs from the three 
sources; however, the second stimulation was not able to match the transcript 
levels of CXCL5 found in Condition 2 in BM and Is MSCs. Ad MSCs, at the contrary, 
produced 400 times more CXCL5 after the second stimulation than Ad MSCs 
under resting conditions or 27 times more than in Condition 2. After 72 hours of 
stimulation with LPS (Condition 1), CXCL5 levels were downregulated to almost 
undetectable levels in BM MSCs, while Is and Ad MSCs upregulated their levels 
even if they were still very low. 24 hours stimulation with LPS produced a 
statistically non-significant upregulation in BM and Is MSCs while Ad MSCs 
upregulated their CXCL5 transcript levels in a statistically significant manner. A 
second stimulation of MSCs 48 hours after the first one (Condition 3) with LPS led 
to higher transcript levels of CXCL5 in MSCs from every source compared to 
Condition 1, but lower levels than those obtained by the cells harvested 24 hours 
after stimulation. After 72 hours of stimulation with LTA (Condition 1), CXCL5 
levels were downregulated to almost undetectable levels in MSCs from every 
source, while 24 hours licensing with LTA produced no variation in BM MSCs but 
an upregulation of the transcript levels in Is and Ad MSCs. A second LTA 
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stimulation 48 hours after the first one led to a downregulation of CXCL5 
transcript levels in MSCs from every source. After 72 hours of stimulation with 
Poly I:C (Condition 1), CXCL5 levels were downregulated to almost undetectable 
levels in MSCs from every source, with BM MSCs showing the lowest levels of 
CXCL5 transcript. 24 hours licensing with Poly I:C (Condition 2) produced a 
similar downregulation as Condition 1 in BM MSCs, had no effect in Is MSCs but 
led to an upregulation of the transcript levels in Ad MSCs. A second Poly I:C 
stimulation 48 hours after the first one led to a downregulation of CXCL5 
transcript levels in BM MSCs while it produced an upregulation in Is and Ad MSCs 
bigger than the one in Condition 2.  
CXCL10 levels were very low in MSCs from all the tissue sources under resting 
conditions, with Is MSCs having the highest transcript levels (Figure 8-3, D). After 
72 hours of stimulation (Condition 1), cytokine-mediated licensing led to a 
decrease in the transcript levels in BM and Is MSCs, while it produced no 
variation in Ad MSCs. 24 hours after stimulation with the cytokine cocktail 
(Condition 2), MSCs from the three tissues upregulated their CXCL10 transcript 
levels, with Is MSCs expressing the highest levels. A second stimulation with the 
cytokine cocktail 48 hours after the first stimulation (Condition 3) was able to 
induce the production of CXCL10 in MSCs from the three sources, however, the 
second stimulation was not able to match the transcript levels of CXCL10 found 
in Condition 2 in BM and Is MSCs. Ad MSCs, at the contrary, produced 900 times 
more CXCL10 after the second stimulation than Ad MSCs under resting conditions 
or 18 times more than in Condition 2. After 72 hours of stimulation with LPS 
(Condition 1), CXCL10 levels were downregulated to almost undetectable levels 
in BM and Ad MSCs, while Is MSCs upregulated their levels even if they were still 
very low. 24 hours stimulation with LPS produced an upregulation in MSCs from 
the three sources. A second stimulation of MSCs 48 hours after the first one 
(Condition 3) with LPS led to no variation in CXCL10 transcript levels in BM and Is 
MSCs and to a small downregulation in Ad MSCs. After 72 hours of stimulation 
with LTA (Condition 1), CXCL10 levels were downregulated to almost 
undetectable levels in BM and Ad MSCs, while it produced no effect on Is MSCs. 
24 hours licensing (Condition 2) with LTA produced no variation in BM and Is 
MSCs but an upregulation of the transcript levels on Is MSCs. Double stimulation 
of MSCs (Condition 3) with LTA led to a downregulation in BM MSCs and to an 
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upregulation in Is and Ad MSCs. 72 hours of Poly I:C-mediated licensing 
(Condition 1) led to downregulation of CXCL10 transcript levels in MSCs from 
every source. After 24 hours of licensing, MSCs from every source upregulated 
their transcript levels but this upregulation was only significant in BM MSCs. A 
second stimulation of MSCs 48 hours after the first one (Condition 3) with Poly 
I:C was able to induce the production of CXCL10 in BM and Is MSCs; however, the 
double stimulation was not able to match the transcript levels of CXCL10 found 
in Condition 2. On the contrary, double stimulation of Ad MSCs with Poly I:C led 
to a downregulation of the transcript levels.  
As previously mentioned, during resting conditions BM MSCs were able to 
produce significantly higher transcript amounts of CXCL12 than Is and Ad MSCs, 
which produced very little (Figure 8-3, E). After 72 hours of stimulation 
(Condition 1), cytokine-mediated licensing led to a decrease of the transcript 
levels in BM and Is MSCs, while it produced an increase in Ad MSCs. 24 hours 
after stimulation with the cytokine cocktail (Condition 2), BM and Is MSCs had 
downregulated their transcript levels and this downregulation was more 
pronounced in Is MSCs compared to Condition 1. On the other hand, Ad MSCs 
upregulated their CXCL12 transcript levels after 24 hours licensing with the 
cytokine cocktail. A second stimulation with the cytokine cocktail 48 hours after 
the first stimulation (Condition 3) was able to increase the transcript levels 
obtained after a single stimulation; however, despite being higher than in 
Conditions 1 and 2, the transcript levels found in BM and Is MSCs were still lower 
than in resting cells. 24 hours stimulation with the cytokine cocktail led to 
doubling the transcript levels of Ad MSCs, while the double stimulation was able 
to increase five times the amount of CXCL12 transcript in Ad MSCs. After 72 
hours of stimulation with LPS (Condition 1), CXCL12 levels were downregulated 
in BM and Ad MSCs, while Is MSCs upregulated their levels; 24 hours stimulation 
produced a downregulation in BM MSCs and an upregulation in Is and Ad MSCs. A 
second stimulation of MSCs 48 hours after the first one (Condition 3) with LPS led 
to a downregulation of CXCL12 transcript levels in BM and Ad MSCs and to a 
small upregulation in Is MSCs. 72 hours of licensing with LTA (Condition 1) 
produced no effect on CXCL12 transcript levels in BM and Ad MSCs, while it 
produced an upregulation in Is MSCs. 24-hour licensing (Condition 2) with LTA 
produced a small upregulation in BM and Is MSCs and no variation in Ad MSCs, 
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while a second stimulation 48 hours after the first one (Condition 3) led to an 
upregulation in BM and Ad MSCs and to a downregulation in Is MSCs. 72 hours of 
Poly I:C-mediated licensing (Condition 1) led to downregulation of CXCL12 
transcript levels in BM and Ad MSCs while it led to an upregulation in Is MSCs. 24 
hours after Poly I:C licensing (Condition 2) CXCL12 transcript levels were 
downregulated in BM MSCs, but the transcript levels were not as low as the ones 
obtained on Condition 1; Is MSCs had upregulated their CXCL12 transcript levels 
to the same level as in Condition 1 and Ad MSCs showed no variation on their 
transcript levels. A second stimulation of MSCs 48 hours after the first one 
(Condition 3) with Poly I:C was able to induce the downregulation of CXCL12 
transcript level in BM MSCs, while it produced an upregulation of CXCL12 
transcript level in Is and Ad MSCs.  
Lastly, CXCL16 transcript was barely expressed by MSCs of every source during 
resting conditions (Figure 8-3, F). After 72 hours of stimulation (Condition 1), 
cytokine-mediated licensing led to an increase of the transcript level in BM and 
Ad MSCs, while it produced a decrease in Is MSCs. 24 hours after stimulation with 
the cytokine cocktail (Condition 2), MSCs from every source had upregulated 
their CXCL16 transcript level, with Ad MSCs expressing the highest transcript 
levels. A second stimulation with the cytokine cocktail 48 hours after the first 
stimulation (Condition 3) was able to increase the transcript levels of CXCL16 in 
MSCs from the three sources; however, the second stimulation was not able to 
match the transcript levels of CXCL16 found in Condition 2 in BM and Is MSCs. Ad 
MSCs, on the contrary, were able to produce even higher CXCL16 transcript 
levels after a second stimulation with the cytokine cocktail. After 72 hours of 
stimulation with LPS (Condition 1), CXCL16 levels were upregulated in BM MSCs, 
no variation was observed in Is MSCs and CXCL16 transcript levels were 
downregulated in Ad MSCs. 24 hours licensing with LPS produced an upregulation 
in MSCs from every source while a second stimulation of MSCs 48 hours after the 
first one (Condition 3) with LPS led to an upregulation of CXCL16 transcript 
levels in BM and Ad MSCs and to a small downregulation in Is MSCs. 72 hours of 
LTA-mediated stimulation (Condition 1) produced an upregulation of CXCL16 
transcript levels in BM MSCs, while it produced a downregulation of the 
transcript levels in Ad and Is MSCs. 24 hours licensing (Condition 2) with LTA 
produced an upregulation in BM and Ad MSCs and a small downregulation in Is 
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MSCs. A second stimulation 48 hours after the first one (Condition 3) led to an 
upregulation of CXCL16 in MSCs from every source, but this upregulation was 
only significant in BM MSCs. 72 hours of Poly I:C-mediated licensing (Condition 1) 
led to no variation in BM MSCs while it led to a downregulation of CXCL16 
transcript levels in Is and Ad MSCs. 24 hours after Poly I:C licensing (Condition 2) 
CXCL16 transcript levels were upregulated in a statistically non-significant 
manner in MSCs from every source. A second stimulation of MSCs 48 hours after 
the first one (Condition 3) with Poly I:C was able to induce the upregulation of 
CXCL16 transcript levels in MSCs from every source in similar levels as the ones 
observed in Condition 2.  
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Figure 8-3. Inflammatory agent, repetitive stimulus and MSC tissue origin impacts CXCL 
chemokine transcript levels in MSCs. 
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with a cocktail of cytokines (40 ng/ mL of IFN-ϒ, 
TNF-α and IL-1β), or 100 ng/ mL LPS, or 100 ng/ mL LTA or 4 µg/ mL Poly I:C. Unstimulated cells 
were left growing in MSC culture medium as a control. Three different licensing conditions were 
tested. In the first one, cells were stimulated for 48 hours, after which cells were washed twice with 
PBS and fresh culture medium was added; cells were harvested 24 hours later. In the second 
condition, cells were washed twice with PBS, the culture medium was replaced with fresh one and 
the cells were left growing for 48 hours. Cells were then washed twice with PBS, the culture 
medium was replaced with supplemented one and the cells were harvested 24 hours later. In the 
last condition, cells were stimulated for 48 hours, after which cells were washed twice with PBS 
and were stimulated again for another 24 hours. Figure 4-7 illustrates the time points at which 
supplemented medium was added. Quantitative reverse transcription PCR (qRT-PCR) was 
performed to evaluate CXCL transcripts in BM, Is and Ad MSCs under resting and inflammatory 
conditions. Each bar represents an n of 4 independent experiments and is graphed as mean ± 
SEM. Data are normalised to the housekeeping gene B2M and expressed as 2(-ΔCT). Statistically 
significant differences are marked with a colour code in Table 4-8.  
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Table 8-2. Fold change in CXC chemokine transcript levels of cytokine, LPS, LTA or Poly 
I:C-mediated licensed BM, Is and Ad MSCs compared to unstimulated cells from the same 
source.  
Following the experimental set up explained in Figure 8-3, fold change in transcript levels of CXC 
chemokines is represented as mean of fold change ± standard deviation. One Way ANOVA with 
Tukey’s multiple comparisons post-test was performed to compare all MSC sources and the 
different conditions. p = 0.05 was considered the limit for statistical significance. Statistically 
significant differences are marked with a colour code, where p < 0.05 is represented by green, p < 
0.01 is represented by orange, p < 0.001 is represented by blue and p < 0.0001 is represented by 
red. 
Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
CXCL1 
1 
Cyt 3.70 ± 3.41 3.04 ± 3.73 0.09 ± 0.06 
LPS 0.35 ± 0.25 0.78 ± 0.87 0.23 ± 0.06 
LTA 0.09 ± 0.07 1.94 ± 2.28 0.11 ± 0.04 
Poly I:C 0.06 ± 0.05 2.11 ± 2.17 0.13 ± 0.03 
2 
Cyt 13.66 ± 10.35 7.77 ± 7.58 2.56 ± 0.23 
LPS 1.78 ± 0.56 5.05 ± 5.82 1.96 ± 0.41 
LTA 0.62 ± 0.10 0.93 ± 0.64 0.95 ± 0.06 
Poly I:C 1.01 ± 0.77 1.21 ± 1.20 0.91 ± 0.12 
3 
Cyt 2.49 ± 0.30 3.19 ± 2.58 57.55 ± 4.31 
LPS 2.25 ± 1.25 1.20 ± 0.63 1.58 ± 0.09 
LTA 0.18 ± 0.11 2.41 ± 2.56 0.89 ± 0.19 
Poly I:C 0.16 ± 0.08 0.44 ± 0.29 1.45 ± 0.22 
CXCL2 
1 
Cyt 0.95 ± 0.20 0.70 ± 0.41 64.35 ± 10.64 
LPS 3.24 ± 0.66 13.12 ± 12.57 0.52 ± 0.17 
LTA 1.01 ± 0.13 0.61 ± 0.22 0.33 ± 0.21 
Poly I:C 0.69 ± 0.28 0.40 ± 0.15 0.19 ± 0.08 
2 
Cyt 7.14 ± 1.15 10.04 ± 3.51 3.18 ± 0.49 
LPS 15.99 ± 4.05 8.70 ± 2.38 3.63 ± 1.65 
LTA 3.03 ± 0.65 0.98 ± 0.71 2.70 ± 0.89 
Poly I:C 2.56 ± 1.19 2.91 ± 0.50 1.40 ± 0.46 
3 
Cyt 2.21 ± 0.95 5.49 ± 1.02 110.74 ± 34.09 
LPS 12.61 ± 2.99 1.95 ± 0.49 1.34 ± 0.53 
LTA 2.05 ± 1.16 0.52 ± 0.50 0.97 ± 0.42 
Poly I:C 1.20 ± 0.14 1.86 ± 0.44 3.12 ± 1.31 
CXCL5 
1 
Cyt 0.41 ± 0.15 27.08 ± 24.87 0.97 ± 0.50 
LPS 0.05 ± 0.01 5.60 ± 4.80 4.38 ± 0.98 
LTA 0.01 ± 0.00 0.40 ± 0.17 0.51 ± 0.09 
Poly I:C 0.01 ± 0.00 0.89 ± 0.62 0.51 ± 0.12 
2 
Cyt 6.86 ± 1.60 182.44 ± 101.70 26.79 ± 4.95 
LPS 2.27 ± 2.22 13.58 ± 4.69 28.05 ± 10.42 
LTA 1.09 ± 1.06 1.40 ± 1.15 2.96 ± 0.48 
Poly I:C 0.02 ± 0.00 1.46 ± 1.33 2.30 ± 0.46 
3 
Cyt 2.22 ± 1.94 108.75 ± 37.36 402.41 ± 86.69 
LPS 1.85 ± 1.62 14.43 ± 6.41 19.12 ± 4.38 
LTA 0.14 ± 0.13 0.10 ± 0.05 0.65 ± 0.20 
Poly I:C 0.13 ± 0.10 1.68 ± 1.53 26.34 ± 6.16 
CXCL10 1 
Cyt 0.11 ± 0.06 0.19 ± 0.15 1.02 ± 0.63 
LPS 0.43 ± 0.31 11.88 ± 15.22 0.31 ± 0.08 
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Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
LTA 0.50 ± 0.21 1.42 ± 1.21 0.48 ± 0.18 
Poly I:C 0.69 ± 0.23 0.62 ± 0.50 0.91 ± 0.46 
2 
Cyt 10.16 ± 5.26 19.21 ± 10.64 45.62 ± 21.79 
LPS 1.64 ± 0.46 1.23 ± 1.06 3.65 ± 1.84 
LTA 0.99 ± 0.47 1.14 ± 0.63 12.40 ± 6.16 
Poly I:C 97.19 ± 36.00 3.61 ± 2.02 6.92 ± 2.85 
3 
Cyt 4.09 ± 2.34 6.51 ± 5.88 913.91 ± 470.61 
LPS 1.07 ± 0.69 1.21 ± 0.58 0.64 ± 0.25 
LTA 0.80 ± 0.38 2.73 ± 3.09 1.62 ± 1.12 
Poly I:C 30.72 ± 14.62 2.58 ± 1.92 0.15 ± 0.04 
CXCL12 
1 
Cyt 0.13 ± 0.09 0.87 ± 0.90 2.87 ± 1.41 
LPS 0.27 ± 0.11 5.88 ± 1.89 0.66 ± 0.23 
LTA 1.15 ± 0.92 5.47 ± 4.99 1.02 ± 0.46 
Poly I:C 0.17 ± 0.14 2.68 ± 1.59 0.41 ± 0.23 
2 
Cyt 0.16 ± 0.12 0.36 ± 0.30 2.09 ± 0.86 
LPS 0.39 ± 0.18 1.48 ± 1.62 1.54 ± 0.60 
LTA 1.98 ± 1.13 1.43 ± 0.75 1.14 ± 0.83 
Poly I:C 0.61 ± 0.39 2.69 ± 2.03 1.04 ± 0.57 
3 
Cyt 0.22 ± 0.19 0.81 ± 0.59 5.50 ± 2.08 
LPS 0.63 ± 0.38 1.70 ± 0.41 0.53 ± 0.27 
LTA 1.88 ± 1.43 0.44 ± 0.38 2.20 ± 1.04 
Poly I:C 0.32 ± 0.23 1.95 ± 1.89 3.01 ± 1.13 
CXCL16 
1 
Cyt 2.95 ± 0.24 0.35 ± 0.23 1.81 ± 0.92 
LPS 5.07 ± 2.20 1.15 ± 0.47 0.70 ± 0.31 
LTA 8.30 ± 2.33 0.52 ± 0.42 0.81 ± 0.50 
Poly I:C 1.20 ± 0.47 0.31 ± 0.12 0.46 ± 0.23 
2 
Cyt 7.59 ± 1.34 5.13 ± 2.00 43.11 ± 16.81 
LPS 4.20 ± 0.62 1.52 ± 0.90 4.96 ± 3.71 
LTA 10.53 ± 3.08 0.54 ± 0.31 1.89 ± 0.97 
Poly I:C 3.25 ± 2.57 1.87 ± 1.42 1.57 ± 0.75 
3 
Cyt 5.30 ± 1.62 5.01 ± 3.71 62.89 ± 24.29 
LPS 7.48 ± 2.10 0.74 ± 0.44 1.57 ± 0.61 
LTA 13.80 ± 1.23 2.68 ± 3.20 1.29 ± 0.66 
Poly I:C 2.26 ± 0.14 1.04 ± 0.59 2.33 ± 1.11 
 
8.1.3 Transcription of CX3CL1 chemokine and atypical chemokine 
receptor ACKR4 under resting and inflammatory conditions  
Under resting conditions, BM, Is and Ad MSCs transcribed very little, if any, 
CX3CL1 (Figure 8-4, A), while ACKR4 (Figure 8-4, B) was transcribed at higher 
rates, but in both cases transcript level variations were not observed among the 
MSCs isolated from the different sources under resting conditions. However, in 
both cases tissue of origin and licensing agent did have an influence in the levels 
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of transcript levels after inflammatory stimulation. CX3CL1 showed a pattern of 
transcriptional upregulation after licensing while ACKR4 showed a pattern of 
transcriptional downregulation. With a few exceptions, CX3CL1 transcript levels 
increase after a 24 hours stimulation (Condition 2) in MSCs from every tissue 
source; however, this upregulation was not sustained, as cells harvested 72 
hours after licensing (Condition 1) showed a decrease in the transcript levels of 
CX3CL1 compared to Condition 2. A second stimulation 48 hours after the first 
stimulation (Condition 3) was able to induce the transcription of CX3CL1 in MSCs 
from the three sources; however, the second stimulation was not able to match 
the transcript levels observed in Condition 2. Overall, ACKR4 transcript levels 
decreased after a 24-hour stimulation (Condition 2) in MSCs from every tissue 
source; however, this downregulation was not sustained, as even if the 
downregulation was still notable, cells harvested 72 hours after licensing 
(Condition 1) showed higher transcript levels than the ones observed 24 hours 
after licensing. A second stimulation 48 hours after the first stimulation 
(Condition 3) was able to sustain the downregulation in MSCs from the three 
sources as ACKR4 transcript levels were like the ones observed 24 hours after 
licensing. Fold changes of transcriptional regulation upon licensing of MSCs are 
specified in Table 8-3. 
As previously mentioned, during resting conditions BM, Is and Ad MSCs 
transcribed very little CX3CL1 (Figure 8-4, A). After 72 hours of stimulation 
(Condition 1), cytokine-mediated licensing led to an increase in the transcript 
levels in MSCs from all sources, where Ad MSCs had the highest transcript levels. 
24 hours after stimulation with the cytokine cocktail (Condition 2), MSCs from 
the three sources had upregulated their transcript levels, but it was only 
statistically significant in BM and Ad MSCs. A second stimulation with the 
cytokine cocktail 48 hours after the first stimulation (Condition 3) was able to 
induce the transcription of CX3CL1 in MSCs from the three sources; however, the 
second stimulation was not able to match the transcript levels observed in 
Condition 2. 72 hours after LPS licensing BM and Is MSCs had upregulated their 
CX3CL1 transcript levels, while Ad MSCs had downregulated their transcript 
levels. 24 hours stimulation with LPS led to a downregulation in BM and Ad MSCs 
while it produced no variation in Is MSCs transcript levels; a second stimulation 
of MSCs 48 hours after the first one (Condition 3) with LPS led to a 
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downregulation of CX3CL1 transcript levels in MSCs from the three sources. 72 
hours of licensing with LTA (Condition 1) produced an upregulation of CX3CL1 
transcript levels in BM and Is MSCs, while it produced no effect in Ad MSCs. 24-
hour licensing (Condition 2) with LTA produced an upregulation of CX3CL1 
transcript levels in BM and Is MSCs; however, transcript levels were not as high 
as in Condition 1. 24 hours LTA licensing produced a downregulation in Ad MSCs. 
A second stimulation 48 hours after the first one (Condition 3) led to no variation 
in BM MSCs and to upregulation of CX3CL1 transcript levels in Is and Ad MSCs. 72 
hours of Poly I:C-mediated licensing (Condition 1) led to downregulation of 
CX3CL1 transcript levels in BM and Ad MSCs while it led to an upregulation in Is 
MSCs. 24 hours after Poly I:C licensing (Condition 2) CX3CL1 transcript levels 
were upregulated in BM and Is MSCs, while Ad MSCs had downregulated their 
CX3CL1 transcript levels. A second stimulation of MSCs 48 hours after the first 
one (Condition 3) with Poly I:C was able to induce the downregulation of CX3CL1 
transcript levels in BM MSCs, while it produced an upregulation of CX3CL1 
transcript levels in Is and Ad MSCs. 
As indicated previously, during resting conditions BM, Is and Ad MSCs transcribed 
very little ACKR4 (Figure 8-4, B). After 72 hours of stimulation (Condition 1), 
cytokine-mediated licensing produced a downregulation in the transcript levels 
of BM and Is MSCs, while it produced a small upregulation in Ad MSCs. 24 hours 
after stimulation with the cytokine cocktail (Condition 2), MSCs from the three 
sources had downregulated their transcript levels. After the double stimulation 
with the cytokine cocktail (Condition 3), ACKR4 transcript levels remained 
downregulated at the same level as in Condition 2 in MSCs from the three 
sources. 72 hours after LPS licensing, BM and Is MSCs had downregulated their 
transcript levels, while Ad MSCs showed no variation in their ACKR4 transcript 
levels. 24 hours stimulation with LPS led to a downregulation in MSCs from the 
three sources, but this downregulation was only significant in BM and Is MSCs. 
After the double stimulation with LPS (Condition 3), ACKR4 transcript levels 
remained downregulated at the same level as in Condition 2 in MSCs from the 
three sources. 72 hours of licensing with LTA (Condition 1) produced a 
downregulation of ACKR4 transcript levels in BM and Is MSCs, while it produced 
no effect in Ad MSCs. 24 hours licensing (Condition 2) with LTA produced a 
downregulation in MSCs from the three sources, but this downregulation was 
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only significant in BM and Is MSCs. A second stimulation 48 hours after the first 
one (Condition 3) led to the downregulation of transcript levels in BM and Is 
MSCs, while Ad MSCs upregulated their ACKR4 transcript levels. 72 hours of Poly 
I:C-mediated licensing (Condition 1) led to a downregulation of ACKR4 transcript 
levels in MSCs from the three sources, while 24 hours after Poly I:C licensing 
(Condition 2) ACKR4 transcript levels were upregulated in MSCs from the three 
sources. Lastly, after the double stimulation with Poly I:C (Condition 3), ACKR4 
transcript levels remained downregulated at the same level as in Condition 2 in 
BM and Is MSCs, while they remained downregulated, but slightly higher, in Ad 
MSCs. 
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Figure 8-4. Inflammatory agent, repetitive stimulus and MSC tissue origin impacts CX3CL1 
and ACKR4 chemokine transcript levels in MSCs. 
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with either a cocktail of cytokines (40 ng/ mL of 
IFN-ϒ, TNF-α and IL-1β), 100 ng/ mL LPS, 100 ng/ mL LTA or 4 µg/ mL Poly I:C. Unstimulated cells 
were left growing in MSC culture medium as a control. Three different licensing conditions were 
tested. In the first one, cells were stimulated for 48 hours, after which cells were washed twice with 
PBS and fresh culture medium was added; cells were harvested 24 hours later. In the second 
condition, cells were washed twice with PBS, the culture medium was replaced with fresh one and 
the cells were left growing for 48 hours. Cells were then washed twice with PBS, the culture 
medium was replaced with supplemented one and the cells were harvested 24 hours later. In the 
last condition, cells were stimulated for 48 hours, after which cells were washed twice with PBS 
and were stimulated again for another 24 hours. Figure 4-7 illustrates the time points at which 
supplemented medium was added. Quantitative reverse transcription PCR (qRT-PCR) was 
performed to evaluate transcripts in BM, Is and Ad MSCs under resting and inflammatory 
conditions. Each bar represents an n of 4 independent experiments and is graphed as mean ± 
SEM. Data are normalised to the housekeeping gene B2M and expressed as 2(-ΔCT). Statistically 
significant differences are marked with a colour code in Table 4-9. 
 
Table 8-3. Fold change in CX3CL1 and ACKR4 transcript levels of cytokine, LPS, LTA or 
Poly I:C-mediated licensed BM, Is and Ad MSCs compared to unstimulated cells from the 
same source.  
Following the experimental set up explained in Figure 8-4, fold change in transcript levels of 
CX3CL1 and ACKR4 is represented as mean of fold change ± standard deviation. One Way 
ANOVA with Tukey’s multiple comparisons post-test was performed to compare all MSC sources 
and the different conditions. p = 0.05 was considered the limit for statistical significance. 
Statistically significant differences are marked with a colour code, where p < 0.05 is represented by 
green, p < 0.01 is represented by orange, p < 0.001 is represented by blue and p < 0.0001 is 
represented by red. 
Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
CX3CL1 
1 
Cyt 2.39 ± 0.51 2.34 ± 2.02 2.19 ± 0.73 
LPS 1.40 ± 0.10 7.44 ± 3.38 0.29 ± 0.12 
LTA 5.13 ± 3.48 2.84 ± 1.46 1.09 ± 0.75 
Poly I:C 0.49 ± 0.32 5.71 ± 1.25 0.28 ± 0.14 
2 
Cyt 7.07 ± 3.78 4.82 ± 4.06 23.71 ± 5.55 
LPS 0.61 ± 0.16 1.01 ± 0.88 0.15 ± 0.04 
LTA 2.40 ± 0.65 2.38 ± 2.75 0.24 ± 0.05 
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Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
Poly I:C 1.74 ± 1.62 4.29 ± 3.14 0.30 ± 0.09 
3 
Cyt 1.24 ± 0.96 1.17 ± 0.80 12.29 ± 2.38 
LPS 0.73 ± 0.27 0.77 ± 0.75 0.42 ± 0.11 
LTA 1.20 ± 0.79 4.24 ± 2.95 5.63 ± 1.68 
Poly I:C 0.32 ± 0.20 1.92 ± 1.60 1.99 ± 0.43 
ACKR4 
1 
Cyt 0.02 ± 0.02 0.01 ± 0.00 1.66 ± 1.30 
LPS 0.07 ± 0.01 0.18 ± 0.09 0.85 ± 0.30 
LTA 0.16 ± 0.05 0.23 ± 0.04 0.80 ± 0.49 
Poly I:C 0.01 ± 0.00 0.82 ± 0.57 0.52 ± 0.16 
2 
Cyt 0.02 ± 0.01 0.01 ± 0.00 0.26 ± 0.14 
LPS 0.05 ± 0.02 0.08 ± 0.02 0.12 ± 0.09 
LTA 0.26 ± 0.11 0.47 ± 0.23 0.31 ± 0.18 
Poly I:C 0.03 ± 0.01 0.13 ± 0.03 0.19 ± 0.05 
3 
Cyt 0.01 ± 0.00 0.01 ± 0.00 0.29 ± 0.12 
LPS 0.18 ± 0.08 0.17 ± 0.18 0.18 ± 0.04 
LTA 0.11 ± 0.04 0.60 ± 0.11 3.15 ± 0.66 
Poly I:C 0.00 ± 0.00 0.13 ± 0.14 0.50 ± 0.16 
 
8.1.4 Transcription of the receptors of the stimulatory agents 
under resting and inflammatory conditions 
Under resting conditions, BM, Is and Ad MSCs transcribed very little, if any, IL1R1 
(Figure 8-5, A), IL1R2 (B), IFNGR2 (F), TLR2 (G), TLR3 (H) and TLR4 (I), while 
TNFR1a (C), TNFR1b (D) and IFNGR1 (E) were transcribed at higher rates. In all 
the cases, transcript level variations were not observed among the MSCs isolated 
from the different sources under resting conditions. However, tissue of origin did 
influence the transcriptional regulation upon exposure to the different licensing 
agents and the different conditions. Fold changes of transcriptional regulation 
upon licensing of MSCs are summarised in Table 8-4. 
Briefly, cytokine-mediated stimulation led to the downregulation of the cytokine 
receptors (IL1R1 [Figure 8-5, A], IL1R2 [B], TNFR1a [C], TNFR1b [D], IFNGR1 [E] 
and IFNGR2 [F]) in BM and Is MSCs under all conditions. Cytokine-mediated 
stimulation downregulated the cytokine receptors in Ad MSCs too; however, this 
downregulation was not sustained 72 hours after stimulation and, in some cases, 
even led to the upregulation of the receptors. LPS and LTA were able to produce 
the upregulation of the cytokine receptors transcript levels in certain conditions 
in MSCs from the three sources. The effects of Poly I:C in the regulation of the 
cytokine receptors transcription levels was tissue specific; Poly I:C stimulation of 
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BM MSCs led to the downregulation of all the cytokine receptors but IFNGR2 in 
all the conditions tested. Poly I:C was able to downregulate the transcription of 
all the cytokine receptors but IFNGR2 in Is MSCs; however, 24 hours after the 
stimulation the downregulation was not sustained, and the transcript levels 
started increasing. The effect of Poly I:C stimulation in Ad MSCs was gene 
dependent and the effect it produced in each of the genes at the established 
time points will be described later in detail.  
LPS-mediated stimulation downregulated its receptor, TLR4, after 24 hours 
licensing in BM MSCs; however, 24 hours after the stimulation the 
downregulation was not sustained and the transcript levels started increasing 
(Figure 8-5, I). LPS produced no variation on TLR4 transcript levels after a single 
stimulation in Is MSCs; however, a second stimulation 48 hours after the first one 
downregulated the receptor transcript levels. Overall, LPS-mediated licensing 
produced no variation on TLR4 transcript levels in Ad MSCs under any condition. 
Cytokine and Poly I:C-mediated licensing were able to downregulate the 
transcription of TLR4 in BM and Is MSCs; while cytokines upregulated its 
transcription in every condition and Poly I:C was able to upregulate the 
transcription of TLR4 after a double stimulation. LTA-mediated stimulation 
produced an upregulation of TLR4 transcript levels in BM MSCs, a downregulation 
that was not sustained 72 hours after in Is MSCs and was only able to upregulate 
the transcription in Ad MSCs after a double stimulation.  
LTA-mediated stimulation upregulated its receptor, TLR2, in BM MSCs under 
every condition, while it produced no variation in Is MSCs and a small 
downregulation in Ad MSCs after a single stimulation but no variation after a 
double stimulation (Figure 8-5, G). All the licensing agents were able to increase 
the transcript levels of TLR2 in BM MSCs. LPS and Poly I:C produced no variation 
on TLR2 transcript levels in Is and Ad MSCs while cytokine-mediated licensing 
produced an upregulation after 24 hours in Is MSCs which was not sustained and 
Ad MSCs required a double stimulation to upregulate TLR2 transcript levels.  
Poly I:C-mediated stimulation downregulated its receptor, TLR3, in MSCs from 
the three sources under every condition tested. All the licensing agents were 
able to decrease the transcript levels of TLR3 in BM MSCs (Figure 8-5, H). 
Cytokine-mediated licensing downregulated TLR3 transcript levels in Is MSCs 
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under every condition while it produced an upregulation in Ad MSCs. LPS or LTA-
mediated stimulation produced a decrease on the transcript levels 24 hours after 
the first or second stimulation, while they produced an upregulation 72 hours 
later in Is MSCs. On the contrary, Ad MSCs responded to LPS or LTA licensing by 
downregulating their TLR3 receptor, but this downregulation was not sustained 
as transcription levels started increasing after 24 hours.  
As indicated previously, during resting conditions BM, Is and Ad MSCs transcribed 
very little IL1R1 and no variation in the transcript levels were observed among 
MSCs from different sources (Figure 8-5, A). After 72 hours of stimulation 
(Condition 1), cytokine-mediated licensing produced a downregulation in the 
transcript levels of BM and Is MSCs, while it produced a statistically significant 
upregulation in Ad MSCs. 24 hours after stimulation with the cytokine cocktail 
(Condition 2), BM and Is MSCs had downregulated their transcript levels, while 
Ad MSCs had upregulated their transcript levels in a smaller amount than in 
Condition 1. After the double stimulation with the cytokine cocktail (Condition 
3), IL1R1 transcript levels were downregulated in MSCs from the three sources. 
72 hours after LPS licensing, BM MSCs had downregulated their transcript levels, 
while Is and Ad MSCs had upregulated their IL1R1 transcript levels. 24-hour 
stimulation with LPS led to a downregulation of transcript levels in MSCs from 
the three sources. After the double stimulation with LPS (Condition 3) IL1R1 
transcript levels remained downregulated at the same level as in Condition 2 in 
MSCs from the three sources. 72 hours of licensing with LTA (Condition 1) 
produced a downregulation of IL1R1 transcript levels in BM MSCs, while it 
produced an upregulation in Is and Ad MSCs. 24 hours licensing (Condition 2) with 
LTA produced an upregulation in BM MSCs while it produced a downregulation in 
Is and Ad MSCs. A second stimulation 48 hours after the first one (Condition 3) 
produced no variation in BM MSCs and an upregulation in Is and Ad MSCs. 72 
hours of Poly I:C-mediated licensing (Condition 1) led to a downregulation of 
IL1R1 transcript levels in BM MSCs while it led to an upregulation in Is MSCs and 
to no variation in Ad MSCs. 24 hours after Poly I:C licensing (Condition 2) IL1R1 
transcript levels were downregulated in MSCs from the three sources. Lastly, 
after a double stimulation with Poly I:C (Condition 3), IL1R1 transcript levels 
were downregulated more than in Condition 2 in MSCs from the three sources.  
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During resting conditions BM, Is and Ad MSCs transcribed very little, if any, IL1R2 
and no variation in the transcript levels were observed among MSCs from 
different sources (Figure 8-5, B). After 72 hours of stimulation (Condition 1), 
cytokine-mediated licensing produced a downregulation in the transcript levels 
of BM and Is MSCs, while it produced an upregulation in Ad MSCs. 24 hours after 
stimulation with the cytokine cocktail (Condition 2), BM and Is MSCs had 
downregulated their transcript levels, while Ad MSCs had upregulated their 
transcript levels. After a double stimulation with the cytokine cocktail 
(Condition 3), IL1R2 transcript levels were downregulated in BM and Is MSCs, 
while they were upregulated in Ad MSCs. 72 hours after LPS licensing, MScs from 
the three sources had upregulated their IL1R2 transcript. 24 hours stimulation 
with LPS led to no variation in BM MSCs, a small downregulation in Is MSCs and to 
an upregulation in Ad MSCs. After the double stimulation with LPS (Condition 3) 
IL1R2 transcript levels showed no change in BM MSCs, Is MSCs had downregulated 
their transcript levels while Ad MSCs had upregulated them. 72 hours of licensing 
with LTA (Condition 1) produced an upregulation of IL1R2 transcript levels in 
MSCs from the three sources. 24-hour licensing (Condition 2) with LTA produced 
an upregulation in MSCs from the three sources; in the case of BM MSCs, this 
upregulation was higher than in Condition 1, while it was smaller in Is and Ad 
MSCs. A second stimulation 48 hours after the first one (Condition 3) produced 
no variation in BM MSCs but it led to a significant upregulation in Is and Ad MSCs. 
72 hours of Poly I:C-mediated licensing (Condition 1) led to a downregulation of 
IL1R2 transcript levels in BM MSCs while it led to an upregulation in Is and Ad 
MSCs. 24 hours after Poly I:C licensing (Condition 2) IL1R2 transcript levels were 
downregulated in BM and Is MSCs and upregulated in Ad MSCs. After the double 
stimulation with Poly I:C (Condition 3), IL1R2 transcript levels were 
downregulated in BM MSCs and upregulated in Is and Ad MSCs.  
During resting conditions BM, Is and Ad MSCs transcribed substantial levels of 
TNFR1a and no variation in the transcript levels were observed among MSCs from 
different sources (Figure 8-5, C). After 72 hours of stimulation (Condition 1), 
cytokine-mediated licensing produced a downregulation in the transcript levels 
of MSCs from the three sources. 24 hours after stimulation with the cytokine 
cocktail (Condition 2), MSCs from the three sources had downregulated their 
TNFR1a transcript levels in similar levels as in the previous condition. After the 
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double stimulation with the cytokine cocktail (Condition 3), TNFR1a transcript 
levels were downregulated in BM and Is MSCs, while they were upregulated in Ad 
MSCs. 72 hours after LPS licensing, BM and Ad MSCs downregulated their TNFR1a 
transcript levels while Is MSCs upregulated them. 24 hours stimulation with LPS 
led to a downregulation in MSCs from the three sources while a second 
stimulation 48 hours after the first one (Condition 3) led to a downregulation of 
TNFR1a transcript levels in BM and Is MSCs and to an upregulation in Ad MSCs. 72 
hours of LTA licensing (Condition 1) produced an upregulation of TNFR1a 
transcript levels in BM and Is MSCs, while it produced a downregulation in Ad 
MSCs. 24 hours licensing (Condition 2) with LTA produced a smaller upregulation 
in BM MSCs compared to Condition 1 and a downregulation in Is and Ad MSCs; this 
downregulation in Ad MSCs was bigger than in Condition 1. A second stimulation 
48 hours after the first one (Condition 3) produced an upregulation in BM MSCs 
and Ad MSCs, and a downregulation in Is MSCs. 72 hours of Poly I:C-mediated 
licensing (Condition 1) led to a downregulation of TNFR1a transcript levels in 
MSCs from the three sources, as well as after 24 hours stimulation (Condition 2). 
A second stimulation with Poly I:C 48 hours after the first one (Condition 3) led 
to a downregulation of TNFR1a transcript levels in BM and Is MSCs, where these 
downregulations were increased compared to previous conditions. On the 
contrary, a second stimulation with Poly I:C produced a significant upregulation 
of TNFR1a transcript levels in Ad MSCs.   
During resting conditions BM, Is and Ad MSCs transcribed TNFR1b at substantial 
levels and no variation in the transcript levels were observed among MSCs from 
different sources (Figure 8-5, D). After 72 hours of stimulation (Condition 1), 
cytokine-mediated licensing produced a downregulation in the transcript levels 
of MSCs from the three sources. 24 hours after stimulation with the cytokine 
cocktail (Condition 2), MSCs from the three sources had downregulated their 
TNFR1b transcript levels in similar levels as in the previous condition. After the 
double stimulation with the cytokine cocktail (Condition 3), TNFR1b transcript 
levels were downregulated in BM and Is MSCs, while they were upregulated in Ad 
MSCs. 72 hours after LPS licensing, MSCs isolated from the three tissues had 
downregulated their TNFR1b transcript levels. 24 hours stimulation with LPS led 
to a smaller downregulation in MSCs from the three sources while a second 
stimulation 48 hours after the first one (Condition 3) led to no effect in BM and 
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Ad MSCs, while it led to a downregulation of TNFR1b transcript levels in Is MSCs. 
72 hours of LTA licensing (Condition 1) produced no variation in TNFR1b 
transcript levels in BM and Ad MSCs, while it produced a downregulation in Is 
MSCs. 24 hours licensing (Condition 2) with LTA produced no variation in BM MSCs 
and a downregulation in Is and Ad MSCs. A second stimulation 48 hours after the 
first one (Condition 3) produced an upregulation in BM MSCs, a downregulation in 
Is MSCs and no effect in Ad MSCs. 72 hours of Poly I:C-mediated licensing 
(Condition 1) led to a downregulation of TNFR1b transcript levels in MSCs from 
the three sources, as well as after 24 hours stimulation (Condition 2). A second 
stimulation with Poly I:C 48 hours after the first one (Condition 3) led to a 
downregulation of TNFR1a transcript levels in BM and Is MSCs, where the 
downregulation was increased compared to previous conditions in BM MSCs. On 
the contrary, a second stimulation with Poly I:C produced a significant 
upregulation of TNFR1b transcript levels in Ad MSCs.   
During resting conditions BM MSCs transcribed the highest IFNGR1 transcript 
levels but MSCs from the three sources transcribed IFNGR1 at substantial levels 
(Figure 8-5, E). After 72 hours of stimulation (Condition 1), cytokine-mediated 
licensing produced a downregulation in the transcript levels of BM and Is MSCs, 
while it produced no effect in Ad MSCs. 24 hours after stimulation with the 
cytokine cocktail (Condition 2) MSCs from the three sources had downregulated 
their IFNGR1 transcript levels and in the case of the BM and Is MSCs, this 
downregulation was in similar levels as in the previous condition. After the 
double stimulation with the cytokine cocktail (Condition 3), IFNGR1 transcript 
levels were downregulated in BM and Is MSCs, while there was no variation in Ad 
MSCs. 72 hours after LPS licensing, MSCs isolated from the three tissues had 
downregulated their IFNGR1 transcript levels. 24 hours stimulation with LPS led 
to downregulation in MSCs from the three sources while a second stimulation 48 
hours after the first one (Condition 3), led to a downregulation in BM and Is MSCs 
while it produced no effect in Ad MSCs. 72 hours of LTA licensing (Condition 1) 
produced no variation in the IFNGR1 transcript levels in BM and Is MSCs, while it 
produced a downregulation in Ad MSCs. 24 hours licensing (Condition 2) with LTA 
produced no variation in BM MSCs and a downregulation in Is and Ad MSCs. A 
second stimulation 48 hours after the first one (Condition 3) produced no 
variation in BM MSCs, a downregulation in Is MSCs and an upregulation in Ad 
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MSCs. 72 hours of Poly I:C-mediated licensing (Condition 1) led to a 
downregulation of IFNGR1 transcript levels in MSCs from the three sources, as 
well as after 24 hours stimulation (Condition 2). A second stimulation with Poly 
I:C 48 hours after the first one (Condition 3) led to a downregulation of IFNGR1 
transcript levels in MSCs from the three sources and the downregulation was 
bigger than in previous conditions.  
During resting conditions BM, Is and Ad MSCs transcribed very little IFNGR2 
transcript levels and no variation in the transcript levels were observed among 
MSCs from different sources (Figure 8-5, F). After 72 hours of stimulation 
(Condition 1), cytokine-mediated licensing produced no effect in BM MSCs, a 
downregulation in the transcript levels of Is MSCs and an upregulation in Ad 
MSCs. 24 hours after stimulation with the cytokine cocktail (Condition 2), BM and 
Is MSCs had downregulated their IFNGR2 transcript levels, while Ad MSCs had 
upregulated them. After the double stimulation with the cytokine cocktail 
(Condition 3), IFNGR2 transcript levels were downregulated in BM and Is MSCs, 
while they were upregulated in Ad MSCs. 72 hours after LPS licensing, MSCs 
isolated from the three tissues had upregulated their IFNGR2 transcript levels. 
24-hour stimulation with LPS led to a downregulation in BM MSCs and to an 
upregulation in Is and Ad MSCs. A second stimulation 48 hours after the first one 
(Condition 3) led to a downregulation in BM and Is MSCs while it produced an 
upregulation in Ad MSCs. 72 hours of LTA licensing (Condition 1) produced an 
upregulation of the IFNGR2 transcript levels in MSCs from the three sources. 24-
hour licensing (Condition 2) with LTA produced an upregulation of the transcript 
levels in BM MSCs, a downregulation in Is MSCs and no variation in Ad MSCs. A 
second stimulation 48 hours after the first one (Condition 3) produced an 
upregulation in MSCs isolated from the three sources. 72 hours of Poly I:C-
mediated licensing (Condition 1) led to no effect in BM MSCs, an upregulation in 
Is MSCs and to a downregulation of IFNGR2 transcript levels in Ad MSCs; while 24 
hours of Poly I:C licensing led to an upregulation of the transcript levels in BM 
and Is MSCs while it produced no variation in Ad MSCs. A second stimulation with 
Poly I:C 48 hours after the first one (Condition 3) led to a downregulation of 
IFNGR2 transcript levels in BM MSCs and an upregulation in Is and Ad MSCs.  
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During resting conditions BM, Is and Ad MSCs transcribed very little TLR2 
transcript levels and no variation in the transcript levels were observed among 
MSCs from different sources (Figure 8-5, G). After 72 hours of stimulation 
(Condition 1), cytokine-mediated licensing produced an upregulation in BM MSCs, 
a downregulation in Is MSCs and no effect in Ad MSCs. 24 hours after stimulation 
with the cytokine cocktail (Condition 2), BM and Is MSCs had upregulated their 
TLR2 transcript levels, while Ad MSCs had downregulated them. After the double 
stimulation with the cytokine cocktail (Condition 3), TLR2 transcript levels were 
upregulated in BM and Ad MSCs, while they were downregulated in Is MSCs. 72 
hours after LPS licensing, BM MSCs had upregulated their transcript levels, no 
variation was observed in Is MSCs and Ad MSCs had downregulated their TLR2 
transcript levels. 24 hours stimulation with LPS led to an upregulation in BM 
MSCs, to no variation in Is MSCs and to a downregulation in Ad MSCs. A second 
stimulation with LPS 48 hours after the first one (Condition 3) led to an 
upregulation of TLR2 transcript levels in MSCs isolated from the three sources. 
72 hours of LTA licensing (Condition 1) produced an upregulation of the TLR2 
transcript levels in BM and Is MSCs and a downregulation in Ad MSCs. 24-hour 
licensing (Condition 2) with LTA produced a bigger upregulation of the transcript 
levels in BM and Is MSCs and a bigger downregulation in Ad MSCs. A second 
stimulation 48 hours after the first one (Condition 3) produced an even bigger 
upregulation in BM and Is MSCs and no variation in Ad MSCs. 72 hours of Poly I:C-
mediated licensing (Condition 1) led to an upregulation in BM MSCs and a 
downregulation of TLR2 transcript levels in Is and Ad MSCs; while 24 hours of 
Poly I:C licensing led to an upregulation of the transcript levels in BM and Is MSCs 
while it produced a downregulation in Ad MSCs. A second stimulation with Poly 
I:C 48 hours after the first one (Condition 3) led to an upregulation of TLR2 
transcript levels in MSCs from the three sources.  
Under resting conditions BM, Is and Ad MSCs transcribed very little TLR3 
transcript levels and no variation in the transcript levels were observed among 
BM, Is and Ad MSCs (Figure 8-5, H). After 72 hours of stimulation (Condition 1), 
cytokine-mediated licensing produced a downregulation in BM and Is MSCs and an 
upregulation in Ad MSCs. 24 hours after stimulation with the cytokine cocktail 
(Condition 2), BM and Is MSCs had upregulated their TLR3 transcript levels, while 
Ad MSCs were not affected by the licensing. After the double stimulation with 
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the cytokine cocktail (Condition 3), TLR3 transcript levels were downregulated 
in BM and Is MSCs, while they were upregulated in Ad MSCs. 72 hours after LPS 
licensing, BM MSCs showed no variation in their transcript levels, while Is and Ad 
MSCs had upregulated their TLR2 transcript levels. 24-hour stimulation with LPS 
led to no variations in BM and Is MSCs, while it produced a downregulation in Ad 
MSCs. A second stimulation with LPS 48 hours after the first one (Condition 3) 
led to no variation of TLR2 transcript levels in BM and Ad MSCs while it produced 
a downregulation in Ad MSCs. 72 hours of LTA licensing (Condition 1) produced 
an upregulation of the TLR2 transcript levels in MSCs from the three tissues. 24 
hours licensing (Condition 2) with LTA produced an upregulation of the transcript 
levels in BM and Is MSCs and a downregulation in Ad MSCs. A second stimulation 
48 hours after the first one (Condition 3) produced an upregulation in MSCs from 
the three sources, but this upregulation of TLR3 transcript levels was smaller 
than the one observed 72 hours after a single stimulation. 72 hours of Poly I:C-
mediated licensing (Condition 1) led to an upregulation in BM and Is MSCs and a 
downregulation of TLR3 transcript levels in Ad MSCs. 24 hours licensing with Poly 
I:C led to a bigger upregulation of transcript levels in BM and Is MSCs than the 
one observed in the previous conditions, while the downregulation observed in 
Ad MSCs was smaller than the one in Condition 1. A second stimulation with Poly 
I:C 48 hours after the first one (Condition 3) led to an upregulation of TLR3 
transcript levels in MSCs from the three sources.  
During resting conditions BM, Is and Ad MSCs transcribed very little TLR4 and no 
variation in the transcript levels were observed among MSCs from different 
sources (Figure 8-5, I). After 72 hours of stimulation (Condition 1), cytokine-
mediated licensing produced a downregulation in BM and Is MSCs and an 
upregulation in Ad MSCs. 24 hours after stimulation with the cytokine cocktail 
(Condition 2), BM and Is MSCs had downregulated their TLR4 transcript levels in 
smaller amounts than in Condition 1, while Ad MSCs had upregulated their 
transcript levels in smaller amounts compared to Condition 1. After the double 
stimulation with the cytokine cocktail (Condition 3), TLR4 transcript levels were 
downregulated in BM and Is MSCs at the same level as Condition 1, while Ad MSCs 
had doubled their transcript levels compared to Condition 1. 72 hours after LPS 
licensing, BM MSCs had downregulated their transcript levels, Is MSCs showed no 
variation in their transcript levels and Ad MSCs had upregulated their TLR4 
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transcript levels. 24-hour stimulation with LPS led to a downregulation in MSCs 
from the three sources. A second stimulation with LPS 48 hours after the first 
one (Condition 3) led to a downregulation of TLR4 transcript levels in BM and Is 
MSCs while it produced no effect in Ad MSCs. 72 hours of LTA licensing 
(Condition 1) produced an upregulation of the TLR4 transcript levels in MSCs 
from the three tissues. 24-hour LTA licensing (Condition 2) produced an 
upregulation of the transcript levels in BM MSCs and a downregulation in Is and 
Ad MSCs. A second stimulation 48 hours after the first one (Condition 3) 
produced an upregulation in BM and Ad MSCs, while it produced a 
downregulation of TLR4 transcript levels in Is MSCs. 72 hours of Poly I:C-
mediated licensing (Condition 1) led to a downregulation of MSCs from the three 
sources. 24 hours licensing with Poly I:C led to a downregulation of TLR4 
transcript levels in BM and Ad MSCs, while it produced an upregulation in Is 
MSCs. A second stimulation with Poly I:C 48 hours after the first one (Condition 
3) led to a downregulation of TLR4 transcript levels in BM and Is MSCs, while it 
produced an upregulation in Ad MSCs.  
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Figure 8-5. Comparison of the transcriptional expression of the receptors of the stimulatory 
agents among MSC tissue source under resting and inflammatory conditions. 
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with either a cocktail of cytokines (40 ng/ mL of 
IFN-ϒ, TNF-α and IL-1β), 100 ng/ mL LPS, 100 ng/ mL LTA or 4 µg/ mL Poly I:C. Unstimulated cells 
were left growing in MSC culture medium as a control. Three different licensing conditions were 
tested. In the first one, cells were stimulated for 48 hours, after which cells were washed twice with 
PBS and fresh culture medium was added; cells were harvested 24 hours later. In the second 
condition, cells were washed twice with PBS, the culture medium was replaced with fresh one and 
the cells were left growing for 48 hours. Cells were then washed twice with PBS, the culture 
medium was replaced with supplemented one and the cells were harvested 24 hours later. In the 
last condition, cells were stimulated for 48 hours, after which cells were washed twice with PBS 
and were stimulated again for another 24 hours. Figure 4-7 illustrates the time points at which 
supplemented medium was added. Quantitative reverse transcription PCR (qRT-PCR) was 
performed to evaluate transcripts in BM, Is and Ad MSCs under resting and inflammatory 
conditions. Each bar represents an n of 4 independent experiments and is graphed as mean ± 
SEM. Data are normalised to the housekeeping gene B2M and expressed as 2(-ΔCT). Statistically 
significant differences are marked with a colour code in Table 4-10.  
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Table 8-4. Fold change in the receptors of the stimulatory agents’ transcript levels of 
cytokine, LPS, LTA or Poly I:C-mediated licensed BM, Is and Ad MSCs compared to 
unstimulated cells from the same source.  
Following the experimental set up explained in Figure 8-5, fold change in transcript levels of the 
receptors of the stimulatory agents is represented as mean of fold change ± standard deviation. 
One Way ANOVA with Tukey’s multiple comparisons post-test was performed to compare all MSC 
sources and the different conditions. p = 0.05 was considered the limit for statistical significance. 
Statistically significant differences are marked with a colour code, where p < 0.05 is represented by 
green, p < 0.01 is represented by orange, p < 0.001 is represented by blue and p < 0.0001 is 
represented by red. 
Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
IL1R1 
1 
Cyt 0.07 ± 0.04 0.22 ± 0.13 3.20 ± 2.13 
LPS 0.20 ± 0.07 3.47 ± 1.35 3.27 ± 2.77 
LTA 0.25 ± 0.06 3.62 ± 2.31 2.03 ± 1.11 
Poly I:C 0.05 ± 0.02 1.88 ± 1.82 1.04 ± 0.58 
2 
Cyt 0.18 ± 0.11 0.04 ± 0.02 1.99 ± 1.00 
LPS 0.48 ± 0.39 0.54 ± 0.25 0.73 ± 0.35 
LTA 1.61 ± 1.53 0.64 ± 0.29 0.73 ± 0.48 
Poly I:C 0.14 ± 0.09 0.56 ± 0.28 0.93 ± 0.39 
3 
Cyt 0.19 ± 0.14 0.03 ± 0.01 0.01 ± 0.01 
LPS 0.59 ± 0.41 0.53 ± 0.13 0.83 ± 0.61 
LTA 0.92 ± 1.01 1.38 ± 0.40 5.59 ± 3.74 
Poly I:C 0.05 ± 0.04 0.33 ± 0.26 0.00 ± 0.00 
IL1R2 
1 
Cyt 0.07 ± 0.07 0.86 ± 1.27 13476.79 ± 13682.54 
LPS 2.30 ± 1.21 8.66 ± 12.92 1.72 ± 1.91 
LTA 1.95 ± 1.48 4.04 ± 1.76 5.11 ± 4.66 
Poly I:C 0.52 ± 0.46 3.34 ± 3.13 4.72 ± 7.66 
2 
Cyt 0.19 ± 0.17 0.10 ± 0.09 25.20 ± 38.61 
LPS 0.99 ± 1.11 0.71 ± 0.48 1.79 ± 0.79 
LTA 2.88 ± 3.17 2.50 ± 2.97 1.39 ± 1.48 
Poly I:C 0.53 ± 0.28 0.86 ± 0.31 1.70 ± 2.57 
3 
Cyt 0.57 ± 0.64 0.47 ± 0.43 17.83 ± 18.07 
LPS 0.96 ± 0.31 0.77 ± 0.76 4.54 ± 6.34 
LTA 0.96 ± 0.46 5.51 ± 6.58 34.53 ± 53.66 
Poly I:C 0.17 ± 0.14 9.71 ± 14.87 2.13 ± 2.64 
TNFR1a 
1 
Cyt 0.69 ± 0.30 0.29 ± 0.18 0.80 ± 0.31 
LPS 0.76 ± 0.10 1.52 ± 0.60 0.47 ± 0.11 
LTA 2.65 ± 1.39 1.53 ± 1.58 0.78 ± 0.24 
Poly I:C 0.39 ± 0.20 0.95 ± 0.65 0.47 ± 0.06 
2 
Cyt 0.74 ± 0.49 0.44 ± 0.31 0.89 ± 0.09 
LPS 0.32 ± 0.07 0.84 ± 0.30 0.32 ± 0.06 
LTA 1.71 ± 0.81 0.54 ± 0.54 0.17 ± 0.03 
Poly I:C 0.48 ± 0.08 0.82 ± 0.78 0.32 ± 0.04 
3 
Cyt 0.36 ± 0.26 0.08 ± 0.05 5.92 ± 0.68 
LPS 0.62 ± 0.38 0.38 ± 0.14 2.95 ± 0.32 
LTA 1.64 ± 1.36 0.69 ± 0.89 7.05 ± 1.26 
Poly I:C 0.20 ± 0.15 0.17 ± 0.02 2.63 ± 0.50 
TNFR1b 1 
Cyt 0.32 ± 0.04 0.12 ± 0.08 0.65 ± 0.35 
LPS 0.53 ± 0.11 0.43 ± 0.05 0.45 ± 0.06 
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Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
LTA 1.13 ± 0.16 0.69 ± 0.25 0.88 ± 0.19 
Poly I:C 0.19 ± 0.05 0.34 ± 0.21 0.44 ± 0.06 
2 
Cyt 0.47 ± 0.11 0.24 ± 0.08 0.68 ± 0.09 
LPS 0.71 ± 0.07 0.55 ± 0.04 0.63 ± 0.19 
LTA 1.06 ± 0.25 0.50 ± 0.19 0.28 ± 0.03 
Poly I:C 0.34 ± 0.03 0.30 ± 0.09 0.38 ± 0.09 
3 
Cyt 0.41 ± 0.06 0.19 ± 0.01 2.81 ± 0.17 
LPS 0.84 ± 0.16 0.55 ± 0.06 1.01 ± 0.03 
LTA 1.25 ± 0.18 0.67 ± 0.36 0.99 ± 0.19 
Poly I:C 0.20 ± 0.01 0.45 ± 0.04 4.07 ± 0.66 
IFNGR1 
1 
Cyt 0.10 ± 0.10 0.12 ± 0.07 1.18 ± 0.44 
LPS 0.23 ± 0.12 0.68 ± 0.14 0.32 ± 0.28 
LTA 1.01 ± 0.17 1.13 ± 0.12 0.63 ± 0.07 
Poly I:C 0.10 ± 0.01 0.37 ± 0.26 0.42 ± 0.24 
2 
Cyt 0.10 ± 0.09 0.15 ± 0.06 0.52 ± 0.49 
LPS 0.10 ± 0.07 0.60 ± 0.19 0.40 ± 0.38 
LTA 0.97 ± 0.22 0.72 ± 0.24 0.38 ± 0.03 
Poly I:C 0.16 ± 0.05 0.48 ± 0.27 0.57 ± 0.10 
3 
Cyt 0.06 ± 0.05 0.07 ± 0.03 1.18 ± 0.98 
LPS 0.16 ± 0.10 0.52 ± 0.11 1.04 ± 0.73 
LTA 0.95 ± 0.26 0.88 ± 0.40 2.25 ± 0.40 
Poly I:C 0.07 ± 0.02 0.26 ± 0.12 0.53 ± 0.13 
IFNGR2 
1 
Cyt 0.99 ± 0.27 0.69 ± 0.61 4.84 ± 1.61 
LPS 1.37 ± 0.19 5.73 ± 2.99 1.90 ± 0.70 
LTA 5.81 ± 3.38 6.09 ± 2.63 2.92 ± 0.88 
Poly I:C 0.93 ± 0.63 4.10 ± 2.21 0.85 ± 0.34 
2 
Cyt 0.68 ± 0.29 0.84 ± 0.11 2.71 ± 0.81 
LPS 0.59 ± 0.27 2.12 ± 0.90 1.73 ± 0.40 
LTA 2.43 ± 1.26 0.84 ± 0.11 1.11 ± 0.21 
Poly I:C 2.81 ± 1.70 2.38 ± 0.88 1.02 ± 0.21 
3 
Cyt 0.39 ± 0.28 0.26 ± 0.29 19.05 ± 5.19 
LPS 0.78 ± 0.22 0.58 ± 0.30 3.51 ± 1.54 
LTA 2.04 ± 1.50 2.08 ± 1.77 10.72 ± 2.57 
Poly I:C 0.28 ± 0.21 2.12 ± 0.90 9.77 ± 2.59 
TLR2 
1 
Cyt 1.44 ± 0.83 0.42 ± 0.19 0.97 ± 0.62 
LPS 4.34 ± 2.29 1.16 ± 0.44 0.41 ± 0.13 
LTA 5.60 ± 2.63 1.56 ± 1.05 0.79 ± 0.21 
Poly I:C 1.30 ± 0.83 0.79 ± 0.19 0.32 ± 0.09 
2 
Cyt 4.42 ± 0.83 2.68 ± 0.32 0.32 ± 0.28 
LPS 4.16 ± 2.60 1.41 ± 0.13 0.47 ± 0.10 
LTA 6.85 ± 1.86 1.71 ± 0.84 0.46 ± 0.11 
Poly I:C 5.60 ± 2.41 1.69 ± 0.26 0.20 ± 0.20 
3 
Cyt 3.63 ± 1.06 0.82 ± 0.22 22.83 ± 4.59 
LPS 10.22 ± 0.53 2.64 ± 1.42 0.97 ± 0.15 
LTA 8.72 ± 1.01 2.03 ± 0.89 1.13 ± 0.34 
Poly I:C 3.40 ± 0.98 3.07 ± 1.70 1.51 ± 0.14 
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Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
TLR3 
1 
Cyt 0.87 ± 0.74 0.45 ± 0.25 5.50 ± 5.82 
LPS 1.00 ± 0.38 3.16 ± 2.25 1.40 ± 1.06 
LTA 2.07 ± 0.92 3.61 ± 2.06 2.73 ± 1.04 
Poly I:C 1.14 ± 0.39 2.01 ± 2.33 0.37 ± 0.23 
2 
Cyt 2.23 ± 1.21 1.77 ± 0.67 1.01 ± 0.44 
LPS 0.92 ± 0.29 1.07 ± 0.45 0.49 ± 0.31 
LTA 2.09 ± 0.82 1.24 ± 0.47 0.83 ± 0.51 
Poly I:C 1.48 ± 0.95 3.16 ± 1.01 0.82 ± 0.62 
3 
Cyt 0.73 ± 0.40 0.41 ± 0.12 13.84 ± 9.93 
LPS 0.97 ± 0.45 0.40 ± 0.11 1.01 ± 0.72 
LTA 1.42 ± 0.62 1.22 ± 0.57 1.75 ± 0.93 
Poly I:C 1.70 ± 0.99 1.36 ± 1.44 2.19 ± 1.65 
TLR4 
1 
Cyt 0.53 ± 0.22 0.20 ± 0.16 2.31 ± 0.61 
LPS 0.73 ± 0.20 2.20 ± 0.77 1.19 ± 0.21 
LTA 2.01 ± 0.81 3.11 ± 1.21 1.27 ± 0.43 
Poly I:C 0.51 ± 0.22 0.98 ± 0.44 0.60 ± 0.12 
2 
Cyt 0.80 ± 0.43 0.52 ± 0.25 1.17 ± 0.26 
LPS 0.43 ± 0.14 0.82 ± 0.41 0.91 ± 0.38 
LTA 2.23 ± 1.29 0.52 ± 0.25 0.44 ± 0.08 
Poly I:C 0.49 ± 0.08 1.19 ± 0.30 0.60 ± 0.20 
3 
Cyt 0.60 ± 0.36 0.13 ± 0.06 5.64 ± 1.31 
LPS 0.76 ± 0.25 0.36 ± 0.15 1.12 ± 0.26 
LTA 1.86 ± 1.15 0.82 ± 0.26 3.54 ± 1.36 
Poly I:C 0.29 ± 0.18 0.37 ± 0.20 2.82 ± 1.17 
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8.2 Analysis of the effect of a double inflammatory 
stimulus over time on the transcription of the 
complement system and other immunoregulatory and 
anti-inflammatory molecules   
As described in Chapter 6, pro-inflammatory cytokine-mediated MSC licensing 
produced a transcriptional regulation of genes involved in the regulation of the 
immune response and immunomodulatory mediators, which could explain why 
MSCs are more immunosuppressive upon activation. Within clinical settings, it 
has been reported that pre-treatment of MSCs with inflammatory cytokines prior 
to administration within animal models of inflammatory diseases boosts the 
therapeutic effect of MSCs (Duijvestein et al., 2011, Noronha et al., 2019). For 
this reason, we wondered if pre-licensing the MSCs prior to expose them to an 
inflammatory environment in vitro would lead to even bigger variations in 
chemokines transcriptional levels and therefore, in enhanced therapeutic 
potential. For this aim, cells were pre-licensed for 48 hours, after which cells 
were washed twice with PBS and stimulated again for another 24 hours. The first 
stimulation primes the MSCs, while the second stimulation would mimic the 
inflammatory environment MSCs would face when infused into a patient with an 
inflammatory disorder. Figure 8-6 illustrates the time points at which 
supplemented medium was added. Culture medium was removed at the time 
cells were harvested and was kept for experimental procedures.  
 
Figure 8-6. Diagrammatic illustration of the time course of the MSC licensing. 
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Two different control conditions were used. In the first one, cells were 
stimulated for 48 hours, after which, cells were washed twice with PBS and fresh 
culture medium was added; cells were harvested 24 hours later. In the second 
condition, cells were washed twice with PBS, the culture medium was replaced 
with fresh medium and cells were left growing for 48 hours. Cells were then 
washed twice with PBS, the culture medium was replaced with supplemented 
medium and the cells were harvested 24 hours later. There is wide literature 
about how cytokine-mediated licensing enhances the potential therapeutic 
efficacy of MSCs, however, little is known about the role of TLR ligands-
mediated activation on the secretion of chemotactic cytokines by MSCs. For this 
reason, 100 ng/ mL LPS, 100 ng/ mL LTA and 4 mg/ mL poly I:C, as well as the 
previously described cytokine cocktail, was used for MSC licensing.  
According to the results described in Section 6.2, the genes regulating their 
transcript levels in a statistically significant manner upon stimulation were 
selected and their transcriptional levels were assessed after licensing with 
different inflammatory molecules and different inflammatory conditions.  
8.2.1 Transcription of the complement system under homeostatic 
and inflammatory conditions  
Under resting conditions, BM, Is and Ad MSCs transcribed very little, if any, of 
the elements of the complement system and only the transcription of CFH 
(Figure 8-7, A), C1Qc (B) and C5AR1 (C) was affected by MSC licensing in a 
statistically significant manner. A pattern of transcriptional upregulation was 
observed in CFH (E), C1Qc (B) and C5AR1 (C) after cytokine, LPS and Poly I:C-
mediated licensing, while LTA licensing led to a pattern of transcriptional 
upregulation; however, these genes were upregulated differentially in MSCs 
according to their tissue of origin. Fold changes of transcriptional regulation 
upon licensing of MSCs are specified in Table 8-5.  
As previously described, CFH was expressed at very low levels by MSCs from all 
sources and Ad MSCs had the highest CFH transcript levels under resting 
conditions (Figure 8-7, A). 24 hours after stimulation with the cytokine cocktail 
(Condition 2), MSCs from the three tissues downregulated their CFH transcript 
levels and this downregulation increased after 72 hours of stimulation (Condition 
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1) in BM MSCs, while it was maintained in Is and Ad MSCs. A second stimulation 
with the cytokine cocktail 48 hours after the first stimulation (Condition 3) 
produced no variation compared to Condition 2 in MSCs from every source. 72 
hours after LPS-mediated stimulation (Condition 1) MSCs from every source had 
downregulated their CFH transcript levels and this downregulation was smaller 
after 24 hours of stimulation (Condition 2). Double stimulation of MSCs with LPS 
(Condition 3) led to an increase in the transcript levels compared to Condition 2 
in MSCs from every source. 72 hours LTA-mediated licensing led to an increase in 
CFH transcript levels in BM and Is MSCs while it produced no effect in Ad MSCs. 
24 hours LTA-mediated licensing led to no variation in BM MSCs, led to an 
upregulation smaller than the one achieved after 72 hours in Is MSCs and to a 
downregulation in Ad MSCs. A second stimulation 48 hours after the first 
stimulation (Condition 3) led to no variation in BM MSC and led to the biggest 
upregulation in Is and Ad MSCs compared to the previous conditions. 24-hour 
Poly I:C-mediated stimulation (Condition 2) led to the downregulation of CFH 
transcript levels in BM MSCs and this downregulation was increased 72 hours 
after stimulation (Condition 1) and a second stimulation (Condition 3). Poly I:C-
mediated stimulation led to a decrease in CFH transcript levels in Is and Ad MSCs 
under every condition however, this downregulation was bigger after 24 hours of 
stimulation (Condition 2) compared to 72 hours after stimulation (Condition 1) 
and a second stimulation (Condition 3).  
C1Qc was expressed at low levels by MSCs from the three sources but was 
expressed the highest by Is MSCs under resting conditions (Figure 8-7, B). 24-
hour cytokine and LPS-mediated stimulation (Condition 2) led to the decrease of 
C1Qc transcript levels in MSCs from all sources; 72 hours after stimulation 
(Condition 1) BM and Is MSCs had still downregulated C1Qc transcript levels but 
less than in Condition 2 and a second stimulation 48 hours after the first one 
(Condition 3) led to the same transcript levels as in Condition 1 in these cells. 
However, 72 hours after cytokine-mediated stimulation or after a double 
stimulation Ad MSCs had upregulated their C1Qc transcript levels while LPS-
mediated stimulation led to a smaller downregulation 72 hours after licensing 
and to an increased downregulation after a double licensing with LPS in Ad MSCs. 
LTA-mediated licensing produced an upregulation in BM MSCs in the three 
conditions. 24-hour LTA-mediated licensing (Condition 2) led to the 
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downregulation of C1Qc transcript levels in Is and Ad MSCs and this 
downregulation started to reverse 72 hours after stimulation (Condition 1). A 
second stimulation 48 hours after the first one (Condition 3), led to an 
upregulation of C1Qc transcript levels in Is MSCs while it produced a bigger 
downregulation than in Conditions 1 and 2 in Ad MSCs. Regarding Poly I:C-
mediated licensing, 24-hour stimulation (Condition 2) led to the downregulation 
of C1Qc transcript levels in MSCs from all sources, this downregulation started to 
reverse 72 hours after stimulation (Condition 1) in Is and Ad MSCs while it was 
bigger in BM MSCs. A second stimulation 48 hours after the first one (Condition 3) 
did not increase the downregulation in BM and Is MSCs but it did lead to an 
increased downregulation in Ad MSCs.  
C5AR1 was expressed at low levels by MSCs from the three sources but was 
expressed the highest by Is MSCs under resting conditions (Figure 8-7, C). 24-
hour cytokine-mediated licensing (Condition 2) led to an upregulation of C5AR1 
transcript levels in BM MSCs, a downregulation in Is MSCs and to no effect in Ad 
MSCs, these effects were slightly more pronounced 72 hours after the cytokine-
mediated stimulation (Condition 1) as the upregulation and downregulation in 
BM and Is MSCs respectively was increased in both MSCs while it produced no 
effect in Ad MSCs. A second stimulation 48 hours after the first one (Condition 3) 
did not make a difference in BM and Is MSCs when compared to Condition 1; 
however, it led to the downregulation of C5AR1 transcript levels in Ad MSCs. 24-
hour LPS-mediated licensing (Condition 2) led to the upregulation of C5AR1 
transcript levels in BM MSCs and to downregulation in Is and Ad MSCs; these 
effects were slightly more pronounced 72 hours after the cytokine-mediated 
stimulation (Condition 1) in BM MSCs, while Is and Ad MSCs had started to 
reverse the downregulation. A 24-hour stimulation 48 hours after the first one 
(Condition 3) led to the same levels of upregulation in BM MSCs, while it 
increased C5AR1 transcript levels in Is and Ad MSCs without reaching control 
unstimulated levels. 24-hour LTA-mediated licensing (Condition 2) led to the 
upregulation of C5AR1 transcript levels in BM MSCs and to downregulation in Is 
and Ad MSCs. This regulation started to reverse 48 hours later (Condition 1) in 
BM and Ad MSCs as the upregulation in BM MSCs and the downregulation of 
C5AR1 transcript levels in Ad MSCs was less pronounced; however, C5AR1 
transcript levels remained as downregulated as 48 hours before in Is MSCs. A 
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second stimulation 48 hours after the first one (Condition 3) led to the same 
levels of upregulation in BM MSCs, while it slightly increased C5AR1 transcript 
levels in Is and Ad MSCs compared to Conditions 1 and 2. Lastly, 24-hour Poly I:C-
mediated licensing (Condition 2) led to a small upregulation in BM MSCs while it 
led to the downregulation of C5AR1 transcript levels in Is and Ad MSCs. This 
transcriptional regulation was not sustained as 72 hours after a single stimulation 
(Condition 1) BM MSCs transcript levels had returned to the same level as the 
control ones and Is and Ad MSCs had a less pronounced downregulation of their 
C5AR1 transcript levels. A second stimulation 48 hours after the first one 
(Condition 3) led to the downregulation of C5AR1 transcript levels in MSCs from 
every source.  
 
 
369 
 
 
Figure 8-7. Inflammatory agent, repetitive stimulus and MSC tissue origin impacts 
complement system molecules transcript levels in MSCs. 
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with either a cocktail of cytokines (40 ng/ mL of 
IFN-ϒ, TNF-α and IL-1β), 100 ng/ mL LPS, 100 ng/ mL LTA or 4 µg/ mL Poly I:C. Unstimulated 
cells were left growing in MSC culture medium as a control. Three different licensing conditions 
were tested. In the first one, cells were stimulated for 48 hours, after which cells were washed twice 
with PBS and fresh culture medium was added; cells were harvested 24 hours later. In the second 
condition, cells were washed twice with PBS, the culture medium was replaced with fresh one and 
the cells were left growing for 48 hours. Cells were then washed twice with PBS, the culture 
medium was replaced with supplemented one and the cells were harvested 24 hours later. In the 
last condition, cells were stimulated for 48 hours, after which cells were washed twice with PBS 
and were stimulated again for another 24 hours. Figure 6-4 illustrates the time points at which 
supplemented medium was added. Quantitative reverse transcription PCR (qRT-PCR) was 
performed to evaluate complement system molecules transcripts in BM, Is and Ad MSCs under 
resting and inflammatory conditions. Each bar represents an n of 4 independent experiments and is 
graphed as mean ± SEM. Data are normalised to the housekeeping gene B2M and expressed as 
2(-ΔCT). Statistically significant differences are marked with a colour code in Table 4-7. 
 
Table 8-5. Fold change in complement system molecules transcript levels of cytokine, LPS, 
LTA or Poly I:C-mediated licensed BM, Is and Ad MSCs compared to unstimulated cells 
from the same source.  
Following the experimental set up explained in Figure 8-2, fold change in transcript levels is 
represented as mean of fold change ± standard deviation. One Way ANOVA with Tukey’s multiple 
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comparisons post-test was performed to compare all MSC sources and the different conditions. p = 
0.05 was considered the limit for statistical significance. Statistically significant differences are 
marked with a colour code, where p < 0.05 is represented by green, p < 0.01 is represented by 
orange, p < 0.001 is represented by blue and p < 0.0001 is represented by red. 
Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
CFH 
1 
Cyt 0.21 ± 0.07 0.10 ± 0.12 0.69 ± 0.50 
LPS 0.37 ± 0.10 0.32 ± 0.26 0.30 ± 0.04 
LTA 3.40 ± 2.12 46.04 ± 25.45 0.72 ± 0.24 
Poly I:C 0.03 ± 0.01 0.24 ± 0.23 0.46 ± 0.10 
2 
Cyt 0.38 ± 0.26 0.03 ± 0.00 0.24 ± 0.04 
LPS 0.22 ± 0.07 0.15 ± 0.11 0.17 ± 0.12 
LTA 0.91 ± 0.34 15.74 ± 7.32 0.18 ± 0.06 
Poly I:C 0.09 ± 0.01 0.08 ± 0.04 0.19 ± 0.03 
3 
Cyt 0.26 ± 0.17 0.03 ± 0.02 0.27 ± 0.07 
LPS 0.63 ± 0.37 0.20 ± 0.14 0.43 ± 0.09 
LTA 1.26 ± 0.71 149.39 ± 91.04 1.24 ± 0.35 
Poly I:C 0.03 ± 0.02 0.28 ± 0.24 0.64 ± 0.13 
C1Qc 
1 
Cyt 0.59 ± 0.25 0.15 ± 0.07 0.94 ± 0.23 
LPS 0.92 ± 0.42 0.12 ± 0.07 0.47 ± 0.05 
LTA 2.19 ± 0.86 0.50 ± 0.18 0.63 ± 0.10 
Poly I:C 0.22 ± 0.08 0.21 ± 0.18 0.35 ± 0.05 
2 
Cyt 0.52 ± 0.19 0.04 ± 0.02 0.18 ± 0.03 
LPS 0.32 ± 0.04 0.08 ± 0.05 0.27 ± 0.07 
LTA 2.04 ± 1.26 0.40 ± 0.17 0.25 ± 0.05 
Poly I:C 0.40 ± 0.17 0.08 ± 0.03 0.14 ± 0.04 
3 
Cyt 0.52 ± 0.26 0.13 ± 0.05 1.04 ± 0.18 
LPS 0.67 ± 0.33 0.21 ± 0.13 0.14 ± 0.02 
LTA 1.59 ± 0.51 2.52 ± 0.75 0.36 ± 0.08 
Poly I:C 0.39 ± 0.35 0.52 ± 0.65 0.07 ± 0.01 
C5AR1 
1 
Cyt 1.59 ± 0.26 0.09 ± 0.06 1.06 ± 0.44 
LPS 3.14 ± 0.44 0.24 ± 0.09 0.74 ± 0.14 
LTA 6.45 ± 0.57 0.40 ± 0.10 0.88 ± 0.16 
Poly I:C 0.89 ± 0.07 0.22 ± 0.12 0.46 ± 0.13 
2 
Cyt 2.71 ± 0.51 0.06 ± 0.03 0.81 ± 0.13 
LPS 2.49 ± 0.92 0.22 ± 0.04 0.48 ± 0.06 
LTA 8.17 ± 0.42 0.41 ± 0.06 0.25 ± 0.07 
Poly I:C 1.72 ± 0.70 0.13 ± 0.07 0.34 ± 0.09 
3 
Cyt 1.63 ± 0.12 0.08 ± 0.03 0.01 ± 0.01 
LPS 2.87 ± 0.24 0.40 ± 0.17 1.00 ± 0.11 
LTA 8.49 ± 1.17 1.52 ± 0.82 1.44 ± 0.38 
Poly I:C 0.61 ± 0.02 0.22 ± 0.19 0.29 ± 0.08 
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8.2.2 Transcription of other immunoregulatory and anti-
inflammatory molecules under homeostatic and 
inflammatory conditions  
Under resting conditions BM, Is and Ad MSCs transcribed very little, if any, of the 
immunoregulatory and anti-inflammatory genes with the exception of IL-6 
(Figure 8-8, A), VEGFa (C), VEGFd (F) and CD142 (J). The effect of inflammatory 
licensing in these genes was tissue of origin and stimulatory agent dependent 
and fold changes of transcriptional regulation upon licensing of MSCs are 
specified in Table 8-6. 
IL-6 was expressed at substantial levels by MSCs from the three sources but was 
expressed the highest by Ad MSCs under resting conditions (Figure 8-8, A). 24-
hour cytokine-mediated stimulation (Condition 2) led to the upregulation of IL-6 
transcript levels in BM and Is MSCs, while it produced no effect in Ad MSCs. This 
upregulation was not sustained as 72 hours after stimulation (Condition 1) BM 
and Is MSCs had downregulated their IL-6 transcript levels to control levels while 
72 hours cytokine-mediated licensing produced the downregulation of IL-6 
transcript levels in Ad MSCs. A second stimulation 48 hours after the first one 
(Condition 3) led to the upregulation of IL-6 transcript levels in MSCs from all 
sources; an increased upregulation of IL-6 transcript levels in BM MSCs, a smaller 
upregulation in Is MSCs compared to Condition 2 and >50 times upregulation in 
Ad MSCs. 24-hour LPS-mediated licensing (Condition 2) led to an upregulation of 
IL-6 transcript levels in BM and Is MSCs, while it produced no effect in Ad MSCs. 
This upregulation was not sustained in BM MSCs as 72 hours after LPS licensing 
(Condition 1) BM MSCs had downregulated their IL-6 transcript levels compared 
to the control; the upregulation had started to reverse in Is MSCs but these cells 
were still transcribing higher levels of IL-6 than the unstimulated control cells 
and 72 hours licensing led to the downregulation of IL-6 transcript levels in Ad 
MSCs. LTA and Poly I:C-mediated 24-hour licensing (Condition 2) led to the 
downregulation of IL-6 transcript levels in BM MSCs. This downregulation was 
increased 72 hours after the licensing (Condition 1) and was maintained when 
the cells were stimulated 48 hours after the first stimulation with LTA or Poly I:C 
(Condition 3). LTA and Poly I:C licensing produced no effect in the transcription 
of IL-6 in Is MSCs under any of the conditions tested while LTA and Poly I:C-
mediated licensing produced a downregulation in IL-6 transcript levels 72 hours 
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after licensing (Condition 1) in Ad MSCs, but they made no effect in IL-6 
transcript levels 24 hours after a single stimulation (Condition 2) or after a 
double stimulation (Condition 3).  
As previously described, TSG-6 was expressed at very low levels by MSCs from all 
sources and BM MSCs had the highest TSG-6 transcript levels under resting 
conditions (Figure 8-8, B). 24-hour cytokine-mediated licensing (Condition 2) led 
to the downregulation of TSG-6 transcript levels in MSCs from the three sources; 
this downregulation was not sustained in MSCs from the three sources as 72 
hours after the stimulation (Condition 1) BM MSCs were transcribing slightly more 
TSG-6 than 48 hours before, Is MSCs were transcribing almost the same amount 
of TSG-6 as unstimulated cells and Ad MSCs had upregulated the transcription of 
TSG-6. A second stimulation 48 hours after the first one (Condition 3) maintained 
the downregulation in BM and Is MSCs while it produced no effect in Ad MSCs as 
these cells were generating the same TSG-6 levels as under resting conditions. 
24-hour LPS-mediated licensing (Condition 2) produced the downregulation of 
TSG-6 transcript levels in BM and Ad MSCs while it produced an upregulation in Is 
MSCs. This regulation was maintained as 72 hours after LPS licensing (Condition 
1) MSCs from the three sources were expressing similar levels of TSG-6 transcript 
levels as 48 hours before. A second stimulation 48 hours after the first one 
(Condition 3) increased TSG-6 transcript levels to almost the control levels in BM 
MSCs, decreased the upregulation to almost control levels in Is MSCs and 
maintained the downregulation obtained 24 and 72 hours after stimulation in Ad 
MSCs. 24-hour LTA-mediated licensing produced the downregulation of TSG-6 
transcript levels in BM and Ad MSCs while it produced a small increase in Is MSCs; 
these transcription levels were maintained 72 hours after stimulation (Condition 
1) in Is and Ad MSCs while the downregulation was bigger in BM MSCs. A second 
stimulation with LTA 48 hours after the first one (Condition 3) led to a small 
downregulation in BM and Ad MSCs compared to control and a bigger 
upregulation in Is MSCs. Poly I:C licensing of BM MSCs led to the downregulation 
of TSG-6 transcript levels under every condition tested, while it produced no 
effect in Is MSCs. 24 hours Poly I:C licensing (Condition 2) led to the 
downregulation of TSG-6 transcript levels in Ad MSCs; this downregulation was 
smaller 72 hours after stimulation (Condition 1). A second stimulation 48 hours 
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after the first one (Condition 3) led to no effect in Ad MSCs as these cells had 
the same transcript levels as control unstimulated Ad MSCs.  
VEGFa was expressed at substantial levels by MSCs from the three sources but 
was expressed the highest by Is MSCs under resting conditions (Figure 8-8, C). 
24-hour cytokine-mediated stimulation (Condition 2) led to the downregulation 
of VEGFa transcript levels in BM and Is MSCs, while it produced a small 
upregulation in Ad MSCs. This regulation was increased over time as 72 hours 
after stimulation (Condition 1) BM and Is MSCs had downregulated more their 
VEGFa transcript levels while 72 hours cytokine-mediated licensing produced a 
bigger upregulation of VEGFa transcript levels in Ad MSCs. A second stimulation 
48 hours after the first one (Condition 3) led to similar levels of downregulation 
of VEGFa transcript levels in BM and Is MSCs as after 24 hours of stimulation, 
while a second stimulation enhanced the upregulation in Ad MSCs. 24-hour LPS-
mediated stimulation (Condition 2) led to the downregulation of VEGFa 
transcript levels in BM and Is MSCs, while it produced no effect in Ad MSCs. 72 
hours after stimulation (Condition 1) BM and Is MSCs had started to reverse the 
downregulation while 72 hours LPS-mediated licensing produced a 
downregulation of VEGFa transcript levels in Ad MSCs. A second stimulation 48 
hours after the first one (Condition 3) led to a small downregulation of VEGFa 
transcript levels in Is and Ad MSCs, while a second LPS stimulation had no effect 
in BM MSCs. 72-hour LTA-mediated stimulation (Condition 1) led to no effect in 
MSCs from the three sources while 24-hour LTA-mediated stimulation (Condition 
2) led to a small upregulation of VEGFa transcript levels in MSCs from the three 
sources. A second stimulation 48 hours after the first one (Condition 3) led to a 
small downregulation of VEGFa transcript levels in BM and Ad MSCs while it 
produced a small upregulation in Is MSCs. 24-hour Poly I:C-mediated stimulation 
(Condition 2) led to the downregulation of VEGFa transcript levels in MSCs from 
the three sources and 72 hours Poly I:C-mediated licensing produced a bigger 
downregulation of VEGFa transcript levels in MSCs from the three sources. A 
second stimulation 48 hours after the first one (Condition 3) led to a 
downregulation of VEGFa transcript levels in BM MSCs of the same level as 24-
hour licensing while a second Poly I:C stimulation had no effect in Is and Ad 
MSCs. 
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VEGFb was expressed at very low levels by MSCs from all sources and Is MSCs had 
the highest VEGFb transcript levels under resting conditions (Figure 8-8, D). 24-
hour cytokine-mediated stimulation (Condition 2) led to the downregulation of 
VEGFb transcript levels in MSCs from the three sources and this downregulation 
was maintained 72 hours after the licensing (Condition 1) in MSCs from the three 
sources. A second stimulation 48 hours after the first one (Condition 3) produced 
the biggest downregulation of VEGFb transcript levels in BM and Is MSCs, while it 
produced an upregulation in Ad MSCs. 24-hour LPS and LTA-mediated stimulation 
(Condition 2) led to the downregulation of VEGFb transcript levels in MSCs from 
the three sources and this downregulation started to reverse 72 hours after the 
licensing (Condition 1) in MSCs from the three sources at different levels; BM 
MSCs had upregulated their VEGFb transcript levels while Is and Ad MSCs had not 
yet reached the control unstimulated VEGFb transcript levels. A second LPS 
stimulation 48 hours after the first one (Condition 3) led to the downregulation 
of VEGFb transcript levels in MSCs from the three sources, however this 
downregulation was not as strong as the one generated after 24-hour LPS 
stimulation. A second LTA stimulation 48 hours after the first one (Condition 3) 
led to no variation in VEGFb transcript levels compared to the control 
unstimulated MSCs in the three sources. 24-hour Poly I:C-mediated stimulation 
(Condition 2) led to the downregulation of VEGFb transcript levels in MSCs from 
the three sources and this downregulation was maintained 72 hours after 
licensing (Condition 1) in MSCs from the three sources. A second LPS stimulation 
48 hours after the first one (Condition 3) led to the downregulation of VEGFb 
transcript levels in MSCs from the three sources; however, this downregulation 
was not as strong as the one generated after 24-hour Poly I:C stimulation in Is 
and Ad MSCs.  
VEGFc was expressed at very low levels by MSCs from all sources and Is MSCs had 
the highest VEGFc transcript levels under resting conditions (Figure 8-8, E). 24-
hour cytokine-mediated stimulation (Condition 2) led to the downregulation of 
VEGFc transcript levels in BM MSCs, while it had no effect in Is and Ad MSCs; 
however, 72-hour cytokine-mediated stimulation (Condition 1) led to the 
downregulation of VEGFc transcript levels in MSCs from the three sources. A 
second stimulation 48 hours after the first one (Condition 3) produced a small 
downregulation of VEGFc transcript levels in BM and Is MSCs, while it produced 
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an upregulation in Ad MSCs. 24-hour LPS-mediated stimulation (Condition 2) led 
to the downregulation of VEGFc transcript levels in BM and Ad MSCs, while it had 
no effect in Is MSCs. 72 hours after LPS licensing (Condition 1) BM and Ad MSCs 
had still downregulated their VEGFc transcript levels, while 72 hours after the 
licensing Is MSCs had their VEGFc transcript levels upregulated. A second 
stimulation 48 hours after the first one (Condition 3) produced a small 
downregulation in BM and Ad MSCs, while it had no effect in Is MSCs. 24-hour 
LTA and Poly I:C-mediated stimulation (Condition 2) led to the downregulation 
of VEGFc transcript levels in BM and Ad MSCs, while it upregulated VEGFc 
transcript levels in Is MSCs. This downregulation was sustained in BM and Ad 
MSCs 72 hours after LTA and Poly I:C licensing (Condition 1), while Is MSCs 
slightly increased their VEGFc transcript levels 72 hours after licensing. A second 
stimulation 48 hours after the first one (Condition 3) led to the downregulation 
of VEGFc transcript levels in BM and Is MSCs, while it had no effect in Ad MSCs.  
As previously described, VEGFd was expressed at substantial levels by MSCs from 
the three sources but was expressed the highest by BM MSCs under resting 
conditions (Figure 8-8, F). 24-hour cytokine and LPS-mediated stimulation 
(Condition 2) led to the downregulation of VEGFd transcript levels in MSCs from 
the three sources; these downregulation was maintained 72 hours after licensing 
(Condition 1) in BM and Is MSCs, while Ad MSCs had already recovered from the 
licensing. A second stimulation 48 hours after the first one (Condition 3) led to 
the downregulation of VEGFd transcript levels in MSCs from the three sources, 
where MSCs from the three sources had similar VEGFd transcript levels as after a 
single 24-hour cytokine or LPS licensing. 24-hour LTA-mediated licensing led to a 
small non-significant upregulation of VEGFd transcript levels in BM MSCs, while it 
produced the downregulation of VEGFd transcript levels in Is and Ad MSCs. 72 
hours after licensing (Condition 1), BM MSCs had downregulated their VEGFd 
transcript levels, the downregulation in Is and Ad MSCs was not sustained and 
transcript levels had reached resting levels in Ad MSCs. A second stimulation 48 
hours after the first one (Condition 3) led to a small downregulation of VEGFd 
transcript levels in BM and Is MSCs, while it led to a small upregulation of VEGFd 
transcript levels in Ad MSCs. 24-hour Poly I:C-mediated stimulation (Condition 2) 
led to the downregulation of VEGFd transcript levels in MSCs from the three 
sources and this downregulation was maintained 72 hours after Poly I:C licensing 
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(Condition 1) in MSCs from the three sources. A second stimulation 48 hours 
after the first one (Condition 3) led to similar levels of downregulation of VEGFd 
transcript levels in MSCs of every source as after 24 hours of Poly I:C stimulation. 
iNOS was expressed at very low levels by MSCs from all sources and BM MSCs had 
the highest iNOS transcript levels under resting conditions (Figure 8-8, G). 24-
hour cytokine-mediated stimulation (Condition 2) led to the upregulation of iNOS 
transcript levels in MSCs from the three sources; however, this upregulation was 
not sustained as 72 hours after stimulation MSCs from the three sources were 
expressing similar iNOS transcript levels as control unstimulated MSCs. A second 
cytokine-mediated stimulation 48 hours after the first one (Condition 3) led to 
an upregulation of iNOS transcript levels in MSCs from the three sources; 
however, this upregulation did not match the one after 24-hour cytokine-
mediated licensing in BM and Is MSCs while it was bigger in Ad MSCs. LPS, LTA 
and Poly I:C-mediated licensing in every condition led to statistically non-
significant variations and to very little, if any, iNOS transcript levels.  
COX2 was expressed at low levels by MSCs from all sources and Ad MSCs had the 
highest COX2 transcript levels under resting conditions (Figure 8-8, H). 24-hour 
cytokine-mediated stimulation (Condition 2) led to the upregulation of COX2 
transcript levels in MSCs from the three sources; however, this upregulation 
started to reverse 48 hours later (Condition 1) in BM and Ad MSC as despite 
showing upregulated COX2 transcript levels, they were lower than 48 hours 
before. Is MSCs, on the contrary, were able to maintain the upregulation 72 
hours after the cytokine-mediated stimulation. A second stimulation 48 hours 
after the first one (Condition 3) increased the COX2 transcript levels in BM MSCs 
compared to 72 hours after stimulation, but did not match the transcript levels 
recorded 24 hours after stimulation; while a second cytokine-mediated 
stimulation increased COX2 transcript levels in Is and Ad MSCs. 24-hour LPS-
mediated stimulation (Condition 2) led to the upregulation of COX2 transcript 
levels in MSCs from the three sources and this upregulation was not sustained as 
72 hours after licensing BM MSCs had reached control transcript levels and Is and 
Ad MSCs were closer to control levels. A second stimulation 48 hours after the 
first one (Condition 3) increased the COX2 transcript levels in MSCs from every 
source but this upregulation could not match the COX2 transcript levels observed 
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after 24-hour LPS-mediated stimulation in BM and Ad MSCs. 24-hour LTA-
mediated stimulation (Condition 2) led to the upregulation of COX2 transcript 
levels in MSCs from the three sources and this upregulation was not sustained in 
MSCs from every tissue as MSCs had lower COX2 transcript levels than the control 
unstimulated MSCs. A second stimulation 48 hours after the first one (Condition 
3) led to the downregulation of COX2 transcript levels to similar levels as 
observed 72 hours after stimulation. 24-hour Poly I:C-mediated stimulation 
(Condition 2) led to the downregulation of COX2 transcript levels in BM MSCs, 
while it produced an upregulation in Is and Ad MSCs. 72 hours after Poly I:C-
mediated stimulation (Condition 1) MSCs from the three sources had 
downregulated their COX2 transcript levels. A second stimulation 48 hours after 
the first one (Condition 3) led to a smaller downregulation of COX2 transcript 
levels in BM MSCs, while it led to the upregulation of COX2 transcript levels in Is 
and Ad MSCs to higher levels than the ones observed in Condition 1 or 2.  
HGF was expressed at low levels by MSCs from all sources and Is MSCs had the 
highest HGF transcript levels under resting conditions (Figure 8-8, I). 24-hour 
cytokine-mediated stimulation (Condition 2) led to the downregulation of HGF 
transcript levels in MSCs from the three sources; this downregulation was more 
intense 48 hours later (Condition 1) in BM and Is MSC, while Ad MSCs had 
upregulated their HGF transcript levels compared to control unstimulated levels. 
A second stimulation 48 hours after the first one (Condition 3) maintained the 
downregulation in BM MSCs, it was not sustained in Is MSCs as transcript levels 
were getting back to control conditions and maintained the upregulation 
observed 72 hours after cytokine-mediated licensing in Ad MSCs. 24-hour LPS-
mediated stimulation (Condition 2) led to the downregulation of HGF transcript 
levels in BM MSCs and to a small non-significant upregulation in Is and Ad MSCs; 
however, 72 hours after LPS-mediated licensing BM and Is MSCs had 
downregulated their HGF transcript levels, while Ad MSCs was expressing the 
same level of HGF transcript levels as under control unstimulated conditions. A 
second stimulation 48 hours after the first one led to the downregulation of BM 
MSCs, to no effect in Is MSCs and to the upregulation of HGF transcript levels in 
Ad MSCS. 24-hour LTA-mediated stimulation (Condition 2) led to no effect in BM 
MSCs, to the upregulation of HGF transcript levels in Is MSCs and to a small non-
significant downregulation in Ad MSCs; however, 72 hours after LTA-mediated 
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licensing BM MSCs had downregulated their HGF transcript levels in a statistically 
significant manner, the upregulation in Is MSC was not sustained, while Ad MSCs 
had upregulated their HGF transcript levels. A second stimulation 48 hours after 
the first one led to control-like transcript levels in BM MSCs, to a small non-
significant upregulation in Is MSCs and to a small non-significant downregulation 
in Ad MSCs. 24-hour Poly I:C-mediated stimulation (Condition 2) led to the 
downregulation of HGF transcript levels in MSCs from the three sources; this 
downregulation was maintained in BM MSCs 72 hours after stimulation (Condition 
1), while Is and Ad MSCs reversed the downregulation. A second stimulation 48 
hours after the first one was able to mimic the HGF transcript levels observed 
after 24 hours of stimulation as it led to the downregulation of HGF transcript 
levels in MSCs from every source.  
CD142 was expressed at substantial levels by MSCs from the three sources but 
was expressed the highest by BM MSCs under resting conditions (Figure 8-8, J). 
24-hour cytokine-mediated stimulation (Condition 2) led to the downregulation 
of CD142 transcript levels in MSCs from the three sources and this 
downregulation was maintained 72 hours after stimulation (Condition 1) in BM 
and Is MSCs, while it was not sustained in Ad MSCs. A second stimulation 48 hours 
after the first one (Condition 3) led to similar levels of downregulation of CD142 
transcript levels in BM and Is MSCs as after 24 and 72 hours of stimulation, while 
a second stimulation led to the upregulation of CD142 transcript levels in Ad 
MSCs. 24-hour LPS-mediated stimulation (Condition 2) led to the downregulation 
of CD142 transcript levels in MSCs from the three sources and this 
downregulation was maintained 72 hours after stimulation (Condition 1) in MSCs 
from the three sources. A second stimulation 48 hours after the first one 
(Condition 3) was not able to mimic the downregulation achieved in Conditions 1 
and 2 but still led to the downregulation of CD142 transcript levels in MSCs from 
the three sources. 24-hour LTA-mediated stimulation (Condition 2) led to a small 
upregulation of CD142 transcript levels in BM MSCs and to a downregulation in Is 
and Ad MSCs; however, 72 hours after LTA licensing BM, Is and Ad MSCs had 
downregulated their CD142 transcript levels. A second stimulation 48 hours after 
the first one (Condition 3) led to small non-significant downregulation of CD142 
transcript levels in BM and Is MSCs, while it produced a small non-significant 
upregulation of CD142 transcript levels in Ad MSCs. 24-hour Poly I:C-mediated 
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stimulation (Condition 2) led to the downregulation of CD142 transcript levels in 
MSCs from the three sources and this downregulation was maintained 72 hours 
after stimulation (Condition 1) in MSCs from the three sources. A second 
stimulation 48 hours after the first one (Condition 3) was not able to mimic the 
downregulation achieved in Conditions 1 and 2 but still led to the 
downregulation of CD142 transcript levels in MSCs from the three sources. 
GMCSF was expressed at low levels by MSCs from all sources and Ad MSCs had 
the highest GMCSF transcript levels under resting conditions (Figure 8-8, K). 24-
hour cytokine-mediated stimulation (Condition 2) led to the upregulation of 
GMCSF transcript levels in MSCs from the three sources and this upregulation was 
maintained, at lower level, 72 hours after stimulation (Condition 1). A second 
stimulation 48 hours after the first one (Condition 3) led to the upregulation of 
GMCSF transcript levels but none of these upregulations was statistically 
significant due to the big variability between samples. 24-hour LPS-mediated 
stimulation (Condition 2) led to the downregulation of GMCSF transcript levels in 
BM MSCs while it upregulated GMCSF transcript levels in Is and Ad MSCs; this 
transcriptional regulation was maintained 72-hours after stimulation (Condition 
1). A second stimulation 48 hours after the first one (Condition 3) led to a 
statistically non-significant upregulation of GMCSF transcript levels in MSCs from 
the three sources. 24-hour LTA-mediated stimulation (Condition 2) led to the 
upregulation of GMCSF transcript levels in MSCs from the three sources; this 
transcriptional upregulation was increased 72-hours after stimulation (Condition 
1). A second stimulation 48 hours after the first one (Condition 3) led to the 
downregulation of GMCSF transcript levels in BM MSCs, while it led to the 
upregulation of GMCSF transcript levels in Is and Ad MSCs.  
24-hour Poly I:C-mediated stimulation (Condition 2) led to the downregulation of 
GMCSF transcript levels in MSCs from the three sources; however, 72 hours after 
stimulation with Poly I:C BM and Is MSCs had upregulated their transcript levels, 
while Ad MSCs had reach similar transcript levels as under control unstimulated 
conditions. A second stimulation 48 hours after the first one (Condition 3) led to 
the downregulation of GMCSF transcript levels in BM MSCs, while led to the 
upregulation of GMCSF transcript levels in Is and Ad MSCs. 
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Figure 8-8. Inflammatory agent, repetitive stimulus and MSC tissue origin impacts 
immunomodulatory molecules transcript levels in MSCs. 
MSCs isolated from BM, Is and Ad tissues were grown in culture until passage 3. Once MSCs had 
reached 80% confluence, cells were stimulated with either a cocktail of cytokines (40 ng/ mL of 
IFN-ϒ, TNF-α and IL-1β), 100 ng/ mL LPS, 100 ng/ mL LTA or 4 µg/ mL Poly I:C. Unstimulated 
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cells were left growing in MSC culture medium as a control. Three different licensing conditions 
were tested. In the first one, cells were stimulated for 48 hours, after which, cells were washed 
twice with PBS and fresh culture medium was added; cells were harvested 24 hours later. In the 
second condition, cells were washed twice with PBS, the culture medium was replaced with fresh 
one and the cells were left growing for 48 hours. Cells were then washed twice with PBS, the 
culture medium was replaced with supplemented one and cells were harvested 24 hours later. In 
the last condition, cells were stimulated for 48 hours, after which cells were washed twice with PBS 
and were stimulated again for another 24 hours. Figure 6-4 illustrates the time points at which 
supplemented medium was added. Quantitative reverse transcription PCR (qRT-PCR) was 
performed to evaluate immunomodulatory molecule transcripts in BM, Is and Ad MSCs under 
homeostatic and inflammatory conditions. Each bar represents an n of 4 independent experiments 
and is graphed as mean ± SEM. Data are normalised to the housekeeping gene B2M and 
expressed as 2(-ΔCT). Statistically significant differences are marked with a colour code in Table 6-5.  
 
Table 8-6. Fold change in immunomodulatory molecules transcript levels of cytokine, LPS, 
LTA or Poly I:C-mediated licensed BM, Is and Ad MSCs compared to unstimulated cells 
from the same source.  
Following the experimental set up explained in Figure 8-8, fold change in transcript levels is 
represented as mean of fold change ± standard deviation. One Way ANOVA with Tukey’s multiple 
comparisons post-test was performed to compare all MSC sources and the different conditions. p = 
0.05 was considered the limit for statistical significance. Statistically significant differences are 
marked with a colour code, where p < 0.05 is represented by green, p < 0.01 is represented by 
orange, p < 0.001 is represented by blue and p < 0.0001 is represented by red. 
 
Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
IL-6 
1 
Cyt 1.15 ± 0.90 1.56 ± 0.97 0.11 ± 0.05 
LPS 0.26 ± 0.22 2.35 ± 1.05 0.42 ± 0.06 
LTA 0.17 ± 0.12 1.24 ± 0.62 0.22 ± 0.02 
Poly I:C 0.15 ± 0.11 1.92 ± 1.31 0.23 ± 0.03 
2 
Cyt 53.97 ± 44.65 8.04 ± 4.83 0.65 ± 0.06 
LPS 2.02 ± 0.64 3.09 ± 1.63 0.89 ± 0.29 
LTA 0.49 ± 0.06 1.38 ± 0.51 1.07 ± 0.13 
Poly I:C 0.78 ± 0.72 1.46 ± 0.36 0.66 ± 0.11 
3 
Cyt 76.21 ± 61.41 3.41 ± 1.35 10.74 ± 1.08 
LPS 1.72 ± 0.72 2.26 ± 1.29 0.51 ± 0.02 
LTA 0.30 ± 0.20 0.88 ± 0.21 0.70 ± 0.18 
Poly I:C 0.86 ± 0.43 1.04 ± 0.79 0.80 ± 0.13 
TSG-6  
1 
Cyt 0.08 ± 0.03 0.74 ± 0.14 3.98 ± 2.09 
LPS 0.13 ± 0.01 2.86 ± 0.90 0.66 ± 0.21 
LTA 0.17 ± 0.02 2.24 ± 0.34 0.54 ± 0.18 
Poly I:C 0.07 ± 0.03 1.53 ± 0.40 0.42 ± 0.21 
2 
Cyt 0.06 ± 0.03 0.62 ± 0.17 0.51 ± 0.28 
LPS 0.23 ± 0.09 2.34 ± 1.30 0.56 ± 0.17 
LTA 0.76 ± 0.36 1.40 ± 0.39 0.31 ± 0.30 
Poly I:C 0.07 ± 0.03 1.09 ± 0.25 0.37 ± 0.21 
3 
Cyt 0.13 ± 0.09 0.29 ± 0.19 1.12 ± 0.40 
LPS 0.66 ± 0.35 1.44 ± 0.36 0.51 ± 0.20 
LTA 0.54 ± 0.31 4.18 ± 1.52 1.06 ± 0.53 
Poly I:C 0.08 ± 0.05 0.82 ± 0.58 1.27 ± 0.66 
VEGFa 1 
Cyt 0.40 ± 0.05 0.22 ± 0.10 2.43 ± 0.51 
LPS 0.54 ± 0.17 0.93 ± 0.19 0.63 ± 0.06 
LTA 1.04 ± 0.14 1.77 ± 0.57 1.16 ± 0.10 
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Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
Poly I:C 0.24 ± 0.04 0.46 ± 0.14 0.47 ± 0.05 
2 
Cyt 0.76 ± 0.12 0.37 ± 0.27 1.04 ± 0.17 
LPS 0.65 ± 0.19 0.68 ± 0.05 1.01 ± 0.35 
LTA 1.07 ± 0.26 1.14 ± 0.29 0.67 ± 0.05 
Poly I:C 0.41 ± 0.29 1.02 ± 0.31 0.46 ± 0.07 
3 
Cyt 0.49 ± 0.04 0.38 ± 0.13 3.17 ± 0.47 
LPS 0.98 ± 0.07 0.73 ± 0.17 0.80 ± 0.08 
LTA 0.92 ± 0.21 1.25 ± 0.17 1.10 ± 0.26 
Poly I:C 0.37 ± 0.02 0.83 ± 0.08 1.19 ± 0.29 
VEGFb 
1 
Cyt 0.35 ± 0.10 0.16 ± 0.06 0.61 ± 0.14 
LPS 3.30 ± 4.00 0.69 ± 0.17 0.34 ± 0.13 
LTA 2.10 ± 0.97 0.71 ± 0.22 0.48 ± 0.18 
Poly I:C 0.19 ± 0.10 0.36 ± 0.21 0.35 ± 0.04 
2 
Cyt 0.25 ± 0.11 0.21 ± 0.13 0.66 ± 0.19 
LPS 0.21 ± 0.07 0.38 ± 0.03 0.38 ± 0.11 
LTA 1.21 ± 0.66 0.82 ± 0.07 0.27 ± 0.04 
Poly I:C 0.14 ± 0.04 0.31 ± 0.29 0.34 ± 0.07 
3 
Cyt 0.19 ± 0.11 0.09 ± 0.02 4.45 ± 0.52 
LPS 0.71 ± 0.31 0.30 ± 0.12 0.75 ± 0.11 
LTA 1.45 ± 0.76 0.94 ± 0.34 1.10 ± 0.27 
Poly I:C 0.11 ± 0.06 0.28 ± 0.07 0.60 ± 0.10 
VEGFc 
1 
Cyt 0.27 ± 0.15 1.00 ± 0.28 0.29 ± 0.18 
LPS 0.56 ± 0.23 3.07 ± 0.34 0.67 ± 0.13 
LTA 0.67 ± 0.17 2.50 ± 1.14 0.56 ± 0.13 
Poly I:C 0.22 ± 0.06 1.83 ± 0.68 0.47 ± 0.10 
2 
Cyt 0.45 ± 0.05 0.96 ± 0.36 1.12 ± 0.07 
LPS 0.63 ± 0.08 1.05 ± 0.26 0.86 ± 0.31 
LTA 0.62 ± 0.22 1.64 ± 0.92 0.38 ± 0.12 
Poly I:C 0.53 ± 0.28 1.60 ± 0.71 0.54 ± 0.11 
3 
Cyt 0.20 ± 0.08 0.61 ± 0.21 7.80 ± 1.71 
LPS 0.74 ± 0.46 1.09 ± 0.51 1.05 ± 0.28 
LTA 0.65 ± 0.25 0.91 ± 0.39 1.14 ± 0.36 
Poly I:C 0.38 ± 0.10 0.65 ± 0.19 1.14 ± 0.23 
VEGFd 
1 
Cyt 0.15 ± 0.04 0.05 ± 0.03 1.44 ± 0.35 
LPS 0.27 ± 0.03 0.25 ± 0.10 1.10 ± 0.41 
LTA 0.37 ± 0.07 0.42 ± 0.07 1.30 ± 0.13 
Poly I:C 0.10 ± 0.03 0.11 ± 0.10 0.66 ± 0.11 
2 
Cyt 0.16 ± 0.07 0.01 ± 0.00 0.29 ± 0.07 
LPS 0.54 ± 0.10 0.09 ± 0.03 0.20 ± 0.07 
LTA 1.15 ± 0.37 0.30 ± 0.07 0.31 ± 0.08 
Poly I:C 0.12 ± 0.03 0.13 ± 0.02 0.40 ± 0.07 
3 
Cyt 0.15 ± 0.08 0.00 ± 0.00 0.23 ± 0.03 
LPS 0.61 ± 0.08 0.16 ± 0.11 0.38 ± 0.05 
LTA 0.72 ± 0.19 0.46 ± 0.08 2.06 ± 0.41 
Poly I:C 0.10 ± 0.04 0.09 ± 0.02 0.41 ± 0.08 
iNOS 1 Cyt 18.43 ± 14.56 4.52 ± 3.84 4.06 ± 3.80 
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Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
LPS 5.04 ± 7.56 0.54 ± 0.40 1.99 ± 1.86 
LTA 0.09 ± 0.09 0.23 ± 0.24 1.01 ± 0.93 
Poly I:C 0.57 ± 0.40 0.16 ± 0.15 1.88 ± 1.73 
2 
Cyt 191.3 ± 171.7 170.15 ± 178.95 49.31 ± 47.41 
LPS 2.25 ± 1.86 0.20 ± 0.21 271.90 ± 239.85 
LTA 0.25 ± 0.22 0.25 ± 0.04 1.04 ± 1.13 
Poly I:C 135.1 ± 222.2 0.14 ± 0.05 22.15 ± 31.04 
3 
Cyt 77.75 ± 55.07 83.97 ± 86.59 40476 ± 37122 
LPS 4.61 ± 3.70 1.99 ± 1.83 32.53 ± 51.05 
LTA 0.22 ± 0.09 45.06 ± 53.10 28.72 ± 37.91 
Poly I:C 4.38 ± 3.46 0.15 ± 0.16 147.15 ± 153.43 
COX2 
1 
Cyt 0.85 ± 0.16 5.46 ± 1.93 2.45 ± 0.86 
LPS 1.00 ± 0.46 29.93 ± 4.88 0.46 ± 0.05 
LTA 1.39 ± 0.19 11.11 ± 7.88 0.69 ± 0.17 
Poly I:C 0.50 ± 0.07 5.41 ± 1.65 0.37 ± 0.05 
2 
Cyt 1.65 ± 0.67 5.16 ± 1.41 3.34 ± 0.19 
LPS 1.48 ± 0.67 3.96 ± 2.32 1.52 ± 0.53 
LTA 1.19 ± 0.59 6.46 ± 0.44 0.79 ± 0.06 
Poly I:C 1.31 ± 0.47 6.15 ± 4.01 0.75 ± 0.08 
3 
Cyt 0.93 ± 0.09 8.71 ± 3.77 23.83 ± 2.96 
LPS 1.57 ± 0.59 7.92 ± 5.36 1.52 ± 0.15 
LTA 0.97 ± 0.35 6.73 ± 2.58 0.89 ± 0.54 
Poly I:C 0.57 ± 0.06 4.33 ± 1.81 1.88 ± 0.27 
HGF 
1 
Cyt 0.09 ± 0.01 0.17 ± 0.06 2.48 ± 0.99 
LPS 0.17 ± 0.05 0.87 ± 0.36 1.13 ± 0.25 
LTA 0.37 ± 0.07 1.40 ± 1.24 1.68 ± 0.56 
Poly I:C 0.04 ± 0.01 1.75 ± 0.53 0.87 ± 0.19 
2 
Cyt 0.32 ± 0.24 0.48 ± 0.28 0.67 ± 0.16 
LPS 0.39 ± 0.28 1.68 ± 1.01 1.27 ± 0.74 
LTA 1.06 ± 0.69 5.03 ± 0.70 0.61 ± 0.11 
Poly I:C 0.11 ± 0.05 0.43 ± 0.08 0.33 ± 0.08 
3 
Cyt 0.22 ± 0.13 1.24 ± 1.02 2.20 ± 0.38 
LPS 0.74 ± 0.56 1.01 ± 0.63 0.52 ± 0.10 
LTA 0.97 ± 0.45 2.12 ± 0.69 0.65 ± 0.24 
Poly I:C 0.12 ± 0.07 0.35 ± 0.22 0.53 ± 0.14 
CD142 
1 
Cyt 0.32 ± 0.03 0.11 ± 0.00 0.93 ± 0.11 
LPS 0.74 ± 0.12 0.47 ± 0.14 0.42 ± 0.05 
LTA 0.70 ± 0.12 0.79 ± 0.32 0.55 ± 0.06 
Poly I:C 0.27 ± 0.06 0.40 ± 0.18 0.35 ± 0.03 
2 
Cyt 0.45 ± 0.26 0.18 ± 0.11 0.53 ± 0.06 
LPS 0.59 ± 0.17 0.90 ± 0.37 0.39 ± 0.14 
LTA 1.19 ± 0.25 0.78 ± 0.27 0.42 ± 0.04 
Poly I:C 0.32 ± 0.05 0.18 ± 0.07 0.49 ± 0.08 
3 
Cyt 0.33 ± 0.20 0.13 ± 0.06 1.48 ± 0.15 
LPS 0.79 ± 0.21 0.27 ± 0.03 0.50 ± 0.06 
LTA 0.83 ± 0.25 0.37 ± 0.11 1.44 ± 0.40 
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Gene Condition Licensing  BM MSCs Is MSCs Ad MSCs 
Poly I:C 0.55 ± 0.37 0.53 ± 0.36 0.87 ± 0.13 
GMCSF 
1 
Cyt 1.56 ± 1.30 6.07 ± 8.72 14.53 ± 12.02 
LPS 0.66 ± 0.30 13.17 ± 22.47 1.65 ± 1.05 
LTA 14.41 ± 24.03 10.08 ± 9.00 2.62 ± 1.26 
Poly I:C 145.6 ± 250.5 7.51 ± 11.31 1.07 ± 0.86 
2 
Cyt 8.85 ± 8.64 2.75 ± 2.17 1.22 ± 0.60 
LPS 0.74 ± 0.40 1.59 ± 1.77 1.98 ± 2.17 
LTA 1.31 ± 0.84 10.35 ± 16.41 1.31 ± 1.05 
Poly I:C 0.87 ± 0.75 0.78 ± 0.27 0.55 ± 0.28 
3 
Cyt 1.26 ± 0.95 8.57 ± 13.07 365.9 ± 300.6 
LPS 1.25 ± 0.67 1.59 ± 1.99 1.53 ± 1.14 
LTA 0.72 ± 0.40 8.85 ± 11.71 2.35 ± 1.37 
Poly I:C 0.74 ± 0.40 3.32 ± 5.56 4.37 ± 3.01 
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